PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33901462-8	2021	Studies using ruxolitinib inhibitors have showed that suppression of the JAK/STAT pathway in podocytes subjected to high glucose could increase autophagic flux and autophagy-related protein expression.	ruxolitinib	14-25	signal transducer and activator of transcription 1	Mus musculus	77-81
33930555-0	2021	IFN-alpha levels in ruxolitinib-treatead Aicardi-Goutieres patient during SARS-CoV-2 infection: A case report.	ruxolitinib	20-31	interferon alpha 1	Homo sapiens	0-9
33781828-2	2021	To evaluate the anti-inflammatory and regulatory T cells effects of JAK1/2 and STAT3 inhibition, we assessed the JAK 1/2 inhibitor ruxolitinib effects on Th17 cell/Tregs balance.	ruxolitinib	131-142	Janus kinase 1	Mus musculus	113-120
33534941-0	2021	Ruxolitinib inhibits poly(I:C) and type 2 cytokines-induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma.	ruxolitinib	0-11	C-C motif chemokine ligand 5	Homo sapiens	60-64
33534941-12	2021	The JAK1/2 inhibitor, ruxolitinib, was demonstrated to more effectively decrease CCL5 production in BEAS-2B cells than fluticasone propionate.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-10
33534941-12	2021	The JAK1/2 inhibitor, ruxolitinib, was demonstrated to more effectively decrease CCL5 production in BEAS-2B cells than fluticasone propionate.	ruxolitinib	22-33	C-C motif chemokine ligand 5	Homo sapiens	81-85
34023851-1	2021	JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined.	ruxolitinib	17-28	Janus kinase 1	Homo sapiens	0-6
33860589-2	2021	CASE DESCRIPTION: We reported an exceptional case of a child with relapsed Ph-like ALL with IKZF1 gene deletion treated with high-dose ruxolitinib as monotherapy, after multi-agent chemotherapy.	ruxolitinib	135-146	IKAROS family zinc finger 1	Homo sapiens	92-97
34016956-6	2021	LSD1i pre-treatment induced GFI1, PU.1 and CEBPalpha but depleted c-Myc, overcoming nongenetic resistance to ruxolitinib, or to BETi in post-MPN sAML cells.	ruxolitinib	109-120	lysine demethylase 1A	Homo sapiens	0-4
33694335-0	2021	Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib.	ruxolitinib	94-105	Janus kinase 1	Homo sapiens	76-83
34023851-1	2021	JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined.	ruxolitinib	30-33	Janus kinase 1	Homo sapiens	0-6
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	angiopoietin 2	Homo sapiens	76-82
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	fibroblast growth factor 7	Homo sapiens	84-88
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	5'-nucleotidase ecto	Homo sapiens	90-94
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	colony stimulating factor 3 receptor	Homo sapiens	96-101
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	Janus kinase 1	Homo sapiens	103-107
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	Janus kinase 2	Homo sapiens	109-113
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	Janus kinase 3	Homo sapiens	115-119
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	tyrosine kinase 2	Homo sapiens	121-125
33994432-0	2021	Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2V617F-myeloproliferative neoplasm.	ruxolitinib	69-80	Janus kinase 2	Homo sapiens	132-136
33585999-0	2021	Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.	ruxolitinib	34-45	Janus kinase 1	Homo sapiens	17-23
33994432-1	2021	A 62-year-old woman, who had a 16-year history of JAK2V617F-mutated myeloproliferative neoplasm (MPN), developed Burkitt leukemia (BL) 16 months after treatment with ruxolitinib to control hydroxyurea-refractory conditions.	ruxolitinib	166-177	Janus kinase 2	Homo sapiens	50-54
34007050-6	2021	Despite the anti-MAPK-ERK activity of ruxolitinib in IL7-induced signaling and JAK1 mutant cells, ruxolitinib only synergizes with steroid treatment in IL7-dependent steroid resistant PDX samples but not in IL7-independent steroid resistant PDX samples.	ruxolitinib	38-49	interleukin 7	Homo sapiens	53-56
33982267-2	2021	A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery.	ruxolitinib	23-34	Janus kinase 1	Homo sapiens	55-59
33982267-2	2021	A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery.	ruxolitinib	23-34	Janus kinase 2	Homo sapiens	60-64
33585999-0	2021	Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.	ruxolitinib	34-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-94
33517393-9	2021	Interestingly, the STAT3 phosphorylation could be inhibited with ruxolitinib as well as tofacitinib, which are clinically approved JAK1 and JAK3 (to lesser extent JAK2 and JAK1) inhibitors, respectively.	ruxolitinib	65-76	signal transducer and activator of transcription 3	Homo sapiens	19-24
33523540-3	2021	The JAK1/2 inhibitor ruxolitinib has recently gained attention as a treatment option for HLH due to its broad cytokine-modulating abilities and safety profile.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
33475942-0	2021	Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.	ruxolitinib	91-102	signal transducer and activator of transcription 1	Homo sapiens	49-54
33475942-3	2021	Herein, we aimed to unravel the effect of ruxolitinib as a bridge therapy in a patient with sporadic STAT1 T385M mutation to manage infections and other disease manifestations.	ruxolitinib	42-53	signal transducer and activator of transcription 1	Homo sapiens	101-106
33475942-8	2021	Dysregulation in STAT1 phosphorylation kinetics improved with ruxolitinib treatment and was completely normalized after transplantation.	ruxolitinib	62-73	signal transducer and activator of transcription 1	Homo sapiens	17-22
33843403-6	2021	The addition of the CXCR4 inhibitor plerixafor with ruxolitinib and venetoclax reduces clinical scores and enhances survival.	ruxolitinib	52-63	C-X-C motif chemokine receptor 4	Homo sapiens	20-25
33585999-2	2021	Ruxolitinib is an orally bioavailable JAK1/2 inhibitor.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-44
33585999-3	2021	We aimed to identify the recommended phase 2 dose (RP2D) of ruxolitinib in combination with paclitaxel in patients with HER2-negative metastatic breast cancer (MBC).	ruxolitinib	60-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124
33747208-9	2021	Furthermore, zileuton and ruxolitinib exerted their anticancer effects by suppressing hematopoietic colony formation, inducing apoptosis and arresting the cell cycle of human CD34+ cells from patients with PV.	ruxolitinib	26-37	CD34 molecule	Homo sapiens	175-179
33747209-0	2021	Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	85-91
33747209-0	2021	Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	92-97
33747209-0	2021	Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.	ruxolitinib	0-11	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	98-103
33747209-6	2021	Firstly, JAK1/2-STAT1 was identified as the target of ruxolitinib.	ruxolitinib	54-65	Janus kinase 1	Homo sapiens	9-15
33747209-6	2021	Firstly, JAK1/2-STAT1 was identified as the target of ruxolitinib.	ruxolitinib	54-65	signal transducer and activator of transcription 1	Homo sapiens	16-21
33747209-7	2021	Then, ruxolitinib downregulated myeloid cell leukemia-1 (Mcl-1) mRNA level and decreased its protein level, which enabled Bak to trigger CRC apoptosis.	ruxolitinib	6-17	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	32-55
33747209-7	2021	Then, ruxolitinib downregulated myeloid cell leukemia-1 (Mcl-1) mRNA level and decreased its protein level, which enabled Bak to trigger CRC apoptosis.	ruxolitinib	6-17	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	57-62
33747209-7	2021	Then, ruxolitinib downregulated myeloid cell leukemia-1 (Mcl-1) mRNA level and decreased its protein level, which enabled Bak to trigger CRC apoptosis.	ruxolitinib	6-17	BCL2 antagonist/killer 1	Homo sapiens	122-125
33747209-10	2021	Taken together, the results showed that ruxolitinib decreased JAK1/2-STAT1-Mcl-1 protein level and effectively suppressed CRC cell proliferation in vitro and in vivo.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	62-68
33747209-10	2021	Taken together, the results showed that ruxolitinib decreased JAK1/2-STAT1-Mcl-1 protein level and effectively suppressed CRC cell proliferation in vitro and in vivo.	ruxolitinib	40-51	signal transducer and activator of transcription 1	Homo sapiens	69-74
33747209-10	2021	Taken together, the results showed that ruxolitinib decreased JAK1/2-STAT1-Mcl-1 protein level and effectively suppressed CRC cell proliferation in vitro and in vivo.	ruxolitinib	40-51	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	75-80
33792103-5	2021	Therapies include hydroxyurea for cytoreduction, hypomethylating agents, and the JAK1/2 inhibitor ruxolitinib to address splenomegaly and constitutional symptoms.	ruxolitinib	98-109	Janus kinase 1	Homo sapiens	81-87
32981124-2	2021	We report a case that demonstrated the efficacy and feasibility of ruxolitinib a JAK 1/2 inhibitor in the treatment of chronic steroid-refractory GVHD (SR-GVHD).	ruxolitinib	67-78	Janus kinase 1	Homo sapiens	81-88
33965175-0	2021	Ruxolitinib Inhibits IFNgamma Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.	ruxolitinib	0-11	interferon gamma	Homo sapiens	21-29
33965175-1	2021	Ruxolitinib is a JAK2/JAK1 inhibitor that blocks the inflammatory JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	17-21
33965175-1	2021	Ruxolitinib is a JAK2/JAK1 inhibitor that blocks the inflammatory JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
33965175-1	2021	Ruxolitinib is a JAK2/JAK1 inhibitor that blocks the inflammatory JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-20
33965175-1	2021	Ruxolitinib is a JAK2/JAK1 inhibitor that blocks the inflammatory JAK-STAT signaling pathway.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	70-74
33965175-7	2021	We aimed to define the effect of ruxolitinib on the immunobiology of MSCs that are modulated by IFNgamma.	ruxolitinib	33-44	interferon gamma	Homo sapiens	96-104
33965175-8	2021	Human bone marrow derived MSCs, peripheral blood mononuclear cells (PBMCs), and primary bone marrow aspirates were analyzed for their sensitivity to ruxolitinib-mediated blocking of IFNgamma-induced STAT-1 phosphorylation and downstream effector molecules, utilizing Western blot, flow cytometry, secretome analysis, and phosflow techniques.	ruxolitinib	149-160	interferon gamma	Homo sapiens	182-190
33965175-8	2021	Human bone marrow derived MSCs, peripheral blood mononuclear cells (PBMCs), and primary bone marrow aspirates were analyzed for their sensitivity to ruxolitinib-mediated blocking of IFNgamma-induced STAT-1 phosphorylation and downstream effector molecules, utilizing Western blot, flow cytometry, secretome analysis, and phosflow techniques.	ruxolitinib	149-160	signal transducer and activator of transcription 1	Homo sapiens	199-205
33965175-9	2021	IFNgamma-induced cytostatic effects on MSCs are reversed by ruxolitinib.	ruxolitinib	60-71	interferon gamma	Homo sapiens	0-8
33965175-10	2021	Ruxolitinib inhibits IFNgamma and secretome of activated peripheral PBMC-induced STAT-1 phosphorylation on human bone marrow derived MSCs.	ruxolitinib	0-11	interferon gamma	Homo sapiens	21-29
33965175-10	2021	Ruxolitinib inhibits IFNgamma and secretome of activated peripheral PBMC-induced STAT-1 phosphorylation on human bone marrow derived MSCs.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	81-87
33965175-11	2021	In addition, ruxolitinib inhibits IFNgamma-induced pro-GVHD pathways on MSCs, which includes HLAABC(MHCI), HLADR(MHCII), CX3CL1, and CCL2.	ruxolitinib	13-24	interferon gamma	Homo sapiens	34-42
33965175-11	2021	In addition, ruxolitinib inhibits IFNgamma-induced pro-GVHD pathways on MSCs, which includes HLAABC(MHCI), HLADR(MHCII), CX3CL1, and CCL2.	ruxolitinib	13-24	C-X3-C motif chemokine ligand 1	Homo sapiens	121-127
33965175-11	2021	In addition, ruxolitinib inhibits IFNgamma-induced pro-GVHD pathways on MSCs, which includes HLAABC(MHCI), HLADR(MHCII), CX3CL1, and CCL2.	ruxolitinib	13-24	C-C motif chemokine ligand 2	Homo sapiens	133-137
33965175-12	2021	IFNgamma-induced immunosuppressive molecules IDO and PDL-1 were also inhibited by ruxolitinib on MSCs.	ruxolitinib	82-93	interferon gamma	Homo sapiens	0-8
33965175-12	2021	IFNgamma-induced immunosuppressive molecules IDO and PDL-1 were also inhibited by ruxolitinib on MSCs.	ruxolitinib	82-93	indoleamine 2,3-dioxygenase 1	Homo sapiens	45-48
33965175-12	2021	IFNgamma-induced immunosuppressive molecules IDO and PDL-1 were also inhibited by ruxolitinib on MSCs.	ruxolitinib	82-93	CD274 molecule	Homo sapiens	53-58
33965175-13	2021	Comparative analysis with PBMCs has demonstrated that MSCs are as equal as to HLADR+ PBMC populations in responding to ruxolitinib-mediated inhibition of IFNgamma-induced STAT-1 phosphorylation.	ruxolitinib	119-130	interferon gamma	Homo sapiens	154-162
33965175-13	2021	Comparative analysis with PBMCs has demonstrated that MSCs are as equal as to HLADR+ PBMC populations in responding to ruxolitinib-mediated inhibition of IFNgamma-induced STAT-1 phosphorylation.	ruxolitinib	119-130	signal transducer and activator of transcription 1	Homo sapiens	171-177
33965175-14	2021	Ex vivo analysis of human marrow aspirates has demonstrated that ruxolitinib blocks IFNgamma-induced STAT-1 phosphorylation in CD45+/-HLADR+/- populations at different levels, which is depending on their sensitivity to IFNgamma responsiveness.	ruxolitinib	65-76	interferon gamma	Homo sapiens	84-92
33965175-14	2021	Ex vivo analysis of human marrow aspirates has demonstrated that ruxolitinib blocks IFNgamma-induced STAT-1 phosphorylation in CD45+/-HLADR+/- populations at different levels, which is depending on their sensitivity to IFNgamma responsiveness.	ruxolitinib	65-76	signal transducer and activator of transcription 1	Homo sapiens	101-107
33965175-14	2021	Ex vivo analysis of human marrow aspirates has demonstrated that ruxolitinib blocks IFNgamma-induced STAT-1 phosphorylation in CD45+/-HLADR+/- populations at different levels, which is depending on their sensitivity to IFNgamma responsiveness.	ruxolitinib	65-76	protein tyrosine phosphatase receptor type C	Homo sapiens	127-131
33965175-14	2021	Ex vivo analysis of human marrow aspirates has demonstrated that ruxolitinib blocks IFNgamma-induced STAT-1 phosphorylation in CD45+/-HLADR+/- populations at different levels, which is depending on their sensitivity to IFNgamma responsiveness.	ruxolitinib	65-76	interferon gamma	Homo sapiens	219-227
33517393-9	2021	Interestingly, the STAT3 phosphorylation could be inhibited with ruxolitinib as well as tofacitinib, which are clinically approved JAK1 and JAK3 (to lesser extent JAK2 and JAK1) inhibitors, respectively.	ruxolitinib	65-76	Janus kinase 3	Homo sapiens	140-144
33517393-9	2021	Interestingly, the STAT3 phosphorylation could be inhibited with ruxolitinib as well as tofacitinib, which are clinically approved JAK1 and JAK3 (to lesser extent JAK2 and JAK1) inhibitors, respectively.	ruxolitinib	65-76	Janus kinase 1	Homo sapiens	172-176
33517393-10	2021	Given our results and the recent reports of ruxolitinib and tofacitinib use for the treatment of diseases caused by direct activation of STAT3 or STAT1 we speculate that these drugs may be effective in the treatment of our patient"s condition.	ruxolitinib	44-55	signal transducer and activator of transcription 3	Homo sapiens	137-142
33517393-10	2021	Given our results and the recent reports of ruxolitinib and tofacitinib use for the treatment of diseases caused by direct activation of STAT3 or STAT1 we speculate that these drugs may be effective in the treatment of our patient"s condition.	ruxolitinib	44-55	signal transducer and activator of transcription 1	Homo sapiens	146-151
33895784-0	2021	Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.	ruxolitinib	24-35	cytokine receptor like factor 2	Homo sapiens	67-72
33954282-1	2021	Even after development of the JAK1/JAK2 inhibitor ruxolitinib, myeloproliferative neoplasm (MPN) patients require novel therapeutic options.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	30-34
33954282-1	2021	Even after development of the JAK1/JAK2 inhibitor ruxolitinib, myeloproliferative neoplasm (MPN) patients require novel therapeutic options.	ruxolitinib	50-61	Janus kinase 2	Homo sapiens	35-39
33954282-8	2021	Moreover, in mice, low-dose ruxolitinib synergized with IGF-1R inhibition to increase survival.	ruxolitinib	28-39	insulin-like growth factor I receptor	Mus musculus	56-62
33904202-7	2021	The PBPK model predicted an area under the curve ratio (AUCR) of 1, and 1.8, for ruxolitinib and panobinostat, respectively in the presence of severe RIP.	ruxolitinib	81-92	receptor interacting serine/threonine kinase 1	Homo sapiens	150-153
33895784-7	2021	Based on these findings, we conducted preclinical in vivo drug testing and demonstrated that ruxolitinib enhanced the in vivo efficacy of an induction-type regimen consisting of vincristine, dexamethasone, and L-asparaginase in 2/3 CRLF2-rearranged Ph-like ALL xenografts.	ruxolitinib	93-104	cytokine receptor like factor 2	Homo sapiens	232-237
33895784-8	2021	Overall, our findings support evaluating the addition of ruxolitinib to conventional induction regimens for the treatment of CRLF2-rearranged Ph-like ALL.	ruxolitinib	57-68	cytokine receptor like factor 2	Homo sapiens	125-130
33992887-4	2021	Similarly, preliminary studies have shown that JAK1/2 inhibitor treatment with ruxolitinib or baricitinib may decrease mortality by dampening the deadly cytokine storm, which - in addition to the virus itself - also contributes to multi-organ thrombosis and multi-organ failure.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	47-53
33882638-0	2021	Dual intracellular targeting by ruxolitinib and Mcl-1 inhibitor S63845 in IL-6 dependent myeloma cells blocks in vivo tumor growth.	ruxolitinib	32-43	interleukin 6	Homo sapiens	74-78
33845867-10	2021	INTERVENTION AND COMPARATOR: RUXOLITINIB (RUX) (14 days): An oral selective and potent inhibitor of Janus Associated Kinases (JAK1 and JAK2) and cell proliferation (Verstovek, 2010).	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	126-130
33845867-10	2021	INTERVENTION AND COMPARATOR: RUXOLITINIB (RUX) (14 days): An oral selective and potent inhibitor of Janus Associated Kinases (JAK1 and JAK2) and cell proliferation (Verstovek, 2010).	ruxolitinib	29-40	Janus kinase 2	Homo sapiens	135-139
33845867-10	2021	INTERVENTION AND COMPARATOR: RUXOLITINIB (RUX) (14 days): An oral selective and potent inhibitor of Janus Associated Kinases (JAK1 and JAK2) and cell proliferation (Verstovek, 2010).	ruxolitinib	29-32	Janus kinase 1	Homo sapiens	126-130
33845867-10	2021	INTERVENTION AND COMPARATOR: RUXOLITINIB (RUX) (14 days): An oral selective and potent inhibitor of Janus Associated Kinases (JAK1 and JAK2) and cell proliferation (Verstovek, 2010).	ruxolitinib	29-32	Janus kinase 2	Homo sapiens	135-139
33830087-3	2021	We previously showed that therapeutic targeting of JAK/STAT pathways using the first-generation JAK1/2 inhibitor, ruxolitinib, and the pan-JAK inhibitor, tofacitinib, was highly effective in the treatment of human AA, as well as prevention and reversal of AA in the C3H/HeJ mouse model.	ruxolitinib	114-125	Janus kinase 1	Homo sapiens	96-102
33827897-8	2021	Ruxolitinib, a JAK1/2 inhibitor, normalized interferon signature genes and all complement gene transcripts induced by SARS-CoV-2 in lung epithelial cell lines, but did not affect NF-kappaB-regulated genes.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
33827897-9	2021	Ruxolitinib, alone or in combination with the antiviral remdesivir, inhibited C3a protein produced by infected cells.	ruxolitinib	0-11	complement C3	Homo sapiens	78-81
33222197-1	2021	Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	29-33
33509790-9	2021	Targeting the Janus Kinase (JAK)/STAT signaling pathway using the FDA approved drug ruxolitinib overcame these tumor-protective responses and improved anti-PD-1 therapeutic efficacy.	ruxolitinib	84-95	signal transducer and activator of transcription 1	Mus musculus	33-37
33509790-9	2021	Targeting the Janus Kinase (JAK)/STAT signaling pathway using the FDA approved drug ruxolitinib overcame these tumor-protective responses and improved anti-PD-1 therapeutic efficacy.	ruxolitinib	84-95	programmed cell death 1	Mus musculus	156-160
33792220-8	2022	Our findings strongly suggest that overactive JAK2 signaling is a central driver of pcAECyTCL, and consequently, patients with this neoplasm would likely benefit from therapy with JAK2 inhibitors such as FDA-approved ruxolitinib.	ruxolitinib	217-228	Janus kinase 2	Homo sapiens	46-50
33792220-8	2022	Our findings strongly suggest that overactive JAK2 signaling is a central driver of pcAECyTCL, and consequently, patients with this neoplasm would likely benefit from therapy with JAK2 inhibitors such as FDA-approved ruxolitinib.	ruxolitinib	217-228	Janus kinase 2	Homo sapiens	180-184
33222197-1	2021	Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	34-38
33222197-1	2021	Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs).	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	29-33
33222197-1	2021	Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs).	ruxolitinib	13-16	Janus kinase 2	Homo sapiens	34-38
33658996-5	2020	Ruxolitinib cream is a potent and selective JAK1/2 inhibitor currently undergoing clinical evaluation in adults with mild-to-moderate AD (NCT03745638, NCT03920852 and NCT03745651).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	44-50
33069729-0	2021	Targeting the JAK/STAT3 pathway with Ruxolitinib in a mouse model of recessive dystrophic epidermolysis bullosa-squamous cell carcinoma.	ruxolitinib	37-48	signal transducer and activator of transcription 3	Mus musculus	18-23
32814839-0	2021	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.	ruxolitinib	38-49	Janus kinase 1	Homo sapiens	21-27
32814839-2	2021	Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-21
32814839-2	2021	Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	22-26
33784668-11	2021	We encourage reevaluation of the cohorts of patients treated with ruxolitinib in previous and current large prospective studies to study the possible correlation between previous exposition to IFN-alpha2b and TBC reactivation.	ruxolitinib	66-77	interferon alpha 2	Homo sapiens	193-204
33795598-1	2022	BACKGROUND: Ruxolitinib, a JAK1/2 inhibitor, is used to treat chronic graft-versus-host-disease (cGVHD) in adult allogeneic hematopoietic stem cell transplant patients, but experience in children is limited, perhaps due to lack of pediatric dosing information.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	27-33
33693561-2	2022	Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without HIV and HIV reservoir markers ex vivo.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-22
33693561-13	2022	Ruxolitinib reduced CD4+ T-cells expressing HLADR/CD38 (difference in means -0.34%, 90%CI: -0.66,-0.12)) and Bcl-2 (-3.30%, 90%CI: (-4.72,-1.87)).	ruxolitinib	0-11	CD4 molecule	Homo sapiens	20-23
33693561-13	2022	Ruxolitinib reduced CD4+ T-cells expressing HLADR/CD38 (difference in means -0.34%, 90%CI: -0.66,-0.12)) and Bcl-2 (-3.30%, 90%CI: (-4.72,-1.87)).	ruxolitinib	0-11	CD38 molecule	Homo sapiens	50-54
33693561-13	2022	Ruxolitinib reduced CD4+ T-cells expressing HLADR/CD38 (difference in means -0.34%, 90%CI: -0.66,-0.12)) and Bcl-2 (-3.30%, 90%CI: (-4.72,-1.87)).	ruxolitinib	0-11	BCL2 apoptosis regulator	Homo sapiens	109-114
33542546-2	2021	MPN treatment options currently mainly consist of cytoreductive therapy with hydroxyurea and JAK2 inhibitors such as ruxolitinib and fedratinib.	ruxolitinib	117-128	Janus kinase 2	Mus musculus	93-97
33981229-0	2021	Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
33981229-4	2021	Our findings demonstrate that oral ruxolitinib dosing designed to mimic clinically relevant JAK-STAT pathway inhibition significantly reduces the harmful consequences of immune overactivation in multiple hyperinflammatory models.	ruxolitinib	35-46	jak	None	92-95
33455503-5	2021	Ruxolitinib was found to potently inhibit the activities of OAT3, OCT2, MATE1 and MATE2-K (IC50 < 10 microM).	ruxolitinib	0-11	solute carrier family 22 member 8	Homo sapiens	60-64
33455503-5	2021	Ruxolitinib was found to potently inhibit the activities of OAT3, OCT2, MATE1 and MATE2-K (IC50 < 10 microM).	ruxolitinib	0-11	POU class 2 homeobox 2	Homo sapiens	66-70
33455503-5	2021	Ruxolitinib was found to potently inhibit the activities of OAT3, OCT2, MATE1 and MATE2-K (IC50 < 10 microM).	ruxolitinib	0-11	solute carrier family 47 member 1	Homo sapiens	72-77
33455503-5	2021	Ruxolitinib was found to potently inhibit the activities of OAT3, OCT2, MATE1 and MATE2-K (IC50 < 10 microM).	ruxolitinib	0-11	solute carrier family 47 member 2	Homo sapiens	82-89
33455503-8	2021	When applying the US FDA criteria for transporters-related drug-drug interaction risk, OCT2 and MATE2-K, unlike MATE1 andOAT3, were predicted to be in vivo inhibited by ruxolitinib.	ruxolitinib	169-180	POU class 2 homeobox 2	Homo sapiens	87-91
33455503-8	2021	When applying the US FDA criteria for transporters-related drug-drug interaction risk, OCT2 and MATE2-K, unlike MATE1 andOAT3, were predicted to be in vivo inhibited by ruxolitinib.	ruxolitinib	169-180	solute carrier family 47 member 2	Homo sapiens	96-103
33455503-9	2021	Cellular uptake studies additionally indicated that ruxolitinib is a substrate for MATE1 and MATE2-K, but not for OAT3 and OCT2.	ruxolitinib	52-63	solute carrier family 47 member 1	Homo sapiens	83-88
33455503-9	2021	Cellular uptake studies additionally indicated that ruxolitinib is a substrate for MATE1 and MATE2-K, but not for OAT3 and OCT2.	ruxolitinib	52-63	solute carrier family 47 member 2	Homo sapiens	93-100
33936902-6	2021	Ruxolitinib reduces the JAK2V617F mutation burden and is used as a second-line drug.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	24-28
33706427-5	2021	Rats in burn+JAK/STAT3 inhibitor group were intraperitoneally injected with JAK/STAT3 inhibitor ruxolitinib.	ruxolitinib	96-107	signal transducer and activator of transcription 3	Rattus norvegicus	17-22
33706427-5	2021	Rats in burn+JAK/STAT3 inhibitor group were intraperitoneally injected with JAK/STAT3 inhibitor ruxolitinib.	ruxolitinib	96-107	signal transducer and activator of transcription 3	Rattus norvegicus	80-85
33662027-4	2021	Although ruxolitinib inhibited hyperactivity in the scratch assay in keloid fibroblasts, it paradoxically exacerbated the hyper-glycolytic state, possibly by further limiting OxPhos via alterations in mitochondrial phosphorylated STAT3 (pSTAT3Ser727).	ruxolitinib	9-20	signal transducer and activator of transcription 3	Homo sapiens	230-235
33570945-0	2021	Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.	ruxolitinib	44-55	Janus kinase 2	Homo sapiens	25-29
33598678-8	2021	Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	10-13
33598678-8	2021	Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	36-42
33598678-8	2021	Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax.	ruxolitinib	53-64	BCL2 apoptosis regulator	Homo sapiens	132-137
33567809-12	2021	Ruxolitinib decreased the abdominal aorta diameter and the incidence of abdominal AA in the JAK2V617F-BMT mice.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	92-96
32805756-7	2021	Ruxolitinib increased PD-1 levels on donor T cells by suppressing Tbx21 expression.	ruxolitinib	0-11	MHC class I antigen 1	Sus scrofa	22-26
32805756-7	2021	Ruxolitinib increased PD-1 levels on donor T cells by suppressing Tbx21 expression.	ruxolitinib	0-11	T-box transcription factor 21	Sus scrofa	66-71
32805756-8	2021	Ruxolitinib increased apoptosis of T cells which was reversed by the PD-1 antibody.	ruxolitinib	0-11	MHC class I antigen 1	Sus scrofa	69-73
32805756-9	2021	PD-1 antibody preserved expression of granzyme B and cytotoxicity of T cells which were decreased by ruxolitinib.	ruxolitinib	101-112	MHC class I antigen 1	Sus scrofa	0-4
32805756-9	2021	PD-1 antibody preserved expression of granzyme B and cytotoxicity of T cells which were decreased by ruxolitinib.	ruxolitinib	101-112	granzyme B	Mus musculus	38-48
33341940-0	2021	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.	ruxolitinib	0-11	CD274 molecule	Homo sapiens	55-85
33341940-0	2021	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.	ruxolitinib	0-11	CD274 molecule	Homo sapiens	87-92
33341940-7	2021	Furthermore, RUX treatment resulted in a concentration-dependent reduction of PD-L1 gene expression in the MM tumour cells cultured alone or co-cultured with stromal cells compared with untreated cells.	ruxolitinib	13-16	CD274 molecule	Homo sapiens	78-83
33502001-0	2021	Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.	ruxolitinib	12-23	pericentriolar material 1	Homo sapiens	62-66
33502001-0	2021	Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	67-71
33509955-5	2021	METHODS: Assessment of cell senescence in lungs and cultured lung cells from patients with COPD and controls subjected to PLA2R1 knock-down, PLA2R1 gene transduction and treatment with the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	206-217	Janus kinase 1	Homo sapiens	189-195
33509955-9	2021	PLA2R1-mediated cell senescence in COPD was largely reversed by treatment with the potent JAK1/2 inhibitor ruxolitinib.	ruxolitinib	107-118	phospholipase A2 receptor 1	Mus musculus	0-6
33509955-9	2021	PLA2R1-mediated cell senescence in COPD was largely reversed by treatment with the potent JAK1/2 inhibitor ruxolitinib.	ruxolitinib	107-118	Janus kinase 1	Mus musculus	90-96
33509955-12	2021	LV-PLA2R1-treated mice developed lung emphysema within 4 weeks, and this was markedly attenuated by concomitant ruxolitinib treatment.	ruxolitinib	112-123	phospholipase A2 receptor 1	Mus musculus	3-9
33503434-5	2021	Pre-LSC evolution to LSCs is marked by STAT3 editing, STAT3beta isoform switching, elevated phospho-STAT3, and increased ADAR1p150 expression, which can be prevented by JAK2/STAT3 inhibition with ruxolitinib or fedratinib or lentiviral ADAR1 shRNA knockdown.	ruxolitinib	196-207	Janus kinase 2	Homo sapiens	169-173
33503434-5	2021	Pre-LSC evolution to LSCs is marked by STAT3 editing, STAT3beta isoform switching, elevated phospho-STAT3, and increased ADAR1p150 expression, which can be prevented by JAK2/STAT3 inhibition with ruxolitinib or fedratinib or lentiviral ADAR1 shRNA knockdown.	ruxolitinib	196-207	adenosine deaminase RNA specific	Homo sapiens	121-126
33501441-7	2021	JAK inhibitor ruxolitinib ablated STAT1 and dACE2 expression after interferon treatment.	ruxolitinib	14-25	signal transducer and activator of transcription 1	Homo sapiens	34-39
33501441-7	2021	JAK inhibitor ruxolitinib ablated STAT1 and dACE2 expression after interferon treatment.	ruxolitinib	14-25	Acetylcholine esterase	Drosophila melanogaster	44-49
33413168-4	2021	CASE PRESENTATION: A 70-year-old Thai man who was diagnosed with JAK2V617F-mutation-positive primary myelofibrosis had been treated with ruxolitinib for 4 years.	ruxolitinib	137-148	Janus kinase 2	Homo sapiens	65-69
33052714-7	2021	In vitro, IL-6 induced proliferation and migration of HPASMCs from healthy individuals as well as from IPAH patients were reduced in a dose-dependent manner by the FDA-approved Jak1 and Jak2 inhibitor ruxolitinib.	ruxolitinib	201-212	interleukin 6	Homo sapiens	10-14
33052714-7	2021	In vitro, IL-6 induced proliferation and migration of HPASMCs from healthy individuals as well as from IPAH patients were reduced in a dose-dependent manner by the FDA-approved Jak1 and Jak2 inhibitor ruxolitinib.	ruxolitinib	201-212	Janus kinase 2	Homo sapiens	186-190
33052714-9	2021	Therefore, we propose that ruxolitinib may present a novel therapeutic option for PAH patients by reducing pulmonary vascular remodeling through effectively blocking Jak2-Stat3 mediated signaling pathways.	ruxolitinib	27-38	Janus kinase 2	Homo sapiens	166-170
33052714-9	2021	Therefore, we propose that ruxolitinib may present a novel therapeutic option for PAH patients by reducing pulmonary vascular remodeling through effectively blocking Jak2-Stat3 mediated signaling pathways.	ruxolitinib	27-38	signal transducer and activator of transcription 3	Homo sapiens	171-176
33314568-0	2021	Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.	ruxolitinib	0-11	CXADR pseudogene 1	Homo sapiens	52-55
33314568-11	2021	In vitro assays revealed that ruxolitinib could dampen CAR T expansion and cytotoxicity, suggesting that the timing and dosage of ruxolitinib should be carefully considered to avoid dampening anti-leukaemia response.	ruxolitinib	30-41	CXADR pseudogene 1	Homo sapiens	55-58
33338537-9	2021	Conversely, JAK2 inhibition by Ruxolitinib (JAK1/2 inhibitor) or BMS-911543 (JAK2 inhibitor) abrogated the differentiation from monocytes into IDEC.	ruxolitinib	31-42	Janus kinase 2	Homo sapiens	12-16
33338537-9	2021	Conversely, JAK2 inhibition by Ruxolitinib (JAK1/2 inhibitor) or BMS-911543 (JAK2 inhibitor) abrogated the differentiation from monocytes into IDEC.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	44-50
33490193-6	2020	The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6.	ruxolitinib	129-140	interleukin 6	Homo sapiens	18-22
33490193-6	2020	The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6.	ruxolitinib	129-140	signal transducer and activator of transcription 3	Homo sapiens	112-117
33490193-6	2020	The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6.	ruxolitinib	129-140	signal transducer and activator of transcription 3	Homo sapiens	112-117
32789663-7	2020	Ruxolitinib, a tyrosine kinase inhibitor selective for JAK1, 2, blocks many pro- and anti-inflammatory cytokines including IL6.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	55-59
32789663-7	2020	Ruxolitinib, a tyrosine kinase inhibitor selective for JAK1, 2, blocks many pro- and anti-inflammatory cytokines including IL6.	ruxolitinib	0-11	interleukin 6	Homo sapiens	123-126
33224394-1	2020	Ruxolitinib is a highly potent JAK2 inhibitor approved for the treatment of myelofibrosis (idiopathic or post-polycythemia vera or post-essential thrombocythemia) and, more recently, for polycythemia vera with an inadequate response to or intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	31-35
33067379-3	2020	Ongoing activation of IFN receptors in patients on ibrutinib was suggested by the presence of type I and II IFN in blood together with the cycling behavior of IFN-stimulated gene (ISG) products when IFN signaling was blocked intermittently with the JAK inhibitor ruxolitinib.	ruxolitinib	263-274	interferon alpha 1	Homo sapiens	22-25
33067379-7	2020	Effects of IFN on survival remained intact as type I and II IFN-protected CLL cells from ibrutinib in vitro, which could be prevented by ruxolitinib and IFNR blocking Abs.	ruxolitinib	137-148	interferon alpha 1	Homo sapiens	60-63
32844992-8	2020	JAK inhibitor ruxolitinib inhibited STAT3 phosphorylation in MM cell lines, upregulated CD38 expression in MM cell lines and primary patient MM cells, and augmented DARA-mediated ADCC against MM cell lines.	ruxolitinib	14-25	signal transducer and activator of transcription 3	Homo sapiens	36-41
32844992-8	2020	JAK inhibitor ruxolitinib inhibited STAT3 phosphorylation in MM cell lines, upregulated CD38 expression in MM cell lines and primary patient MM cells, and augmented DARA-mediated ADCC against MM cell lines.	ruxolitinib	14-25	CD38 molecule	Homo sapiens	88-92
32738501-1	2020	Ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor, has recently been proposed for steroid refractory chronic graft-versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in severe skin cGVHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	39-46
33114733-1	2020	Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, is approved for second-line therapy in patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
33114733-1	2020	Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, is approved for second-line therapy in patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	26-30
33114733-1	2020	Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, is approved for second-line therapy in patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	21-25
33114733-1	2020	Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, is approved for second-line therapy in patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea.	ruxolitinib	13-16	Janus kinase 2	Homo sapiens	26-30
33087723-5	2020	Accordingly, patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	175-186	interferon gamma	Homo sapiens	99-115
33087723-5	2020	Accordingly, patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	175-186	interleukin 2	Homo sapiens	117-121
33087723-5	2020	Accordingly, patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	175-186	interleukin 4	Homo sapiens	126-130
33087723-5	2020	Accordingly, patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	175-186	Janus kinase 1	Homo sapiens	155-159
33087723-5	2020	Accordingly, patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	175-186	Janus kinase 2	Homo sapiens	160-164
33162993-8	2020	Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD.	ruxolitinib	89-100	Janus kinase 1	Homo sapiens	32-36
33162993-8	2020	Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD.	ruxolitinib	89-100	Janus kinase 2	Homo sapiens	41-45
33162993-8	2020	Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD.	ruxolitinib	89-100	Janus kinase 1	Homo sapiens	102-112
33050000-7	2020	IAV replication was also inhibited by Ruxolitinib (Rux), a JAK inhibitor, but not by PF-4708671, an S6K1 inhibitor.	ruxolitinib	38-49	jak	None	59-62
32697338-3	2020	Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts.	ruxolitinib	47-58	Janus kinase 1	Homo sapiens	27-31
32697338-3	2020	Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts.	ruxolitinib	47-58	Janus kinase 2	Homo sapiens	32-36
32697338-3	2020	Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts.	ruxolitinib	60-63	Janus kinase 1	Homo sapiens	27-31
32697338-3	2020	Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts.	ruxolitinib	60-63	Janus kinase 2	Homo sapiens	32-36
32777959-2	2020	Materials & methods: We report successful clinical experience using ruxolitinib as adjuvant therapy to treat steroid-refractory CRS, which was related to CD22/CD19 chimeric antigen receptor-modified T cell sequential infusion, in a patient with Philadelphia chromosome-like acute lymphoblastic leukemia.	ruxolitinib	68-79	CD22 molecule	Homo sapiens	154-158
32777959-2	2020	Materials & methods: We report successful clinical experience using ruxolitinib as adjuvant therapy to treat steroid-refractory CRS, which was related to CD22/CD19 chimeric antigen receptor-modified T cell sequential infusion, in a patient with Philadelphia chromosome-like acute lymphoblastic leukemia.	ruxolitinib	68-79	CD19 molecule	Homo sapiens	159-163
32732635-0	2020	Ruxolitinib Response in an Infant with Very-Early-Onset Inflammatory Bowel Disease and Gain-of-Function STAT1 Mutation.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	104-109
32536506-8	2020	Fresh EA NK cells generated high levels of gamma interferon (IFN-gamma), which was abrogated by JAK1/JAK2 inhibition with ruxolitinib, but C/T EA NK cells showed lower IFN-gamma unaffected by JAK1/JAK2 inhibition.	ruxolitinib	122-133	interferon gamma	Homo sapiens	43-70
32536506-8	2020	Fresh EA NK cells generated high levels of gamma interferon (IFN-gamma), which was abrogated by JAK1/JAK2 inhibition with ruxolitinib, but C/T EA NK cells showed lower IFN-gamma unaffected by JAK1/JAK2 inhibition.	ruxolitinib	122-133	Janus kinase 1	Homo sapiens	96-100
32536506-8	2020	Fresh EA NK cells generated high levels of gamma interferon (IFN-gamma), which was abrogated by JAK1/JAK2 inhibition with ruxolitinib, but C/T EA NK cells showed lower IFN-gamma unaffected by JAK1/JAK2 inhibition.	ruxolitinib	122-133	Janus kinase 2	Homo sapiens	101-105
32536506-8	2020	Fresh EA NK cells generated high levels of gamma interferon (IFN-gamma), which was abrogated by JAK1/JAK2 inhibition with ruxolitinib, but C/T EA NK cells showed lower IFN-gamma unaffected by JAK1/JAK2 inhibition.	ruxolitinib	122-133	interferon gamma	Homo sapiens	61-70
32636055-1	2020	Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	34-38
32636055-1	2020	Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	43-47
32297800-1	2020	Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management.	ruxolitinib	61-72	Janus kinase 1	Homo sapiens	43-49
32732359-8	2021	Low numbers of PD1+/CD4+ and PD1+/CD8+ cells were associated with complete resolution of palpable splenomegaly and improved survival rate, suggesting that low levels of exhausted T cells confer a favorable response to ruxolitinib treatment.	ruxolitinib	218-229	patr class I histocompatibility antigen, A-126 alpha chain-like	Sus scrofa	15-18
32732367-4	2021	This prospective study aimed to investigate the efficacy and safety of ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, as a front-line therapy in children with secondary HLH.	ruxolitinib	71-82	Janus kinase 1	Homo sapiens	86-108
32234492-8	2020	Low expression of JAK2 were resistant to QL-VIII-58, TL-1-85, Ruxolitinib, TG101348 and Sunitinib.	ruxolitinib	62-73	Janus kinase 2	Homo sapiens	18-22
32279331-8	2020	We conclude that i) responses on ruxolitinib may only be transient in the majority of JAK2 fusion gene positive patients with allo SCT being an important early treatment option, and ii) nilotinib or dasatinib may be more effective than imatinib to induce durable complete remissions in ETV6-ABL1 positive patients.	ruxolitinib	33-44	Janus kinase 2	Homo sapiens	86-90
32492985-0	2020	The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway.	ruxolitinib	30-41	interferon gamma	Homo sapiens	111-127
32492985-0	2020	The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway.	ruxolitinib	30-41	signal transducer and activator of transcription 1	Homo sapiens	141-145
32492985-3	2020	This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids.	ruxolitinib	60-71	interferon alpha 1	Homo sapiens	120-129
32492985-3	2020	This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids.	ruxolitinib	60-71	signal transducer and activator of transcription 1	Homo sapiens	148-152
32492985-3	2020	This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids.	ruxolitinib	60-71	interferon gamma	Homo sapiens	157-166
32492985-3	2020	This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids.	ruxolitinib	60-71	signal transducer and activator of transcription 1	Homo sapiens	167-191
32492985-3	2020	This study aimed to determine the dose-dependent effects of ruxolitinib, an inhibitor of JAK, on the interferon (IFN)-I/IFN-alpha/IFN-beta receptor/STAT and IFN-gamma/IFN-gamma receptor/STAT1 axes of the IFN-receptor-dependent JAK/STAT signaling pathway in glioblastoma invasion and tumorigenesis in U87 glioblastoma tumor spheroids.	ruxolitinib	60-71	signal transducer and activator of transcription 1	Homo sapiens	186-190
32492985-6	2020	Results: Quantitative real-time polymerase chain reaction analysis demonstrated that ruxolitinib led to upregulated of the IFN-alpha and IFN-gamma while no change on the hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression levels.	ruxolitinib	85-96	interferon alpha 1	Homo sapiens	123-132
32492985-6	2020	Results: Quantitative real-time polymerase chain reaction analysis demonstrated that ruxolitinib led to upregulated of the IFN-alpha and IFN-gamma while no change on the hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression levels.	ruxolitinib	85-96	interferon gamma	Homo sapiens	137-146
32492985-7	2020	Additionally, we showed that ruxolitinib inhibited phosphorylation of JAK/STAT proteins.	ruxolitinib	29-40	signal transducer and activator of transcription 1	Homo sapiens	74-78
32492985-8	2020	The inhibition of IFNs dependent JAK/STAT signaling by ruxolitinib leads to decreases of the U87 cells invasiveness and tumorigenesis.	ruxolitinib	55-66	signal transducer and activator of transcription 1	Homo sapiens	37-41
32492985-9	2020	We demonstrate that ruxolitinib may inhibit glioma invasion and tumorigenesis through inhibition of the IFN-induced JAK/STAT signaling pathway.	ruxolitinib	20-31	signal transducer and activator of transcription 1	Homo sapiens	120-124
32492985-10	2020	Conclusion: Collectively, our results revealed that ruxolitinib may have therapeutic potential in glioblastomas, possibly by JAK/STAT signaling triggered by IFN-alpha and IFN-gamma.	ruxolitinib	52-63	signal transducer and activator of transcription 1	Homo sapiens	129-133
32492985-10	2020	Conclusion: Collectively, our results revealed that ruxolitinib may have therapeutic potential in glioblastomas, possibly by JAK/STAT signaling triggered by IFN-alpha and IFN-gamma.	ruxolitinib	52-63	interferon alpha 1	Homo sapiens	157-166
32492985-10	2020	Conclusion: Collectively, our results revealed that ruxolitinib may have therapeutic potential in glioblastomas, possibly by JAK/STAT signaling triggered by IFN-alpha and IFN-gamma.	ruxolitinib	52-63	interferon gamma	Homo sapiens	171-180
32334833-2	2020	Several JAK2 inhibitors such as ruxolitinib and gandotinib (LY2784544) currently in clinical trials and, provide improvements in MPNs including myelofibrosis.	ruxolitinib	32-43	Janus kinase 2	Homo sapiens	8-12
32923146-3	2020	Therapy with Ruxolitinib (RUX), a JAK1/2 inhibitor, may further increase the infectious risk.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	34-40
32923146-3	2020	Therapy with Ruxolitinib (RUX), a JAK1/2 inhibitor, may further increase the infectious risk.	ruxolitinib	26-29	Janus kinase 1	Homo sapiens	34-40
32198525-9	2020	Fedratinib and two other JAK2 inhibitors in later stages of clinical development, pacritinib and momelotinib, have been shown to induce clinical responses and improve symptoms in patients previously treated with ruxolitinib.	ruxolitinib	212-223	Janus kinase 2	Homo sapiens	25-29
32436276-2	2020	Herein, we investigated the inhibitory effects of two commonly used TKIs, midostaurin and ruxolitinib, on human UGTs and quantitatively evaluated their DDI potential via UGT inhibition.	ruxolitinib	90-101	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	112-115
32436276-4	2020	While ruxolitinib exhibited weak inhibition towards the activity of almost all of the tested UGT isoforms.	ruxolitinib	6-17	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	93-96
32017044-1	2020	Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-44
32017044-1	2020	Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	45-49
33548083-10	2021	Moreover, SHARPIN-mediated expression of IL-33 was reduced after treatment of HaCaT cells with the JAK/STAT inhibitor ruxolitinib.	ruxolitinib	118-129	SHANK associated RH domain interactor	Homo sapiens	10-17
33548083-10	2021	Moreover, SHARPIN-mediated expression of IL-33 was reduced after treatment of HaCaT cells with the JAK/STAT inhibitor ruxolitinib.	ruxolitinib	118-129	interleukin 33	Homo sapiens	41-46
33548083-10	2021	Moreover, SHARPIN-mediated expression of IL-33 was reduced after treatment of HaCaT cells with the JAK/STAT inhibitor ruxolitinib.	ruxolitinib	118-129	signal transducer and activator of transcription 3	Homo sapiens	103-107
32577845-0	2021	Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.	ruxolitinib	23-34	colony stimulating factor 3 receptor	Homo sapiens	123-128
33465556-6	2021	Notably, STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced breast cancer cell metastasis and migration in vitro and in vivo.	ruxolitinib	84-95	signal transducer and activator of transcription 3	Homo sapiens	9-14
33465556-6	2021	Notably, STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced breast cancer cell metastasis and migration in vitro and in vivo.	ruxolitinib	84-95	Janus kinase 1	Homo sapiens	60-66
33243417-8	2021	The JAK2 inhibitor, ruxolitinib is not sufficient in eliminating the underlying myeloid progenitor clone, as disease inevitably returns with therapy discontinuation.	ruxolitinib	20-31	Janus kinase 2	Homo sapiens	4-8
33505919-11	2020	In conclusion, this report describes a novel STRBP-JAK2 gene fusion in a Ph-like ALL patient with a very aggressive disease course, which proved resistant to chemotherapy combined with ruxolitinib but sensitive to immunotherapy.	ruxolitinib	185-196	spermatid perinuclear RNA binding protein	Homo sapiens	45-50
33505919-11	2020	In conclusion, this report describes a novel STRBP-JAK2 gene fusion in a Ph-like ALL patient with a very aggressive disease course, which proved resistant to chemotherapy combined with ruxolitinib but sensitive to immunotherapy.	ruxolitinib	185-196	Janus kinase 2	Homo sapiens	51-55
33489899-8	2020	Accordingly, ruxolitinib is the only selective JAK1 and JAK2-inhibitor approved for the treatment of myelofibrosis and aGVHD.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	47-51
33489899-8	2020	Accordingly, ruxolitinib is the only selective JAK1 and JAK2-inhibitor approved for the treatment of myelofibrosis and aGVHD.	ruxolitinib	13-24	Janus kinase 2	Homo sapiens	56-60
33403775-8	2021	In the 31 patients who received ruxolitinib symptoms improved (dyspnea scale) at day 7 in 25 out of 31 patients (80.6%); C-reactive protein decreased progressively from baseline (79.1+-73.4 mg/dl) to day15 (18.6+-33.2, p=0.022).	ruxolitinib	32-43	C-reactive protein	Homo sapiens	121-139
33502484-1	2021	Importance: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT).	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	54-71
33197049-7	2021	RAS/CBL mutations predicted resistance to ruxolitinib therapy.	ruxolitinib	42-53	Cbl proto-oncogene	Homo sapiens	4-7
33129109-4	2021	We previously performed a high-throughput screen that demonstrated additive/synergistic activity of Ruxolitinib, a JAK1/2 inhibitor, with AZD8055, an mTORC1/C2 inhibitor.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	115-121
33129109-5	2021	However, effects of unintended JAK2 inhibition with Ruxolitinib limits it therapeutic potential for ATL patients, which lead us to evaluate a JAK1-specific inhibitor.	ruxolitinib	52-63	Janus kinase 2	Homo sapiens	31-35
32818555-1	2020	Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-29
33017633-7	2020	Gene expression analysis revealed a lower expression of HLA-A and -B in MPN CD34+ cells compared with normal CD34+ cells, which was modulated by ruxolitinib and interferon-alpha treatment.	ruxolitinib	145-156	major histocompatibility complex, class I, A	Homo sapiens	56-68
32593209-4	2020	Here, we report a compelling case of a 55-yo patient with proven COVID-19 pneumonia, who was taking the JAK1/2 inhibitor ruxolitinib in-label for co-existing primary myelofibrosis for 15 months prior to coronavirus infection.	ruxolitinib	121-132	Janus kinase 1	Homo sapiens	104-110
32777582-2	2020	This case report on a critically ill patient with secondary hemophagocytic lymphohistiocytosis due to falciparum malaria treated successfully with ruxolitinib, demonstrates that JAK1/2 inhibition might be a promising treatment option for severe cases.	ruxolitinib	147-158	Janus kinase 1	Homo sapiens	178-184
32944850-0	2020	Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Homo sapiens	59-64
32818511-0	2020	Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	58-62
32818511-0	2020	Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Mus musculus	63-68
32818511-3	2020	Ruxolitinib, a potent Janus kinase (JAK) 1 and 2 inhibitor, has been reported to significantly block the proliferation-related signaling pathway of JAK2/signal transducers and activators of transcription 3 (STAT3) and harbor a broad spectrum of anti-cancer activities, including proliferation inhibition, apoptosis induction, and anti-inflammation.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	22-48
32818511-3	2020	Ruxolitinib, a potent Janus kinase (JAK) 1 and 2 inhibitor, has been reported to significantly block the proliferation-related signaling pathway of JAK2/signal transducers and activators of transcription 3 (STAT3) and harbor a broad spectrum of anti-cancer activities, including proliferation inhibition, apoptosis induction, and anti-inflammation.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	148-152
32818511-3	2020	Ruxolitinib, a potent Janus kinase (JAK) 1 and 2 inhibitor, has been reported to significantly block the proliferation-related signaling pathway of JAK2/signal transducers and activators of transcription 3 (STAT3) and harbor a broad spectrum of anti-cancer activities, including proliferation inhibition, apoptosis induction, and anti-inflammation.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Mus musculus	207-212
32818511-10	2020	The JAK2/STAT3 signaling pathway involved in the effects of ruxolitinib on VSMCs was detected by western blotting with the specific pathway inhibitor AG490.	ruxolitinib	60-71	Janus kinase 2	Mus musculus	4-8
32818511-10	2020	The JAK2/STAT3 signaling pathway involved in the effects of ruxolitinib on VSMCs was detected by western blotting with the specific pathway inhibitor AG490.	ruxolitinib	60-71	signal transducer and activator of transcription 3	Mus musculus	9-14
32818511-11	2020	RESULTS: In vivo, ruxolitinib significantly decreased the ratio-of-intima ratio (I/M ratio) by inhibiting the expression of PCNA and cyclinD1 (p < 0.05).	ruxolitinib	18-29	proliferating cell nuclear antigen	Mus musculus	124-128
32818511-11	2020	RESULTS: In vivo, ruxolitinib significantly decreased the ratio-of-intima ratio (I/M ratio) by inhibiting the expression of PCNA and cyclinD1 (p < 0.05).	ruxolitinib	18-29	cyclin D1	Mus musculus	133-141
32818511-13	2020	In addition, ruxolitinib inhibited the PDGF-BB-induced activation of the JAK2/STAT3 signaling pathway and decreased the expression of proliferation related-proteins cyclinD1 and PCNA in VSMCs (p < 0.05).	ruxolitinib	13-24	Janus kinase 2	Mus musculus	73-77
32818511-13	2020	In addition, ruxolitinib inhibited the PDGF-BB-induced activation of the JAK2/STAT3 signaling pathway and decreased the expression of proliferation related-proteins cyclinD1 and PCNA in VSMCs (p < 0.05).	ruxolitinib	13-24	signal transducer and activator of transcription 3	Mus musculus	78-83
32818511-13	2020	In addition, ruxolitinib inhibited the PDGF-BB-induced activation of the JAK2/STAT3 signaling pathway and decreased the expression of proliferation related-proteins cyclinD1 and PCNA in VSMCs (p < 0.05).	ruxolitinib	13-24	cyclin D1	Mus musculus	165-173
32818511-13	2020	In addition, ruxolitinib inhibited the PDGF-BB-induced activation of the JAK2/STAT3 signaling pathway and decreased the expression of proliferation related-proteins cyclinD1 and PCNA in VSMCs (p < 0.05).	ruxolitinib	13-24	proliferating cell nuclear antigen	Mus musculus	178-182
32818511-14	2020	CONCLUSION: Our findings suggest that ruxolitinib inhibits VSMC proliferation in vivo and in vitro by suppressing the activation of the JAK2/STAT3 signaling pathway.	ruxolitinib	38-49	Janus kinase 2	Mus musculus	136-140
32818511-14	2020	CONCLUSION: Our findings suggest that ruxolitinib inhibits VSMC proliferation in vivo and in vitro by suppressing the activation of the JAK2/STAT3 signaling pathway.	ruxolitinib	38-49	signal transducer and activator of transcription 3	Mus musculus	141-146
33194542-0	2020	Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	116-120
33194542-0	2020	Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.	ruxolitinib	12-23	splicing factor 3b subunit 1	Homo sapiens	122-127
33194542-0	2020	Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.	ruxolitinib	12-23	tumor protein p53	Homo sapiens	132-136
33194706-3	2020	MS is treated with ruxolitinib, a selective JAK1 and JAK2 inhibitor.	ruxolitinib	19-30	Janus kinase 1	Homo sapiens	44-48
33194706-3	2020	MS is treated with ruxolitinib, a selective JAK1 and JAK2 inhibitor.	ruxolitinib	19-30	Janus kinase 2	Homo sapiens	53-57
33102814-9	2020	Furthermore, while JAK2 inhibition leads to decreased viability in SeAx cells (IC50 of 9.98 and 29.15 muM for AZD1480 and ruxolitinib respectively), both JAK1 and JAK3 do not.	ruxolitinib	122-133	Janus kinase 2	Homo sapiens	19-23
33102814-9	2020	Furthermore, while JAK2 inhibition leads to decreased viability in SeAx cells (IC50 of 9.98 and 29.15 muM for AZD1480 and ruxolitinib respectively), both JAK1 and JAK3 do not.	ruxolitinib	122-133	Janus kinase 1	Homo sapiens	154-158
33116596-0	2020	Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS.	ruxolitinib	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	163-167
33116596-3	2020	We reported a case of a JAK2-negative but KRAS-positive MDS/MPN-U patient treated with ruxolitinib plus decitabine.	ruxolitinib	87-98	Janus kinase 2	Homo sapiens	24-28
33116596-3	2020	We reported a case of a JAK2-negative but KRAS-positive MDS/MPN-U patient treated with ruxolitinib plus decitabine.	ruxolitinib	87-98	KRAS proto-oncogene, GTPase	Homo sapiens	42-46
32583904-5	2020	Most patients had CD4+ and/or CD8+ T-cells below the normal range; these reductions were related to the duration of ruxolitinib treatment.	ruxolitinib	116-127	CD4 molecule	Homo sapiens	18-21
32583904-5	2020	Most patients had CD4+ and/or CD8+ T-cells below the normal range; these reductions were related to the duration of ruxolitinib treatment.	ruxolitinib	116-127	CD8a molecule	Homo sapiens	30-33
32929154-5	2020	Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells.	ruxolitinib	60-71	Janus kinase 2	Mus musculus	43-47
32929154-5	2020	Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells.	ruxolitinib	60-71	erb-b2 receptor tyrosine kinase 2	Mus musculus	189-193
33230423-3	2020	Specifically, cancer therapeutics have been hypothesized to treat cytokine release syndrome in patients with COVID-19, and the JAK1/2 inhibitor, ruxolitinib, is currently being used in a Phase III trial to assess its efficacy.	ruxolitinib	145-156	Janus kinase 1	Homo sapiens	127-133
32962959-7	2021	MAIN RESULTS: Ruxolitinib impacted on a network composed of redox signaling-related genes, and DUOX1 and DUOX2 were identified as potential modulators of ruxolitinib response.	ruxolitinib	154-165	dual oxidase 1	Homo sapiens	95-100
32962959-7	2021	MAIN RESULTS: Ruxolitinib impacted on a network composed of redox signaling-related genes, and DUOX1 and DUOX2 were identified as potential modulators of ruxolitinib response.	ruxolitinib	154-165	dual oxidase 2	Homo sapiens	105-110
32962959-10	2021	DPI combined with ruxolitinib increased PARP1 cleavage in SET2 cells and potentiated ruxolitinib-reduced STAT3, STAT5 and S6 ribosomal protein in HEL cells.	ruxolitinib	18-29	poly(ADP-ribose) polymerase 1	Homo sapiens	40-45
32962959-10	2021	DPI combined with ruxolitinib increased PARP1 cleavage in SET2 cells and potentiated ruxolitinib-reduced STAT3, STAT5 and S6 ribosomal protein in HEL cells.	ruxolitinib	18-29	signal transducer and activator of transcription 3	Homo sapiens	105-110
32962959-10	2021	DPI combined with ruxolitinib increased PARP1 cleavage in SET2 cells and potentiated ruxolitinib-reduced STAT3, STAT5 and S6 ribosomal protein in HEL cells.	ruxolitinib	18-29	signal transducer and activator of transcription 5A	Homo sapiens	112-117
32962959-10	2021	DPI combined with ruxolitinib increased PARP1 cleavage in SET2 cells and potentiated ruxolitinib-reduced STAT3, STAT5 and S6 ribosomal protein in HEL cells.	ruxolitinib	85-96	signal transducer and activator of transcription 3	Homo sapiens	105-110
32962959-10	2021	DPI combined with ruxolitinib increased PARP1 cleavage in SET2 cells and potentiated ruxolitinib-reduced STAT3, STAT5 and S6 ribosomal protein in HEL cells.	ruxolitinib	85-96	signal transducer and activator of transcription 5A	Homo sapiens	112-117
33042272-9	2020	By contrast, pharmacological inhibition of JAK1/2 by ruxolitinib reversed paclitaxel resistance both in vitro and in vivo.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	43-49
32585295-4	2020	As many of the elevated cytokines signal through Janus kinase (JAK)1/JAK2, inhibition of these pathways with ruxolitinib has the potential to mitigate the COVID-19-associated cytokine storm and reduce mortality.	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	49-68
32585295-4	2020	As many of the elevated cytokines signal through Janus kinase (JAK)1/JAK2, inhibition of these pathways with ruxolitinib has the potential to mitigate the COVID-19-associated cytokine storm and reduce mortality.	ruxolitinib	109-120	Janus kinase 2	Homo sapiens	69-73
32629176-10	2020	Inhibition of JAK1 activity by ruxolitinib or knockdown of JAK1 expression by siRNA significantly inhibits TROY-induced STAT3 activation, GBM cell migration, and decreases resistance to temozolomide.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	14-18
32530039-5	2020	Notably, many cytokines that are elevated in HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in murine HLH models and humans with refractory disease.	ruxolitinib	105-116	Janus kinase 1	Mus musculus	88-94
32530039-5	2020	Notably, many cytokines that are elevated in HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in murine HLH models and humans with refractory disease.	ruxolitinib	118-121	Janus kinase 1	Mus musculus	88-94
32530039-9	2020	Upon exposure to RUX, this apoptotic potential is restored, thereby sensitizing CD8 T cells to DEX-induced apoptosis in vitro and significantly reducing tissue immunopathology and HLH disease manifestations in vivo.	ruxolitinib	17-20	CD8a molecule	Homo sapiens	80-83
32850921-6	2020	Methods: Ruxolitinib, a JAK1 and JAK2 inhibitor, has been successfully used to treat severe immune-mediated diseases, such as graft vs. host disease and Hemophagocytic lymphohistiocytosis.	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	24-28
32850921-6	2020	Methods: Ruxolitinib, a JAK1 and JAK2 inhibitor, has been successfully used to treat severe immune-mediated diseases, such as graft vs. host disease and Hemophagocytic lymphohistiocytosis.	ruxolitinib	9-20	Janus kinase 2	Homo sapiens	33-37
32562787-10	2020	Based on these in vitro results, we also explored the effects of JAK2/1 inhibition by ruxolitinib in vivo, on mouse macrophages in a model of HOCl-induced ILD, that mimics scleroderma-associated ILD.	ruxolitinib	86-97	Janus kinase 2	Mus musculus	65-71
32562787-11	2020	In this model, we showed that ruxolitinib significantly prevented the upregulation of pro-inflammatory M1 markers (TNFalpha, CXCL10, NOS2) and pro-fibrotic M2 markers (Arg1 and Chi3L3).	ruxolitinib	30-41	tumor necrosis factor	Homo sapiens	115-123
32562787-11	2020	In this model, we showed that ruxolitinib significantly prevented the upregulation of pro-inflammatory M1 markers (TNFalpha, CXCL10, NOS2) and pro-fibrotic M2 markers (Arg1 and Chi3L3).	ruxolitinib	30-41	C-X-C motif chemokine ligand 10	Homo sapiens	125-131
32562787-11	2020	In this model, we showed that ruxolitinib significantly prevented the upregulation of pro-inflammatory M1 markers (TNFalpha, CXCL10, NOS2) and pro-fibrotic M2 markers (Arg1 and Chi3L3).	ruxolitinib	30-41	nitric oxide synthase 2	Homo sapiens	133-137
32562787-11	2020	In this model, we showed that ruxolitinib significantly prevented the upregulation of pro-inflammatory M1 markers (TNFalpha, CXCL10, NOS2) and pro-fibrotic M2 markers (Arg1 and Chi3L3).	ruxolitinib	30-41	arginase 1	Homo sapiens	168-172
32180118-0	2020	Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	85-90
32180118-2	2020	We report the effect of oral ruxolitinib, an inhibitor of Janus kinase (JAK) family tyrosine kinases, on the clinical and immune status of a 3-year-old male with steroid-dependent severe autoimmunity due to a STAT1 GOF T385M mutation.	ruxolitinib	29-40	signal transducer and activator of transcription 1	Homo sapiens	209-214
32180118-10	2020	We report the potential of JAK1/2 inhibition with ruxolitinib for both CMC and steroid-dependent autoimmunity.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	27-31
32758351-6	2020	Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	23-27
32758351-6	2020	Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells.	ruxolitinib	55-66	signal transducer and activator of transcription 3	Homo sapiens	112-117
32758351-6	2020	Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells.	ruxolitinib	55-66	signal transducer and activator of transcription 1	Homo sapiens	144-149
32758351-6	2020	Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	195-199
32698510-11	2020	Ruxolitinib activated several molecules in the Wnt/beta-catenin signaling pathway, including Lef1 and beta-catenin, and suppressed the transcription of DKK1 in hDPCs, but not its translation.	ruxolitinib	0-11	catenin beta 1	Homo sapiens	51-63
32698510-11	2020	Ruxolitinib activated several molecules in the Wnt/beta-catenin signaling pathway, including Lef1 and beta-catenin, and suppressed the transcription of DKK1 in hDPCs, but not its translation.	ruxolitinib	0-11	lymphoid enhancer binding factor 1	Homo sapiens	93-97
32698510-11	2020	Ruxolitinib activated several molecules in the Wnt/beta-catenin signaling pathway, including Lef1 and beta-catenin, and suppressed the transcription of DKK1 in hDPCs, but not its translation.	ruxolitinib	0-11	catenin beta 1	Homo sapiens	102-114
32698510-11	2020	Ruxolitinib activated several molecules in the Wnt/beta-catenin signaling pathway, including Lef1 and beta-catenin, and suppressed the transcription of DKK1 in hDPCs, but not its translation.	ruxolitinib	0-11	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	152-156
32698510-12	2020	Ruxolitinib reverted IFN-gamma-induced expression of caspase-1, IL-1beta, IL-15, and IL-18, and stimulated several growth factors, such as FGF7.	ruxolitinib	0-11	interferon gamma	Homo sapiens	21-30
32698510-12	2020	Ruxolitinib reverted IFN-gamma-induced expression of caspase-1, IL-1beta, IL-15, and IL-18, and stimulated several growth factors, such as FGF7.	ruxolitinib	0-11	caspase 1	Homo sapiens	53-62
32698510-12	2020	Ruxolitinib reverted IFN-gamma-induced expression of caspase-1, IL-1beta, IL-15, and IL-18, and stimulated several growth factors, such as FGF7.	ruxolitinib	0-11	interleukin 1 alpha	Homo sapiens	64-72
32698510-12	2020	Ruxolitinib reverted IFN-gamma-induced expression of caspase-1, IL-1beta, IL-15, and IL-18, and stimulated several growth factors, such as FGF7.	ruxolitinib	0-11	interleukin 15	Homo sapiens	74-79
32698510-12	2020	Ruxolitinib reverted IFN-gamma-induced expression of caspase-1, IL-1beta, IL-15, and IL-18, and stimulated several growth factors, such as FGF7.	ruxolitinib	0-11	interleukin 18	Homo sapiens	85-90
32698510-12	2020	Ruxolitinib reverted IFN-gamma-induced expression of caspase-1, IL-1beta, IL-15, and IL-18, and stimulated several growth factors, such as FGF7.	ruxolitinib	0-11	fibroblast growth factor 7	Homo sapiens	139-143
32698510-13	2020	Ruxolitinib suppressed the phosphorylation of JAK1, JAK2 and JAK3, and STAT1 and 3 compared to IFN-gamma pretreated hDPCs.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	46-50
32698510-13	2020	Ruxolitinib suppressed the phosphorylation of JAK1, JAK2 and JAK3, and STAT1 and 3 compared to IFN-gamma pretreated hDPCs.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	52-56
32698510-13	2020	Ruxolitinib suppressed the phosphorylation of JAK1, JAK2 and JAK3, and STAT1 and 3 compared to IFN-gamma pretreated hDPCs.	ruxolitinib	0-11	Janus kinase 3	Homo sapiens	61-65
32698510-13	2020	Ruxolitinib suppressed the phosphorylation of JAK1, JAK2 and JAK3, and STAT1 and 3 compared to IFN-gamma pretreated hDPCs.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	71-82
32698510-14	2020	Ruxolitinib pretreatment showed a protective effect on IFN-gamma-induced expression of MHC-class II molecules in cultured hair follicles.	ruxolitinib	0-11	interferon gamma	Homo sapiens	55-64
32698510-15	2020	In conclusion, ruxolitinib modulated and reverted the interferon-induced inflammatory changes by blocking the JAK-STAT pathway in hDPCs under an AA-like environment.	ruxolitinib	15-26	signal transducer and activator of transcription 1	Homo sapiens	114-118
32698510-16	2020	Ruxolitinib directly stimulated anagen-re-entry signals in hDPCs by affecting the Wnt/beta-catenin pathway and promoting growth factors in hDPCs.	ruxolitinib	0-11	catenin beta 1	Homo sapiens	86-98
32698510-17	2020	Ruxolitinib treatment prevented IFN-gamma-induced collapse of hair-follicle immune privilege.	ruxolitinib	0-11	interferon gamma	Homo sapiens	32-41
32614965-7	2020	Inhibition of JAK/STAT signaling using the selective JAK1/2 inhibitor ruxolitinib resulted in significant antileukemic activity in AML in vitro which is mediated through both cell-autonomous and microenvironment-mediated mechanisms.	ruxolitinib	70-81	Janus kinase 1	Homo sapiens	53-59
32660441-10	2020	Because of a detected CSF3R (p.T618I) mutation and constitutional symptoms treatment with ruxolitinib was initiated.	ruxolitinib	90-101	colony stimulating factor 3 receptor	Homo sapiens	22-27
32660441-13	2020	Molecular work-up revealed that under ruxolitinib treatment, the CSF3R clone was depleted, yet the expansion of a NRAS mutated subclone was promoted.	ruxolitinib	38-49	colony stimulating factor 3 receptor	Homo sapiens	65-70
32660441-13	2020	Molecular work-up revealed that under ruxolitinib treatment, the CSF3R clone was depleted, yet the expansion of a NRAS mutated subclone was promoted.	ruxolitinib	38-49	NRAS proto-oncogene, GTPase	Homo sapiens	114-118
32279331-1	2020	We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n=8; BCR-JAK2, n=1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n=9).	ruxolitinib	139-150	pericentriolar material 1	Homo sapiens	152-156
32279331-1	2020	We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n=8; BCR-JAK2, n=1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n=9).	ruxolitinib	139-150	Janus kinase 2	Homo sapiens	157-161
32417942-3	2020	JAK 1/2 inhibitors, such as ruxolitinib and fedratinib, are the mainstay of therapy and produce significant and durable reductions in spleen volume.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	0-7
32676080-11	2020	(v) Ruxolitinib, a selective JAK-1/2 inhibitor, attenuated SAg-induced T cell activation, cytokine production, and small bowel pathology, thereby completely protecting from lethal CRS in both WT and IL-17A deficient HLA-DR3 mice.	ruxolitinib	4-15	Janus kinase 1	Mus musculus	29-36
32676080-11	2020	(v) Ruxolitinib, a selective JAK-1/2 inhibitor, attenuated SAg-induced T cell activation, cytokine production, and small bowel pathology, thereby completely protecting from lethal CRS in both WT and IL-17A deficient HLA-DR3 mice.	ruxolitinib	4-15	interleukin 17A	Mus musculus	199-205
32560455-8	2020	Next, we tested IL89"s sensitivity to the JAK inhibitor ruxolitinib and observed a potent anti-tumor effect, both in vitro and in vivo.	ruxolitinib	56-67	Janus kinase 1	Homo sapiens	42-45
32198525-5	2020	Until the recent approval of fedratinib, a JAK2 inhibitor, ruxolitinib was the only available JAK inhibitor for treatment of intermediate- or high-risk myelofibrosis.	ruxolitinib	59-70	Janus kinase 2	Homo sapiens	43-47
31227936-2	2020	Although JAK2 inhibitors such as ruxolitinib have been shown to be clinically efficacious, the hematological toxicity and eventual drug resistance limit its use as monotherapy.	ruxolitinib	33-44	Janus kinase 2	Homo sapiens	9-13
32330554-7	2020	The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway inhibitor ruxolitinib effectively suppressed the effects of LINC00691.	ruxolitinib	106-117	Janus kinase 2	Homo sapiens	67-70
32330554-7	2020	The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway inhibitor ruxolitinib effectively suppressed the effects of LINC00691.	ruxolitinib	106-117	signal transducer and activator of transcription 3	Homo sapiens	71-75
32330554-7	2020	The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway inhibitor ruxolitinib effectively suppressed the effects of LINC00691.	ruxolitinib	106-117	long intergenic non-protein coding RNA 691	Homo sapiens	156-165
31227936-7	2020	Cotreatment with ruxolitinib and vorinostat synergistically induced apoptosis, cell cycle arrest and inhibition of the colony-forming capacity of HEL cells by attenuating the JAK/signal transducer and activator of transcription (STAT) and protein kinase-B (AKT) signaling pathways.	ruxolitinib	17-28	protein tyrosine kinase 2 beta	Homo sapiens	239-255
31227936-7	2020	Cotreatment with ruxolitinib and vorinostat synergistically induced apoptosis, cell cycle arrest and inhibition of the colony-forming capacity of HEL cells by attenuating the JAK/signal transducer and activator of transcription (STAT) and protein kinase-B (AKT) signaling pathways.	ruxolitinib	17-28	AKT serine/threonine kinase 1	Homo sapiens	257-260
32057960-7	2020	42.5% of patients who applied 1.5% RUX BID experienced minimal clinically important difference in itch within 36 hours of treatment (vehicle, 13.6%; P&lt;0.01); near-maximal improvement was observed by Week 4.	ruxolitinib	35-38	BH3 interacting domain death agonist	Homo sapiens	39-42
31575356-2	2020	Three publications reported success with ruxolitinib, a Janus-associated kinase (JAK1/2) inhibitor.	ruxolitinib	41-52	Janus kinase 1	Homo sapiens	81-87
32234672-6	2020	IL-22 was next found to activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway, whose inhibition by the JAK inhibitor ruxolitinib fully prevented the IL-22-mediated CYP3A4, CYP2B6 and NTCP repression in HepaRG cells.	ruxolitinib	161-172	interleukin 22	Homo sapiens	0-5
32234672-6	2020	IL-22 was next found to activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway, whose inhibition by the JAK inhibitor ruxolitinib fully prevented the IL-22-mediated CYP3A4, CYP2B6 and NTCP repression in HepaRG cells.	ruxolitinib	161-172	signal transducer and activator of transcription 3	Homo sapiens	56-113
32234672-6	2020	IL-22 was next found to activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway, whose inhibition by the JAK inhibitor ruxolitinib fully prevented the IL-22-mediated CYP3A4, CYP2B6 and NTCP repression in HepaRG cells.	ruxolitinib	161-172	interleukin 22	Homo sapiens	193-198
32234672-6	2020	IL-22 was next found to activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway, whose inhibition by the JAK inhibitor ruxolitinib fully prevented the IL-22-mediated CYP3A4, CYP2B6 and NTCP repression in HepaRG cells.	ruxolitinib	161-172	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	208-214
32234672-6	2020	IL-22 was next found to activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway, whose inhibition by the JAK inhibitor ruxolitinib fully prevented the IL-22-mediated CYP3A4, CYP2B6 and NTCP repression in HepaRG cells.	ruxolitinib	161-172	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	216-222
32234672-6	2020	IL-22 was next found to activate the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) 3 pathway, whose inhibition by the JAK inhibitor ruxolitinib fully prevented the IL-22-mediated CYP3A4, CYP2B6 and NTCP repression in HepaRG cells.	ruxolitinib	161-172	solute carrier family 10 member 1	Homo sapiens	227-231
32127173-5	2020	Mechanistically, IL-4 treatment increased insulin-stimulated glucose uptake and Akt phosphorylation in skeletal muscle C2C12 cells, and inhibition of IL-4 signaling via ruxolitinib, a Janus kinase (JAK) inhibitor, attenuated IL-4-induced insulin sensitivity.	ruxolitinib	169-180	interleukin 4	Mus musculus	150-154
32127173-5	2020	Mechanistically, IL-4 treatment increased insulin-stimulated glucose uptake and Akt phosphorylation in skeletal muscle C2C12 cells, and inhibition of IL-4 signaling via ruxolitinib, a Janus kinase (JAK) inhibitor, attenuated IL-4-induced insulin sensitivity.	ruxolitinib	169-180	interleukin 4	Mus musculus	150-154
32320566-2	2020	In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD.	ruxolitinib	20-31	Janus kinase 1	Homo sapiens	59-63
32320566-2	2020	In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD.	ruxolitinib	20-31	Janus kinase 2	Homo sapiens	68-72
32411769-1	2020	Background: Ruxolitinib is an inhibitor of Janus kinases (JAK) 1/2.	ruxolitinib	12-23	Janus kinase 1	Mus musculus	43-66
32318300-6	2020	We present a case of a 32-year-old male on ruxolitinib with GVHD status postmatched unrelated donor stem cell transplant (MUD SCT) for acute myeloid leukemia (AML) with FLT3 mutation currently on ruxolitinib for 5 years who is not able to tolerate reduction in dosage due to flare-ups.	ruxolitinib	43-54	fms related receptor tyrosine kinase 3	Homo sapiens	169-173
32196928-0	2020	The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
32196928-5	2020	Here, we show that JAK1/2 inhibition with ruxolitinib rescues progerin-induced cell cycle arrest, cellular senescence, and misshapen nuclei in human normal fibroblasts expressing progerin.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	19-23
31843590-15	2020	Addition of IL22 to cultured acinar cells increased their expression of markers of ductal metaplasia; these effects of IL22 were prevented with inhibitors of JAK signaling to STAT (ruxolitinib) or MEK (trametinib) and with STAT3 knockdown.	ruxolitinib	181-192	interleukin 22	Mus musculus	12-16
31843590-15	2020	Addition of IL22 to cultured acinar cells increased their expression of markers of ductal metaplasia; these effects of IL22 were prevented with inhibitors of JAK signaling to STAT (ruxolitinib) or MEK (trametinib) and with STAT3 knockdown.	ruxolitinib	181-192	interleukin 22	Mus musculus	119-123
31843590-17	2020	Incubation of IL22R-expressing PDAC cells with IL22 promoted spheroid formation and invasive activity, resulted increased expression of stem-associated transcription factors (GATA4, SOX2, SOX17, and NANOG), and increased markers of the epithelial-mesenchymal transition (CDH1, SNAI2, TWIST1, and beta catenin); ruxolitinib blocked these effects.	ruxolitinib	311-322	interleukin 22 receptor, alpha 1	Mus musculus	14-19
31843590-17	2020	Incubation of IL22R-expressing PDAC cells with IL22 promoted spheroid formation and invasive activity, resulted increased expression of stem-associated transcription factors (GATA4, SOX2, SOX17, and NANOG), and increased markers of the epithelial-mesenchymal transition (CDH1, SNAI2, TWIST1, and beta catenin); ruxolitinib blocked these effects.	ruxolitinib	311-322	interleukin 22	Mus musculus	14-18
31562605-5	2020	Molecular docking of FA showed promising Janus kinase 2 (JAK2) inhibition with a docking score of - 6.7, which is comparable with that of ruxolitinib, a standard inhibitor.	ruxolitinib	138-149	Janus kinase 2	Rattus norvegicus	41-55
31562605-5	2020	Molecular docking of FA showed promising Janus kinase 2 (JAK2) inhibition with a docking score of - 6.7, which is comparable with that of ruxolitinib, a standard inhibitor.	ruxolitinib	138-149	Janus kinase 2	Rattus norvegicus	57-61
31880950-2	2020	We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	49-55
31732720-0	2020	Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.	ruxolitinib	20-31	Janus kinase 2	Mus musculus	63-67
31732720-4	2020	Whereas ruxolitinib inhibits Stat5 activation in erythroid progenitor populations, it fails to inhibit this same pathway in HSCs.	ruxolitinib	8-19	signal transducer and activator of transcription 5A	Mus musculus	29-34
31286322-0	2020	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells.	ruxolitinib	33-44	Janus kinase 2	Homo sapiens	66-70
31286322-2	2020	We hypothesized that selective inhibition of JAK1/2 by ruxolitinib could induce autophagy and limit drug efficacy in myeloproliferative neoplasms (MPN).	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	45-49
31286322-4	2020	In SET2 JAK2V617F cells, ruxolitinib treatment induced autophagy and modulated 26 out of 79 autophagy-related genes.	ruxolitinib	25-36	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	3-7
31286322-5	2020	Ruxolitinib treatment reduced the expressions of important autophagy regulators, including mTOR/p70S6K/4EBP1 and the STAT/BCL2 axis, in a dose- and time-dependent manner.	ruxolitinib	0-11	mechanistic target of rapamycin kinase	Homo sapiens	91-95
31286322-5	2020	Ruxolitinib treatment reduced the expressions of important autophagy regulators, including mTOR/p70S6K/4EBP1 and the STAT/BCL2 axis, in a dose- and time-dependent manner.	ruxolitinib	0-11	BCL2 apoptosis regulator	Homo sapiens	122-126
31286322-8	2020	In conclusion, ruxolitinib induces autophagy in JAK2V617F cells, potentially by modulation of mTOR-, STAT- and BCL2-mediated signaling.	ruxolitinib	15-26	mechanistic target of rapamycin kinase	Homo sapiens	94-98
31286322-8	2020	In conclusion, ruxolitinib induces autophagy in JAK2V617F cells, potentially by modulation of mTOR-, STAT- and BCL2-mediated signaling.	ruxolitinib	15-26	BCL2 apoptosis regulator	Homo sapiens	111-115
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	9-20	nitric oxide synthase 2, inducible	Mus musculus	70-101
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	9-20	nitric oxide synthase 2, inducible	Mus musculus	103-107
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	9-20	tumor necrosis factor	Mus musculus	110-119
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	9-20	interleukin 6	Mus musculus	125-129
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	158-169	nitric oxide synthase 2, inducible	Mus musculus	70-101
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	158-169	tumor necrosis factor	Mus musculus	110-119
32411769-9	2020	Results: Ruxolitinib was found to significantly reduce NO production, inducible nitric oxide synthase (iNOS), TNF-alpha, and IL-6 expression, suggesting that ruxolitinib blocks LPS signaling that leads to pro-inflammatory factor expression.	ruxolitinib	158-169	interleukin 6	Mus musculus	125-129
32411769-11	2020	The results taken together indicate that ruxolitinib can significantly suppress LPS-stimulated NO production and improve the survival of septic mice, perhaps by interfering with the NF-kappaB pathway.	ruxolitinib	41-52	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	182-191
31992541-9	2020	Patient-derived organoids (PDOs) obtained from tumors with high AXL and JAK1 were sensitive to TP-0903 and ruxolitinib (JAK inhibitor) treatments supporting the CyTOF findings.	ruxolitinib	107-118	AXL receptor tyrosine kinase	Homo sapiens	64-67
31992541-9	2020	Patient-derived organoids (PDOs) obtained from tumors with high AXL and JAK1 were sensitive to TP-0903 and ruxolitinib (JAK inhibitor) treatments supporting the CyTOF findings.	ruxolitinib	107-118	Janus kinase 1	Homo sapiens	72-76
32034662-3	2020	Other currently available therapies include pegylated interferon alfa-2a and the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	98-109	Janus kinase 1	Homo sapiens	81-87
32153201-1	2020	Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas Covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD.	ruxolitinib	14-25	Janus kinase 1	Homo sapiens	47-51
32153201-1	2020	Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas Covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD.	ruxolitinib	14-25	Janus kinase 2	Homo sapiens	52-56
32153201-1	2020	Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas Covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD.	ruxolitinib	14-25	Janus kinase 1	Homo sapiens	324-328
32153201-1	2020	Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas Covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD.	ruxolitinib	14-25	Janus kinase 2	Homo sapiens	329-333
32153201-3	2020	Based on the data from the REACH1 trial, ruxolitinib was approved by the FDA in May 2019 for SR acute GVHD in adult and pediatric patients 12 years and older.Expert Opinion: Ruxolitinib and other JAK1/JAK2 inhibitors hold promise in other treatment settings such as GVHD prevention and/or first line therapy.	ruxolitinib	41-52	Janus kinase 1	Homo sapiens	196-200
32153201-3	2020	Based on the data from the REACH1 trial, ruxolitinib was approved by the FDA in May 2019 for SR acute GVHD in adult and pediatric patients 12 years and older.Expert Opinion: Ruxolitinib and other JAK1/JAK2 inhibitors hold promise in other treatment settings such as GVHD prevention and/or first line therapy.	ruxolitinib	41-52	Janus kinase 2	Homo sapiens	201-205
31732720-8	2020	This work provides a mechanistic rationale informing how pegylated IFN-alpha reduces JAK2V617F allelic burden in the clinical setting and may inform future clinical efforts to combine ruxolitinib with pegylated IFN-alpha in patients with MPN.	ruxolitinib	184-195	interferon alpha 1	Homo sapiens	67-76
31732720-8	2020	This work provides a mechanistic rationale informing how pegylated IFN-alpha reduces JAK2V617F allelic burden in the clinical setting and may inform future clinical efforts to combine ruxolitinib with pegylated IFN-alpha in patients with MPN.	ruxolitinib	184-195	Janus kinase 2	Homo sapiens	85-89
32123064-10	2020	In vivo studies showed that blocking of the GHRH-R/JAK2/STAT3 axis with the JAK inhibitor Ruxolitinib alleviated partially the LPS-induced acute ocular inflammation by reducing inflammatory cells and protein leakage in the aqueous humor and by repressing expression of STAT3 target genes in rat ciliary body and iris and in human ciliary epithelial cells.	ruxolitinib	90-101	growth hormone releasing hormone receptor	Rattus norvegicus	44-50
32296013-11	2020	Moreover, a similar antitumor effect was observed for DCZ0858 and the JAK2 inhibitor ruxolitinib, and combining the two could significantly enhance cancer-suppressive signaling.	ruxolitinib	85-96	Janus kinase 2	Homo sapiens	70-74
32196489-9	2020	Blockade of IL-6 signaling with IL-6 receptor antibody and JAK inhibitor (Ruxolitinib) inhibited M2 polarization of THP-1-derived macrophages and proliferation of the macrophages.	ruxolitinib	74-85	interleukin 6	Homo sapiens	12-16
32196489-9	2020	Blockade of IL-6 signaling with IL-6 receptor antibody and JAK inhibitor (Ruxolitinib) inhibited M2 polarization of THP-1-derived macrophages and proliferation of the macrophages.	ruxolitinib	74-85	GLI family zinc finger 2	Homo sapiens	116-121
32047890-0	2020	Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3.	ruxolitinib	0-11	leptin	Homo sapiens	46-52
32047890-0	2020	Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	80-84
32047890-0	2020	Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Homo sapiens	85-90
32201152-4	2021	The only and curative option for PMF is allogeneic hematopoietic stem cell transplant (allo-HSCT); however, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib is highly effective in reducing constitutional symptoms and spleen volume, and has been found to improve survival.	ruxolitinib	145-156	Janus kinase 1	Homo sapiens	112-132
32201152-5	2021	Ruxolitinib decreases the activity of type I T-helper cells, leading to decreased release of cytokines including tumor necrosis factor-alpha, interleukin-1 (IL-1), IL-6, interferon-gamma, and production of IL-12, which can be a risk factor for opportunistic infections.	ruxolitinib	0-11	interleukin 6	Homo sapiens	164-168
32201152-5	2021	Ruxolitinib decreases the activity of type I T-helper cells, leading to decreased release of cytokines including tumor necrosis factor-alpha, interleukin-1 (IL-1), IL-6, interferon-gamma, and production of IL-12, which can be a risk factor for opportunistic infections.	ruxolitinib	0-11	interferon gamma	Homo sapiens	170-186
31968212-8	2020	Inhibitors of the Janus tyrosine kinase (JAK)-STAT pathway (ruxolitinib and tofacitinib) suppressed the uptake of Ac-LDL and the expression of both CD36 and CD204 in LPS-activated macrophages.	ruxolitinib	60-71	signal transducer and activator of transcription 1	Mus musculus	46-50
32169038-10	2020	Ruxolitinib, an inhibitor of the Janus kinase 2 (JAK2), substantially reduced the area of atherosclerotic plaques in rabbits treated with high fat diet and balloon injury of the aorta.	ruxolitinib	0-11	tyrosine-protein kinase JAK2	Oryctolagus cuniculus	33-47
32169038-10	2020	Ruxolitinib, an inhibitor of the Janus kinase 2 (JAK2), substantially reduced the area of atherosclerotic plaques in rabbits treated with high fat diet and balloon injury of the aorta.	ruxolitinib	0-11	tyrosine-protein kinase JAK2	Oryctolagus cuniculus	49-53
32169038-11	2020	Moreover, ruxolitinib significantly decreased IL-6, IL-1beta, IFN-gamma and TNF-alpha, but increased IL-10 and IL-17 levels in plasma of atherosclerotic rabbits.	ruxolitinib	10-21	interleukin-6	Oryctolagus cuniculus	46-50
32169038-11	2020	Moreover, ruxolitinib significantly decreased IL-6, IL-1beta, IFN-gamma and TNF-alpha, but increased IL-10 and IL-17 levels in plasma of atherosclerotic rabbits.	ruxolitinib	10-21	interleukin-1 alpha	Oryctolagus cuniculus	52-60
32169038-11	2020	Moreover, ruxolitinib significantly decreased IL-6, IL-1beta, IFN-gamma and TNF-alpha, but increased IL-10 and IL-17 levels in plasma of atherosclerotic rabbits.	ruxolitinib	10-21	interferon gamma	Oryctolagus cuniculus	62-71
32169038-11	2020	Moreover, ruxolitinib significantly decreased IL-6, IL-1beta, IFN-gamma and TNF-alpha, but increased IL-10 and IL-17 levels in plasma of atherosclerotic rabbits.	ruxolitinib	10-21	tumor necrosis factor	Oryctolagus cuniculus	76-85
32169038-11	2020	Moreover, ruxolitinib significantly decreased IL-6, IL-1beta, IFN-gamma and TNF-alpha, but increased IL-10 and IL-17 levels in plasma of atherosclerotic rabbits.	ruxolitinib	10-21	interleukin-10	Oryctolagus cuniculus	101-106
32169038-14	2020	Interestingly, ruxolitinib could inactivate JAK2 and STAT3 pathway and decrease SOCS3 expression.	ruxolitinib	15-26	tyrosine-protein kinase JAK2	Oryctolagus cuniculus	44-48
32169038-14	2020	Interestingly, ruxolitinib could inactivate JAK2 and STAT3 pathway and decrease SOCS3 expression.	ruxolitinib	15-26	signal transducer and activator of transcription 3	Oryctolagus cuniculus	53-58
32169038-14	2020	Interestingly, ruxolitinib could inactivate JAK2 and STAT3 pathway and decrease SOCS3 expression.	ruxolitinib	15-26	suppressor of cytokine signaling 3	Oryctolagus cuniculus	80-85
32123064-10	2020	In vivo studies showed that blocking of the GHRH-R/JAK2/STAT3 axis with the JAK inhibitor Ruxolitinib alleviated partially the LPS-induced acute ocular inflammation by reducing inflammatory cells and protein leakage in the aqueous humor and by repressing expression of STAT3 target genes in rat ciliary body and iris and in human ciliary epithelial cells.	ruxolitinib	90-101	Janus kinase 2	Rattus norvegicus	51-55
32123064-10	2020	In vivo studies showed that blocking of the GHRH-R/JAK2/STAT3 axis with the JAK inhibitor Ruxolitinib alleviated partially the LPS-induced acute ocular inflammation by reducing inflammatory cells and protein leakage in the aqueous humor and by repressing expression of STAT3 target genes in rat ciliary body and iris and in human ciliary epithelial cells.	ruxolitinib	90-101	signal transducer and activator of transcription 3	Rattus norvegicus	56-61
32123064-10	2020	In vivo studies showed that blocking of the GHRH-R/JAK2/STAT3 axis with the JAK inhibitor Ruxolitinib alleviated partially the LPS-induced acute ocular inflammation by reducing inflammatory cells and protein leakage in the aqueous humor and by repressing expression of STAT3 target genes in rat ciliary body and iris and in human ciliary epithelial cells.	ruxolitinib	90-101	signal transducer and activator of transcription 3	Rattus norvegicus	269-274
31837586-10	2020	Antagonism of JAK/STAT3 by ruxolitinib abrogated benefits in ATM pathway-mediated DNA repair; and identification of the ruxolitinib-sensitive component of cytoprotection allowed separations of these pathway intersections.	ruxolitinib	27-38	signal transducer and activator of transcription 3	Homo sapiens	18-23
31885183-0	2020	Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.	ruxolitinib	138-149	RNA binding region (RNP1, RRM) containing 3	Homo sapiens	18-23
32022429-0	2020	LPS-induced inflammation desensitizes hepatocytes to Fas-induced apoptosis through Stat3 activation-The effect can be reversed by ruxolitinib.	ruxolitinib	130-141	signal transducer and activator of transcription 3	Homo sapiens	83-88
32022429-6	2020	Pre-treatment with ruxolitinib, a selective Janus kinase (JAK) 1/2 inhibitor, prevented the LPS-induced Stat3 phosphorylation and restored the sensitivity of hepatocytes to Fas-mediated apoptosis.	ruxolitinib	19-30	Janus kinase 1	Homo sapiens	44-66
32022429-6	2020	Pre-treatment with ruxolitinib, a selective Janus kinase (JAK) 1/2 inhibitor, prevented the LPS-induced Stat3 phosphorylation and restored the sensitivity of hepatocytes to Fas-mediated apoptosis.	ruxolitinib	19-30	signal transducer and activator of transcription 3	Homo sapiens	104-109
32022429-7	2020	Furthermore, ruxolitinib pre-treatment diminished the LPS-induced Bcl-xL up-regulation without an inhibitory effect on LPS-induced expression of pro-inflammatory cytokines.	ruxolitinib	13-24	BCL2 like 1	Homo sapiens	66-72
31711337-1	2020	Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-23
31885183-0	2020	Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.	ruxolitinib	138-149	Janus kinase 2	Homo sapiens	35-39
31697835-3	2020	Both receptors could be expressed in human T lymphocytes; Epo ligation induced STAT5 phosphorylation, which was abrogated by nontoxic concentrations of the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	173-184	erythropoietin	Homo sapiens	58-61
31629805-0	2020	Treatment of Atopic Dermatitis With Ruxolitinib Cream (JAK1/JAK2 Inhibitor) or Triamcinolone Cream.	ruxolitinib	36-47	Janus kinase 1	Homo sapiens	55-59
31629805-0	2020	Treatment of Atopic Dermatitis With Ruxolitinib Cream (JAK1/JAK2 Inhibitor) or Triamcinolone Cream.	ruxolitinib	36-47	Janus kinase 2	Homo sapiens	60-64
31629805-2	2020	Ruxolitinib, a selective inhibitor of Janus kinase (JAK)-1 and JAK2, potently suppresses cytokine signaling involved in AD pathogenesis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-58
31629805-2	2020	Ruxolitinib, a selective inhibitor of Janus kinase (JAK)-1 and JAK2, potently suppresses cytokine signaling involved in AD pathogenesis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	63-67
31123029-9	2020	JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and Ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive peripheral T-cell lymphoma development, defining both STAT5 molecules as targets for therapeutic intervention.	ruxolitinib	80-91	signal transducer and activator of transcription 5A	Mus musculus	30-35
31123029-9	2020	JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and Ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive peripheral T-cell lymphoma development, defining both STAT5 molecules as targets for therapeutic intervention.	ruxolitinib	80-91	signal transducer and activator of transcription 5A	Mus musculus	151-157
31123029-9	2020	JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and Ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive peripheral T-cell lymphoma development, defining both STAT5 molecules as targets for therapeutic intervention.	ruxolitinib	80-91	signal transducer and activator of transcription 5B	Mus musculus	161-167
31123029-9	2020	JAK inhibitors or a selective STAT5 SH2 domain inhibitor induced cell death and Ruxolitinib blocked T-cell neoplasia in vivo We conclude that enhanced STAT5A or STAT5B action both drive peripheral T-cell lymphoma development, defining both STAT5 molecules as targets for therapeutic intervention.	ruxolitinib	80-91	signal transducer and activator of transcription 5A	Mus musculus	151-156
31941838-3	2020	Among MF patients who were treated with the JAK inhibitor ruxolitinib, we compared noncoding RNA profiles of ruxolitinib therapy responders versus nonresponders and found miR-543 was significantly upregulated in nonresponders.	ruxolitinib	58-69	microRNA 543	Homo sapiens	171-178
31941838-3	2020	Among MF patients who were treated with the JAK inhibitor ruxolitinib, we compared noncoding RNA profiles of ruxolitinib therapy responders versus nonresponders and found miR-543 was significantly upregulated in nonresponders.	ruxolitinib	109-120	microRNA 543	Homo sapiens	171-178
31941838-9	2020	Furthermore, miR-543 upregulation promotes the expression of genes related to drug metabolism, including CYP3A4, which is involved in ruxolitinib metabolism.	ruxolitinib	134-145	microRNA 543	Homo sapiens	13-20
31941838-9	2020	Furthermore, miR-543 upregulation promotes the expression of genes related to drug metabolism, including CYP3A4, which is involved in ruxolitinib metabolism.	ruxolitinib	134-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
31534088-3	2020	We describe the case of a patient with MF-associated PH who developed left ventricular dysfunction after five years of treatment with the JAK 1/2 inhibitor, ruxolitinib.	ruxolitinib	157-168	Janus kinase 1	Homo sapiens	138-145
31982039-2	2020	Ruxolitinib, a JAK 1 and JAK 2 inhibitor, showed superiority over best available therapy in a phase 2 study in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-20
31982039-2	2020	Ruxolitinib, a JAK 1 and JAK 2 inhibitor, showed superiority over best available therapy in a phase 2 study in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	25-30
32050632-0	2020	Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells.	ruxolitinib	119-130	ubiquitin specific peptidase 9 X-linked	Homo sapiens	14-19
32050632-0	2020	Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells.	ruxolitinib	119-130	Janus kinase 2	Homo sapiens	142-146
32050632-2	2020	However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells.	ruxolitinib	23-34	Janus kinase 2	Homo sapiens	128-132
32050632-2	2020	However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells.	ruxolitinib	88-99	Janus kinase 2	Homo sapiens	128-132
32050632-7	2020	Although autophosphorylated JAK2-V617F was resistant to WP1130 in the ruxolitinib-persistent HEL-R cells, these cells expressed Bcl-2 and Bcl-xL at lower levels and showed an increased sensitivity to WP1130 as well as BH3 mimetics as compared with ruxolitinib-naive HEL cells.	ruxolitinib	70-81	Janus kinase 2	Homo sapiens	28-32
32050632-7	2020	Although autophosphorylated JAK2-V617F was resistant to WP1130 in the ruxolitinib-persistent HEL-R cells, these cells expressed Bcl-2 and Bcl-xL at lower levels and showed an increased sensitivity to WP1130 as well as BH3 mimetics as compared with ruxolitinib-naive HEL cells.	ruxolitinib	248-259	Janus kinase 2	Homo sapiens	28-32
32050632-8	2020	Thus, USP9X represents a promising target along with anti-apoptotic Bcl-2 family members for novel therapeutic strategies against JAK2-V617F-positive myeloproliferative neoplasms, particularly under the ruxolitinib persistence conditions.	ruxolitinib	203-214	ubiquitin specific peptidase 9 X-linked	Homo sapiens	6-11
32050632-8	2020	Thus, USP9X represents a promising target along with anti-apoptotic Bcl-2 family members for novel therapeutic strategies against JAK2-V617F-positive myeloproliferative neoplasms, particularly under the ruxolitinib persistence conditions.	ruxolitinib	203-214	Janus kinase 2	Homo sapiens	130-134
31697835-3	2020	Both receptors could be expressed in human T lymphocytes; Epo ligation induced STAT5 phosphorylation, which was abrogated by nontoxic concentrations of the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	173-184	signal transducer and activator of transcription 5A	Homo sapiens	79-84
31697835-3	2020	Both receptors could be expressed in human T lymphocytes; Epo ligation induced STAT5 phosphorylation, which was abrogated by nontoxic concentrations of the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	173-184	Janus kinase 1	Homo sapiens	156-162
30962501-1	2020	Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-27
32067619-1	2020	BACKGROUND: Ruxolitinib is a selective JAK1/2 inhibitor approved by FDA for myelofibrosis in 2014 and nowadays, comprehensive investigations on the potential of the agent as a targeted therapy for haematological malignancies are on the rise.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	39-45
32067619-6	2020	Apoptotic effects of ruxolitinib were analyzed with Annexin V-FITC Detection Kit and flow cytometry.	ruxolitinib	21-32	annexin A5	Homo sapiens	52-61
32067619-7	2020	We performed RT-qPCR to demonstrate the expression changes of the genes in IL-6/JAK/STAT pathway in ARH-77 and NCI-BL 2171 cells treated with ruxolitinib.	ruxolitinib	142-153	interleukin 6	Homo sapiens	75-79
32067619-10	2020	Treatment with ruxolitinib decreased the expressions of IL-6, IL-18, JAK2, TYK2 and, AKT genes which play significant roles in MM pathogenesis.	ruxolitinib	15-26	interleukin 6	Homo sapiens	56-60
32067619-10	2020	Treatment with ruxolitinib decreased the expressions of IL-6, IL-18, JAK2, TYK2 and, AKT genes which play significant roles in MM pathogenesis.	ruxolitinib	15-26	interleukin 18	Homo sapiens	62-67
32067619-10	2020	Treatment with ruxolitinib decreased the expressions of IL-6, IL-18, JAK2, TYK2 and, AKT genes which play significant roles in MM pathogenesis.	ruxolitinib	15-26	Janus kinase 2	Homo sapiens	69-73
32067619-10	2020	Treatment with ruxolitinib decreased the expressions of IL-6, IL-18, JAK2, TYK2 and, AKT genes which play significant roles in MM pathogenesis.	ruxolitinib	15-26	tyrosine kinase 2	Homo sapiens	75-79
32067619-10	2020	Treatment with ruxolitinib decreased the expressions of IL-6, IL-18, JAK2, TYK2 and, AKT genes which play significant roles in MM pathogenesis.	ruxolitinib	15-26	AKT serine/threonine kinase 1	Homo sapiens	85-88
32067619-11	2020	CONCLUSION: All in all, ruxolitinib is a promising agent for the regulation of IL-6/JAK/STAT pathway and interfering with autophagy mechanism in MM.	ruxolitinib	24-35	interleukin 6	Homo sapiens	79-83
31423579-5	2020	Ruxolitinib (RUX) is an inhibitor of the Janus kinase family of protein tyrosine kinases (JAKs) and is effective for treating patients with myeloproliferative disorders.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	90-94
31423579-5	2020	Ruxolitinib (RUX) is an inhibitor of the Janus kinase family of protein tyrosine kinases (JAKs) and is effective for treating patients with myeloproliferative disorders.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	90-94
30962501-1	2020	Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF).	ruxolitinib	0-3	Janus kinase 1	Homo sapiens	21-27
31654094-0	2020	Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.	ruxolitinib	81-92	C-reactive protein	Homo sapiens	21-39
31654094-0	2020	Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.	ruxolitinib	81-92	C-reactive protein	Homo sapiens	41-44
31654094-0	2020	Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.	ruxolitinib	81-92	Janus kinase 1	Homo sapiens	64-70
31654094-1	2020	OBJECTIVE AND DESIGN: To determine whether inflammatory hepatocytes may constitute primary targets for ruxolitinib, a Janus kinase (JAK) inhibitor, its effects towards expression of hepatic acute-phase proteins, especially C-reactive protein (CRP), were assessed.	ruxolitinib	103-114	C-reactive protein	Homo sapiens	223-241
31654094-3	2020	RESULTS: Ruxolitinib was found to fully inhibit lipopolysaccharide (LPS)-induced CRP secretion and mRNA expression, at concentrations (IC50 = 12.9 nM) achievable in human blood.	ruxolitinib	9-20	C-reactive protein	Homo sapiens	81-84
31654094-5	2020	Ruxolitinib was additionally found to block the activation of the IL6/JAK/signal transducer and activator of transcription (STAT) pathway triggered by LPS and whose inhibition by the neutralizing anti-IL6 receptor antibody tocilizumab prevented CRP induction.	ruxolitinib	0-11	interleukin 6	Homo sapiens	66-69
31654094-5	2020	Ruxolitinib was additionally found to block the activation of the IL6/JAK/signal transducer and activator of transcription (STAT) pathway triggered by LPS and whose inhibition by the neutralizing anti-IL6 receptor antibody tocilizumab prevented CRP induction.	ruxolitinib	0-11	interleukin 6	Homo sapiens	201-204
31929748-1	2020	Ruxolitinib is a selective inhibitor of Jak1/2.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	40-46
31654094-5	2020	Ruxolitinib was additionally found to block the activation of the IL6/JAK/signal transducer and activator of transcription (STAT) pathway triggered by LPS and whose inhibition by the neutralizing anti-IL6 receptor antibody tocilizumab prevented CRP induction.	ruxolitinib	0-11	C-reactive protein	Homo sapiens	245-248
31654094-6	2020	CONCLUSION: Ruxolitinib can potently repress induction of CRP in inflammatory human hepatocytes, most likely through targeting the IL6/JAK/STAT signalling cascade.	ruxolitinib	12-23	C-reactive protein	Homo sapiens	58-61
31929748-7	2020	Ruxolitinib treatment suppressed fibroblast activation and extracellular matrix (ECM) production in UUO kidneys and TGF-beta1-treated fibroblasts.	ruxolitinib	0-11	transforming growth factor, beta 1	Mus musculus	116-125
31929748-8	2020	Ruxolitinib treatment also blocked epithelial-mesenchymal transition (EMT) in UUO kidneys and TGF-beta 1-treated renal tubular epithelial cells.	ruxolitinib	0-11	transforming growth factor, beta 1	Mus musculus	94-104
31654094-6	2020	CONCLUSION: Ruxolitinib can potently repress induction of CRP in inflammatory human hepatocytes, most likely through targeting the IL6/JAK/STAT signalling cascade.	ruxolitinib	12-23	interleukin 6	Homo sapiens	131-134
31929748-10	2020	Mechanistically, Ruxolitinib treatment attenuated activation of both Stat3 and Akt/mTOR/Yap pathways.	ruxolitinib	17-28	signal transducer and activator of transcription 3	Mus musculus	69-74
31749302-4	2020	Unfortunately, ruxolitinib, the JAK1/2 inhibitor approved by FDA and EMEA for PMF, ameliorates symptoms but does not improve the natural course of the disease, and the cure of PMF is still an unmet clinical need.	ruxolitinib	15-26	Janus kinase 1	Mus musculus	32-38
31929748-10	2020	Mechanistically, Ruxolitinib treatment attenuated activation of both Stat3 and Akt/mTOR/Yap pathways.	ruxolitinib	17-28	thymoma viral proto-oncogene 1	Mus musculus	79-82
31929748-10	2020	Mechanistically, Ruxolitinib treatment attenuated activation of both Stat3 and Akt/mTOR/Yap pathways.	ruxolitinib	17-28	mechanistic target of rapamycin kinase	Mus musculus	83-87
31929748-10	2020	Mechanistically, Ruxolitinib treatment attenuated activation of both Stat3 and Akt/mTOR/Yap pathways.	ruxolitinib	17-28	yes-associated protein 1	Mus musculus	88-91
33162516-9	2020	A JAK2 inhibitor, ruxolitinib, improves splenomegaly and disease-related constitutive symptoms.	ruxolitinib	18-29	Janus kinase 2	Homo sapiens	2-6
33521321-5	2020	JAK inhibitors, particularly the JAK1/2 inhibitor ruxolitinib, sensitize cell lines and murine models to chemotherapy, immunotherapy, and oncolytic viral therapy.	ruxolitinib	50-61	Janus kinase 1	Mus musculus	33-39
31778911-1	2020	Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-29
31778911-1	2020	Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	30-34
31666386-0	2020	Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage.	ruxolitinib	7-18	COPI coat complex subunit alpha	Homo sapiens	22-26
31666386-4	2020	Based on these results she was treated with the JAK1/2 inhibitor ruxolitinib, which resulted in reduction in IFN signalling and appeared to be associated with partial though incomplete decrease in the severity of her pulmonary disease.	ruxolitinib	65-76	Janus kinase 1	Homo sapiens	48-54
31407334-5	2019	Accordingly, administration of the JAK1/2 selective tyrosine kinase inhibitor ruxolitinib reduced proliferation of tumor cells and effectively reduced tumor progression in immunodeficient and immunocompetent mouse models of K-RAS-driven lung AC.	ruxolitinib	78-89	Janus kinase 1	Mus musculus	35-41
31452174-0	2020	Inhibition of the invasion of human glioblastoma U87 cell line by ruxolitinib: a molecular player of miR-17 and miR-20a regulating JAK/STAT pathway.	ruxolitinib	66-77	microRNA 17	Homo sapiens	101-107
31452174-0	2020	Inhibition of the invasion of human glioblastoma U87 cell line by ruxolitinib: a molecular player of miR-17 and miR-20a regulating JAK/STAT pathway.	ruxolitinib	66-77	microRNA 20a	Homo sapiens	112-119
31452174-4	2020	RESULTS: Our results indicated that a therapeutic dose of ruxolitinib (195 nM) significantly increased miR-17 and miR-20a expression.	ruxolitinib	58-69	microRNA 17	Homo sapiens	103-109
31452174-4	2020	RESULTS: Our results indicated that a therapeutic dose of ruxolitinib (195 nM) significantly increased miR-17 and miR-20a expression.	ruxolitinib	58-69	microRNA 20a	Homo sapiens	114-121
31452174-5	2020	Ruxolitinib treatment resulted in the production of IL-6 and active formation of IL-6 receptor complex for the subsequent activation of the IL-6R/JAK2/STAT3 axis.	ruxolitinib	0-11	interleukin 6	Homo sapiens	52-56
31452174-5	2020	Ruxolitinib treatment resulted in the production of IL-6 and active formation of IL-6 receptor complex for the subsequent activation of the IL-6R/JAK2/STAT3 axis.	ruxolitinib	0-11	interleukin 6	Homo sapiens	81-85
31452174-5	2020	Ruxolitinib treatment resulted in the production of IL-6 and active formation of IL-6 receptor complex for the subsequent activation of the IL-6R/JAK2/STAT3 axis.	ruxolitinib	0-11	interleukin 6 receptor	Homo sapiens	140-145
31452174-5	2020	Ruxolitinib treatment resulted in the production of IL-6 and active formation of IL-6 receptor complex for the subsequent activation of the IL-6R/JAK2/STAT3 axis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	146-150
31452174-5	2020	Ruxolitinib treatment resulted in the production of IL-6 and active formation of IL-6 receptor complex for the subsequent activation of the IL-6R/JAK2/STAT3 axis.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Homo sapiens	151-156
31452174-6	2020	However, ruxolitinib treatment significantly decreased the expression of JAK2 and PI3K.	ruxolitinib	9-20	Janus kinase 2	Homo sapiens	73-77
31452174-9	2020	CONCLUSION: The specific JAK2 inhibitor ruxolitinib plays an important role in glioblastoma angiogenesis biology via inhibiting IL-6 receptor-dependent JAK/STAT signaling.	ruxolitinib	40-51	Janus kinase 2	Homo sapiens	25-29
31452174-9	2020	CONCLUSION: The specific JAK2 inhibitor ruxolitinib plays an important role in glioblastoma angiogenesis biology via inhibiting IL-6 receptor-dependent JAK/STAT signaling.	ruxolitinib	40-51	interleukin 6	Homo sapiens	128-132
31452174-10	2020	Additionally, both miR-17a-3p and miR-20a overexpression induced by ruxolitinib treatment may be playing a major role in downregulated JAK2, STAT3, and PI3K proteins.	ruxolitinib	68-79	microRNA 20a	Homo sapiens	34-41
31452174-10	2020	Additionally, both miR-17a-3p and miR-20a overexpression induced by ruxolitinib treatment may be playing a major role in downregulated JAK2, STAT3, and PI3K proteins.	ruxolitinib	68-79	Janus kinase 2	Homo sapiens	135-139
31452174-10	2020	Additionally, both miR-17a-3p and miR-20a overexpression induced by ruxolitinib treatment may be playing a major role in downregulated JAK2, STAT3, and PI3K proteins.	ruxolitinib	68-79	signal transducer and activator of transcription 3	Homo sapiens	141-146
31920387-2	2019	In late 2019, the FDA approved the highly selective JAK2 inhibitor, fedratinib, for intermediate-2 or high-risk primary or secondary MF, making it the second drug approved for MF after ruxolitinib, a JAK1/2 inhibitor, which was approved for MF in 2011.	ruxolitinib	185-196	Janus kinase 2	Homo sapiens	52-56
31407334-5	2019	Accordingly, administration of the JAK1/2 selective tyrosine kinase inhibitor ruxolitinib reduced proliferation of tumor cells and effectively reduced tumor progression in immunodeficient and immunocompetent mouse models of K-RAS-driven lung AC.	ruxolitinib	78-89	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	224-229
31821455-0	2019	Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	101-112	Janus kinase 1	Homo sapiens	84-90
32023730-0	2019	[The anti-proliferative and anti-inflammatory mechanisms of JAK1 inhibitor SHR0302 versus Ruxolitinib in SET2 cell line and primary cells].	ruxolitinib	90-101	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	105-109
32023730-1	2019	Objective: To explore the effects and molecular mechanism of the selective JAK1inhibitor SHR0302 and Ruxolitinib on myeloproliterative neoplasms (MPN) cell line SET2 and primary cells in vitro.	ruxolitinib	101-112	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	161-165
32023730-7	2019	The inhibitory rates of 2.5 mumol/L SHR0302 and 0.1 mumol/L Ruxolitinib on SET2 cells for 72 h were comparable, i.e. (59.94+-0.60) % and (64.00+-0.66) %, respectively, suggesting that the inhibitory effect of SHR0302 was weaker than that of Ruxolitinib.	ruxolitinib	60-71	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	75-79
32023730-10	2019	Except IL-12, the expression of other 5 cytokines (IL-6, TNF-alpha, IL-1beta, IL-2, IL-8) was significantly inhibited by 1.6 mumol/L SHR0302 in SET2 cells at 24 h (P&lt;0.01) , while Ruxolitinib 1.0 mumol/L had the same effect.	ruxolitinib	183-194	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	144-148
31867003-6	2019	Using the HSG cell line, our results showed that both ICAM-1 and PD-L1 are induced by ROS through pSTAT3, and that this activation pathway is reversed by the use of JAK inhibitors, AG490 and ruxolitinib, as well as by N-acetylcysteine, which is a direct inhibitor of ROS.	ruxolitinib	191-202	intercellular adhesion molecule 1	Homo sapiens	54-60
31867003-6	2019	Using the HSG cell line, our results showed that both ICAM-1 and PD-L1 are induced by ROS through pSTAT3, and that this activation pathway is reversed by the use of JAK inhibitors, AG490 and ruxolitinib, as well as by N-acetylcysteine, which is a direct inhibitor of ROS.	ruxolitinib	191-202	CD274 molecule	Homo sapiens	65-70
31578205-8	2019	Specifically, TP53 (p=0.01) and splicing factor (SF, SF3B1, ZRSR2, SRSF2; p&amp;lt;0.001), but not TET2 mutations were associated with reduced TFS which was not mitigated by RUX treatment.	ruxolitinib	174-177	tumor protein p53	Homo sapiens	14-18
31817106-9	2019	Finally, we demonstrate that the clinically available JAK2 inhibitor Ruxolitinib synergises with cisplatin in inducing apoptosis, highlighting JAK2 as a promising therapeutic target in HPV-driven cancers.	ruxolitinib	69-80	Janus kinase 2	Homo sapiens	54-58
31817106-9	2019	Finally, we demonstrate that the clinically available JAK2 inhibitor Ruxolitinib synergises with cisplatin in inducing apoptosis, highlighting JAK2 as a promising therapeutic target in HPV-driven cancers.	ruxolitinib	69-80	Janus kinase 2	Homo sapiens	143-147
31637674-2	2019	Currently, only allogeneic stem cell transplantation is curative in those who are candidates, while administration of the JAK1/2 inhibitor ruxolitinib carries a risk of worsening cytopenia.	ruxolitinib	139-150	Janus kinase 1	Mus musculus	122-128
31537486-4	2019	We therefore aimed to determine the activity and safety of ruxolitinib, a JAK inhibitor, in adults with secondary haemophagocytic lymphohistiocytosis.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	74-77
31725895-0	2019	The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.	ruxolitinib	77-88	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	8-11
31725895-7	2019	Here we report that the recently developed pan-PIM inhibitor INCB053914 augments the efficacy of the US Food and Drug Administration-approved JAK1/2 inhibitor ruxolitinib in both in vitro and in vivo MPN models.	ruxolitinib	159-170	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	47-50
31725895-7	2019	Here we report that the recently developed pan-PIM inhibitor INCB053914 augments the efficacy of the US Food and Drug Administration-approved JAK1/2 inhibitor ruxolitinib in both in vitro and in vivo MPN models.	ruxolitinib	159-170	Janus kinase 1	Homo sapiens	142-148
31725895-8	2019	INCB053914 synergizes with ruxolitinib to inhibit cell growth in JAK2-driven MPN models and induce apoptosis.	ruxolitinib	27-38	Janus kinase 2	Homo sapiens	65-69
31814788-4	2019	Ruxolitinib (RUX) is a JAK2 inhibitor approved for patients intolerant or resistant to hydroxyurea (HA).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	23-27
31597782-5	2019	Interferon alpha (IFN-alpha) treatment enhanced cell surface levels of SERINC5 in a ruxolitinib-sensitive manner in the absence of modulation of mRNA and protein quantities.	ruxolitinib	84-95	interferon alpha 1	Homo sapiens	18-27
31814788-4	2019	Ruxolitinib (RUX) is a JAK2 inhibitor approved for patients intolerant or resistant to hydroxyurea (HA).	ruxolitinib	13-16	Janus kinase 2	Homo sapiens	23-27
31719581-1	2019	Ruxolitinib is an FDA approved janus kinase (JAK)1/2 inhibitor used to treat myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	31-50
31698461-10	2019	Both synthetic models and patient-derived xenografts of NUP98-rearranged AMKL showed in vitro therapeutic vulnerability to ruxolitinib, a clinically approved JAK2 inhibitor.	ruxolitinib	123-134	nucleoporin 98 and 96 precursor	Homo sapiens	56-61
31698461-10	2019	Both synthetic models and patient-derived xenografts of NUP98-rearranged AMKL showed in vitro therapeutic vulnerability to ruxolitinib, a clinically approved JAK2 inhibitor.	ruxolitinib	123-134	Janus kinase 2	Homo sapiens	158-162
31707975-2	2019	Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib.	ruxolitinib	104-115	Janus kinase 2	Homo sapiens	29-33
31704999-0	2019	Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models.	ruxolitinib	0-11	albumin	Homo sapiens	29-42
31704999-0	2019	Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	107-111
31704999-1	2019	Ruxolitinib is a type I JAK inhibitor approved by FDA for targeted therapy of Philadelphia-negative myeloproliferative neoplasms (MPNs), all characterized by mutations activating the JAK2/STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	183-187
31704999-7	2019	Ruxolitinib binds to the FA1 and FA7 sites of HSA with high affinity (Kr = 3.1 muM and 4.6 muM, respectively, at pH 7.3 and 37.0  C).	ruxolitinib	0-11	latexin	Homo sapiens	79-82
31704999-7	2019	Ruxolitinib binds to the FA1 and FA7 sites of HSA with high affinity (Kr = 3.1 muM and 4.6 muM, respectively, at pH 7.3 and 37.0  C).	ruxolitinib	0-11	latexin	Homo sapiens	91-94
31704999-8	2019	Moreover, HSA selectively blocks, in a dose dependent manner, the cytotoxic activity of ruxolitinib in JAK2V617F+ cellular models for MPN, in vitro.	ruxolitinib	88-99	serine protease 27	Homo sapiens	134-137
30622322-10	2019	The addition of ruxolitinib inhibited STAT1 phosphorylation and to a lesser extent STAT3 phosphorylation.	ruxolitinib	16-27	signal transducer and activator of transcription 1	Homo sapiens	38-43
30622322-11	2019	Ruxolitinib treatment prevented NSCLC cells from enhancing PDL-1 expression in response to virotherapy.	ruxolitinib	0-11	CD274 antigen	Mus musculus	59-64
31512162-0	2019	Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib.	ruxolitinib	99-110	signal transducer and activator of transcription 1	Homo sapiens	35-40
31597782-5	2019	Interferon alpha (IFN-alpha) treatment enhanced cell surface levels of SERINC5 in a ruxolitinib-sensitive manner in the absence of modulation of mRNA and protein quantities.	ruxolitinib	84-95	serine incorporator 5	Homo sapiens	71-78
31719581-9	2019	Patients treated with ruxolitinib had a higher systolic blood pressure, serum AST, and ALT at 72 weeks, compared with baseline (p = 0.03, p = 0.01, p = 0.04, respectively).	ruxolitinib	22-33	solute carrier family 17 member 5	Homo sapiens	78-81
31195136-4	2019	This effect was blocked by ruxolitinib, a JAK1/JAK2 inhibitor.	ruxolitinib	27-38	Janus kinase 1	Mus musculus	42-46
31788449-4	2019	Ruxolitinib is a potent and selective oral inhibitor of both JAK2 and JAK1 protein kinases.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	61-65
31788449-4	2019	Ruxolitinib is a potent and selective oral inhibitor of both JAK2 and JAK1 protein kinases.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	70-74
31195136-4	2019	This effect was blocked by ruxolitinib, a JAK1/JAK2 inhibitor.	ruxolitinib	27-38	Janus kinase 2	Mus musculus	47-51
31427260-2	2019	The EXPAND study recently suggested tolerability of ruxolitinib, with a maximum starting dose of 10 mg 2 times a day (BID).	ruxolitinib	52-63	BH3 interacting domain death agonist	Homo sapiens	118-121
31681603-6	2019	Silencing the identified alternative proteins via siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7, RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8).	ruxolitinib	159-170	AKT serine/threonine kinase 1	Homo sapiens	186-189
31681603-6	2019	Silencing the identified alternative proteins via siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7, RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8).	ruxolitinib	159-170	erb-b2 receptor tyrosine kinase 2	Homo sapiens	244-248
31681603-6	2019	Silencing the identified alternative proteins via siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7, RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8).	ruxolitinib	159-170	BCL2 apoptosis regulator	Homo sapiens	280-284
31681603-6	2019	Silencing the identified alternative proteins via siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7, RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8).	ruxolitinib	159-170	baculoviral IAP repeat containing 8	Homo sapiens	289-294
31297883-5	2019	The proportions of PD-L1+ B cells and PD-1+ B cells were significantly higher in patients with myelofibrosis or polycythemia vera than in HDs and decreased during ruxolitinib and COMBI treatment.	ruxolitinib	163-174	CD274 molecule	Sus scrofa	19-24
31324935-1	2019	PURPOSE: Ruxolitinib is metabolized by cytochrome P450 (CYP)3A4 and CYP2C9.	ruxolitinib	9-20	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	68-74
31297883-7	2019	The proportion of IL-6+ B cells decreased, and the proportion of IL-10+ B cells increased during ruxolitinib treatment.	ruxolitinib	97-108	interleukin 10	Homo sapiens	65-70
28834694-8	2019	Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, was then utilized as a novel salvage therapy based on available in vivo murine data at the time.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	15-37
31560729-0	2019	Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.	ruxolitinib	56-67	Janus kinase 2	Homo sapiens	40-44
31560729-3	2019	Moreover, 4 therapeutic JAK2 inhibitors (ruxolitinib, fedratinib, momelotinib, and pacritinib) have either been approved or are in advanced clinical development for myelofibrosis.	ruxolitinib	41-52	Janus kinase 2	Homo sapiens	24-28
30650179-6	2019	JAK1/2 inhibition via ruxolitinib decreased, while stimulation with LIF increased, phosphorylation of STAT3 and the number of cells with CSC properties indicating that JAK-STAT signalling controlled the number of cells with CSC features.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	0-6
31549971-7	2019	Preclinical studies have demonstrated that the JAK1/2 inhibitor ruxolitinib, in combination with lenalidomide and dexamethasone, reduces proliferation of the MM cell lines and primary tumor cells derived from MM patients, and this inhibition is greater when these drugs are combined than with single agents.	ruxolitinib	64-75	Janus kinase 1	Homo sapiens	47-51
31228096-4	2019	RECENT FINDINGS: The advances in molecular insights, especially the discovery of the Janus kinase 2 (JAK2) V617F mutation and its role in JAK-STAT pathway dysregulation, led to the development of the JAK inhibitor ruxolitinib, which currently represents the cornerstone of medical therapy in MF and hydroxyurea-resistant/intolerant PV.	ruxolitinib	214-225	Janus kinase 2	Homo sapiens	85-99
31228096-4	2019	RECENT FINDINGS: The advances in molecular insights, especially the discovery of the Janus kinase 2 (JAK2) V617F mutation and its role in JAK-STAT pathway dysregulation, led to the development of the JAK inhibitor ruxolitinib, which currently represents the cornerstone of medical therapy in MF and hydroxyurea-resistant/intolerant PV.	ruxolitinib	214-225	Janus kinase 2	Homo sapiens	101-105
31382969-4	2019	This expression was dependent on activation of either NF-kappaB, JAK1/JAK2 or BTK pathways since these pathways were activated in tumor B-cells and ex vivo treatment with the inhibitory molecules PHA-408, ruxolitinib and ibrutinib led to decrease of its expression.	ruxolitinib	205-216	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	78-81
31201513-1	2019	Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	47-53
31319994-0	2019	A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.	ruxolitinib	52-63	epidermal growth factor receptor	Homo sapiens	67-71
32565533-6	2019	Taken together, our data suggest that soluble factors in MM can trigger contemporary JAK2 signaling and autophagy in neutrophils, targetable with ruxolitinib.	ruxolitinib	146-157	Janus kinase 2	Homo sapiens	85-89
31015190-2	2019	Previously, we reported that the JAK inhibitor ruxolitinib dampens T-cell activation and lessens inflammation in a model of HLH in which perforin-deficient (Prf1 -/-) mice are infected with lymphocytic choriomeningitis virus (LCMV).	ruxolitinib	47-58	perforin 1 (pore forming protein)	Mus musculus	157-161
31015190-3	2019	Ruxolitinib inhibits signaling downstream of IFN-gamma, as well as several other JAK-dependent cytokines.	ruxolitinib	0-11	interferon gamma	Mus musculus	45-54
31015190-6	2019	In both models, ruxolitinib and alphaIFN-gamma reduced inflammation-associated anemia, indicating that ruxolitinib operates in an IFN-gamma-dependent manner to reverse this HLH manifestation.	ruxolitinib	103-114	interferon gamma	Mus musculus	37-46
31015190-10	2019	Thus, ruxolitinib operates through IFN-gamma-dependent and -independent mechanisms to dampen HLH by targeting the deleterious effects of T cells and neutrophils, with the latter representing an unappreciated and understudied cell type that contributes to HLH pathogenesis.	ruxolitinib	6-17	interferon gamma	Mus musculus	35-44
31289316-1	2019	JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor.	ruxolitinib	128-139	Janus kinase 2	Homo sapiens	0-4
31354696-9	2019	The velocity of pSTAT1 dephosphorylation after treatment of IFNgamma stimulated CD14+ monocytes with the Janus Kinase (JAK)-inhibitor ruxolitinib was significantly faster in patient cells.	ruxolitinib	134-145	interferon gamma	Homo sapiens	60-68
31354696-9	2019	The velocity of pSTAT1 dephosphorylation after treatment of IFNgamma stimulated CD14+ monocytes with the Janus Kinase (JAK)-inhibitor ruxolitinib was significantly faster in patient cells.	ruxolitinib	134-145	CD14 molecule	Homo sapiens	80-84
31289316-1	2019	JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor.	ruxolitinib	128-139	Janus kinase 1	Homo sapiens	143-149
31289316-3	2019	In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose- and time-dependent manner by ruxolitinib.	ruxolitinib	110-121	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	3-7
31289316-3	2019	In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose- and time-dependent manner by ruxolitinib.	ruxolitinib	110-121	aurora kinase A	Homo sapiens	15-20
31289316-3	2019	In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose- and time-dependent manner by ruxolitinib.	ruxolitinib	110-121	aurora kinase B	Homo sapiens	25-30
31289316-8	2019	Synergism experiments indicated that low dose of reversine had a potentiating effect under ruxolitinib treatment at low doses in SET2 cells.	ruxolitinib	91-102	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	129-133
30997845-0	2019	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.	ruxolitinib	52-63	Janus kinase 1	Homo sapiens	67-73
30711510-8	2019	JAK1 inhibitor ruxolitinib was given by oral lavage.	ruxolitinib	15-26	Janus kinase 1	Rattus norvegicus	0-4
31144250-5	2019	The JAK1/2 inhibitor ruxolitinib was administered on an off-label basis.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
30696950-6	2019	Addition of the janus kinase inhibitor ruxolitinib to block ibrutinib-insensitive signals increased GILZ transcription in pseudofollicle conditions in vitro and in a clinical trial (NCT02912754), and also increased GR(S211)/GR(S226) ratios and DEX-mediated killing in patient samples in vitro.	ruxolitinib	39-50	TSC22 domain family member 3	Homo sapiens	100-104
30997845-0	2019	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.	ruxolitinib	52-63	Janus kinase 3	Homo sapiens	146-150
30899259-13	2019	Finally, administration of ruxolitinib for 7 days post-surgery significantly reduced STAT3 phosphorylation in injured muscles in vivo as well as NHO volume at all analyzed time-points up to 3 weeks post-surgery.	ruxolitinib	27-38	signal transducer and activator of transcription 3	Mus musculus	85-90
31147469-6	2019	Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib.	ruxolitinib	222-233	signal transducer and activator of transcription 3	Homo sapiens	29-34
31147469-6	2019	Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib.	ruxolitinib	222-233	prostaglandin-endoperoxide synthase 2	Homo sapiens	168-173
30997748-1	2019	Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	63-77
30997748-1	2019	Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	79-83
30997748-1	2019	Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	89-93
33911570-1	2019	Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-36
33911570-1	2019	Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	41-45
30930994-0	2019	Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor.	ruxolitinib	90-101	Janus kinase 2	Homo sapiens	115-119
30930994-7	2019	Ruxolitinib, a potent JAK2 inhibitor, was demonstrated to attenuate STAT3 phosphorylation and the proliferation of TAMR-MCF-7 cells.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	22-26
30930994-7	2019	Ruxolitinib, a potent JAK2 inhibitor, was demonstrated to attenuate STAT3 phosphorylation and the proliferation of TAMR-MCF-7 cells.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Homo sapiens	68-73
30930994-10	2019	Ruxolitinib significantly inhibited VEGF mRNA expression and transcriptional activity.	ruxolitinib	0-11	vascular endothelial growth factor A	Homo sapiens	36-40
30899259-11	2019	As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells.	ruxolitinib	147-158	signal transducer and activator of transcription 3	Mus musculus	3-8
30899259-11	2019	As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells.	ruxolitinib	147-158	Janus kinase 1	Mus musculus	39-45
30899259-11	2019	As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells.	ruxolitinib	147-158	oncostatin M receptor	Mus musculus	77-81
30992267-5	2019	JAK inhibitors (ruxolitinib and tofacitinib) inhibited the growth of pro-B1 ALL cell lines established from Bcor sgRNA/NP23 recipients at clinically achievable concentrations (100 nM).	ruxolitinib	16-27	proline rich basic protein 1	Mus musculus	69-75
30992267-5	2019	JAK inhibitors (ruxolitinib and tofacitinib) inhibited the growth of pro-B1 ALL cell lines established from Bcor sgRNA/NP23 recipients at clinically achievable concentrations (100 nM).	ruxolitinib	16-27	BCL6 interacting corepressor	Mus musculus	108-112
31182137-9	2019	Finally, we used the cigarette metabolites to promote AKR1C1 expression and ruxolitinib to overcome AKR1C1-induced cisplatin-resistance.	ruxolitinib	76-87	aldo-keto reductase family 1 member C1	Homo sapiens	100-106
31182137-14	2019	Transcriptome analyses revealed that STAT1 and STAT3 activation enable AKR1C1-induced cisplatin-resistance and can be overcome by ruxolitinib treatment.	ruxolitinib	130-141	signal transducer and activator of transcription 1	Homo sapiens	37-42
31182137-14	2019	Transcriptome analyses revealed that STAT1 and STAT3 activation enable AKR1C1-induced cisplatin-resistance and can be overcome by ruxolitinib treatment.	ruxolitinib	130-141	signal transducer and activator of transcription 3	Homo sapiens	47-52
31182137-14	2019	Transcriptome analyses revealed that STAT1 and STAT3 activation enable AKR1C1-induced cisplatin-resistance and can be overcome by ruxolitinib treatment.	ruxolitinib	130-141	aldo-keto reductase family 1 member C1	Homo sapiens	71-77
29651917-1	2019	Ruxolitinib is a small molecule JAK-2 inhibitor approved for the treatment of certain myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	32-37
29651917-4	2019	Awareness of this unusual skin toxicity with ruxolitinib becomes even more important as JAK-2 inhibition might soon find clinical applications in dermatology.	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	88-93
31145690-0	2019	Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.	ruxolitinib	43-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
31145690-0	2019	Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.	ruxolitinib	43-54	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	87-93
31145690-1	2019	Ruxolitinib is mainly metabolized by cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9 followed by minor contributions of other hepatic CYP enzymes in vitro.	ruxolitinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
31145690-1	2019	Ruxolitinib is mainly metabolized by cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9 followed by minor contributions of other hepatic CYP enzymes in vitro.	ruxolitinib	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	78-84
31145690-2	2019	A physiologically based pharmacokinetic (PBPK) model was established to evaluate the changes in the ruxolitinib systemic exposures with co-administration of CYP3A4 and CYP2C9 perpetrators.	ruxolitinib	100-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-163
31145690-2	2019	A physiologically based pharmacokinetic (PBPK) model was established to evaluate the changes in the ruxolitinib systemic exposures with co-administration of CYP3A4 and CYP2C9 perpetrators.	ruxolitinib	100-111	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	168-174
31145690-3	2019	The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).	ruxolitinib	145-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
31145690-3	2019	The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).	ruxolitinib	145-156	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	90-96
31145690-7	2019	The estimated AUC ratios of ruxolitinib by co-administration of the moderate CYP3A4 inhibitor erythromycin (500 mg) and the strong CYP3A4 inducer rifampicin (600 mg) were within a 20% error compared with the clinically observed values.	ruxolitinib	28-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
31145690-7	2019	The estimated AUC ratios of ruxolitinib by co-administration of the moderate CYP3A4 inhibitor erythromycin (500 mg) and the strong CYP3A4 inducer rifampicin (600 mg) were within a 20% error compared with the clinically observed values.	ruxolitinib	28-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137
31145690-9	2019	Furthermore, an AUC increase of ruxolitinib in the absence or presence of the dual CYP3A4 and CYP2C9 inhibitor fluconazole (100-400 mg) was prospectively estimated to be 1.94- to 4.31-fold.	ruxolitinib	32-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
31145690-9	2019	Furthermore, an AUC increase of ruxolitinib in the absence or presence of the dual CYP3A4 and CYP2C9 inhibitor fluconazole (100-400 mg) was prospectively estimated to be 1.94- to 4.31-fold.	ruxolitinib	32-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	94-100
31145690-11	2019	A ruxolitinib PBPK model with optimized fm,CYP3A4 and fm,CYP2C9 was established to evaluate victim DDI risks.	ruxolitinib	2-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
31145690-11	2019	A ruxolitinib PBPK model with optimized fm,CYP3A4 and fm,CYP2C9 was established to evaluate victim DDI risks.	ruxolitinib	2-13	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	57-63
30545926-6	2019	We evaluated the molecular mechanisms of combined ruxolitinib/nilotinib/prednisone and observed inhibition of JAK/STAT (STAT5, 69.2+11.8% inhibition) and MAPK (ERK, 29.4+4.5% inhibition) signaling pathways.	ruxolitinib	50-61	signal transducer and activator of transcription 5A	Homo sapiens	120-125
30545926-6	2019	We evaluated the molecular mechanisms of combined ruxolitinib/nilotinib/prednisone and observed inhibition of JAK/STAT (STAT5, 69.2+11.8% inhibition) and MAPK (ERK, 29.4+4.5% inhibition) signaling pathways.	ruxolitinib	50-61	mitogen-activated protein kinase 1	Homo sapiens	154-158
30545926-6	2019	We evaluated the molecular mechanisms of combined ruxolitinib/nilotinib/prednisone and observed inhibition of JAK/STAT (STAT5, 69.2+11.8% inhibition) and MAPK (ERK, 29.4+4.5% inhibition) signaling pathways.	ruxolitinib	50-61	mitogen-activated protein kinase 1	Homo sapiens	160-163
30846331-9	2019	IFN-gamma-induced Delta42PD1 upregulation was abolished by JAK inhibitors Ruxolitinib and Tasocitinib, PI3K inhibitor LY294002, and AKT inhibitor MK-2206, respectively, but not by STAT1 inhibitor and MAPK signaling pathway inhibitors.	ruxolitinib	74-85	interferon gamma	Homo sapiens	0-9
30655323-8	2019	In vivo, estrogen and ruxolitinib significantly reduced tumor size and decreased expression of MUC1, P-STAT1, and IFITM1.	ruxolitinib	22-33	mucin 1, cell surface associated	Homo sapiens	95-99
30655323-8	2019	In vivo, estrogen and ruxolitinib significantly reduced tumor size and decreased expression of MUC1, P-STAT1, and IFITM1.	ruxolitinib	22-33	signal transducer and activator of transcription 1	Homo sapiens	103-108
30655323-8	2019	In vivo, estrogen and ruxolitinib significantly reduced tumor size and decreased expression of MUC1, P-STAT1, and IFITM1.	ruxolitinib	22-33	interferon induced transmembrane protein 1	Homo sapiens	114-120
30959824-11	2019	The mechanism was primarily verified by the JAK2 inhibitor Ruxolitinib and the STAT3 inhibitor Stattic.	ruxolitinib	59-70	Janus kinase 2	Mus musculus	44-48
30760472-0	2019	Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib.	ruxolitinib	166-177	interleukin 21	Homo sapiens	126-131
30760472-13	2019	Blocking IL-21R or using the JAK1/2 inhibitor ruxolitinib reduced the Tfh cells" capacity to stimulate the plasmablasts and decreased the Ig production.	ruxolitinib	46-57	Janus kinase 1	Homo sapiens	29-35
30760472-15	2019	The IL-21 pathway or JAK1/2 blockade by ruxolitinib could be a promising strategy in the treatment of SSc.	ruxolitinib	40-51	interleukin 21	Homo sapiens	4-9
30760472-15	2019	The IL-21 pathway or JAK1/2 blockade by ruxolitinib could be a promising strategy in the treatment of SSc.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	21-25
30843659-3	2019	The JAK1/2 inhibitor ruxolitinib was prescribed to 12 CLL patients with abnormal serum beta-2 microglobulin levels after 6 months or persistent lymphadenopathy or splenomegaly after 12 months on ibrutinib using a 3 + 3 phase 1 trial design (NCT02912754).	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
30843659-3	2019	The JAK1/2 inhibitor ruxolitinib was prescribed to 12 CLL patients with abnormal serum beta-2 microglobulin levels after 6 months or persistent lymphadenopathy or splenomegaly after 12 months on ibrutinib using a 3 + 3 phase 1 trial design (NCT02912754).	ruxolitinib	21-32	beta-2-microglobulin	Homo sapiens	87-107
30899259-11	2019	As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells.	ruxolitinib	147-158	Janus kinase 1	Mus musculus	114-120
30899259-11	2019	As STAT3 is tyrosine phosphorylated by JAK1/2 tyrosine kinases downstream of OSMR:gp130, we demonstrated that the JAK1/2 tyrosine kinase inhibitor ruxolitinib blocked OSM driven STAT3 tyrosine phosphorylation in mouse muscle progenitor cells.	ruxolitinib	147-158	signal transducer and activator of transcription 3	Mus musculus	178-183
30894853-12	2019	The pIC induction of Atlantic cod viperin was significantly inhibited with 2-Aminopurine, Chloroquine, SB202190, and Ruxolitinib.	ruxolitinib	117-128	radical S-adenosyl methionine domain containing 2	Homo sapiens	34-41
30536806-7	2019	Ruxolitinib was associated with an increase in CD4 effector memory (EM), and decrease of CD4 central memory percentage.	ruxolitinib	0-11	CD4 molecule	Homo sapiens	47-50
30536806-7	2019	Ruxolitinib was associated with an increase in CD4 effector memory (EM), and decrease of CD4 central memory percentage.	ruxolitinib	0-11	CD4 molecule	Homo sapiens	89-92
30956968-0	2019	Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib.	ruxolitinib	135-146	BCR activator of RhoGEF and GTPase	Homo sapiens	15-18
30956968-0	2019	Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib.	ruxolitinib	135-146	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	19-23
30956968-0	2019	Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib.	ruxolitinib	135-146	Janus kinase 2	Homo sapiens	62-66
30639623-1	2019	Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-22
31933900-9	2019	In addition, The JAK1 inhibitor, Ruxolitinib, was applied to manipulate the proposed pathway.	ruxolitinib	33-44	Janus kinase 1	Rattus norvegicus	17-21
30639623-1	2019	Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	23-28
30201397-4	2019	Ruxolitinib, a selective JAK1/2 inhibitor, has recently gained favor as a second-line approach in patients with steroid-refractory cGVHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-31
30557559-0	2019	Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation.	ruxolitinib	12-23	signal transducer and activator of transcription 3	Homo sapiens	89-94
30030153-5	2019	After intermittent UVB exposure, melanocytes treated with the JAK inhibitor ruxolitinib reduced expression of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of transcription 1 (pSTAT1).	ruxolitinib	76-87	high mobility group box 1	Homo sapiens	110-115
30305729-10	2019	Importantly, the in vivo pro-tumorigenic effect of CA-MSC is abrogated by dual blockade with the JAK2 inhibitor ruxolitinib to a much greater extent than treatment with anti-IL6 or anti-LIF antibody alone.	ruxolitinib	112-123	Janus kinase 2	Mus musculus	97-101
30305729-12	2019	Ruxolitinib-treated tumors in both the immunocompromised and immunocompetent animal models demonstrate decreased phospho-STAT3, indicating on-target activity.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Mus musculus	121-126
30675650-1	2019	OPINION STATEMENT: Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis.	ruxolitinib	93-104	Janus kinase 1	Homo sapiens	75-81
30203226-6	2019	Interferon-alpha2 being the cornerstone treatment in MPNs and having the potential of inducing minimal residual disease (MRD) with normalization of the bone marrow and low-JAK2V617F allele burden, we believe that combination therapy with ruxolitinib may be even more efficacious and hopefully revert disease progression in many more patients to enter the path towards MRD.	ruxolitinib	238-249	interferon alpha 2	Homo sapiens	0-17
30571852-1	2019	Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolitinib.	ruxolitinib	93-104	Janus kinase 1	Homo sapiens	76-82
30571852-2	2019	To explore the mechanism of ruxolitinib"s limited effect, we examined the JAK1/2 mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory interleukin-6 (IL-6) in MPN granulocytes and JAK2V617F mutated human erythroleukemia (HEL) cells.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	74-80
30571852-2	2019	To explore the mechanism of ruxolitinib"s limited effect, we examined the JAK1/2 mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory interleukin-6 (IL-6) in MPN granulocytes and JAK2V617F mutated human erythroleukemia (HEL) cells.	ruxolitinib	28-39	interleukin 6	Homo sapiens	169-182
30571852-2	2019	To explore the mechanism of ruxolitinib"s limited effect, we examined the JAK1/2 mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory interleukin-6 (IL-6) in MPN granulocytes and JAK2V617F mutated human erythroleukemia (HEL) cells.	ruxolitinib	28-39	interleukin 6	Homo sapiens	184-188
30571852-5	2019	Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	5-11
30571852-5	2019	Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes.	ruxolitinib	22-33	mitogen-activated protein kinase 3	Homo sapiens	52-58
30571852-6	2019	Regarding a cell cycle, we found that IL-6 reduction of HEL cells percentage in G2M phase was reversed by ruxolitinib (2.6 fold).	ruxolitinib	106-117	interleukin 6	Homo sapiens	38-42
30571852-8	2019	Regarding DNA replication, we found that ruxolitinib prevented the IL-6 augmentation of MPN granulocytes frequency in the S phase of the cell cycle (up to 2.9 fold).	ruxolitinib	41-52	interleukin 6	Homo sapiens	67-71
30701084-5	2019	We identified that inhibition of the downstream signal transducer of the LIFR/gp130 pathway through treatment with Ruxolitinib, a specific JAK1/2 antagonist, suppressed the cellular effects of preconditioning.	ruxolitinib	115-126	interleukin 6 cytokine family signal transduce	Danio rerio	78-83
30701084-5	2019	We identified that inhibition of the downstream signal transducer of the LIFR/gp130 pathway through treatment with Ruxolitinib, a specific JAK1/2 antagonist, suppressed the cellular effects of preconditioning.	ruxolitinib	115-126	Janus kinase 1	Danio rerio	139-145
33094033-1	2019	Introduction: The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	18-39
29884903-7	2019	Conversely, JAK/STAT signaling was selectively activated in CBL iPSCs and abrogated by the JAKi momelotinib and ruxolitinib.	ruxolitinib	112-123	Cbl proto-oncogene	Homo sapiens	60-63
31484895-4	2019	The Jak1/2 inhibitor ruxolitinib can simultaneously inhibit the signaling pathway of multiple cytokines with relevance for GvHD, such as interferon (IFN-gamma), IL-2, and IL-6.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
31484895-4	2019	The Jak1/2 inhibitor ruxolitinib can simultaneously inhibit the signaling pathway of multiple cytokines with relevance for GvHD, such as interferon (IFN-gamma), IL-2, and IL-6.	ruxolitinib	21-32	interferon gamma	Homo sapiens	149-158
31484895-4	2019	The Jak1/2 inhibitor ruxolitinib can simultaneously inhibit the signaling pathway of multiple cytokines with relevance for GvHD, such as interferon (IFN-gamma), IL-2, and IL-6.	ruxolitinib	21-32	interleukin 2	Homo sapiens	161-165
31484895-4	2019	The Jak1/2 inhibitor ruxolitinib can simultaneously inhibit the signaling pathway of multiple cytokines with relevance for GvHD, such as interferon (IFN-gamma), IL-2, and IL-6.	ruxolitinib	21-32	interleukin 6	Homo sapiens	171-175
31597841-5	2019	Ruxolitinib appears promising also in chronic neutrophilic leukemia, where mutations in CSF3R are common.	ruxolitinib	0-11	colony stimulating factor 3 receptor	Homo sapiens	88-93
30361243-0	2018	Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia.	ruxolitinib	50-61	Janus kinase 2	Homo sapiens	91-95
30558676-5	2018	Ruxolitinib is a tyrosine kinase inhibitor which inhibits JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	58-62
30558676-5	2018	Ruxolitinib is a tyrosine kinase inhibitor which inhibits JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	67-71
30030153-5	2019	After intermittent UVB exposure, melanocytes treated with the JAK inhibitor ruxolitinib reduced expression of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of transcription 1 (pSTAT1).	ruxolitinib	76-87	MX dynamin like GTPase 1	Homo sapiens	120-123
30030153-5	2019	After intermittent UVB exposure, melanocytes treated with the JAK inhibitor ruxolitinib reduced expression of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of transcription 1 (pSTAT1).	ruxolitinib	76-87	Janus kinase 1	Homo sapiens	149-153
30030153-5	2019	After intermittent UVB exposure, melanocytes treated with the JAK inhibitor ruxolitinib reduced expression of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of transcription 1 (pSTAT1).	ruxolitinib	76-87	signal transducer and activator of transcription 1	Homo sapiens	166-216
29939445-0	2018	The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	4-8
30056580-6	2018	The alterations of JAK2 V617F allele burden in patients treated with ruxolitinib were measured by both methods with equal accuracy.	ruxolitinib	69-80	Janus kinase 2	Homo sapiens	19-23
30501733-4	2018	Ruxolitinib, JAK2 inhibitor, combined with lenalidomide not only can improve the quality of life of patients, but also extend the survival of patients.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	13-17
30504300-4	2018	Danazol, erythropoietin-stimulating agents, and spleen-directed therapies can be useful in the ruxolitinib-resistant setting.	ruxolitinib	95-106	erythropoietin	Homo sapiens	9-23
30498775-1	2018	Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activation loop phosphorylation and is associated with a life-threatening cytokine-rebound syndrome if rapidly withdrawn.	ruxolitinib	86-97	Janus kinase 2	Homo sapiens	120-124
30498775-2	2018	We developed a time-dependent assay to mimic ruxolitinib withdrawal in primary JAK2V617F and CALR mutant myelofibrosis patient samples and observed notable activation of spontaneous STAT signaling in JAK2V617F samples after drug washout.	ruxolitinib	45-56	calreticulin	Homo sapiens	93-97
30498775-2	2018	We developed a time-dependent assay to mimic ruxolitinib withdrawal in primary JAK2V617F and CALR mutant myelofibrosis patient samples and observed notable activation of spontaneous STAT signaling in JAK2V617F samples after drug washout.	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	79-83
30498775-3	2018	Accumulation of ruxolitinib-induced JAK2 phosphorylation was dose dependent and correlated with rebound signaling and the presence of a JAK2V617F mutation.	ruxolitinib	16-27	Janus kinase 2	Homo sapiens	36-40
30498775-3	2018	Accumulation of ruxolitinib-induced JAK2 phosphorylation was dose dependent and correlated with rebound signaling and the presence of a JAK2V617F mutation.	ruxolitinib	16-27	Janus kinase 2	Homo sapiens	136-140
30498775-4	2018	Ruxolitinib prevented dephosphorylation of a cryptic site involving Tyr1007/1008 in JAK2 blocking ubiquitination and degradation.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	84-88
30463599-8	2018	In particular, we identified ruxolitinib (INCB018424) (3 muM), an inhibitor of JAK-STAT signaling that inhibited osteoblastic differentiation and matrix mineralization of hMSCs in vitro and reduced ectopic bone formation in vivo.	ruxolitinib	29-40	latexin	Homo sapiens	57-60
30463599-8	2018	In particular, we identified ruxolitinib (INCB018424) (3 muM), an inhibitor of JAK-STAT signaling that inhibited osteoblastic differentiation and matrix mineralization of hMSCs in vitro and reduced ectopic bone formation in vivo.	ruxolitinib	42-52	latexin	Homo sapiens	57-60
30453910-4	2018	Ruxolitinib is a small molecule inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	45-49
30453910-4	2018	Ruxolitinib is a small molecule inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	54-58
30519495-1	2018	Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	33-58
30519495-1	2018	Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	60-64
30519495-1	2018	Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	70-74
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	364-375	signal transducer and activator of transcription 5A	Homo sapiens	133-138
29939445-0	2018	The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.	ruxolitinib	25-36	Janus kinase 2	Homo sapiens	9-13
29939445-7	2018	Ruxolitinib, a JAK1/JAK2 inhibitor, indeed decreases symptoms like pruritus and fatigue in patients with myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
29939445-7	2018	Ruxolitinib, a JAK1/JAK2 inhibitor, indeed decreases symptoms like pruritus and fatigue in patients with myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	20-24
30123970-2	2018	This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regorafenib in patients with relapsed/refractory metastatic CRC.	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	59-65
30123970-9	2018	Ruxolitinib 20 mg BID was well tolerated in the safety run-in (n = 11).	ruxolitinib	0-11	BH3 interacting domain death agonist	Homo sapiens	18-21
29939445-9	2018	OBJECTIVE: To investigate the effect of JAK1/2-inhibition with ruxolitinib in the human mast cell lines LAD2 and HMC1.	ruxolitinib	63-74	Janus kinase 1	Homo sapiens	40-46
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	interleukin 6	Homo sapiens	59-63
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	tumor necrosis factor	Homo sapiens	65-74
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	C-C motif chemokine ligand 2	Homo sapiens	79-84
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	signal transducer and activator of transcription 5A	Homo sapiens	133-138
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	344-348
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	349-353
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	signal transducer and activator of transcription 5A	Homo sapiens	431-436
30115545-4	2018	Studies have shown that JAK2 inhibitors such as ruxolitinib are effective in reducing both splenomegaly and symptom burden.	ruxolitinib	48-59	Janus kinase 2	Homo sapiens	24-28
30324817-1	2018	INTRODUCTION: Despite the dramatic progress made in the treatment of patients with myelofibrosis since the introduction of the JAK1/2 inhibitor ruxolitinib, a therapeutic option that can modify the natural history of the disease and prevent evolution to blast-phase is still lacking.	ruxolitinib	144-155	Janus kinase 1	Homo sapiens	127-133
30035369-9	2018	Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis.	ruxolitinib	83-94	Janus kinase 1	Homo sapiens	98-102
30340199-7	2018	Plasma inhibitory assay results revealed a decrease in phospho-STAT3 levels after treatment with ruxolitinib.	ruxolitinib	97-108	signal transducer and activator of transcription 3	Homo sapiens	63-68
30035369-9	2018	Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis.	ruxolitinib	83-94	Janus kinase 2	Homo sapiens	103-107
30247637-13	2018	Forty-eight hour inhibition of JAK1 with Ruxolitinib of PND2 ovaries in vitro demonstrated concomitant acceleration of primordial follicle activation and apoptosis (P &lt;= 0.001) and upregulation of downstream JAK-STAT pathway members STAT3 and suppressors of cytokine signalling 4 (SOCS4).	ruxolitinib	41-52	Janus kinase 1	Mus musculus	31-35
30035369-9	2018	Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis.	ruxolitinib	83-94	signal transducer and activator of transcription 1	Homo sapiens	143-148
30247637-13	2018	Forty-eight hour inhibition of JAK1 with Ruxolitinib of PND2 ovaries in vitro demonstrated concomitant acceleration of primordial follicle activation and apoptosis (P &lt;= 0.001) and upregulation of downstream JAK-STAT pathway members STAT3 and suppressors of cytokine signalling 4 (SOCS4).	ruxolitinib	41-52	signal transducer and activator of transcription 3	Mus musculus	236-241
30035369-9	2018	Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis.	ruxolitinib	83-94	interferon production regulator	Homo sapiens	179-183
30247637-13	2018	Forty-eight hour inhibition of JAK1 with Ruxolitinib of PND2 ovaries in vitro demonstrated concomitant acceleration of primordial follicle activation and apoptosis (P &lt;= 0.001) and upregulation of downstream JAK-STAT pathway members STAT3 and suppressors of cytokine signalling 4 (SOCS4).	ruxolitinib	41-52	suppressor of cytokine signaling 4	Mus musculus	246-282
30247637-13	2018	Forty-eight hour inhibition of JAK1 with Ruxolitinib of PND2 ovaries in vitro demonstrated concomitant acceleration of primordial follicle activation and apoptosis (P &lt;= 0.001) and upregulation of downstream JAK-STAT pathway members STAT3 and suppressors of cytokine signalling 4 (SOCS4).	ruxolitinib	41-52	suppressor of cytokine signaling 4	Mus musculus	284-289
30035369-9	2018	Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis.	ruxolitinib	83-94	CD274 molecule	Homo sapiens	193-198
30247637-16	2018	Ruxolitinib also inhibits JAK2, with decreased efficacy.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	26-30
30209193-10	2018	CLCF1-induced SR-A1 upregulation, triglyceride accumulation, and acetylated-low-density lipoprotein uptake could be prevented using ruxolitinib, a JAK inhibitor, indicating that the effects of the cytokine on myeloid cells result from activation of the canonical JAK/STAT signaling pathway.	ruxolitinib	132-143	cardiotrophin like cytokine factor 1	Homo sapiens	0-5
32004164-2	2018	Ruxolitinib is a selective inhibitor of JAK-1 and JAK-2 used to treat PMF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	40-45
32004164-2	2018	Ruxolitinib is a selective inhibitor of JAK-1 and JAK-2 used to treat PMF.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	50-55
30257946-7	2018	Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.	ruxolitinib	27-38	CD4 molecule	Homo sapiens	9-12
30257946-7	2018	Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.	ruxolitinib	27-38	Janus kinase 1	Homo sapiens	56-60
30257946-7	2018	Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.	ruxolitinib	27-38	Janus kinase 2	Homo sapiens	65-69
30257946-7	2018	Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.	ruxolitinib	27-38	interleukin 15	Homo sapiens	91-96
30257946-7	2018	Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.	ruxolitinib	27-38	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	105-111
30257946-7	2018	Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.	ruxolitinib	27-38	CD4 molecule	Homo sapiens	142-145
30257946-11	2018	Time-limited interventions with JAK1 inhibitors, such as Ruxolitinib, should prevent the inactivation of the endogenous restriction factor SAMHD1 and protect this long-lived CD4+ T-memory cell population from HIV infection.	ruxolitinib	57-68	Janus kinase 1	Homo sapiens	32-36
30257946-11	2018	Time-limited interventions with JAK1 inhibitors, such as Ruxolitinib, should prevent the inactivation of the endogenous restriction factor SAMHD1 and protect this long-lived CD4+ T-memory cell population from HIV infection.	ruxolitinib	57-68	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Homo sapiens	139-145
30257946-11	2018	Time-limited interventions with JAK1 inhibitors, such as Ruxolitinib, should prevent the inactivation of the endogenous restriction factor SAMHD1 and protect this long-lived CD4+ T-memory cell population from HIV infection.	ruxolitinib	57-68	CD4 molecule	Homo sapiens	174-177
30010187-2	2018	Ruxolitinib is a JAK1/2 inhibitor that may control myelofibrosis (MF)-related splenomegaly and symptoms and can be prescribed regardless of age.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-23
30224514-6	2018	IFN-lambda receptor 1 knockdown and a JAK inhibitor, ruxolitinib, attenuated polyI:C-induced IFN-lambda expression, confirming that a positive autocrine feedback loop, the IFN-lambda receptor-JAK-STAT pathway, was involved in IFN-lambda expression.	ruxolitinib	53-64	interferon alpha 1	Homo sapiens	93-96
30224514-6	2018	IFN-lambda receptor 1 knockdown and a JAK inhibitor, ruxolitinib, attenuated polyI:C-induced IFN-lambda expression, confirming that a positive autocrine feedback loop, the IFN-lambda receptor-JAK-STAT pathway, was involved in IFN-lambda expression.	ruxolitinib	53-64	signal transducer and activator of transcription 1	Homo sapiens	196-200
30224514-6	2018	IFN-lambda receptor 1 knockdown and a JAK inhibitor, ruxolitinib, attenuated polyI:C-induced IFN-lambda expression, confirming that a positive autocrine feedback loop, the IFN-lambda receptor-JAK-STAT pathway, was involved in IFN-lambda expression.	ruxolitinib	53-64	interferon alpha 1	Homo sapiens	93-96
30185657-5	2018	We in turn inhibited SCC growth with an FDA-approved JAK1/2 inhibitor, ruxolitinib.	ruxolitinib	71-82	Janus kinase 1	Homo sapiens	53-59
29800615-9	2018	Levels of inflammatory cytokines IL-8, IL-10, IL-6, TNFR2, INF-alpha, and INF-beta were reduced after ruxolitinib treatment.	ruxolitinib	102-113	C-X-C motif chemokine ligand 8	Homo sapiens	33-37
29800615-9	2018	Levels of inflammatory cytokines IL-8, IL-10, IL-6, TNFR2, INF-alpha, and INF-beta were reduced after ruxolitinib treatment.	ruxolitinib	102-113	interleukin 10	Homo sapiens	39-44
29800615-9	2018	Levels of inflammatory cytokines IL-8, IL-10, IL-6, TNFR2, INF-alpha, and INF-beta were reduced after ruxolitinib treatment.	ruxolitinib	102-113	interleukin 6	Homo sapiens	46-50
29800615-9	2018	Levels of inflammatory cytokines IL-8, IL-10, IL-6, TNFR2, INF-alpha, and INF-beta were reduced after ruxolitinib treatment.	ruxolitinib	102-113	TNF receptor superfamily member 1B	Homo sapiens	52-57
29800615-9	2018	Levels of inflammatory cytokines IL-8, IL-10, IL-6, TNFR2, INF-alpha, and INF-beta were reduced after ruxolitinib treatment.	ruxolitinib	102-113	interferon alpha 17	Homo sapiens	59-68
29933930-10	2018	In TNBC cell lines with 9p24.1 gain or amplification, PD-L1 expression rapidly and strikingly increased 5- to 38-fold with interferon-gamma (P &lt; .05), and inducible PD-L1 expression was completely blocked by JAK2 knockdown and the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	251-262	CD274 molecule	Homo sapiens	54-59
29933930-10	2018	In TNBC cell lines with 9p24.1 gain or amplification, PD-L1 expression rapidly and strikingly increased 5- to 38-fold with interferon-gamma (P &lt; .05), and inducible PD-L1 expression was completely blocked by JAK2 knockdown and the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	251-262	CD274 molecule	Homo sapiens	168-173
30245189-4	2018	Since ruxolitinib, a JAK1/JAK2 inhibitor, suppresses NF-kB expression, we conducted a phase 1 dose-escalation study to determine the safety and efficacy of ruxolitinib in previously treated lower-risk MDS patients with evidence of NF-kB activation.	ruxolitinib	6-17	Janus kinase 1	Homo sapiens	21-25
30245189-4	2018	Since ruxolitinib, a JAK1/JAK2 inhibitor, suppresses NF-kB expression, we conducted a phase 1 dose-escalation study to determine the safety and efficacy of ruxolitinib in previously treated lower-risk MDS patients with evidence of NF-kB activation.	ruxolitinib	6-17	Janus kinase 2	Homo sapiens	26-30
30590943-14	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	ruxolitinib	20-31	Janus kinase 1	Homo sapiens	0-4
30590943-14	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	ruxolitinib	20-31	Janus kinase 2	Homo sapiens	5-9
29681434-2	2018	We evaluated the JAK1/JAK2 inhibitor ruxolitinib plus pemetrexed/cisplatin first-line in patients with stage IIIB/IV or recurrent nonsquamous NSCLC with systemic inflammation (modified Glasgow prognostic score [mGPS] 1/2).	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	17-21
30012499-6	2018	In the present study, we use ruxolitinib (potent JAK2 inhibitor) to increase the sensitivity of AML cells to ATO treatment.	ruxolitinib	29-40	Janus kinase 2	Homo sapiens	49-53
30043249-1	2018	The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012.	ruxolitinib	52-63	Janus kinase 1	Homo sapiens	34-40
29945795-0	2018	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).	ruxolitinib	11-22	Janus kinase 2	Homo sapiens	75-79
29945795-0	2018	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).	ruxolitinib	11-22	histone deacetylase 6	Homo sapiens	84-105
29945795-0	2018	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).	ruxolitinib	11-22	histone deacetylase 6	Homo sapiens	107-112
30001163-1	2018	INTRODUCTION: Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly improved the lives of patients with myelofibrosis.	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	54-60
29773603-0	2018	Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.	ruxolitinib	21-32	golgin A5	Homo sapiens	129-135
29773603-0	2018	Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.	ruxolitinib	21-32	Janus kinase 2	Homo sapiens	136-140
29971909-1	2018	Allogeneic stem cell transplantation is currently the only curative therapy for primary myelofibrosis (MF), while the JAK2 inhibitor, ruxolitinib.	ruxolitinib	134-145	Janus kinase 2	Mus musculus	118-122
29988117-8	2018	Treatment with the JAK inhibitor ruxolitinib ameliorated colitis in TRAG mice.	ruxolitinib	33-44	WD repeat domain 7	Mus musculus	68-72
30114348-5	2018	Currently ruxolitinib, a JAK1/JAK2 inhibitor, is also approved for PV patients with hydroxyurea resistance or intolerance.	ruxolitinib	10-21	Janus kinase 1	Homo sapiens	25-29
30114348-5	2018	Currently ruxolitinib, a JAK1/JAK2 inhibitor, is also approved for PV patients with hydroxyurea resistance or intolerance.	ruxolitinib	10-21	Janus kinase 2	Homo sapiens	30-34
30159126-5	2018	Therefore in this study we investigated whether inhibiting both JAK1/2 and CDK4/6, using LEE011 and ruxolitinib respectively is effective in NKTL.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	64-70
30159126-5	2018	Therefore in this study we investigated whether inhibiting both JAK1/2 and CDK4/6, using LEE011 and ruxolitinib respectively is effective in NKTL.	ruxolitinib	100-111	cyclin dependent kinase 4	Homo sapiens	75-81
29565699-7	2018	He recently was started on the JAK2 inhibitor ruxolitinib.	ruxolitinib	46-57	Janus kinase 2	Homo sapiens	31-35
30074114-9	2018	Among JAK2 inhibitors, ruxolitinib (RUX) has been approved for (1) treatment of intermediate-2 and high-risk MF and (2) PV patients who are resistant to or intolerant to hydroxyurea.	ruxolitinib	23-34	Janus kinase 2	Homo sapiens	6-10
30074114-9	2018	Among JAK2 inhibitors, ruxolitinib (RUX) has been approved for (1) treatment of intermediate-2 and high-risk MF and (2) PV patients who are resistant to or intolerant to hydroxyurea.	ruxolitinib	36-39	Janus kinase 2	Homo sapiens	6-10
29616317-2	2018	Ruxolitinib, a JAK1/2 inhibitor, is the lone therapy approved for MF, offering a clear symptom and spleen benefit at the expense of treatment-related cytopenias.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
29675680-0	2018	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.	ruxolitinib	45-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	127-131
29675680-0	2018	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.	ruxolitinib	45-56	C-reactive protein	Homo sapiens	168-186
29675680-2	2018	This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] &gt;= 1).	ruxolitinib	83-94	Janus kinase 1	Homo sapiens	98-102
29675680-2	2018	This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] &gt;= 1).	ruxolitinib	83-94	Janus kinase 2	Homo sapiens	103-107
29675680-2	2018	This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] &gt;= 1).	ruxolitinib	83-94	erb-b2 receptor tyrosine kinase 2	Homo sapiens	152-156
29681434-2	2018	We evaluated the JAK1/JAK2 inhibitor ruxolitinib plus pemetrexed/cisplatin first-line in patients with stage IIIB/IV or recurrent nonsquamous NSCLC with systemic inflammation (modified Glasgow prognostic score [mGPS] 1/2).	ruxolitinib	37-48	Janus kinase 2	Homo sapiens	22-26
29508247-1	2018	Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] &gt;13 mg/dL) in the randomized phase II RECAP study.	ruxolitinib	11-22	Janus kinase 1	Homo sapiens	42-46
29508247-1	2018	Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] &gt;13 mg/dL) in the randomized phase II RECAP study.	ruxolitinib	11-22	Janus kinase 2	Homo sapiens	48-52
29508247-1	2018	Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] &gt;13 mg/dL) in the randomized phase II RECAP study.	ruxolitinib	11-22	C-reactive protein	Homo sapiens	225-243
30058088-13	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	ruxolitinib	20-31	Janus kinase 1	Homo sapiens	0-4
30058088-13	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	ruxolitinib	20-31	Janus kinase 2	Homo sapiens	5-9
30123428-7	2018	Next, we investigated the effects of ruxolitinib, an inhibitor of both JAK1 and JAK2, which phosphorylates and activates STAT3.	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	71-75
30123428-7	2018	Next, we investigated the effects of ruxolitinib, an inhibitor of both JAK1 and JAK2, which phosphorylates and activates STAT3.	ruxolitinib	37-48	Janus kinase 2	Homo sapiens	80-84
30123428-7	2018	Next, we investigated the effects of ruxolitinib, an inhibitor of both JAK1 and JAK2, which phosphorylates and activates STAT3.	ruxolitinib	37-48	signal transducer and activator of transcription 3	Homo sapiens	121-126
30123428-8	2018	Ruxolitinib suppressed the phosphorylation of STAT3 in EBV-positive T- or NK-cell lines.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Homo sapiens	46-51
29622655-6	2018	Surprisingly, we found that ruxolitinib, an FDA approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	73-77
30038614-11	2018	The patient was treated with corticosteroids and the JAK inhibitor Ruxolitinib, resulting in a rapid improvement of pulmonary hypertension, general well-being, and resolution of the IFN gene signature.	ruxolitinib	67-78	interferon alpha 1	Homo sapiens	182-185
29645296-8	2018	Moreover, Ruxolitinib reduced MSC secretion of MCP-1 and IL-6.	ruxolitinib	10-21	C-C motif chemokine ligand 2	Homo sapiens	47-52
29645296-8	2018	Moreover, Ruxolitinib reduced MSC secretion of MCP-1 and IL-6.	ruxolitinib	10-21	interleukin 6	Homo sapiens	57-61
29645296-9	2018	CONCLUSION: Ruxolitinib affected JAK2 signaling in MSC at clinically relevant doses, which is likely to contribute to the normalization of the inflammatory milieu in MPNs.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	33-37
29622655-6	2018	Surprisingly, we found that ruxolitinib, an FDA approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects.	ruxolitinib	28-39	Janus kinase 2	Homo sapiens	82-86
31723782-5	2018	Ruxolitinib, a Janus Kinase (JAK) 1/JAK2 inhibitor, has demonstrated efficacy in patients with both myelofibrosis (MF) and polycythemia vera and is well tolerated.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-35
29934865-0	2018	Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.	ruxolitinib	11-22	signal transducer and activator of transcription 1	Homo sapiens	91-96
29934865-2	2018	We aim to report the effect of oral ruxolitinib, the Janus kinase (JAK) family tyrosine kinase inhibitor, on clinical and immune status of a 12-year-old boy with severe CMC due to a novel STAT1 GOF mutation.	ruxolitinib	36-47	signal transducer and activator of transcription 1	Homo sapiens	188-193
29934865-6	2018	RESULTS: A novel STAT1 GOF mutation (c.617T > C; p.L206P), detected in a child with recalcitrant CMC, was shown to be reversible in vitro with ruxolitinib.	ruxolitinib	143-154	signal transducer and activator of transcription 1	Homo sapiens	17-22
29934865-7	2018	Major clinical improvement was achieved after 8 weeks of ruxolitinib treatment, while sustained suppression of IFNgamma- and IFNalpha-induced phosphorylation of STAT1, STAT3, and STAT5, as well as increased STAT3-inducible and Th17-related gene expression, was demonstrated ex vivo.	ruxolitinib	57-68	interferon alpha 1	Homo sapiens	125-133
29934865-8	2018	Clinical relapse and spike of all monitored phosphorylated STAT activity was registered shortly after unplanned withdrawal, decreasing again after ruxolitinib reintroduction.	ruxolitinib	147-158	signal transducer and activator of transcription 1	Homo sapiens	59-63
29934865-11	2018	CONCLUSION: JAK1/2 inhibition with ruxolitinib represents a viable option for treatment of refractory CMC, if HSCT is not considered.	ruxolitinib	35-46	Janus kinase 1	Homo sapiens	12-18
29645296-2	2018	The JAK1/2 inhibitor Ruxolitinib has remarkable clinical efficacy, including spleen reduction, improvement of constitutional symptoms, and bone marrow (BM) fibrosis reversal.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
31723778-8	2018	Moreover, low doses of IMG-7289 and ruxolitinib synergize in normalizing the MPN phenotype in mice, offering a rationale for investigating combination therapy.	ruxolitinib	36-47	protease, serine 27	Mus musculus	77-80
31723782-5	2018	Ruxolitinib, a Janus Kinase (JAK) 1/JAK2 inhibitor, has demonstrated efficacy in patients with both myelofibrosis (MF) and polycythemia vera and is well tolerated.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	36-40
29907650-2	2018	In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-approved ruxolitinib) provided limited single-agent responses, possibly due to paradoxical JAK2Y1007/1008 hyperphosphorylation induced by these agents.	ruxolitinib	138-149	Janus kinase 2	Homo sapiens	37-41
29417241-5	2018	Treatment with the JAK inhibitor ruxolitinib abrogated the MxA-mediated suppression of HCV replication and activation of the JAK-STAT pathway.	ruxolitinib	33-44	MX dynamin like GTPase 1	Homo sapiens	59-62
29907650-2	2018	In preclinical studies, treatment of JAK2 mutant leukemias with type I JAK2 inhibitors (e.g., Food and Drug Administration [FDA]-approved ruxolitinib) provided limited single-agent responses, possibly due to paradoxical JAK2Y1007/1008 hyperphosphorylation induced by these agents.	ruxolitinib	138-149	Janus kinase 2	Homo sapiens	71-75
29907650-6	2018	Combined indirect targeting of c-Myc using the BET bromodomain inhibitor JQ1 and direct targeting of JAK2 with ruxolitinib potently killed JAK2 mutant B-ALLs.	ruxolitinib	111-122	Janus kinase 2	Homo sapiens	101-105
29907650-6	2018	Combined indirect targeting of c-Myc using the BET bromodomain inhibitor JQ1 and direct targeting of JAK2 with ruxolitinib potently killed JAK2 mutant B-ALLs.	ruxolitinib	111-122	Janus kinase 2	Homo sapiens	139-143
29650801-4	2018	Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea.	ruxolitinib	31-42	Janus kinase 2	Homo sapiens	6-10
29928488-0	2018	Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2.	ruxolitinib	75-86	Janus kinase 2	Homo sapiens	131-135
29928488-1	2018	The activated JAK2-V617F mutant is very frequently found in myeloproliferative neoplasms (MPNs), and its inhibitor ruxolitinib has been in clinical use, albeit with limited efficacies.	ruxolitinib	115-126	Janus kinase 2	Homo sapiens	14-18
29928488-2	2018	Here, we examine the signaling mechanisms from JAK2-V617F and responses to ruxolitinib in JAK2-V617F-positive leukemic cell lines, including PVTL-2, newly established from a patient with post-MPN secondary acute myeloid leukemia, and the widely used model cell line HEL.	ruxolitinib	75-86	Janus kinase 2	Homo sapiens	90-94
29928488-3	2018	We have found that ruxolitinib downregulated the mTORC1/S6K/4EBP1 pathway at least partly through inhibition of the STAT5/Pim-2 pathway with concomitant downregulation of c-Myc, MCL-1, and BCL-xL as well as induction of autophagy in these cells.	ruxolitinib	19-30	CREB regulated transcription coactivator 1	Mus musculus	49-55
29928488-3	2018	We have found that ruxolitinib downregulated the mTORC1/S6K/4EBP1 pathway at least partly through inhibition of the STAT5/Pim-2 pathway with concomitant downregulation of c-Myc, MCL-1, and BCL-xL as well as induction of autophagy in these cells.	ruxolitinib	19-30	signal transducer and activator of transcription 5A	Homo sapiens	116-121
29928488-3	2018	We have found that ruxolitinib downregulated the mTORC1/S6K/4EBP1 pathway at least partly through inhibition of the STAT5/Pim-2 pathway with concomitant downregulation of c-Myc, MCL-1, and BCL-xL as well as induction of autophagy in these cells.	ruxolitinib	19-30	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	122-127
29928488-3	2018	We have found that ruxolitinib downregulated the mTORC1/S6K/4EBP1 pathway at least partly through inhibition of the STAT5/Pim-2 pathway with concomitant downregulation of c-Myc, MCL-1, and BCL-xL as well as induction of autophagy in these cells.	ruxolitinib	19-30	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	171-176
29928488-3	2018	We have found that ruxolitinib downregulated the mTORC1/S6K/4EBP1 pathway at least partly through inhibition of the STAT5/Pim-2 pathway with concomitant downregulation of c-Myc, MCL-1, and BCL-xL as well as induction of autophagy in these cells.	ruxolitinib	19-30	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	178-183
29928488-3	2018	We have found that ruxolitinib downregulated the mTORC1/S6K/4EBP1 pathway at least partly through inhibition of the STAT5/Pim-2 pathway with concomitant downregulation of c-Myc, MCL-1, and BCL-xL as well as induction of autophagy in these cells.	ruxolitinib	19-30	BCL2 like 1	Homo sapiens	189-195
29928488-5	2018	However, inhibition of BCL-xL/BCL-2 by the BH3 mimetics ABT-737 and navitoclax or BCL-xL by A-1331852 induced caspase-dependent apoptosis involving activation of Bak and Bax synergistically with ruxolitinib in HEL cells.	ruxolitinib	195-206	BCL2 like 1	Homo sapiens	23-29
29928488-5	2018	However, inhibition of BCL-xL/BCL-2 by the BH3 mimetics ABT-737 and navitoclax or BCL-xL by A-1331852 induced caspase-dependent apoptosis involving activation of Bak and Bax synergistically with ruxolitinib in HEL cells.	ruxolitinib	195-206	BCL2 apoptosis regulator	Homo sapiens	30-35
29928488-5	2018	However, inhibition of BCL-xL/BCL-2 by the BH3 mimetics ABT-737 and navitoclax or BCL-xL by A-1331852 induced caspase-dependent apoptosis involving activation of Bak and Bax synergistically with ruxolitinib in HEL cells.	ruxolitinib	195-206	BCL2 antagonist/killer 1	Homo sapiens	162-165
29928488-7	2018	The present study suggests that autophagy as well as the anti-apoptotic BCL-2 family members, regulated at least partly by the mTORC1 pathway downstream of STAT5/Pim-2, protects JAK2-V617F-positive leukemic cells from ruxolitinib-induced apoptosis depending on cell types and may contribute to development of new strategies against JAK2-V617F-positive neoplasms.	ruxolitinib	218-229	BCL2 apoptosis regulator	Homo sapiens	72-77
29928488-7	2018	The present study suggests that autophagy as well as the anti-apoptotic BCL-2 family members, regulated at least partly by the mTORC1 pathway downstream of STAT5/Pim-2, protects JAK2-V617F-positive leukemic cells from ruxolitinib-induced apoptosis depending on cell types and may contribute to development of new strategies against JAK2-V617F-positive neoplasms.	ruxolitinib	218-229	CREB regulated transcription coactivator 1	Mus musculus	127-133
29111217-0	2018	Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	90-140
29111217-0	2018	Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	142-147
29111217-7	2018	NK cells from patients with STAT1 GOF mutations were treated in vitro with ruxolitinib.	ruxolitinib	75-86	signal transducer and activator of transcription 1	Homo sapiens	28-33
29111217-11	2018	Upstream inhibition of STAT1 signaling with the small-molecule Janus kinase 1/2 inhibitor ruxolitinib in vitro and in vivo restored perforin expression in CD56dim NK cells and partially restored NK cell cytotoxic function.	ruxolitinib	90-101	signal transducer and activator of transcription 1	Homo sapiens	23-28
29111217-13	2018	Modulation of increased STAT1 phosphorylation with ruxolitinib is an important option for therapeutic intervention in patients with STAT1 GOF mutations.	ruxolitinib	51-62	signal transducer and activator of transcription 1	Homo sapiens	24-29
29111217-13	2018	Modulation of increased STAT1 phosphorylation with ruxolitinib is an important option for therapeutic intervention in patients with STAT1 GOF mutations.	ruxolitinib	51-62	signal transducer and activator of transcription 1	Homo sapiens	132-137
29650801-4	2018	Among JAK2 inhibitors (JAKis), ruxolitinib (RUX) has been approved for the treatment of intermediate and high-risk MF and for PV inadequately controlled by or intolerant of hydroxyurea.	ruxolitinib	44-47	Janus kinase 2	Homo sapiens	6-10
29854301-6	2018	In vitro, treating the transformed cell line with the JAK1/2 inhibitor ruxolitinib inhibited ligand-independent signaling and induced cell death.	ruxolitinib	71-82	Janus kinase 1	Mus musculus	54-60
29761158-0	2018	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.	ruxolitinib	18-29	Janus kinase 1	Homo sapiens	43-49
29761158-2	2018	Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	76-80
29761158-2	2018	Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	85-89
29351986-0	2018	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.	ruxolitinib	49-60	Janus kinase 1	Homo sapiens	29-33
29351986-0	2018	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.	ruxolitinib	49-60	Janus kinase 2	Homo sapiens	34-38
29351986-3	2018	In this phase II study we assessed the safety and efficacy of ruxolitinib, an oral JAK1/2 inhibitor, in patients with relapsed/refractory Hodgkin lymphoma.	ruxolitinib	62-73	Janus kinase 1	Homo sapiens	83-89
29515238-6	2018	Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea.	ruxolitinib	116-127	Janus kinase 1	Homo sapiens	96-100
29515238-6	2018	Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea.	ruxolitinib	116-127	Janus kinase 2	Homo sapiens	101-105
29750040-2	2018	This Phase Ib study evaluated ruxolitinib, a potent JAK1/2 inhibitor, in combination with gemcitabine with or without nab-paclitaxel in patients with advanced solid tumors.	ruxolitinib	30-41	Janus kinase 1	Homo sapiens	52-58
29778097-8	2018	Furthermore, we showed that only two-week treatment of mice with ruxolitinib, a JAK1/2 inhibitor, blocked STAT5 activation, restored apoptosis, and prevented early lesion progression.	ruxolitinib	65-76	Janus kinase 1	Mus musculus	80-86
29778097-8	2018	Furthermore, we showed that only two-week treatment of mice with ruxolitinib, a JAK1/2 inhibitor, blocked STAT5 activation, restored apoptosis, and prevented early lesion progression.	ruxolitinib	65-76	signal transducer and activator of transcription 5A	Mus musculus	106-111
29785143-4	2018	Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients.	ruxolitinib	55-66	Janus kinase 2	Homo sapiens	9-13
29785143-4	2018	Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	38-44
29785143-4	2018	Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients.	ruxolitinib	170-181	Janus kinase 2	Homo sapiens	9-13
29785143-4	2018	Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients.	ruxolitinib	170-181	Janus kinase 2	Homo sapiens	75-79
29363542-8	2018	In contrast, JAK1/2 inhibitor ruxolitinib significantly ameliorated skin GVHD, protected Lgr5+ HFSCs, and restored hair regeneration and wound healing after SCT.	ruxolitinib	30-41	Janus kinase 1	Mus musculus	13-19
29363542-8	2018	In contrast, JAK1/2 inhibitor ruxolitinib significantly ameliorated skin GVHD, protected Lgr5+ HFSCs, and restored hair regeneration and wound healing after SCT.	ruxolitinib	30-41	leucine rich repeat containing G protein coupled receptor 5	Mus musculus	89-93
29468276-10	2018	The JAK1/2 inhibitor ruxolitinib also seems to be effective across a range of patient ages.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
29251529-1	2018	BACKGROUND: Primary myelofibrosis is a chronic myeloproliferative neoplasm that may cause debilitating symptoms, which can be improved with the use of Ruxolitinib, a Janus kinase 2 inhibitor.	ruxolitinib	151-162	Janus kinase 2	Homo sapiens	166-180
29522138-2	2018	Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib.	ruxolitinib	118-129	Janus kinase 1	Homo sapiens	64-78
29522138-2	2018	Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib.	ruxolitinib	118-129	Janus kinase 2	Homo sapiens	86-100
29522138-2	2018	Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib.	ruxolitinib	118-129	Janus kinase 2	Homo sapiens	102-106
29665922-6	2018	The incidence of anemia significantly increased after ruxolitinib treatment (RR 1.71, 95% CI [1.05-2.77], P=0.16), while the thrombocytopenia (RR 1.04, 95% CI [0.50-2.16], P=0.92) and neutropenia (RR 2.46, 95% CI [0.91-6.61], P=0.07) had no statistical difference as compared with that in control group.	ruxolitinib	54-65	ribonucleotide reductase catalytic subunit M1	Homo sapiens	77-81
29396713-2	2018	This ad hoc analysis focuses on ruxolitinib in relation to IFN in the RESPONSE studies, with attention on the following: (1) safety and efficacy of ruxolitinib and best available therapy in patients who received IFN before study randomization, (2) safety and efficacy of IFN during randomized treatment in best available therapy arm, and (3) use of ruxolitinib after crossover from best available therapy in IFN-treated patients.	ruxolitinib	32-43	interferon alpha 1	Homo sapiens	59-62
29396713-4	2018	In the randomized treatment arms, ruxolitinib was superior to IFN in efficacy [hematocrit control (RESPONSE = 60% of ruxolitinib vs 23% of IFN patients; RESPONSE-2 = 62% of ruxolitinib vs 15% of IFN patients)] and was tolerated better in hydroxyurea-resistant or hydroxyurea-intolerant patients.	ruxolitinib	34-45	interferon alpha 1	Homo sapiens	139-142
29396713-4	2018	In the randomized treatment arms, ruxolitinib was superior to IFN in efficacy [hematocrit control (RESPONSE = 60% of ruxolitinib vs 23% of IFN patients; RESPONSE-2 = 62% of ruxolitinib vs 15% of IFN patients)] and was tolerated better in hydroxyurea-resistant or hydroxyurea-intolerant patients.	ruxolitinib	34-45	interferon alpha 1	Homo sapiens	139-142
29396713-5	2018	After crossing over to receive ruxolitinib, patients who had initially received IFN and did not respond had improved hematologic and spleen responses (62% of patients at any time after crossover) and an overall reduction in phlebotomy procedures.	ruxolitinib	31-42	interferon alpha 1	Homo sapiens	80-83
29396713-7	2018	These data suggest that ruxolitinib is efficacious and well tolerated in patients who were previously treated with IFN.	ruxolitinib	24-35	interferon alpha 1	Homo sapiens	115-118
29713323-8	2018	We found that ruxolitinib-treated CIML NK cells expressed lower levels of CD25 than non-treated CIML NK cells, but exhibited similar proliferation in response to IL-2.	ruxolitinib	14-25	interleukin 2 receptor subunit alpha	Homo sapiens	74-78
29713323-8	2018	We found that ruxolitinib-treated CIML NK cells expressed lower levels of CD25 than non-treated CIML NK cells, but exhibited similar proliferation in response to IL-2.	ruxolitinib	14-25	interleukin 2	Homo sapiens	162-166
29713323-9	2018	In addition, we have also found that ruxolitinib-treated NK cells displayed reduced effector functions after the preactivation, which can be recovered after a 4 days expansion phase in the presence of low doses of IL-2.	ruxolitinib	37-48	interleukin 2	Homo sapiens	214-218
29643232-5	2018	Inhibition of JAK-STAT signaling with the clinically available JAK2 inhibitor ruxolitinib abrogated NET formation and reduced thrombosis in a deep vein stenosis murine model.	ruxolitinib	78-89	Janus kinase 2	Mus musculus	63-67
29235894-2	2018	A few years ago, the first-in-class JAK1/JAK2 inhibitor ruxolitinib, demonstrated reductions in both constitutional symptoms and splenomegaly, leading to the US FDA approval.	ruxolitinib	56-67	Janus kinase 1	Homo sapiens	36-40
29235894-2	2018	A few years ago, the first-in-class JAK1/JAK2 inhibitor ruxolitinib, demonstrated reductions in both constitutional symptoms and splenomegaly, leading to the US FDA approval.	ruxolitinib	56-67	Janus kinase 2	Homo sapiens	41-45
29436642-0	2018	Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells.	ruxolitinib	34-45	estrogen receptor 1	Homo sapiens	64-81
29436642-0	2018	Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells.	ruxolitinib	34-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-132
29436642-9	2018	Annexin V-FITC/PI staining and cell cycle analysis identified a synergistic increase in apoptosis and sub-G1 arrest in the presence of ruxolitinib and calcitriol.	ruxolitinib	135-146	annexin A5	Homo sapiens	0-9
29436642-10	2018	Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins.	ruxolitinib	65-76	Janus kinase 2	Homo sapiens	139-143
29436642-10	2018	Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins.	ruxolitinib	65-76	Janus kinase 2	Homo sapiens	160-164
29436642-10	2018	Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins.	ruxolitinib	65-76	cyclin D1	Homo sapiens	196-205
29436642-10	2018	Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins.	ruxolitinib	65-76	BCL2 apoptosis regulator	Homo sapiens	227-232
29436642-10	2018	Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins.	ruxolitinib	65-76	BCL2 like 1	Homo sapiens	237-257
29436642-10	2018	Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins.	ruxolitinib	65-76	caspase 3	Homo sapiens	288-297
29436642-10	2018	Western blot analysis revealed that these synergistic effects of ruxolitinib and calcitriol were associated with reduced protein levels of JAK2, phosphorylated JAK2, c-Myc proto oncogene protein, cyclin-D1, apoptosis regulator Bcl-2 and Bcl-2-like protein 1, and with increased levels of caspase-3 and Bcl-2-associated agonist of cell death proteins.	ruxolitinib	65-76	BCL2 apoptosis regulator	Homo sapiens	237-242
29436642-11	2018	The results of the present study demonstrated the synergistic anticancer effects of ruxolitinib and calcitriol in ER and HER2-positive MCF7-HER18 breast cancer cells.	ruxolitinib	84-95	estrogen receptor 1	Homo sapiens	114-116
29436642-11	2018	The results of the present study demonstrated the synergistic anticancer effects of ruxolitinib and calcitriol in ER and HER2-positive MCF7-HER18 breast cancer cells.	ruxolitinib	84-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	121-125
29436642-12	2018	Based on these findings, ruxolitinib and calcitriol may have potential as a combination therapy for patients with ER and HER2-positive breast cancer.	ruxolitinib	25-36	estrogen receptor 1	Homo sapiens	114-116
29665922-6	2018	The incidence of anemia significantly increased after ruxolitinib treatment (RR 1.71, 95% CI [1.05-2.77], P=0.16), while the thrombocytopenia (RR 1.04, 95% CI [0.50-2.16], P=0.92) and neutropenia (RR 2.46, 95% CI [0.91-6.61], P=0.07) had no statistical difference as compared with that in control group.	ruxolitinib	54-65	ribonucleotide reductase regulatory subunit M2	Homo sapiens	197-201
29665922-9	2018	CONCLUSION: Ruxolitinib is an efficacious therapeutic strategy on MPD with controlling splenomegaly.	ruxolitinib	12-23	mevalonate diphosphate decarboxylase	Homo sapiens	66-69
29544547-2	2018	The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly, symptom burden, and overall survival in patients with intermediate-2 or high-risk MF compared with placebo or best available therapy (BAT).	ruxolitinib	45-56	Janus kinase 1	Homo sapiens	9-29
29562644-10	2018	In addition, MF patients with &gt;=1 mutations in AZXL1, EZH1 or IDH1/2 had significantly low spleen reduction response in ruxolitinib treatment.	ruxolitinib	123-134	enhancer of zeste 1 polycomb repressive complex 2 subunit	Homo sapiens	57-61
29562644-10	2018	In addition, MF patients with &gt;=1 mutations in AZXL1, EZH1 or IDH1/2 had significantly low spleen reduction response in ruxolitinib treatment.	ruxolitinib	123-134	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	65-71
29189896-1	2018	Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-23
28969943-7	2018	The Jak 1/2 inhibitor ruxolitinib, the mTOR inhibitor rapamycin and the PI3 kinase inhibitor LY294002 all prevented the potentiation of cell death by IL-13.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-11
28969943-7	2018	The Jak 1/2 inhibitor ruxolitinib, the mTOR inhibitor rapamycin and the PI3 kinase inhibitor LY294002 all prevented the potentiation of cell death by IL-13.	ruxolitinib	22-33	interleukin 13	Homo sapiens	150-155
29480036-7	2018	Ruxolitinib, a potent oral JAK1/JAK2 inhibitor remains the only Food and Drug Administration (FDA)-approved medicinal therapy for the treatment of MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	27-31
29480036-7	2018	Ruxolitinib, a potent oral JAK1/JAK2 inhibitor remains the only Food and Drug Administration (FDA)-approved medicinal therapy for the treatment of MF.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	32-36
29107666-0	2018	JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib.	ruxolitinib	94-105	Janus kinase 2	Homo sapiens	0-4
29107666-4	2018	We describe the case of a patient affected by JAK2-positive primary myelofibrosis (PMF) who developed a clonally related LCH while in treatment with ruxolitinib.	ruxolitinib	149-160	Janus kinase 2	Homo sapiens	46-50
29544547-2	2018	The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly, symptom burden, and overall survival in patients with intermediate-2 or high-risk MF compared with placebo or best available therapy (BAT).	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	30-34
29134664-12	2018	The combination of ruxolitinib and azacytidine was well-tolerated with an ICP MDS/MPN-response rate of 57% in patients with MDS/MPNs.	ruxolitinib	19-30	serine protease 27	Homo sapiens	82-85
29472557-2	2018	The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies.	ruxolitinib	81-92	Janus kinase 1	Homo sapiens	64-70
29162613-0	2018	The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
29162613-0	2018	The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes.	ruxolitinib	21-32	interleukin 6	Homo sapiens	42-55
29162613-3	2018	In the present study, we investigated whether ruxolitinib, a small drug acting as a JAK1/2 inhibitor and currently used in the treatment of myeloproliferative neoplasms, may also counteract the repressing effects of IL-6 toward hepatic detoxifying systems.	ruxolitinib	46-57	Janus kinase 1	Homo sapiens	84-90
29162613-3	2018	In the present study, we investigated whether ruxolitinib, a small drug acting as a JAK1/2 inhibitor and currently used in the treatment of myeloproliferative neoplasms, may also counteract the repressing effects of IL-6 toward hepatic detoxifying systems.	ruxolitinib	46-57	interleukin 6	Homo sapiens	216-220
29162613-4	2018	Ruxolitinib was found to fully inhibit IL-6-mediated repression of P450 (CYP1A2, CYP2B6, and CYP3A4) and transporter (NTCP, OATP1B1, and OCT1) mRNA levels in primary human hepatocytes and differentiated hepatoma HepaRG cells.	ruxolitinib	0-11	interleukin 6	Homo sapiens	39-43
29162613-4	2018	Ruxolitinib was found to fully inhibit IL-6-mediated repression of P450 (CYP1A2, CYP2B6, and CYP3A4) and transporter (NTCP, OATP1B1, and OCT1) mRNA levels in primary human hepatocytes and differentiated hepatoma HepaRG cells.	ruxolitinib	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	73-79
29162613-4	2018	Ruxolitinib was found to fully inhibit IL-6-mediated repression of P450 (CYP1A2, CYP2B6, and CYP3A4) and transporter (NTCP, OATP1B1, and OCT1) mRNA levels in primary human hepatocytes and differentiated hepatoma HepaRG cells.	ruxolitinib	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	81-87
29162613-4	2018	Ruxolitinib was found to fully inhibit IL-6-mediated repression of P450 (CYP1A2, CYP2B6, and CYP3A4) and transporter (NTCP, OATP1B1, and OCT1) mRNA levels in primary human hepatocytes and differentiated hepatoma HepaRG cells.	ruxolitinib	0-11	solute carrier organic anion transporter family member 1B1	Homo sapiens	124-131
29162613-4	2018	Ruxolitinib was found to fully inhibit IL-6-mediated repression of P450 (CYP1A2, CYP2B6, and CYP3A4) and transporter (NTCP, OATP1B1, and OCT1) mRNA levels in primary human hepatocytes and differentiated hepatoma HepaRG cells.	ruxolitinib	0-11	POU class 2 homeobox 1	Homo sapiens	137-141
29162613-8	2018	Taken together, our results demonstrated that small drugs acting as JAK inhibitors, like ruxolitinib, counteract IL-6-mediated repression of drug-metabolizing enzymes and drug transporters in cultured human hepatocytes.	ruxolitinib	89-100	interleukin 6	Homo sapiens	113-117
29461617-0	2018	JAK/STAT5 signaling pathway inhibitor ruxolitinib reduces airway inflammation of neutrophilic asthma in mice model.	ruxolitinib	38-49	signal transducer and activator of transcription 5A	Mus musculus	4-9
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	Janus kinase 2	Homo sapiens	133-137
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	calreticulin	Homo sapiens	145-149
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	155-158
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	Janus kinase 1	Homo sapiens	225-239
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	Janus kinase 1	Homo sapiens	241-245
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	Janus kinase 2	Homo sapiens	251-255
29461617-13	2018	CONCLUSIONS: Ruxolitinib may suppress the survival of Th17 cells by inhibiting the JAK/STAT5 signaling pathway and regulate the anti-apoptosis proteins Bcl-2 and Caspase3, thus promoting the increase of Thl7 cells entering the apoptotic pathway and reducing airway inflammation in NA mice.	ruxolitinib	13-24	signal transducer and activator of transcription 5A	Mus musculus	87-92
29461617-13	2018	CONCLUSIONS: Ruxolitinib may suppress the survival of Th17 cells by inhibiting the JAK/STAT5 signaling pathway and regulate the anti-apoptosis proteins Bcl-2 and Caspase3, thus promoting the increase of Thl7 cells entering the apoptotic pathway and reducing airway inflammation in NA mice.	ruxolitinib	13-24	B cell leukemia/lymphoma 2	Mus musculus	152-157
29461617-13	2018	CONCLUSIONS: Ruxolitinib may suppress the survival of Th17 cells by inhibiting the JAK/STAT5 signaling pathway and regulate the anti-apoptosis proteins Bcl-2 and Caspase3, thus promoting the increase of Thl7 cells entering the apoptotic pathway and reducing airway inflammation in NA mice.	ruxolitinib	13-24	caspase 3	Mus musculus	162-170
28956263-1	2018	Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
29388547-11	2018	Ruxolitinib caused a significant increase in the production of IL-6, IL-8 and TNF-alpha in stimulated cells.	ruxolitinib	0-11	interleukin 6	Homo sapiens	63-67
29388547-11	2018	Ruxolitinib caused a significant increase in the production of IL-6, IL-8 and TNF-alpha in stimulated cells.	ruxolitinib	0-11	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
29388547-11	2018	Ruxolitinib caused a significant increase in the production of IL-6, IL-8 and TNF-alpha in stimulated cells.	ruxolitinib	0-11	tumor necrosis factor	Homo sapiens	78-87
29849942-5	2018	We investigated the therapeutic potential of ruxolitinib, a JAK1/JAK2 inhibitor that has been FDA-approved for the treatment of myelofibrosis, to treat ovarian cancer either alone or in combination with conventional chemotherapy agents.	ruxolitinib	45-56	Janus kinase 1	Homo sapiens	60-64
29849942-5	2018	We investigated the therapeutic potential of ruxolitinib, a JAK1/JAK2 inhibitor that has been FDA-approved for the treatment of myelofibrosis, to treat ovarian cancer either alone or in combination with conventional chemotherapy agents.	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	65-69
29849942-6	2018	We show that ruxolitinib inhibits STAT3 activation and ovarian tumor growth both in ovarian cancer cells and in an ovarian cancer mouse model.	ruxolitinib	13-24	signal transducer and activator of transcription 3	Mus musculus	34-39
28852199-4	2018	Signaling pathways regulated by JAK3 mutants were assessed following acute inhibition of JAK1/JAK3 using the JAK kinase inhibitors ruxolitinib or tofacitinib.	ruxolitinib	131-142	Janus kinase 3	Mus musculus	32-36
28956263-1	2018	Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	27-31
29515770-4	2018	Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	38-42
29487712-7	2018	Synergistic cell killing was associated with the greater inhibition of JAK2 phosphorylation by BBT594 than by ruxolitinib and the greater inhibition of AKT and 4E-BP1 phosphorylation by AZD2014 than by rapamycin.	ruxolitinib	110-121	Janus kinase 2	Homo sapiens	71-75
29203240-5	2018	The inhibitory effects of IL-13 on IL-17C expression were abolished when the Janus kinase (JAK)/signal transducer and activator of transcription 6 (STAT6)-signaling pathway was impaired, using either the JAK inhibitor ruxolitinib or a STAT6-specific siRNA.	ruxolitinib	218-229	interleukin 13	Homo sapiens	26-31
29203240-5	2018	The inhibitory effects of IL-13 on IL-17C expression were abolished when the Janus kinase (JAK)/signal transducer and activator of transcription 6 (STAT6)-signaling pathway was impaired, using either the JAK inhibitor ruxolitinib or a STAT6-specific siRNA.	ruxolitinib	218-229	interleukin 17C	Homo sapiens	35-41
29203240-5	2018	The inhibitory effects of IL-13 on IL-17C expression were abolished when the Janus kinase (JAK)/signal transducer and activator of transcription 6 (STAT6)-signaling pathway was impaired, using either the JAK inhibitor ruxolitinib or a STAT6-specific siRNA.	ruxolitinib	218-229	signal transducer and activator of transcription 6	Homo sapiens	96-146
29203240-5	2018	The inhibitory effects of IL-13 on IL-17C expression were abolished when the Janus kinase (JAK)/signal transducer and activator of transcription 6 (STAT6)-signaling pathway was impaired, using either the JAK inhibitor ruxolitinib or a STAT6-specific siRNA.	ruxolitinib	218-229	signal transducer and activator of transcription 6	Homo sapiens	148-153
29056075-0	2018	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.	ruxolitinib	43-54	Janus kinase 1	Homo sapiens	25-31
29056075-1	2018	Ruxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-27
29056075-1	2018	Ruxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.	ruxolitinib	0-3	Janus kinase 1	Homo sapiens	21-27
29399328-6	2018	Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis.	ruxolitinib	149-160	Janus kinase 2	Homo sapiens	128-132
29399328-6	2018	Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis.	ruxolitinib	149-160	Janus kinase 1	Homo sapiens	133-137
29399328-10	2018	This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation.	ruxolitinib	48-59	Janus kinase 2	Homo sapiens	83-87
29399328-10	2018	This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation.	ruxolitinib	48-59	Janus kinase 2	Homo sapiens	139-143
29399328-10	2018	This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation.	ruxolitinib	48-59	Janus kinase 2	Homo sapiens	145-151
29399328-10	2018	This limited effect is related to the fact that ruxolitinib, like the other type I JAK2 inhibitors, inhibits equally mutated and wild-type JAK2 (JAK2WT) and also the JAK2 oncogenic activation.	ruxolitinib	48-59	Janus kinase 2	Homo sapiens	139-143
29295936-7	2018	In addition, STAT3 negatively regulates the lethal type I IFN signaling pathway by inhibiting expression of IRF7, IRF9, STAT1, and STAT2 Inhibition of STAT3 activity by ruxolitinib synergizes with the type I IFN inducer lenalidomide in growth inhibition of ABC DLBCL cells in vitro and in a xenograft mouse model.	ruxolitinib	169-180	signal transducer and activator of transcription 3	Mus musculus	13-18
29295936-7	2018	In addition, STAT3 negatively regulates the lethal type I IFN signaling pathway by inhibiting expression of IRF7, IRF9, STAT1, and STAT2 Inhibition of STAT3 activity by ruxolitinib synergizes with the type I IFN inducer lenalidomide in growth inhibition of ABC DLBCL cells in vitro and in a xenograft mouse model.	ruxolitinib	169-180	interferon regulatory factor 7	Mus musculus	108-112
29295936-7	2018	In addition, STAT3 negatively regulates the lethal type I IFN signaling pathway by inhibiting expression of IRF7, IRF9, STAT1, and STAT2 Inhibition of STAT3 activity by ruxolitinib synergizes with the type I IFN inducer lenalidomide in growth inhibition of ABC DLBCL cells in vitro and in a xenograft mouse model.	ruxolitinib	169-180	interferon regulatory factor 9	Mus musculus	114-118
29295936-7	2018	In addition, STAT3 negatively regulates the lethal type I IFN signaling pathway by inhibiting expression of IRF7, IRF9, STAT1, and STAT2 Inhibition of STAT3 activity by ruxolitinib synergizes with the type I IFN inducer lenalidomide in growth inhibition of ABC DLBCL cells in vitro and in a xenograft mouse model.	ruxolitinib	169-180	signal transducer and activator of transcription 1	Mus musculus	120-125
29295936-7	2018	In addition, STAT3 negatively regulates the lethal type I IFN signaling pathway by inhibiting expression of IRF7, IRF9, STAT1, and STAT2 Inhibition of STAT3 activity by ruxolitinib synergizes with the type I IFN inducer lenalidomide in growth inhibition of ABC DLBCL cells in vitro and in a xenograft mouse model.	ruxolitinib	169-180	signal transducer and activator of transcription 2	Mus musculus	131-136
29295936-7	2018	In addition, STAT3 negatively regulates the lethal type I IFN signaling pathway by inhibiting expression of IRF7, IRF9, STAT1, and STAT2 Inhibition of STAT3 activity by ruxolitinib synergizes with the type I IFN inducer lenalidomide in growth inhibition of ABC DLBCL cells in vitro and in a xenograft mouse model.	ruxolitinib	169-180	signal transducer and activator of transcription 3	Mus musculus	151-156
29202476-5	2018	Importantly, treatment of LKB1-defcient mice with the JAK1/2 inhibitor ruxolitinib dramatically decreased polyposis.	ruxolitinib	71-82	serine/threonine kinase 11	Mus musculus	26-30
29202476-5	2018	Importantly, treatment of LKB1-defcient mice with the JAK1/2 inhibitor ruxolitinib dramatically decreased polyposis.	ruxolitinib	71-82	Janus kinase 1	Mus musculus	54-60
28986762-1	2018	Ruxolitinib, a potent JAK1/JAK2 inhibitor, improved splenomegaly and myelofibrosis-associated symptoms and prolonged survival compared with placebo and best available therapy in the phase 3 COMFORT studies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
28986762-1	2018	Ruxolitinib, a potent JAK1/JAK2 inhibitor, improved splenomegaly and myelofibrosis-associated symptoms and prolonged survival compared with placebo and best available therapy in the phase 3 COMFORT studies.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	27-31
29515770-4	2018	Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	43-47
29515770-6	2018	We demonstrated that ruxolitinib significantly inhibited STAT signaling in both HL and PMBL with constitutively active JAK2 signaling.	ruxolitinib	21-32	Janus kinase 2	Mus musculus	119-123
28554272-2	2018	Ruxolitinib, a JAK inhibitor, is an effective treatment for some MPNs.	ruxolitinib	0-11	Janus kinase 3	Gallus gallus	15-18
30079384-9	2018	We present an index case of a patient with T-PLL with a clonal JAK1 V658F mutation that responded to ruxolitinib therapy.	ruxolitinib	101-112	Janus kinase 1	Homo sapiens	63-67
28554272-5	2018	We investigate the effect of ruxolitinib on the expression of VEGF and HIF-1alpha in JAK2 V617F positive cells.	ruxolitinib	29-40	vascular endothelial growth factor A	Gallus gallus	62-66
28554272-5	2018	We investigate the effect of ruxolitinib on the expression of VEGF and HIF-1alpha in JAK2 V617F positive cells.	ruxolitinib	29-40	hypoxia inducible factor 1 alpha subunit	Gallus gallus	71-81
28554272-5	2018	We investigate the effect of ruxolitinib on the expression of VEGF and HIF-1alpha in JAK2 V617F positive cells.	ruxolitinib	29-40	Janus kinase 2	Gallus gallus	85-89
28554272-7	2018	Ruxolitinib can inhibit p-JAK2, VEGF, HIF-1a expression and suppress blood vessels" formation in chick embryo choriallantoic membrane.	ruxolitinib	0-11	Janus kinase 2	Gallus gallus	26-30
28554272-7	2018	Ruxolitinib can inhibit p-JAK2, VEGF, HIF-1a expression and suppress blood vessels" formation in chick embryo choriallantoic membrane.	ruxolitinib	0-11	vascular endothelial growth factor A	Gallus gallus	32-36
28554272-7	2018	Ruxolitinib can inhibit p-JAK2, VEGF, HIF-1a expression and suppress blood vessels" formation in chick embryo choriallantoic membrane.	ruxolitinib	0-11	hypoxia inducible factor 1 alpha subunit	Gallus gallus	38-44
28554272-8	2018	Our findings indicated that angiogenesis is related to JAK2 V617F burden and ruxolitinib could decrease VEGF and HIF-1a expression in JAK2 V617F positive cells.	ruxolitinib	77-88	vascular endothelial growth factor A	Gallus gallus	104-108
28554272-8	2018	Our findings indicated that angiogenesis is related to JAK2 V617F burden and ruxolitinib could decrease VEGF and HIF-1a expression in JAK2 V617F positive cells.	ruxolitinib	77-88	hypoxia inducible factor 1 alpha subunit	Gallus gallus	113-119
28554272-8	2018	Our findings indicated that angiogenesis is related to JAK2 V617F burden and ruxolitinib could decrease VEGF and HIF-1a expression in JAK2 V617F positive cells.	ruxolitinib	77-88	Janus kinase 2	Gallus gallus	134-138
29042365-0	2017	Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.	ruxolitinib	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	63-67
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	97-117
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	122-126
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	31-41	Janus kinase 1	Homo sapiens	97-117
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	31-41	Janus kinase 2	Homo sapiens	122-126
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	45-51	Janus kinase 1	Homo sapiens	97-117
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	45-51	Janus kinase 2	Homo sapiens	122-126
30069628-10	2018	The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors.	ruxolitinib	22-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
30069628-10	2018	The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors.	ruxolitinib	22-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
29042365-2	2017	Current treatment options for MPNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ruxolitinib, both of which are not curative.	ruxolitinib	97-108	Janus kinase 1	Homo sapiens	76-82
29042365-5	2017	Ruxolitinib inhibited 2 major DSB repair mechanisms, BRCA-mediated homologous recombination and DNA-dependent protein kinase-mediated nonhomologous end-joining, and, when combined with olaparib, caused abundant accumulation of toxic DSBs resulting in enhanced elimination of MPN primary cells, including the disease-initiating cells from the majority of patients.	ruxolitinib	0-11	BRCA1 DNA repair associated	Homo sapiens	53-57
29042365-6	2017	Moreover, the combination of BMN673, ruxolitinib, and hydroxyurea was highly effective in vivo against JAK2(V617F)+ murine MPN-like disease and also against JAK2(V617F)+, CALR(del52)+, and MPL(W515L)+ primary MPN xenografts.	ruxolitinib	37-48	Janus kinase 2	Mus musculus	103-107
29042365-6	2017	Moreover, the combination of BMN673, ruxolitinib, and hydroxyurea was highly effective in vivo against JAK2(V617F)+ murine MPN-like disease and also against JAK2(V617F)+, CALR(del52)+, and MPL(W515L)+ primary MPN xenografts.	ruxolitinib	37-48	Janus kinase 2	Mus musculus	157-161
29042365-6	2017	Moreover, the combination of BMN673, ruxolitinib, and hydroxyurea was highly effective in vivo against JAK2(V617F)+ murine MPN-like disease and also against JAK2(V617F)+, CALR(del52)+, and MPL(W515L)+ primary MPN xenografts.	ruxolitinib	37-48	calreticulin	Mus musculus	171-175
29042365-6	2017	Moreover, the combination of BMN673, ruxolitinib, and hydroxyurea was highly effective in vivo against JAK2(V617F)+ murine MPN-like disease and also against JAK2(V617F)+, CALR(del52)+, and MPL(W515L)+ primary MPN xenografts.	ruxolitinib	37-48	myeloproliferative leukemia virus oncogene	Mus musculus	189-192
29042365-7	2017	In conclusion, we postulate that ruxolitinib-induced deficiencies in DSB repair pathways sensitized MPN cells to synthetic lethality triggered by PARP inhibitors.	ruxolitinib	33-44	poly(ADP-ribose) polymerase 1	Homo sapiens	146-150
29214116-1	2017	Background: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	49-53
29222296-3	2017	The role of conventional therapies and novel agents, interferon alpha and the JAK2 inhibitor ruxolitinib, is critically discussed based on the results of a few basic randomized clinical studies.	ruxolitinib	93-104	Janus kinase 2	Homo sapiens	78-82
28484265-7	2017	The combination of the GC dexamethasone and the JAK1/2 inhibitor ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in samples with IL7-independent GC resistance.	ruxolitinib	65-76	Janus kinase 1	Homo sapiens	48-54
29098608-4	2017	The only approved therapy for MF, JAK1/2 inhibitor ruxolitinib, can ameliorate splenomegaly, improve symptoms, and prolong survival in some patients.	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	34-38
27672139-6	2017	The novel Janus kinase 2 (JAK2) inhibitor, ruxolitinib, has demonstrated marked improvements to constitutional symptoms and splenomegaly.	ruxolitinib	43-54	Janus kinase 2	Homo sapiens	10-24
27672139-6	2017	The novel Janus kinase 2 (JAK2) inhibitor, ruxolitinib, has demonstrated marked improvements to constitutional symptoms and splenomegaly.	ruxolitinib	43-54	Janus kinase 2	Homo sapiens	26-30
28484265-7	2017	The combination of the GC dexamethasone and the JAK1/2 inhibitor ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in samples with IL7-independent GC resistance.	ruxolitinib	65-76	interleukin 7	Homo sapiens	153-156
28953386-0	2017	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.	ruxolitinib	119-130	histone deacetylase 9	Homo sapiens	83-102
28994166-11	2017	Ruxolitinib is a selective inhibitor of JAK1 and JAK2 kinases and the JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	40-44
28994166-11	2017	Ruxolitinib is a selective inhibitor of JAK1 and JAK2 kinases and the JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	49-53
29150291-6	2017	Our data show that gold nanoparticles conjugated with Ruxolitinib inhibit the proliferation of fibroblasts by inhibiting JAK2 protein.	ruxolitinib	54-65	Janus kinase 2	Homo sapiens	121-125
29228628-7	2017	Luminespib decreased the phosphorylation of mutant STAT3 at Y705, whereas JAK1/JAK2 inhibitor ruxolitinib had reduced efficacy on mutant STAT3 phosphorylation.	ruxolitinib	94-105	Janus kinase 1	Homo sapiens	74-78
29228628-7	2017	Luminespib decreased the phosphorylation of mutant STAT3 at Y705, whereas JAK1/JAK2 inhibitor ruxolitinib had reduced efficacy on mutant STAT3 phosphorylation.	ruxolitinib	94-105	Janus kinase 2	Homo sapiens	79-83
29228628-7	2017	Luminespib decreased the phosphorylation of mutant STAT3 at Y705, whereas JAK1/JAK2 inhibitor ruxolitinib had reduced efficacy on mutant STAT3 phosphorylation.	ruxolitinib	94-105	signal transducer and activator of transcription 3	Homo sapiens	137-142
28953386-3	2017	Herein the core features of ruxolitinib (1), a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat (2), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors.	ruxolitinib	28-39	histone deacetylase 9	Homo sapiens	189-193
29262601-2	2017	Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity against JAK3.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	86-90
29262601-2	2017	Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity against JAK3.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	95-99
29262601-2	2017	Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity against JAK3.	ruxolitinib	0-11	tyrosine kinase 2	Homo sapiens	127-131
29262601-2	2017	Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity against JAK3.	ruxolitinib	0-11	Janus kinase 3	Homo sapiens	160-164
29212208-6	2017	Mechanistically, we demonstrated that Taxol induced expression of stress and stemness markers including GRP78 and CD133 was significantly reduced by addition of Ruxolitinib.	ruxolitinib	161-172	heat shock protein family A (Hsp70) member 5	Homo sapiens	104-109
29212208-6	2017	Mechanistically, we demonstrated that Taxol induced expression of stress and stemness markers including GRP78 and CD133 was significantly reduced by addition of Ruxolitinib.	ruxolitinib	161-172	prominin 1	Homo sapiens	114-119
29025600-3	2017	Furthermore, we show that primary ALL mononuclear cells harboring the JAK2 R938Q mutation display reduced sensitivity to the JAK1/2 ATP-competitive inhibitor ruxolitinib in vitro, compared to ALL cells that carry a more common JAK2 pseudokinase domain mutation.	ruxolitinib	158-169	Janus kinase 2	Homo sapiens	70-74
29025600-3	2017	Furthermore, we show that primary ALL mononuclear cells harboring the JAK2 R938Q mutation display reduced sensitivity to the JAK1/2 ATP-competitive inhibitor ruxolitinib in vitro, compared to ALL cells that carry a more common JAK2 pseudokinase domain mutation.	ruxolitinib	158-169	Janus kinase 1	Homo sapiens	125-131
29025600-3	2017	Furthermore, we show that primary ALL mononuclear cells harboring the JAK2 R938Q mutation display reduced sensitivity to the JAK1/2 ATP-competitive inhibitor ruxolitinib in vitro, compared to ALL cells that carry a more common JAK2 pseudokinase domain mutation.	ruxolitinib	158-169	Janus kinase 2	Homo sapiens	227-231
29202299-0	2018	Repression of interferon beta-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.	ruxolitinib	74-85	interferon beta 1	Homo sapiens	14-29
29202299-0	2018	Repression of interferon beta-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.	ruxolitinib	74-85	Janus kinase 1	Homo sapiens	57-63
29202299-1	2018	Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor, currently used in the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-39
29202299-8	2018	Most of cytokines targeted by ruxolitinib were shown to be regulated by IFNbeta in a JAK-sensitive manner.	ruxolitinib	30-41	interferon beta 1	Homo sapiens	72-79
29202299-10	2018	Overall, these data provide evidence for ruxolitinib-mediated repression of inflammatory cytokines in human macrophages through inhibition of the LPS/IFNbeta/JAK/STAT signalling pathway, which probably contributes to the anti-inflammatory effects of the JAK inhibitor.	ruxolitinib	41-52	interferon beta 1	Homo sapiens	150-157
28722170-9	2017	This effect was inhibited by the JAK1/2 inhibitor of the JAK/STAT3 pathway ruxolitinib.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	33-39
28722170-9	2017	This effect was inhibited by the JAK1/2 inhibitor of the JAK/STAT3 pathway ruxolitinib.	ruxolitinib	75-86	signal transducer and activator of transcription 3	Homo sapiens	61-66
29074595-3	2017	MAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC.	ruxolitinib	56-67	Janus kinase 1	Homo sapiens	69-75
29074595-7	2017	Molecular responses were uncommon; there were 2 complete molecular responses (CMR) and 1 partial molecular response in CALR-positive ruxolitinib-treated patients.	ruxolitinib	133-144	calreticulin	Homo sapiens	119-123
29062282-0	2017	Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib.	ruxolitinib	137-148	interleukin 6	Homo sapiens	25-29
28953386-0	2017	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.	ruxolitinib	119-130	histone deacetylase 9	Homo sapiens	104-108
28953386-3	2017	Herein the core features of ruxolitinib (1), a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat (2), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	56-62
28277287-3	2017	The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.	ruxolitinib	155-166	Janus kinase 2	Homo sapiens	19-23
28796569-7	2017	Ibrutinib and idelalisib allowed to improve the outcomes of relapsed/refractory CLL and of patients with poor genetic features, while the first-in-class JAK2 inhibitor ruxolitinib allowed to improve symptoms of advanced MF patients and to prolong survival in responders.	ruxolitinib	168-179	Janus kinase 2	Homo sapiens	153-157
28277287-3	2017	The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.	ruxolitinib	155-166	Janus kinase 2	Homo sapiens	40-44
28277287-3	2017	The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.	ruxolitinib	155-166	Janus kinase 1	Homo sapiens	137-143
29026328-5	2017	However, the combination of rhIL-6 and ruxolitinib, a JAK1/JAK2-selective inhibitor, was a less effective inhibitor of STAT protein activation.	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	54-58
28962635-2	2017	This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in patients with intermediate-2 (int-2) or high-risk MF.	ruxolitinib	60-71	Janus kinase 1	Homo sapiens	75-94
28962635-2	2017	This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in patients with intermediate-2 (int-2) or high-risk MF.	ruxolitinib	60-71	Janus kinase 2	Homo sapiens	95-99
29226168-0	2017	Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease.	ruxolitinib	9-20	signal transducer and activator of transcription 1	Homo sapiens	24-29
29226168-2	2017	We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.	ruxolitinib	71-82	signal transducer and activator of transcription 1	Homo sapiens	88-93
29026328-5	2017	However, the combination of rhIL-6 and ruxolitinib, a JAK1/JAK2-selective inhibitor, was a less effective inhibitor of STAT protein activation.	ruxolitinib	39-50	Janus kinase 2	Homo sapiens	59-63
29163799-6	2017	Momelotinib and ruxolitinib were cytotoxic in both JAK2 translocated and JAK2 mutated cells, although efficacy in JAK2 mutated cells highly depended on cytokine receptor activation by TSLP.	ruxolitinib	16-27	Janus kinase 2	Homo sapiens	51-55
29163799-6	2017	Momelotinib and ruxolitinib were cytotoxic in both JAK2 translocated and JAK2 mutated cells, although efficacy in JAK2 mutated cells highly depended on cytokine receptor activation by TSLP.	ruxolitinib	16-27	Janus kinase 2	Homo sapiens	73-77
29163799-6	2017	Momelotinib and ruxolitinib were cytotoxic in both JAK2 translocated and JAK2 mutated cells, although efficacy in JAK2 mutated cells highly depended on cytokine receptor activation by TSLP.	ruxolitinib	16-27	Janus kinase 2	Homo sapiens	73-77
29163799-6	2017	Momelotinib and ruxolitinib were cytotoxic in both JAK2 translocated and JAK2 mutated cells, although efficacy in JAK2 mutated cells highly depended on cytokine receptor activation by TSLP.	ruxolitinib	16-27	thymic stromal lymphopoietin	Homo sapiens	184-188
28824063-2	2017	Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	28-34
28649004-5	2017	STAT signaling inhibition by the JAK1/2 inhibitor ruxolitinib mimicked MACC1 knockdown-mediated molecular signatures and apoptosis sensitization to Fas activation.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	33-39
28649004-5	2017	STAT signaling inhibition by the JAK1/2 inhibitor ruxolitinib mimicked MACC1 knockdown-mediated molecular signatures and apoptosis sensitization to Fas activation.	ruxolitinib	50-61	MET transcriptional regulator MACC1	Homo sapiens	71-76
28824063-2	2017	Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM.	ruxolitinib	13-17	Janus kinase 1	Homo sapiens	28-34
28649004-9	2017	MACC1 overexpression enhanced STAT1/3 phosphorylation and increased Mcl-1 expression, which was abrogated by ruxolitinib.	ruxolitinib	109-120	MET transcriptional regulator MACC1	Homo sapiens	0-5
28684419-6	2017	Enhancement is accompanied by an increase in signal transducer and activator of transcription 5 (STAT5) phosphorylation and is abrogated by treatment with C188-9, a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.	ruxolitinib	192-203	signal transducer and activator of transcription 5A	Homo sapiens	45-95
29034260-5	2017	The HDP-on proliferates without GMCSF and differentiates into the MPhi upon exposure to tamoxifen and ruxolitinib (GMCSF inhibitor via JAK1/2 blockade).	ruxolitinib	102-113	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	115-120
29034260-5	2017	The HDP-on proliferates without GMCSF and differentiates into the MPhi upon exposure to tamoxifen and ruxolitinib (GMCSF inhibitor via JAK1/2 blockade).	ruxolitinib	102-113	Janus kinase 1	Mus musculus	135-141
28794380-2	2017	We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor.	ruxolitinib	158-169	Janus kinase 1	Homo sapiens	180-184
28794380-2	2017	We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor.	ruxolitinib	158-169	Janus kinase 2	Homo sapiens	185-189
28684419-6	2017	Enhancement is accompanied by an increase in signal transducer and activator of transcription 5 (STAT5) phosphorylation and is abrogated by treatment with C188-9, a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.	ruxolitinib	192-203	signal transducer and activator of transcription 5A	Homo sapiens	97-102
28684419-6	2017	Enhancement is accompanied by an increase in signal transducer and activator of transcription 5 (STAT5) phosphorylation and is abrogated by treatment with C188-9, a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.	ruxolitinib	192-203	signal transducer and activator of transcription 3	Homo sapiens	165-172
28684419-6	2017	Enhancement is accompanied by an increase in signal transducer and activator of transcription 5 (STAT5) phosphorylation and is abrogated by treatment with C188-9, a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.	ruxolitinib	192-203	Janus kinase 1	Homo sapiens	225-231
28042144-6	2017	Co-treatment with ARV-825 and JAK inhibitor ruxolitinib was synergistically lethal against established and PD CD34+ sAML cells.	ruxolitinib	44-55	CD34 molecule	Homo sapiens	110-114
28619982-8	2017	Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model.	ruxolitinib	31-42	BCL2 apoptosis regulator	Homo sapiens	71-75
28674026-7	2017	Of 62 patients with molecular data at baseline and follow-up, 22 (35%) acquired a new mutation while receiving ruxolitinib (14 [61%] in ASXL1).	ruxolitinib	111-122	ASXL transcriptional regulator 1	Homo sapiens	136-141
29296813-6	2017	In vitro screening using a panel of tyrosine kinase inhibitors against 14 different kinase alterations identified the ABL1-inhibitor, dasatinib, as a potent inhibitor of ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB), whereas the JAK1/JAK2 inhibitor ruxolitinib, was most effective against JAK-STAT-activating alterations (JAK1, JAK2, JAK3, IL7R, IL2RB), but not TYK2.	ruxolitinib	249-260	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	118-122
29296813-6	2017	In vitro screening using a panel of tyrosine kinase inhibitors against 14 different kinase alterations identified the ABL1-inhibitor, dasatinib, as a potent inhibitor of ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB), whereas the JAK1/JAK2 inhibitor ruxolitinib, was most effective against JAK-STAT-activating alterations (JAK1, JAK2, JAK3, IL7R, IL2RB), but not TYK2.	ruxolitinib	249-260	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	118-121
28854975-8	2017	Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level.	ruxolitinib	60-71	Janus kinase 1	Mus musculus	39-43
28854975-8	2017	Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level.	ruxolitinib	60-71	Janus kinase 2	Mus musculus	44-48
28854975-8	2017	Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level.	ruxolitinib	60-71	v-crk avian sarcoma virus CT10 oncogene homolog-like	Mus musculus	212-216
28854975-8	2017	Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level.	ruxolitinib	60-71	Janus kinase 2	Mus musculus	229-233
28619982-8	2017	Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	14-20
28687621-6	2017	In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival.	ruxolitinib	110-121	Janus kinase 2	Mus musculus	80-84
28687621-6	2017	In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival.	ruxolitinib	110-121	signal transducer and activator of transcription 3	Mus musculus	85-90
28687621-6	2017	In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival.	ruxolitinib	110-121	midkine	Mus musculus	95-98
28687621-6	2017	In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival.	ruxolitinib	110-121	mitogen-activated protein kinase 3	Mus musculus	99-106
28784136-15	2017	Ruxolitinib, a JAK2 inhibitor, was found to significantly inhibit RAB3C-induced colon cancer cell migration.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	15-19
28784136-15	2017	Ruxolitinib, a JAK2 inhibitor, was found to significantly inhibit RAB3C-induced colon cancer cell migration.	ruxolitinib	0-11	RAB3C, member RAS oncogene family	Homo sapiens	66-71
28784136-17	2017	These results further suggest that inhibition of STAT3 phosphorylation in the RAB3C-IL-6-STAT3 axis by using Ruxolitinib may be a new therapeutic strategy to combat metastatic colon cancers.	ruxolitinib	109-120	signal transducer and activator of transcription 3	Homo sapiens	49-54
28784136-17	2017	These results further suggest that inhibition of STAT3 phosphorylation in the RAB3C-IL-6-STAT3 axis by using Ruxolitinib may be a new therapeutic strategy to combat metastatic colon cancers.	ruxolitinib	109-120	RAB3C, member RAS oncogene family	Homo sapiens	78-83
28784136-17	2017	These results further suggest that inhibition of STAT3 phosphorylation in the RAB3C-IL-6-STAT3 axis by using Ruxolitinib may be a new therapeutic strategy to combat metastatic colon cancers.	ruxolitinib	109-120	interleukin 6	Homo sapiens	84-88
28784136-17	2017	These results further suggest that inhibition of STAT3 phosphorylation in the RAB3C-IL-6-STAT3 axis by using Ruxolitinib may be a new therapeutic strategy to combat metastatic colon cancers.	ruxolitinib	109-120	signal transducer and activator of transcription 3	Homo sapiens	89-94
28710306-0	2017	Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	40-44
27892610-3	2017	Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.	ruxolitinib	29-40	C-X-C motif chemokine ligand 10	Homo sapiens	106-112
27892610-3	2017	Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.	ruxolitinib	29-40	C-X-C motif chemokine ligand 9	Homo sapiens	114-119
27892610-3	2017	Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.	ruxolitinib	29-40	MX dynamin like GTPase 1	Homo sapiens	121-124
28322434-2	2017	A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short-term treatment of alopecia, however little information exists about the long-term use in otherwise healthy individuals in the community setting.	ruxolitinib	49-60	Janus kinase 1	Homo sapiens	28-32
28322434-2	2017	A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short-term treatment of alopecia, however little information exists about the long-term use in otherwise healthy individuals in the community setting.	ruxolitinib	49-60	Janus kinase 2	Homo sapiens	33-37
28031554-4	2017	Moreover, inhibition of Mek1/2 by trametinib alone is sufficient to suppress leukemia induced by both CSF3R proximal and ruxolitinib-resistant compound mutations.	ruxolitinib	121-132	mitogen-activated protein kinase kinase 1	Homo sapiens	24-30
29350220-7	2017	We present a nephrotic syndrome in PMF-related glomerulopathy, associated with EMH, without renal failure, in a patient under treatment for 2 years with JAK2 inhibitor ruxolitinib.	ruxolitinib	168-179	Janus kinase 2	Homo sapiens	153-157
28710306-7	2017	Therefore, treatment was modified to ruxolitinib, a novel-JAK-2 inhibitor; the therapy has been effective for almost 20 months with a good response and has no side effects.	ruxolitinib	37-48	Janus kinase 2	Homo sapiens	58-63
28500170-1	2017	Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing.	ruxolitinib	68-79	Janus kinase 1	Homo sapiens	50-56
28456851-0	2017	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	20-24
28721333-1	2017	We present the case of a 79-year-old man who showed multiple pulmonary nodules on chest computed tomography (CT) after being treated for 6 months with ruxolitinib, an inhibitor of Janus kinase (JAK) 1 and 2, to treat primary myelofibrosis.	ruxolitinib	151-162	Janus kinase 1	Homo sapiens	180-206
28456851-7	2017	Collectively, the data from this exploratory analysis suggest that ruxolitinib treatment for up to 4 years provides progressive reductions in JAK2 p.V617F allele burden in patients with PV who are resistant to or intolerant of hydroxyurea.	ruxolitinib	67-78	Janus kinase 2	Homo sapiens	142-146
28760302-1	2017	The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis (MF) provided much-needed impetus for clinical drug development for the Philadelphia chromosome-negative myeloproliferative neoplasms.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	33-53
28749919-5	2017	In this review, we outline the age-related and geographic incidence of Ph-like ALL, the association with worse clinical outcomes, and early evidence for the use of ruxolitinib (a Janus kinase 2 inhibitor) and dasatinib (a tyrosine kinase inhibitor targeting ABL1).	ruxolitinib	164-175	Janus kinase 2	Homo sapiens	179-193
28749919-5	2017	In this review, we outline the age-related and geographic incidence of Ph-like ALL, the association with worse clinical outcomes, and early evidence for the use of ruxolitinib (a Janus kinase 2 inhibitor) and dasatinib (a tyrosine kinase inhibitor targeting ABL1).	ruxolitinib	164-175	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	258-262
28622305-6	2017	Moreover, treatment of Gata1low mice with the JAK inhibitor ruxolitinib reduced their splenomegaly.	ruxolitinib	60-71	GATA binding protein 1	Mus musculus	23-28
28463395-7	2017	The effect on auto-antibody production was dependent on STAT-3 activation as it was abrogated in the presence of the JAK/STAT-3 pathway inhibitors ruxolitinib and stattic.	ruxolitinib	147-158	signal transducer and activator of transcription 3	Homo sapiens	56-62
28463395-7	2017	The effect on auto-antibody production was dependent on STAT-3 activation as it was abrogated in the presence of the JAK/STAT-3 pathway inhibitors ruxolitinib and stattic.	ruxolitinib	147-158	signal transducer and activator of transcription 3	Homo sapiens	121-127
28540737-6	2017	Ruxolitinib, a Jak2 inhibitor, has been tested to limit stress erythropoiesis in a phase II clinical trial.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	15-19
28602585-0	2017	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.	ruxolitinib	91-102	Janus kinase 2	Homo sapiens	0-14
28602585-3	2017	The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib.	ruxolitinib	88-99	Janus kinase 2	Homo sapiens	18-22
28602585-3	2017	The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib.	ruxolitinib	88-99	Janus kinase 2	Homo sapiens	72-76
28673391-4	2017	The Food and Drug Administration approved the JAK1/JAK2 inhibitor, ruxolitinib, for the treatment of myelofibrosis and polycythemia vera.	ruxolitinib	67-78	Janus kinase 1	Homo sapiens	46-50
28673391-4	2017	The Food and Drug Administration approved the JAK1/JAK2 inhibitor, ruxolitinib, for the treatment of myelofibrosis and polycythemia vera.	ruxolitinib	67-78	Janus kinase 2	Homo sapiens	51-55
28461505-8	2017	Pharmacological or genetic inhibition of USP9X, as well as treatment with low-dose ruxolitinib, enhanced the survival of pre-B ALL cells overexpressing mutated JAK2.	ruxolitinib	83-94	Janus kinase 2	Homo sapiens	160-164
28068330-7	2017	The leukemic CD71+ cells were more sensitive to INCB18424, a potent JAK inhibitor, than KSL cells.	ruxolitinib	48-57	transferrin receptor	Mus musculus	13-17
28232234-11	2017	Ruxolitinib rescued cytoplasmic detection of C-CALR, C-CALR/GR association, and Dex responsiveness in JAK2V617F proErys and its effects were antagonized by nuclear export and Ca2+ flux inhibitors.	ruxolitinib	0-11	calreticulin	Homo sapiens	47-51
28232234-11	2017	Ruxolitinib rescued cytoplasmic detection of C-CALR, C-CALR/GR association, and Dex responsiveness in JAK2V617F proErys and its effects were antagonized by nuclear export and Ca2+ flux inhibitors.	ruxolitinib	0-11	calreticulin	Homo sapiens	55-59
28232234-11	2017	Ruxolitinib rescued cytoplasmic detection of C-CALR, C-CALR/GR association, and Dex responsiveness in JAK2V617F proErys and its effects were antagonized by nuclear export and Ca2+ flux inhibitors.	ruxolitinib	0-11	nuclear receptor subfamily 3 group C member 1	Homo sapiens	60-62
28302714-0	2017	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
28302714-0	2017	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	27-31
28302714-0	2017	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.	ruxolitinib	0-11	colony stimulating factor 3 receptor	Homo sapiens	108-113
29228564-6	2017	To achieve maximal inhibition of STAT5 phosphorylation, we combined ruxolitinib with BKM120, a PI3K inhibitor, and RAD001, an mTOR inhibitor, obtaining improved efficacy in JAK2V617F mutated cell lines, primary patients" cells, and JAK2V617F knock-in mice.	ruxolitinib	68-79	signal transducer and activator of transcription 5A	Homo sapiens	33-38
28410228-5	2017	Moreover, a high sensitivity to the JAK1/2 inhibitor ruxolitinib was observed in S646P mutant model.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	36-42
29228564-1	2017	Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in patients with myeloproliferative neoplasms.	ruxolitinib	114-125	Janus kinase 1	Homo sapiens	43-46
29228564-1	2017	Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in patients with myeloproliferative neoplasms.	ruxolitinib	114-125	Janus kinase 1	Homo sapiens	94-98
29228564-1	2017	Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in patients with myeloproliferative neoplasms.	ruxolitinib	114-125	Janus kinase 2	Homo sapiens	63-67
29228564-3	2017	Here we demonstrate that ruxolitinib causes incomplete inhibition of STAT5 in JAK2V617F mutated cells due to persistence of phosphorylated serine residues of STAT5b, that conversely are targeted by PI3K and mTORC1 inhibitors.	ruxolitinib	25-36	signal transducer and activator of transcription 5A	Homo sapiens	69-74
29228564-3	2017	Here we demonstrate that ruxolitinib causes incomplete inhibition of STAT5 in JAK2V617F mutated cells due to persistence of phosphorylated serine residues of STAT5b, that conversely are targeted by PI3K and mTORC1 inhibitors.	ruxolitinib	25-36	Janus kinase 2	Homo sapiens	78-82
29228564-3	2017	Here we demonstrate that ruxolitinib causes incomplete inhibition of STAT5 in JAK2V617F mutated cells due to persistence of phosphorylated serine residues of STAT5b, that conversely are targeted by PI3K and mTORC1 inhibitors.	ruxolitinib	25-36	signal transducer and activator of transcription 5B	Homo sapiens	158-164
29228564-3	2017	Here we demonstrate that ruxolitinib causes incomplete inhibition of STAT5 in JAK2V617F mutated cells due to persistence of phosphorylated serine residues of STAT5b, that conversely are targeted by PI3K and mTORC1 inhibitors.	ruxolitinib	25-36	CREB regulated transcription coactivator 1	Mus musculus	207-213
28209656-0	2017	Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.	ruxolitinib	149-160	colony stimulating factor 3 receptor	Homo sapiens	33-38
28496202-6	2017	Treatment of cultured PSC with the Jak1/2 inhibitor ruxolitinib reduced STAT3 phosphorylation, cell proliferation, and expression of alpha-smooth muscle actin (alpha-SMA), a marker of PSC activation.	ruxolitinib	52-63	Janus kinase 1	Mus musculus	35-41
28496202-6	2017	Treatment of cultured PSC with the Jak1/2 inhibitor ruxolitinib reduced STAT3 phosphorylation, cell proliferation, and expression of alpha-smooth muscle actin (alpha-SMA), a marker of PSC activation.	ruxolitinib	52-63	signal transducer and activator of transcription 3	Mus musculus	72-77
28496202-6	2017	Treatment of cultured PSC with the Jak1/2 inhibitor ruxolitinib reduced STAT3 phosphorylation, cell proliferation, and expression of alpha-smooth muscle actin (alpha-SMA), a marker of PSC activation.	ruxolitinib	52-63	actin alpha 2, smooth muscle, aorta	Mus musculus	133-158
28496202-6	2017	Treatment of cultured PSC with the Jak1/2 inhibitor ruxolitinib reduced STAT3 phosphorylation, cell proliferation, and expression of alpha-smooth muscle actin (alpha-SMA), a marker of PSC activation.	ruxolitinib	52-63	actin alpha 2, smooth muscle, aorta	Mus musculus	160-169
28496202-10	2017	In vivo treatment with the Jak1/2 inhibitor ruxolitinib reduced the severity of experimental CP, suggesting that targeting Jak/STAT signaling may represent a promising therapeutic strategy for CP.	ruxolitinib	44-55	Janus kinase 1	Mus musculus	27-33
28395559-4	2017	We provide clinical trial evidence behind using the JAK2 inhibitor ruxolitinib, erythropoiesis stimulating agents, androgens, immunomodulatory drugs, interferon, cytoreductive drugs and hypomethylating agents in MF.	ruxolitinib	67-78	Janus kinase 2	Homo sapiens	52-56
28209656-0	2017	Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.	ruxolitinib	149-160	SET binding protein 1	Homo sapiens	43-49
28053127-7	2017	Suppression of JAK1/2 by ruxolitinib prevented STAT3-mediated transcription of ZEB1, SNAI1 and OSMR, as well as the emergence of a mesenchymal/CSC phenotype.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	15-21
27659716-0	2017	Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.	ruxolitinib	30-41	Janus kinase 2	Homo sapiens	60-64
28139313-0	2017	Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	102-152
28139313-0	2017	Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	154-159
28139313-3	2017	OBJECTIVE: We sought to define the effect of increased STAT1 activity on T helper cell polarization and to investigate the therapeutic potential of ruxolitinib in treating autoimmunity secondary to STAT1 GOF mutations.	ruxolitinib	148-159	signal transducer and activator of transcription 1	Homo sapiens	198-203
27807369-0	2017	Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.	ruxolitinib	100-111	calreticulin	Mus musculus	0-12
27860260-0	2017	Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.	ruxolitinib	15-26	Janus kinase 2	Homo sapiens	82-86
27860260-3	2017	Due to concern for an on-therapy relapse, the JAK2 inhibitor ruxolitinib was incorporated into a modified chemotherapy backbone to achieve complete remission prior to stem cell transplant.	ruxolitinib	61-72	Janus kinase 2	Homo sapiens	46-50
28053127-7	2017	Suppression of JAK1/2 by ruxolitinib prevented STAT3-mediated transcription of ZEB1, SNAI1 and OSMR, as well as the emergence of a mesenchymal/CSC phenotype.	ruxolitinib	25-36	signal transducer and activator of transcription 3	Homo sapiens	47-52
28053127-7	2017	Suppression of JAK1/2 by ruxolitinib prevented STAT3-mediated transcription of ZEB1, SNAI1 and OSMR, as well as the emergence of a mesenchymal/CSC phenotype.	ruxolitinib	25-36	zinc finger E-box binding homeobox 1	Homo sapiens	79-83
28053127-7	2017	Suppression of JAK1/2 by ruxolitinib prevented STAT3-mediated transcription of ZEB1, SNAI1 and OSMR, as well as the emergence of a mesenchymal/CSC phenotype.	ruxolitinib	25-36	snail family transcriptional repressor 1	Homo sapiens	85-90
28053127-7	2017	Suppression of JAK1/2 by ruxolitinib prevented STAT3-mediated transcription of ZEB1, SNAI1 and OSMR, as well as the emergence of a mesenchymal/CSC phenotype.	ruxolitinib	25-36	oncostatin M receptor	Homo sapiens	95-99
28356514-12	2017	Finally, ruxolitinib, a JAK1/2 inhibitor, was effective in vivo in a xenograft ALK- ALCL model.	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	24-30
28491265-7	2017	The discovery of the JAK2 V617F mutation and consequently targeted therapy with Janus kinase inhibitors, in particular ruxolitinib, has extended the spectrum of agents that can be used as second or third line in PV.	ruxolitinib	119-130	Janus kinase 2	Homo sapiens	21-25
28356514-12	2017	Finally, ruxolitinib, a JAK1/2 inhibitor, was effective in vivo in a xenograft ALK- ALCL model.	ruxolitinib	9-20	ALK receptor tyrosine kinase	Homo sapiens	79-82
27740634-2	2017	Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-47
27740634-2	2017	Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	49-53
27740634-2	2017	Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	55-59
28339658-5	2017	This activity could be completely blocked by the broad specificity tyrosine kinase inhibitor genistein at either stage, but only at the two-cell stage was there a substantial component of activity that was sensitive to low concentrations of the JAK2-selective inhibitors TG101348 or ruxolitinib.	ruxolitinib	283-294	Janus kinase 2	Mus musculus	245-249
27889820-1	2017	Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
27889820-1	2017	Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	24-28
28579852-3	2017	However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe.	ruxolitinib	145-156	Janus kinase 2	Homo sapiens	41-45
28579852-3	2017	However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe.	ruxolitinib	145-156	Janus kinase 1	Homo sapiens	106-112
27668411-7	2017	Furthermore, treatment of stimulated MYC deprived cells with MLN120b, ACHP, Pyridone 6 or Ruxolitinib showed that IL10/CpG induced proliferation and CDK4 expression were JAK/STAT3 and IKK/NF-kappaB dependent.	ruxolitinib	90-101	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	37-40
27832516-1	2017	Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated durable improvements in splenomegaly, symptoms, and overall survival in controlled clinical trials in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-28
27832516-1	2017	Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated durable improvements in splenomegaly, symptoms, and overall survival in controlled clinical trials in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	29-33
28057739-7	2017	A pan-JAK inhibitor, INC424, increased the expression of let-7a, downregulated the level of Hmga2, and led to increased apoptosis in Ton.JAK2.V617F cells in a dose-dependent manner.	ruxolitinib	21-27	microRNA let7a-1	Mus musculus	57-63
28057739-7	2017	A pan-JAK inhibitor, INC424, increased the expression of let-7a, downregulated the level of Hmga2, and led to increased apoptosis in Ton.JAK2.V617F cells in a dose-dependent manner.	ruxolitinib	21-27	high mobility group AT-hook 2	Homo sapiens	92-97
28057739-7	2017	A pan-JAK inhibitor, INC424, increased the expression of let-7a, downregulated the level of Hmga2, and led to increased apoptosis in Ton.JAK2.V617F cells in a dose-dependent manner.	ruxolitinib	21-27	Janus kinase 2	Homo sapiens	137-141
28260257-1	2017	Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-36
28260257-1	2017	Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-42
28260257-1	2017	Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	44-48
27808416-0	2017	Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment.	ruxolitinib	59-70	muscle associated receptor tyrosine kinase	Homo sapiens	36-40
28279039-1	2017	Objective: To investigate the regulation of JAK2 tyrosine kinase inhibitor ruxolitinib on extracellular matrix metalloproteinase (MMP in JAK2V617F positive myeloproliferative neoplasms (MPN) cells.	ruxolitinib	75-86	Janus kinase 2	Homo sapiens	44-48
28279039-1	2017	Objective: To investigate the regulation of JAK2 tyrosine kinase inhibitor ruxolitinib on extracellular matrix metalloproteinase (MMP in JAK2V617F positive myeloproliferative neoplasms (MPN) cells.	ruxolitinib	75-86	matrix metallopeptidase 2	Homo sapiens	130-133
28279039-13	2017	The mRNA and protein expression levels of JAK2, MMP-2 and MMP-9 decreased with the increased concentration of ruxolitinib.	ruxolitinib	110-121	Janus kinase 2	Homo sapiens	42-46
28279039-13	2017	The mRNA and protein expression levels of JAK2, MMP-2 and MMP-9 decreased with the increased concentration of ruxolitinib.	ruxolitinib	110-121	matrix metallopeptidase 2	Homo sapiens	48-53
28279039-13	2017	The mRNA and protein expression levels of JAK2, MMP-2 and MMP-9 decreased with the increased concentration of ruxolitinib.	ruxolitinib	110-121	matrix metallopeptidase 9	Homo sapiens	58-63
28279039-14	2017	Conclusion: Ruxolitinib inhibits MPN cell migration and expression of MMP-2 and MMP-9 via JAK2 signal pathway.	ruxolitinib	12-23	matrix metallopeptidase 2	Homo sapiens	70-75
28279039-14	2017	Conclusion: Ruxolitinib inhibits MPN cell migration and expression of MMP-2 and MMP-9 via JAK2 signal pathway.	ruxolitinib	12-23	matrix metallopeptidase 9	Homo sapiens	80-85
28279039-14	2017	Conclusion: Ruxolitinib inhibits MPN cell migration and expression of MMP-2 and MMP-9 via JAK2 signal pathway.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	90-94
28028027-1	2017	There has been a major revolution in the management of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly and symptomatic burden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib.	ruxolitinib	253-264	Janus kinase 1	Homo sapiens	229-233
28405527-6	2017	JAK-STAT inhibitor Ruxolitinib selectively inhibits STAT1 and STAT3 activation and increases CTL infiltration to induce a Tc1/Th1 immune response in the tumor microenvironment in an orthotopic pancreatic cancer mouse model.	ruxolitinib	19-30	signal transducer and activator of transcription 1	Mus musculus	52-57
28405527-6	2017	JAK-STAT inhibitor Ruxolitinib selectively inhibits STAT1 and STAT3 activation and increases CTL infiltration to induce a Tc1/Th1 immune response in the tumor microenvironment in an orthotopic pancreatic cancer mouse model.	ruxolitinib	19-30	signal transducer and activator of transcription 3	Mus musculus	62-67
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	74-85	interferon gamma	Mus musculus	22-30
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	74-85	interferon gamma	Mus musculus	153-161
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	180-191	interferon gamma	Mus musculus	22-30
28405527-9	2017	However, neutralizing IFNgamma does not alter tumor growth but diminishes Ruxolitinib-induced tumor suppression in vivo, indicating that lymphocytes and IFNgamma are essential for Ruxolitinib-induced host antitumor immune response.	ruxolitinib	180-191	interferon gamma	Mus musculus	153-161
27983880-1	2017	INTRODUCTION: Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has shown superiority as compared to available conventional chemotherapies, in terms of reduction in splenomegaly and improvement of symptoms and quality of life.	ruxolitinib	14-25	Janus kinase 1	Homo sapiens	52-56
27983880-1	2017	INTRODUCTION: Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has shown superiority as compared to available conventional chemotherapies, in terms of reduction in splenomegaly and improvement of symptoms and quality of life.	ruxolitinib	14-25	Janus kinase 2	Homo sapiens	57-61
27668411-7	2017	Furthermore, treatment of stimulated MYC deprived cells with MLN120b, ACHP, Pyridone 6 or Ruxolitinib showed that IL10/CpG induced proliferation and CDK4 expression were JAK/STAT3 and IKK/NF-kappaB dependent.	ruxolitinib	90-101	interleukin 10	Homo sapiens	114-118
27668411-7	2017	Furthermore, treatment of stimulated MYC deprived cells with MLN120b, ACHP, Pyridone 6 or Ruxolitinib showed that IL10/CpG induced proliferation and CDK4 expression were JAK/STAT3 and IKK/NF-kappaB dependent.	ruxolitinib	90-101	cyclin dependent kinase 4	Homo sapiens	149-153
28089238-3	2017	Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in patients with myelofibrosis, we postulated that ruxolitinib would improve disease-related symptoms in patients with CLL.	ruxolitinib	94-105	Janus kinase 2	Homo sapiens	79-83
28228106-1	2017	BACKGROUND: The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.	ruxolitinib	120-131	Janus kinase 1	Homo sapiens	100-104
28089238-3	2017	Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in patients with myelofibrosis, we postulated that ruxolitinib would improve disease-related symptoms in patients with CLL.	ruxolitinib	175-186	Janus kinase 2	Homo sapiens	53-57
28089238-3	2017	Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in patients with myelofibrosis, we postulated that ruxolitinib would improve disease-related symptoms in patients with CLL.	ruxolitinib	175-186	Janus kinase 2	Homo sapiens	79-83
27613527-0	2017	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.	ruxolitinib	21-32	epidermal growth factor receptor	Homo sapiens	64-68
27793879-5	2017	Interestingly, the expression levels of CIITA and MHC-II significantly increased when CML stem/progenitor cells were treated with the JAK1/2 inhibitor ruxolitinib (RUX).	ruxolitinib	151-162	class II major histocompatibility complex transactivator	Homo sapiens	40-45
27793879-5	2017	Interestingly, the expression levels of CIITA and MHC-II significantly increased when CML stem/progenitor cells were treated with the JAK1/2 inhibitor ruxolitinib (RUX).	ruxolitinib	164-167	class II major histocompatibility complex transactivator	Homo sapiens	40-45
27923824-5	2017	Ruxolitinib treatment completely blocked IL2, IL15, and DC-mediated STAT5 phosphorylation, along with the capacity of NK cells to secrete IFNgamma or lyse NK cell-sensitive targets.	ruxolitinib	0-11	interleukin 2	Homo sapiens	41-44
27923824-5	2017	Ruxolitinib treatment completely blocked IL2, IL15, and DC-mediated STAT5 phosphorylation, along with the capacity of NK cells to secrete IFNgamma or lyse NK cell-sensitive targets.	ruxolitinib	0-11	interleukin 15	Homo sapiens	46-50
27923824-5	2017	Ruxolitinib treatment completely blocked IL2, IL15, and DC-mediated STAT5 phosphorylation, along with the capacity of NK cells to secrete IFNgamma or lyse NK cell-sensitive targets.	ruxolitinib	0-11	signal transducer and activator of transcription 5A	Homo sapiens	68-73
27923824-5	2017	Ruxolitinib treatment completely blocked IL2, IL15, and DC-mediated STAT5 phosphorylation, along with the capacity of NK cells to secrete IFNgamma or lyse NK cell-sensitive targets.	ruxolitinib	0-11	interferon gamma	Homo sapiens	138-146
27923824-9	2017	These results demonstrate that ruxolitinib"s nonselective inhibition of JAK1/2 results in profound NK-cell dysfunction by blocking downstream pSTAT5, hence providing a persuasive rationale for the development of selective JAK2 inhibitors for immunotherapeutic applications.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	72-78
27923824-9	2017	These results demonstrate that ruxolitinib"s nonselective inhibition of JAK1/2 results in profound NK-cell dysfunction by blocking downstream pSTAT5, hence providing a persuasive rationale for the development of selective JAK2 inhibitors for immunotherapeutic applications.	ruxolitinib	31-42	Janus kinase 2	Homo sapiens	222-226
27882812-2	2017	Ruxolitinib, a JAK1/2 inhibitor, is currently the only drug approved for the treatment of patients with intermediate or high risk MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
27884974-5	2017	The landmark discovery of the autonomously activated JAK/STAT signaling pathway paved the way for the clinical development of the first target drug, the JAK1 and JAK2 inhibitor ruxolitinib.	ruxolitinib	177-188	Janus kinase 2	Homo sapiens	162-166
27930945-2	2017	Ruxolitinib, an oral JAK1/2 inhibitor, is highly effective in ameliorating systemic symptoms and reducing splenomegaly.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-27
27777238-7	2017	Combined gedatolisib and ruxolitinib treatment of CRLF2/JAK-mutant models more effectively inhibited ALL proliferation than either inhibitor alone (P &lt; .001) and further enhanced survival.	ruxolitinib	25-36	cytokine receptor like factor 2	Homo sapiens	50-55
28674362-0	2017	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	61-67
28674362-0	2017	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.	ruxolitinib	79-90	Janus kinase 2	Homo sapiens	149-153
28674362-3	2017	We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L).	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	33-39
28674362-3	2017	We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L).	ruxolitinib	51-62	Janus kinase 2	Homo sapiens	201-205
28674362-4	2017	This case suggests that ruxolitinib is a treatment option for post-PV MF in patients with thrombocytopenia or JAK2 exon 12 mutations.	ruxolitinib	24-35	Janus kinase 2	Homo sapiens	110-114
27613527-3	2017	METHODS: We evaluated the toxicity and efficacy of erlotinib and ruxolitinib in patients with EGFR-mutant lung cancers with acquired resistance to erlotinib.	ruxolitinib	65-76	epidermal growth factor receptor	Homo sapiens	94-98
27263544-6	2017	In conclusion, ruxolitinib is effective, with a better outcome in patients with a low-int1 risk score.	ruxolitinib	15-26	Wnt family member 1	Homo sapiens	86-90
28011890-8	2016	Follow-up after 6 weeks of ruxolitinib (JAK2 tyrosine kinase inhibitor) and 9 months of antitubercular therapy revealed resolution of psoas abscesses and lymph nodes.	ruxolitinib	27-38	Janus kinase 2	Homo sapiens	40-44
27916398-1	2017	BACKGROUND: In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling haematocrit and improving splenomegaly and symptoms in patients with polycythaemia vera with splenomegaly who were inadequately controlled with hydroxyurea.	ruxolitinib	43-54	Janus kinase 1	Homo sapiens	58-77
27916398-1	2017	BACKGROUND: In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling haematocrit and improving splenomegaly and symptoms in patients with polycythaemia vera with splenomegaly who were inadequately controlled with hydroxyurea.	ruxolitinib	43-54	Janus kinase 2	Homo sapiens	82-86
28776046-5	2017	Decrease of interferon signaling by Jak 1/2 inhibition (using ruxolitinib) significantly increased ZIKV replication in HC, trophoblasts, and neuroblasts.	ruxolitinib	62-73	tyrosine-protein kinase JAK1	Chlorocebus sabaeus	36-41
28776046-10	2017	Blocking Jak 1/2 signaling (with ruxolitinib) restored replication competence as virions produced under these conditions confer cytopathic effects to naive Vero cells.	ruxolitinib	33-44	tyrosine-protein kinase JAK1	Chlorocebus sabaeus	9-14
27774820-4	2016	Areas covered: Current pharmacologic therapy of MF revolves around the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, which dramatically improves constitutional symptoms and splenomegaly in the majority of patients, and improves overall survival (OS).	ruxolitinib	107-118	Janus kinase 1	Homo sapiens	89-95
27858230-2	2016	Ruxolitinib was given twice a day (bid) at a starting dose of 15 mg (n = 25) or 20 mg (n = 38) based on a baseline platelet count.	ruxolitinib	0-11	BH3 interacting domain death agonist	Homo sapiens	35-38
27157043-7	2016	In a CMML patient with splenomegaly, who was treated with the JAK1/2 inhibitor ruxolitinib off label, we can demonstrate a spleen response and the disappearance of constitutional symptoms which was associated with a decrease in autonomous CFU-GM formation ex vivo.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	62-68
27796499-4	2016	Testing for JAK2 mutations is now included in the World Health Organization (WHO) criteria for the diagnosis of MPN, and in 2011 the oral JAK2 kinase inhibitor ruxolitinib became the first Food and Drug Administration (FDA)-approved drug for the treatment of myelofibrosis.	ruxolitinib	160-171	Janus kinase 2	Homo sapiens	12-16
27554814-0	2016	Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.	ruxolitinib	43-54	stimulator of interferon response cGAMP interactor 1	Homo sapiens	104-111
27956543-4	2016	Appreciation of the universal role of activated JAK/signal transducer and activator of transcription (STAT) signaling in MPNs and improved understanding of the canonical and noncanonical actions of JAK2 have yielded a number of drug targets beyond JAK2 in MPNs, which form the basis for a number of ruxolitinib-based rational combinations that are being explored in MF.	ruxolitinib	299-310	Janus kinase 2	Homo sapiens	198-202
27086927-6	2016	Importantly, Ruxolitinib, a JAK1 inhibitor, could rescue the phenotypic changes induced by miR-23a, -27a and -24 inhibitors.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	28-32
27086927-6	2016	Importantly, Ruxolitinib, a JAK1 inhibitor, could rescue the phenotypic changes induced by miR-23a, -27a and -24 inhibitors.	ruxolitinib	13-24	microRNA 23a	Homo sapiens	91-98
27579615-4	2016	The JAK1/2 inhibitor ruxolitinib blocked STAT3-phosphorylation and partially improved DEX-mediated killing of stimulated CLL cells in vitro but not in CLL patients in vivo.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
27579615-4	2016	The JAK1/2 inhibitor ruxolitinib blocked STAT3-phosphorylation and partially improved DEX-mediated killing of stimulated CLL cells in vitro but not in CLL patients in vivo.	ruxolitinib	21-32	signal transducer and activator of transcription 3	Homo sapiens	41-46
27647628-1	2016	Ruxolitinib is a selective and potent inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Rattus norvegicus	51-71
27647628-1	2016	Ruxolitinib is a selective and potent inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	0-11	Janus kinase 2	Rattus norvegicus	76-80
27567907-1	2016	The Janus kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is currently the only therapy indicated for intermediate- or high-risk myelofibrosis.	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	30-34
27567907-4	2016	However, owing to the myelosuppressive effects of JAK2 inhibition, ruxolitinib is associated with decreases in hemoglobin and platelet counts, particularly during the first 8-12 weeks of therapy.	ruxolitinib	67-78	Janus kinase 2	Homo sapiens	50-54
30645821-14	2016	Ruxolitinib is mainly metabolised by cytochrome P450 isoenzymes CYP3A4 and CYP2C9, creating a risk of multiple drug interactions.	ruxolitinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
30645821-14	2016	Ruxolitinib is mainly metabolised by cytochrome P450 isoenzymes CYP3A4 and CYP2C9, creating a risk of multiple drug interactions.	ruxolitinib	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	75-81
27738655-6	2016	We showed that in vitro this antiviral state could be reverted by combining VSV-GP with the JAK1/2-inhibitor ruxolitinib.	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	92-96
27729820-5	2016	Ruxolitinib, a JAK 1 and 2 inhibitor, has already proven to be efficient in relieving symptoms in primary myelofibrosis and PV.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-26
27449287-4	2016	Of note, CRLF2 over-expression was associated with poor prognosis in the high risk (HR) subgroup where CRLF2-high patients were more frequently allocated.Interestingly, although in T-ALL CRLF2 protein was localized mainly in the cytoplasm, in CRLF2-high blasts we found a trend towards a stronger TSLP-induced pSTAT5 response, sensitive to the JAK inhibitor Ruxolitinib.In conclusion, CRLF2 over-expression is a poor prognostic marker identifying a subset of HR T-ALL patients that could benefit from alternative therapy, potentially targeting the CRLF2 pathway.	ruxolitinib	358-369	cytokine receptor like factor 2	Homo sapiens	9-14
27576133-10	2016	Finally, we determined that metformin enhances the antileukemic action of ruxolitinib in HEL and SET-2 cells.	ruxolitinib	74-85	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	97-102
27716741-8	2016	Furthermore, the expression of mutant CALR caused jak-stat signaling activation in zebrafish that could be blocked by JAK inhibitors (ruxolitinib and fedratinib).	ruxolitinib	134-145	calreticulin	Danio rerio	38-42
27716741-8	2016	Furthermore, the expression of mutant CALR caused jak-stat signaling activation in zebrafish that could be blocked by JAK inhibitors (ruxolitinib and fedratinib).	ruxolitinib	134-145	signal transducer and activator of transcription 4	Danio rerio	54-58
27546300-3	2016	The hepatic histopathological and serum biochemical assessment revealed that ruxolitinib pre-treatments dose-dependently reduced TAA-induced liver injury, caspase 3 cleavage and increase in number of hepatocytes positive for the pro-apoptotic Bax, as well as inflammatory cells positive for F4/80 and myeloperoxidase activity in the liver.	ruxolitinib	77-88	caspase 3	Mus musculus	155-164
27546300-3	2016	The hepatic histopathological and serum biochemical assessment revealed that ruxolitinib pre-treatments dose-dependently reduced TAA-induced liver injury, caspase 3 cleavage and increase in number of hepatocytes positive for the pro-apoptotic Bax, as well as inflammatory cells positive for F4/80 and myeloperoxidase activity in the liver.	ruxolitinib	77-88	BCL2-associated X protein	Mus musculus	243-246
27546300-3	2016	The hepatic histopathological and serum biochemical assessment revealed that ruxolitinib pre-treatments dose-dependently reduced TAA-induced liver injury, caspase 3 cleavage and increase in number of hepatocytes positive for the pro-apoptotic Bax, as well as inflammatory cells positive for F4/80 and myeloperoxidase activity in the liver.	ruxolitinib	77-88	adhesion G protein-coupled receptor E1	Mus musculus	291-316
27546300-4	2016	Ruxolitinib pre-treatments also curbed TAA-induced rise in NF-kappaB nuclear expression and STAT3 phosphorylation.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Mus musculus	92-97
27546300-6	2016	Interestingly, ruxolitinib, especially at a dose of 200 mg/kg, dampened the overproduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-23 and IL-17A), which coincided with boosting the release of the anti-inflammatory cytokine IL-10.	ruxolitinib	15-26	tumor necrosis factor	Mus musculus	122-131
27546300-6	2016	Interestingly, ruxolitinib, especially at a dose of 200 mg/kg, dampened the overproduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-23 and IL-17A), which coincided with boosting the release of the anti-inflammatory cytokine IL-10.	ruxolitinib	15-26	interleukin 1 beta	Mus musculus	133-141
27546300-6	2016	Interestingly, ruxolitinib, especially at a dose of 200 mg/kg, dampened the overproduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-23 and IL-17A), which coincided with boosting the release of the anti-inflammatory cytokine IL-10.	ruxolitinib	15-26	interferon gamma	Mus musculus	143-152
27546300-6	2016	Interestingly, ruxolitinib, especially at a dose of 200 mg/kg, dampened the overproduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-23 and IL-17A), which coincided with boosting the release of the anti-inflammatory cytokine IL-10.	ruxolitinib	15-26	interleukin 23, alpha subunit p19	Mus musculus	154-159
27546300-6	2016	Interestingly, ruxolitinib, especially at a dose of 200 mg/kg, dampened the overproduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-23 and IL-17A), which coincided with boosting the release of the anti-inflammatory cytokine IL-10.	ruxolitinib	15-26	interleukin 17A	Mus musculus	164-170
27546300-6	2016	Interestingly, ruxolitinib, especially at a dose of 200 mg/kg, dampened the overproduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IFN-gamma, IL-23 and IL-17A), which coincided with boosting the release of the anti-inflammatory cytokine IL-10.	ruxolitinib	15-26	interleukin 10	Mus musculus	249-254
27379765-12	2016	They also exhibited increased IFN-beta and -gamma-induced STAT1 phosphorylation that was reversed upon treatment with the JAK kinase inhibitor ruxolitinib.	ruxolitinib	143-154	interferon beta 1	Homo sapiens	30-38
27379765-12	2016	They also exhibited increased IFN-beta and -gamma-induced STAT1 phosphorylation that was reversed upon treatment with the JAK kinase inhibitor ruxolitinib.	ruxolitinib	143-154	signal transducer and activator of transcription 1	Homo sapiens	58-63
27699253-4	2016	Here, we investigated the use of the oral JAK1/2 inhibitor ruxolitinib in the treatment of patients with moderate-to-severe AA.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	42-48
27796499-4	2016	Testing for JAK2 mutations is now included in the World Health Organization (WHO) criteria for the diagnosis of MPN, and in 2011 the oral JAK2 kinase inhibitor ruxolitinib became the first Food and Drug Administration (FDA)-approved drug for the treatment of myelofibrosis.	ruxolitinib	160-171	Janus kinase 2	Homo sapiens	138-142
27474009-18	2016	Ruxolitinib can inhibit JAK and prevent STAT3 activation.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Homo sapiens	40-45
26569516-7	2016	In conclusion, our analysis suggests that JAK2 inhibition with ruxolitinib decreases the risk of arterial and/or venous thrombosis in patients with polycythemia vera or myelofibrosis.	ruxolitinib	63-74	Janus kinase 2	Homo sapiens	42-46
27667294-4	2016	Furthermore, the JAK2 inhibitor ruxolitinib has become available in Hungary since 2015.	ruxolitinib	32-43	Janus kinase 2	Homo sapiens	17-21
28598077-0	2016	[The Effect of Ruxolitinib on the Expression of VEGF and HIF-1alpha in Leukemia HEL Cells].	ruxolitinib	15-26	vascular endothelial growth factor A	Homo sapiens	48-52
28598077-1	2016	OBJECTIVES: To investigate the effect of Ruxolitinib on the expression of vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1alpha) in HEL cells.	ruxolitinib	41-52	vascular endothelial growth factor A	Homo sapiens	74-108
28598077-1	2016	OBJECTIVES: To investigate the effect of Ruxolitinib on the expression of vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1alpha) in HEL cells.	ruxolitinib	41-52	vascular endothelial growth factor A	Homo sapiens	110-114
28598077-1	2016	OBJECTIVES: To investigate the effect of Ruxolitinib on the expression of vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1alpha) in HEL cells.	ruxolitinib	41-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	120-152
28598077-1	2016	OBJECTIVES: To investigate the effect of Ruxolitinib on the expression of vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1alpha) in HEL cells.	ruxolitinib	41-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	154-164
28598077-6	2016	CONCLUSIONS: Ruxolitinib can inhibit VEGF, HIF-1alpha expression and angiogenesis of HEL leukemia cells by inhibiting JAK2 pathway.	ruxolitinib	13-24	vascular endothelial growth factor A	Homo sapiens	37-41
28598077-6	2016	CONCLUSIONS: Ruxolitinib can inhibit VEGF, HIF-1alpha expression and angiogenesis of HEL leukemia cells by inhibiting JAK2 pathway.	ruxolitinib	13-24	hypoxia inducible factor 1 subunit alpha	Homo sapiens	43-53
28598077-6	2016	CONCLUSIONS: Ruxolitinib can inhibit VEGF, HIF-1alpha expression and angiogenesis of HEL leukemia cells by inhibiting JAK2 pathway.	ruxolitinib	13-24	Janus kinase 2	Homo sapiens	118-122
27401783-6	2016	Recently JAK2 inhibitor, ruxolitinib, demonstrated significant improvement in controlling the hematocrit and splenomegaly versus best available therapy in patients with PV who failed or are intolerant to HU and currently is FDA-approved in this setting.	ruxolitinib	25-36	Janus kinase 2	Homo sapiens	9-13
27473820-12	2016	Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	126-132
27570458-7	2016	In clinical trials, the JAK1/JAK2 inhibitor ruxolitinib - the first therapy approved for MF worldwide - improved disease-related splenomegaly and symptoms independent of JAK2 (V617F) mutational status, and prolonged survival compared with placebo or standard therapy in patients with advanced MF.	ruxolitinib	44-55	Janus kinase 1	Homo sapiens	24-28
27774135-6	2016	It is worth noting that both 3f and 11b showed more potent antiproliferative activities than the approved JAKs inhibitor Ruxolitinib.	ruxolitinib	121-132	Janus kinase 1	Homo sapiens	106-110
27507649-9	2016	The JAK inhibitor ruxolitinib also reduced osteoclast activity in Hdac3 conditional knockout mice.	ruxolitinib	18-29	histone deacetylase 3	Mus musculus	66-71
27502249-7	2016	Ruxolitinib, a JAK1/2 inhibitor approved for intermediate-2/high-risk myelofibrosis, was recently employed in SR-GvHD with encouraging overall response rates.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
26858309-1	2016	PURPOSE: To conduct a phase I clinical trial exploring the safety and efficacy of ruxolitinib, a JAK1/2 inhibitor, for chronic myelomonocytic leukemia (CMML).	ruxolitinib	82-93	Janus kinase 1	Homo sapiens	97-103
26979390-2	2016	In this issue, ruxolitinib, a JAK1 and -2 inhibitory drug, is shown to induce objective responses in chronic myelomonocytic leukemia patients.	ruxolitinib	15-26	Janus kinase 1	Homo sapiens	30-41
26975727-0	2016	JAK2(V617F) allele burden &gt;=50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.	ruxolitinib	66-77	Janus kinase 2	Homo sapiens	0-4
27211272-1	2016	Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	37-41
27211272-1	2016	Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	42-46
27570458-7	2016	In clinical trials, the JAK1/JAK2 inhibitor ruxolitinib - the first therapy approved for MF worldwide - improved disease-related splenomegaly and symptoms independent of JAK2 (V617F) mutational status, and prolonged survival compared with placebo or standard therapy in patients with advanced MF.	ruxolitinib	44-55	Janus kinase 2	Homo sapiens	29-33
27570458-7	2016	In clinical trials, the JAK1/JAK2 inhibitor ruxolitinib - the first therapy approved for MF worldwide - improved disease-related splenomegaly and symptoms independent of JAK2 (V617F) mutational status, and prolonged survival compared with placebo or standard therapy in patients with advanced MF.	ruxolitinib	44-55	Janus kinase 2	Homo sapiens	170-174
27379204-2	2016	Ruxolitinib synergistically interacted with dual ERBB1/2/4 inhibitors to kill breast as well as lung, ovarian and brain cancer cells.	ruxolitinib	0-11	epidermal growth factor receptor	Homo sapiens	49-58
27222478-3	2016	Recently, several Janus kinase 1/2 (JAK1/2) inhibitors, such as ruxolitinib, have been developed as immunosuppressive agents.	ruxolitinib	64-75	Janus kinase 1	Mus musculus	36-42
27222478-6	2016	In vivo, ruxolitinib treatment suppressed signal transducer and activator of transcription 1 activation and led to recovery from HLH manifestations in both murine models.	ruxolitinib	9-20	signal transducer and activator of transcription 1	Mus musculus	42-92
27222478-9	2016	In Rab27a(-/-) mice, central nervous system involvement was significantly reduced by ruxolitinib therapy.	ruxolitinib	85-96	RAB27A, member RAS oncogene family	Mus musculus	3-9
27222478-10	2016	Our findings demonstrate that clinically relevant doses of the JAK1/2 inhibitor ruxolitinib suppresses the harmful consequences of macrophage overactivation characterizing HLH in 2 murine models.	ruxolitinib	80-91	Janus kinase 1	Mus musculus	63-69
27123832-5	2016	Consistent with this finding, silencing Stat3 by the specific shRNA or by the chemical inhibitor ruxolitinib results in drastic impediment of leukemia cell growth.	ruxolitinib	97-108	signal transducer and activator of transcription 3	Homo sapiens	40-45
27102499-1	2016	RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera.	ruxolitinib	95-106	Janus kinase 2	Homo sapiens	70-84
27034404-3	2016	We found that STAT3 phosphorylation of neutrophils in Aspergillus fumigatus-infected corne as was inhibited by the JAK/STAT inhibitor Ruxolitinib, resulting in impaired fungal killing and decreased matrix metalloproteinase 9 activity.	ruxolitinib	134-145	signal transducer and activator of transcription 3	Mus musculus	14-19
27034404-3	2016	We found that STAT3 phosphorylation of neutrophils in Aspergillus fumigatus-infected corne as was inhibited by the JAK/STAT inhibitor Ruxolitinib, resulting in impaired fungal killing and decreased matrix metalloproteinase 9 activity.	ruxolitinib	134-145	matrix metallopeptidase 9	Homo sapiens	198-224
27034404-4	2016	In vitro, we showed that fungal killing by IL-6/23-stimulated human peripheral blood neutrophils was impaired by JAK/STAT inhibitors Ruxolitinib and Stattic, and by the retinoic acid receptor-related orphan receptor gammat inhibitor SR1001.	ruxolitinib	133-144	interleukin 6	Homo sapiens	43-47
27034404-6	2016	We also demonstrate that IL-6/23-activated neutrophils exhibit increased elastase and gelatinase (matrix metalloproteinase 9) activity, which is inhibited by Ruxolitinib and Stattic but not by SR1001.	ruxolitinib	158-169	interleukin 23, alpha subunit p19	Mus musculus	25-32
27034404-6	2016	We also demonstrate that IL-6/23-activated neutrophils exhibit increased elastase and gelatinase (matrix metalloproteinase 9) activity, which is inhibited by Ruxolitinib and Stattic but not by SR1001.	ruxolitinib	158-169	matrix metallopeptidase 9	Homo sapiens	98-124
27379204-4	2016	The combination of (ruxolitinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and STAT5, and activated eIF2alpha.	ruxolitinib	20-31	AKT serine/threonine kinase 1	Homo sapiens	75-78
27379204-4	2016	The combination of (ruxolitinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and STAT5, and activated eIF2alpha.	ruxolitinib	20-31	CREB regulated transcription coactivator 1	Mus musculus	80-86
27379204-4	2016	The combination of (ruxolitinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and STAT5, and activated eIF2alpha.	ruxolitinib	20-31	CREB regulated transcription coactivator 2	Mus musculus	88-94
27379204-4	2016	The combination of (ruxolitinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and STAT5, and activated eIF2alpha.	ruxolitinib	20-31	signal transducer and activator of transcription 3	Homo sapiens	96-101
27379204-4	2016	The combination of (ruxolitinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and STAT5, and activated eIF2alpha.	ruxolitinib	20-31	signal transducer and activator of transcription 5A	Homo sapiens	107-112
27379204-4	2016	The combination of (ruxolitinib + ERBB1/2/4 inhibitor) rapidly inactivated AKT, mTORC1, mTORC2, STAT3, and STAT5, and activated eIF2alpha.	ruxolitinib	20-31	eukaryotic translation initiation factor 2A	Homo sapiens	128-137
27017614-5	2016	Ruxolitinib, an oral JAK1/JAK2 inhibitor, is approved in the USA for the treatment of patients with intermediate- or high-risk MF and patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
27068405-0	2016	Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.	ruxolitinib	21-32	colony stimulating factor 3 receptor	Homo sapiens	36-41
26303809-0	2016	Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.	ruxolitinib	0-11	calreticulin	Homo sapiens	42-46
27017614-5	2016	Ruxolitinib, an oral JAK1/JAK2 inhibitor, is approved in the USA for the treatment of patients with intermediate- or high-risk MF and patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	26-30
27551334-4	2016	We found that the HSP90-HMWNC could be disassembled by depleting JAK2 with either Jak2-specific shRNA or treatment with JAK2 inhibitors (TG101209 or Ruxolitinib) and HSP90 inhibitor (AUY922).	ruxolitinib	149-160	heat shock protein 90 alpha family class A member 1	Homo sapiens	18-23
31360077-6	2016	Ruxolitinib is an orally available small-molecule tyrosine kinase inhibitor that is a potent and selective inhibitor of JAK1/JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	120-124
31360077-6	2016	Ruxolitinib is an orally available small-molecule tyrosine kinase inhibitor that is a potent and selective inhibitor of JAK1/JAK2.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	125-129
27551334-4	2016	We found that the HSP90-HMWNC could be disassembled by depleting JAK2 with either Jak2-specific shRNA or treatment with JAK2 inhibitors (TG101209 or Ruxolitinib) and HSP90 inhibitor (AUY922).	ruxolitinib	149-160	Janus kinase 2	Homo sapiens	65-69
27551334-4	2016	We found that the HSP90-HMWNC could be disassembled by depleting JAK2 with either Jak2-specific shRNA or treatment with JAK2 inhibitors (TG101209 or Ruxolitinib) and HSP90 inhibitor (AUY922).	ruxolitinib	149-160	Janus kinase 2	Homo sapiens	120-124
27551334-4	2016	We found that the HSP90-HMWNC could be disassembled by depleting JAK2 with either Jak2-specific shRNA or treatment with JAK2 inhibitors (TG101209 or Ruxolitinib) and HSP90 inhibitor (AUY922).	ruxolitinib	149-160	heat shock protein 90 alpha family class A member 1	Homo sapiens	166-171
26981780-0	2016	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.	ruxolitinib	0-11	BCL2 like 11	Homo sapiens	44-47
26981780-0	2016	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.	ruxolitinib	0-11	superoxide dismutase 2	Homo sapiens	102-106
26981780-0	2016	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.	ruxolitinib	0-11	thioredoxin	Homo sapiens	107-110
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	mitogen-activated protein kinase 3	Homo sapiens	51-57
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	AKT serine/threonine kinase 1	Homo sapiens	59-62
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	signal transducer and activator of transcription 3	Homo sapiens	64-69
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	signal transducer and activator of transcription 5A	Homo sapiens	74-79
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	103-108
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	BCL2 like 1	Homo sapiens	110-116
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	superoxide dismutase 2	Homo sapiens	118-122
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	thioredoxin	Homo sapiens	127-130
26981780-4	2016	The combination of [ruxolitinib + MMF] inactivated ERK1/2, AKT, STAT3 and STAT5; reduced expression of MCL-1, BCL-XL, SOD2 and TRX; increased BIM expression; decreased BAD S112 S136 phosphorylation; and enhanced pro-caspase 3 cleavage.	ruxolitinib	20-31	BCL2 like 11	Homo sapiens	142-145
27033238-7	2016	Transcriptome sequencing studies have identified a network of fusion genes involving kinase genes -ABL1,ABL2,PDGFRB,CSF1R,CRLF2,JAK2 and EPOR in-vitro and in-vivo studies along with emerging clinical observations indicate that patients with a kinase-activating aberration may respond to treatment with small molecular inhibitors like imatinib/dasatinib and ruxolitinib.	ruxolitinib	357-368	erythropoietin receptor	Homo sapiens	137-141
26825707-5	2016	In both models, treatment with the JAK1/2 inhibitor ruxolitinib significantly lessened the clinical and laboratory manifestations of HLH, including weight loss, organomegaly, anemia, thrombocytopenia, hypercytokinemia, and tissue inflammation.	ruxolitinib	52-63	Janus kinase 1	Mus musculus	35-41
26787170-0	2016	Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Homo sapiens	95-100
27035095-4	2016	We subsequently show that treating CADM1 null tumours with the JAK/STAT inhibitor ruxolitinib mimics CADM1 gene restoration in preventing SqCC growth and metastases.	ruxolitinib	82-93	cell adhesion molecule 1	Homo sapiens	35-40
27035095-4	2016	We subsequently show that treating CADM1 null tumours with the JAK/STAT inhibitor ruxolitinib mimics CADM1 gene restoration in preventing SqCC growth and metastases.	ruxolitinib	82-93	cell adhesion molecule 1	Homo sapiens	101-106
27034417-1	2016	In this issue of Blood, Das and colleagues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murine models of hemophagocytic lymphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).	ruxolitinib	118-129	Janus kinase 1	Mus musculus	100-106
26717494-4	2016	Over the last decade, the molecular pathogenesis of MPNs has been elucidated considerably, and the Janus kinase (JAK) 1/2 inhibitor ruxolitinib is the first drug specifically approved by the US Food and Drug Administration to treat patients with intermediate-risk and high-risk myelofibrosis.	ruxolitinib	132-143	Janus kinase 1	Homo sapiens	99-119
26846873-3	2016	Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-28
26589910-0	2016	Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.	ruxolitinib	96-107	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	27-42
26589910-0	2016	Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.	ruxolitinib	96-107	ATP binding cassette subfamily B member 1	Homo sapiens	51-56
27213182-3	2016	Activation of the JAK2 signaling pathway in hematopoietic stem cells commonly causes MF, and ruxolitinib, a drug targeting this pathway, is the treatment of choice for many patients.	ruxolitinib	93-104	Janus kinase 2	Homo sapiens	18-22
27213182-6	2016	Toward the goal of developing an imaging biomarker for treatment response in MF, we present preliminary results from a prospective clinical study evaluating parametric response mapping (PRM) of quantitative Dixon MRI bone marrow fat fraction maps in four MF patients treated with ruxolitinib.	ruxolitinib	280-291	FAT atypical cadherin 1	Homo sapiens	229-232
26115187-0	2016	Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.	ruxolitinib	103-114	Janus kinase 2	Homo sapiens	12-16
26811457-5	2016	In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	25-31
26811457-5	2016	In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2.	ruxolitinib	42-53	signal transducer and activator of transcription 3	Homo sapiens	81-86
26811457-5	2016	In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2.	ruxolitinib	42-53	signal transducer and activator of transcription 6	Homo sapiens	91-96
26811457-5	2016	In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2.	ruxolitinib	42-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	115-120
26811457-6	2016	These changes were enhanced when, on the basis of a matrix screen of drug combinations, ruxolitinib was combined with the Bcl-2/Bcl-xL inhibitor Navitoclax.	ruxolitinib	88-99	BCL2 like 1	Homo sapiens	128-134
26811457-8	2016	The use of the two-agent combination of either ruxolitinib or Navitoclax with BV or the three-agent combination strongly activated Bax and increased activities of cytochrome c and caspase-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.	ruxolitinib	47-58	BCL2 associated X, apoptosis regulator	Homo sapiens	131-134
26811457-8	2016	The use of the two-agent combination of either ruxolitinib or Navitoclax with BV or the three-agent combination strongly activated Bax and increased activities of cytochrome c and caspase-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.	ruxolitinib	47-58	cytochrome c, somatic	Homo sapiens	163-175
26811457-8	2016	The use of the two-agent combination of either ruxolitinib or Navitoclax with BV or the three-agent combination strongly activated Bax and increased activities of cytochrome c and caspase-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.	ruxolitinib	47-58	caspase 9	Homo sapiens	180-196
26811457-8	2016	The use of the two-agent combination of either ruxolitinib or Navitoclax with BV or the three-agent combination strongly activated Bax and increased activities of cytochrome c and caspase-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.	ruxolitinib	47-58	poly(ADP-ribose) polymerase 1	Homo sapiens	231-258
26811457-8	2016	The use of the two-agent combination of either ruxolitinib or Navitoclax with BV or the three-agent combination strongly activated Bax and increased activities of cytochrome c and caspase-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.	ruxolitinib	47-58	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	263-268
26855781-2	2016	According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms.	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	44-48
26855781-2	2016	According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms.	ruxolitinib	29-40	Janus kinase 2	Homo sapiens	49-53
26755644-0	2016	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.	ruxolitinib	66-77	insulin receptor substrate 2	Homo sapiens	0-4
26755644-0	2016	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.	ruxolitinib	66-77	Janus kinase 2	Homo sapiens	81-90
26755644-2	2016	However, the lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, indicates the need for identifying pathways that cooperate with JAK2.	ruxolitinib	91-102	Janus kinase 1	Homo sapiens	73-79
26755644-2	2016	However, the lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, indicates the need for identifying pathways that cooperate with JAK2.	ruxolitinib	91-102	Janus kinase 2	Homo sapiens	168-172
26755644-5	2016	In HEL cells, IRS2 silencing decreased STAT5 phosphorylation, reduced cell viability and increased apoptosis; these effects were enhanced when IRS2 silencing was combined with ruxolitinib.	ruxolitinib	176-187	insulin receptor substrate 2	Homo sapiens	14-18
26755644-7	2016	IRS1/2 pharmacological inhibition in primary MPN samples reduced cell viability in JAK2V617F-positive but not JAK2WT specimens; combination with ruxolitinib had additive effects.	ruxolitinib	145-156	insulin receptor substrate 1	Homo sapiens	0-4
26701727-8	2016	Furthermore,the sensitivity to the treatment of a JAK1/2 inhibitor, ruxolitinib, was observed in JAK1S703I mutant PDX model, but not in other non-activating mutant or wild type models.	ruxolitinib	68-79	Janus kinase 1	Homo sapiens	50-56
26701727-9	2016	Pharmacodynamic analysis showed that phosphorylation of STAT3 in the Ruxolitinib-treated tumor tissues was significantly suppressed.	ruxolitinib	69-80	signal transducer and activator of transcription 3	Homo sapiens	56-61
26115187-0	2016	Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.	ruxolitinib	103-114	CD34 molecule	Homo sapiens	40-44
26459144-0	2016	Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.	ruxolitinib	84-95	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	15-22
26298727-1	2016	Ruxolitinib is the first agent used in myelofibrosis treatment with its potent JAK2 inhibitory effect.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	79-83
26298727-9	2016	Ruxolitinib treatment caused a notable decrease in expression of AKT, mTOR, and STAT autophagy inhibitor genes in K-562 cells, contrariwise control cell line.	ruxolitinib	0-11	AKT serine/threonine kinase 1	Homo sapiens	65-68
26298727-9	2016	Ruxolitinib treatment caused a notable decrease in expression of AKT, mTOR, and STAT autophagy inhibitor genes in K-562 cells, contrariwise control cell line.	ruxolitinib	0-11	mechanistic target of rapamycin kinase	Homo sapiens	70-74
26298727-10	2016	Ruxolitinib is a promising agent in chronic myeloid leukemia treatment by blocking JAK/STAT pathway known as downstream of BCR-ABL and triggering autophagy.	ruxolitinib	0-11	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	123-130
26586478-6	2016	Concomitantly targeting the TGF-beta type I receptor (TbetaRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	88-92
26586478-6	2016	Concomitantly targeting the TGF-beta type I receptor (TbetaRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	123-127
26586478-6	2016	Concomitantly targeting the TGF-beta type I receptor (TbetaRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	123-127
26459144-0	2016	Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.	ruxolitinib	84-95	Janus kinase 2	Homo sapiens	34-38
26274939-3	2016	We hypothesized that, similar to adult patients, the presence of CSF3R-activating mutations would be clinically relevant in pediatric myeloid neoplasms as patients would be sensitive to the JAK inhibitor, ruxolitinib.	ruxolitinib	205-216	colony stimulating factor 3 receptor	Homo sapiens	65-70
27840748-1	2016	The Janus kinase (JAK) 1 and 2 inhibitor, ruxolitinib, was recently approved in Japan and has been effective in many patients with myelofibrosis (MF).	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	4-30
26274939-5	2016	One patient had CSF3R-activating mutation (T618I) and demonstrated a robust response to ruxolitinib, which was used to bridge to a successful stem cell transplant.	ruxolitinib	88-99	colony stimulating factor 3 receptor	Homo sapiens	16-21
26274939-8	2016	As the third documented case successfully treating aCML with ruxolitinib, this case highlights the importance of prompt CSF3R sequencing analysis for myeloproliferative and myelodysplastic/myeloproliferative neoplasms.	ruxolitinib	61-72	colony stimulating factor 3 receptor	Homo sapiens	120-125
26489695-9	2016	Heparanase level and procoagulant activity were higher in U87 cells transfected to over express JAK-2 V617F mutation compared to control and the effect was reversed using JAK-2 inhibitors (Ruxolitinib, VZ3) and hydroxyurea, although the latter drug did not inhibit JAK-2 phosphorylation.	ruxolitinib	189-200	Janus kinase 2	Homo sapiens	96-101
26687007-8	2015	Eight weeks-treatment with ruxolitinib, an FDA-approved JAK1/2 inhibitor, reduced circulating activin A, preserved fat mass, reduced lipotoxicity, and increased insulin sensitivity in 22-month-old mice.	ruxolitinib	27-38	Janus kinase 1	Mus musculus	56-62
26351344-3	2015	PATIENTS AND METHODS: In this double-blind, phase II study, patients with metastatic pancreatic cancer who had experienced treatment failure with gemcitabine were randomly assigned 1:1 to the JAK1/JAK2 inhibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m(2) twice daily) or placebo plus capecitabine.	ruxolitinib	212-223	Janus kinase 2	Homo sapiens	197-201
26351344-7	2015	In a prespecified subgroup analysis of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (ie, 13 mg/L), OS was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI, 0.26 to 0.85; P = .011).	ruxolitinib	200-211	C-reactive protein	Homo sapiens	84-102
26433906-10	2015	A recent phase 3 trial has shown the superiority of the JAK1/2 inhibitor ruxolitinib in comparison to best available treatment in HU-intolerant or -resistant patients.	ruxolitinib	73-84	Janus kinase 1	Homo sapiens	56-62
26443624-1	2015	The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL).	ruxolitinib	64-75	Janus kinase 1	Homo sapiens	46-52
26648193-4	2015	In this article, we present our recommendations for the practical management of myelofibrosis with ruxolitinib, a selective inhibitor of both JAK1 and JAK2.	ruxolitinib	99-110	Janus kinase 1	Homo sapiens	142-146
26648193-4	2015	In this article, we present our recommendations for the practical management of myelofibrosis with ruxolitinib, a selective inhibitor of both JAK1 and JAK2.	ruxolitinib	99-110	Janus kinase 2	Homo sapiens	151-155
26472029-0	2015	The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	113-117
26472029-0	2015	The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.	ruxolitinib	77-88	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	4-7
26472029-10	2015	Importantly, PIM inhibitors re-sensitized ruxolitinib-resistant MPN cells to ruxolitinib by inducing apoptosis.	ruxolitinib	42-53	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	13-16
26472029-10	2015	Importantly, PIM inhibitors re-sensitized ruxolitinib-resistant MPN cells to ruxolitinib by inducing apoptosis.	ruxolitinib	77-88	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	13-16
26472029-11	2015	Finally, exogenous expression of PIM1 induced ruxolitinib resistance in MPN model cells.	ruxolitinib	46-57	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	33-37
26623653-0	2015	The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.	ruxolitinib	93-104	mitogen-activated protein kinase 8	Homo sapiens	133-136
26623653-2	2015	Targeted therapy with Ruxolitinib, a JAK1/2-specific inhibitor, achieves symptomatic improvement but does not eliminate the neoplastic clone.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	37-41
26443624-1	2015	The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL).	ruxolitinib	155-166	Janus kinase 1	Homo sapiens	46-52
26375873-7	2015	Moreover, resveratrol synergized with the selective JAK2 inhibitor ruxolitinib, eliminating tumor cells with the JAK2 mutation.	ruxolitinib	67-78	Janus kinase 2	Homo sapiens	52-56
26446793-10	2015	Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P).	ruxolitinib	10-21	Janus kinase 1	Mus musculus	51-55
26446793-10	2015	Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P).	ruxolitinib	10-21	Janus kinase 2	Mus musculus	60-64
26446793-10	2015	Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P).	ruxolitinib	10-21	Janus kinase 3	Mus musculus	141-145
26446793-10	2015	Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P).	ruxolitinib	10-21	Janus kinase 3	Mus musculus	202-206
26202607-0	2015	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.	ruxolitinib	12-23	pericentriolar material 1	Homo sapiens	50-54
26202607-0	2015	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	55-59
26375873-7	2015	Moreover, resveratrol synergized with the selective JAK2 inhibitor ruxolitinib, eliminating tumor cells with the JAK2 mutation.	ruxolitinib	67-78	Janus kinase 2	Homo sapiens	113-117
26396258-7	2015	The selective JAK inhibitor ruxolitinib was examined in a high-throughput matrix screen combined with &gt;450 potential therapeutic agents, and Bcl-2/Bcl-xL inhibitor navitoclax was identified as a strong candidate for multicomponent therapy.	ruxolitinib	28-39	BCL2 apoptosis regulator	Homo sapiens	144-149
26552452-4	2015	The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-10
26356819-8	2015	We then proposed that an undesired effect of ruxolitinib treatment may constitute Stathmin 1 activation and microtubule instability in JAK2(V617F) cells.	ruxolitinib	45-56	stathmin 1	Homo sapiens	82-92
26356819-8	2015	We then proposed that an undesired effect of ruxolitinib treatment may constitute Stathmin 1 activation and microtubule instability in JAK2(V617F) cells.	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	135-139
26356819-0	2015	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.	ruxolitinib	32-43	stathmin 1	Homo sapiens	0-10
26356819-0	2015	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.	ruxolitinib	32-43	Janus kinase 2	Homo sapiens	65-69
26356819-9	2015	Induction of microtubule stability, through Stathmin 1 silencing or paclitaxel treatment, combined with ruxolitinib could be an effective strategy for promoting apoptosis in JAK2(V617F) cells.	ruxolitinib	104-115	Janus kinase 2	Homo sapiens	174-178
26396258-7	2015	The selective JAK inhibitor ruxolitinib was examined in a high-throughput matrix screen combined with &gt;450 potential therapeutic agents, and Bcl-2/Bcl-xL inhibitor navitoclax was identified as a strong candidate for multicomponent therapy.	ruxolitinib	28-39	BCL2 like 1	Homo sapiens	150-156
26356819-1	2015	The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor.	ruxolitinib	105-116	Janus kinase 1	Homo sapiens	130-136
26356819-3	2015	In support of this hypothesis, we found that, in HEL JAK2(V617F) cells, ruxolitinib treatment decreased STAT3 and Stathmin 1 association, induced Stathmin 1 activation and microtubule instability.	ruxolitinib	72-83	Janus kinase 2	Homo sapiens	53-57
26228487-0	2015	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.	ruxolitinib	24-35	Janus kinase 2	Homo sapiens	49-54
26356819-3	2015	In support of this hypothesis, we found that, in HEL JAK2(V617F) cells, ruxolitinib treatment decreased STAT3 and Stathmin 1 association, induced Stathmin 1 activation and microtubule instability.	ruxolitinib	72-83	signal transducer and activator of transcription 3	Homo sapiens	104-109
26356819-3	2015	In support of this hypothesis, we found that, in HEL JAK2(V617F) cells, ruxolitinib treatment decreased STAT3 and Stathmin 1 association, induced Stathmin 1 activation and microtubule instability.	ruxolitinib	72-83	stathmin 1	Homo sapiens	114-124
26356819-3	2015	In support of this hypothesis, we found that, in HEL JAK2(V617F) cells, ruxolitinib treatment decreased STAT3 and Stathmin 1 association, induced Stathmin 1 activation and microtubule instability.	ruxolitinib	72-83	stathmin 1	Homo sapiens	146-156
26356819-4	2015	Silencing of Stathmin 1 significantly reduced cell proliferation and clonal growth, and increased apoptosis induced by ruxolitinib.	ruxolitinib	119-130	stathmin 1	Homo sapiens	13-23
26356819-5	2015	Stathmin 1 silencing also prevented ruxolitinib-induced microtubule instability.	ruxolitinib	36-47	stathmin 1	Homo sapiens	0-10
26430722-0	2015	Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.	ruxolitinib	113-124	Janus kinase 2	Homo sapiens	12-16
26430722-0	2015	Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.	ruxolitinib	113-124	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	54-61
26227854-2	2015	The JAK2 inhibitor Ruxolitinib is the first FDA-approved treatment for MPNs.	ruxolitinib	19-30	Janus kinase 2	Homo sapiens	4-8
26227854-8	2015	Moreover, GLS inhibitor increased the growth inhibitory effect of Ruxolitinib in both JAK2(V617F)-mutant cell lines and peripheral blood CD34+ cells from MPN patients.	ruxolitinib	66-77	glutaminase	Mus musculus	10-13
26227854-8	2015	Moreover, GLS inhibitor increased the growth inhibitory effect of Ruxolitinib in both JAK2(V617F)-mutant cell lines and peripheral blood CD34+ cells from MPN patients.	ruxolitinib	66-77	Janus kinase 2	Homo sapiens	86-90
26227854-8	2015	Moreover, GLS inhibitor increased the growth inhibitory effect of Ruxolitinib in both JAK2(V617F)-mutant cell lines and peripheral blood CD34+ cells from MPN patients.	ruxolitinib	66-77	CD34 molecule	Homo sapiens	137-141
26362333-1	2015	Ruxolitinib (Jakavi( ), Jakafi( )) is an orally administered, first-in-class Janus Kinase (JAK) 1 and 2 inhibitor that was recently approved for the treatment of patients with polycythaemia vera (PV) who have responded inadequately to or are intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	77-103
26362333-2	2015	By inhibiting JAK 1 and 2, ruxolitinib reduces hyperactive JAK-signal transducers and activators of transcription (STAT) signalling that is implicated in the pathogenesis of PV.	ruxolitinib	27-38	Janus kinase 1	Homo sapiens	14-25
25976292-1	2015	BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	48-52
25976292-1	2015	BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	53-57
25976292-1	2015	BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations.	ruxolitinib	12-23	cytokine receptor like factor 2	Homo sapiens	92-97
26228487-3	2015	This long-term follow-up analysis was performed to determine whether ruxolitinib therapy altered the JAK2p.V617F allele burden in JAK2p.V617F-positive patients.	ruxolitinib	69-80	Janus kinase 2	Homo sapiens	101-106
26228487-3	2015	This long-term follow-up analysis was performed to determine whether ruxolitinib therapy altered the JAK2p.V617F allele burden in JAK2p.V617F-positive patients.	ruxolitinib	69-80	Janus kinase 2	Homo sapiens	130-135
25980454-4	2015	Ruxolitinib is an oral JAK1/JAK2 inhibitor that has been evaluated in Phase II and III clinical trials in patients with PV, who are intolerant of or resistant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-27
25977345-4	2015	EXPERIMENTAL DESIGN: We examined the effect of JAK1/JAK2 modulation by ruxolitinib in a mouse model of fully MHC mismatched bone marrow transplant comprising in vivo tumor inoculation.	ruxolitinib	71-82	Janus kinase 1	Mus musculus	47-51
25977345-4	2015	EXPERIMENTAL DESIGN: We examined the effect of JAK1/JAK2 modulation by ruxolitinib in a mouse model of fully MHC mismatched bone marrow transplant comprising in vivo tumor inoculation.	ruxolitinib	71-82	Janus kinase 2	Mus musculus	52-56
25977345-5	2015	RESULTS: JAK1/JAK2 inhibition by ruxolitinib improved both overall survival (P = 0.03) and acute GVHD pathologic score at target organs (P &lt;= 0.001) of treated mice.	ruxolitinib	33-44	Janus kinase 1	Mus musculus	9-13
25977345-5	2015	RESULTS: JAK1/JAK2 inhibition by ruxolitinib improved both overall survival (P = 0.03) and acute GVHD pathologic score at target organs (P &lt;= 0.001) of treated mice.	ruxolitinib	33-44	Janus kinase 2	Mus musculus	14-18
25915176-1	2015	Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
25915176-1	2015	Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	24-28
25980454-4	2015	Ruxolitinib is an oral JAK1/JAK2 inhibitor that has been evaluated in Phase II and III clinical trials in patients with PV, who are intolerant of or resistant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	28-32
26288713-4	2015	The first of these agents to be approved was ruxolitinib, a JAK1/JAK2 inhibitor, which has been shown to improve both spleen size and symptoms in patients with MF.	ruxolitinib	45-56	Janus kinase 1	Homo sapiens	60-64
26288713-4	2015	The first of these agents to be approved was ruxolitinib, a JAK1/JAK2 inhibitor, which has been shown to improve both spleen size and symptoms in patients with MF.	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	65-69
25315076-2	2015	In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy.	ruxolitinib	99-110	Janus kinase 1	Homo sapiens	121-135
26151455-3	2015	The JAK/STAT signalling pathway provides an example of this paradigm in haematological malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clinically effective JAK2 inhibitors, such as ruxolitinib.	ruxolitinib	260-271	Janus kinase 2	Homo sapiens	128-132
26151455-3	2015	The JAK/STAT signalling pathway provides an example of this paradigm in haematological malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clinically effective JAK2 inhibitors, such as ruxolitinib.	ruxolitinib	260-271	Janus kinase 2	Homo sapiens	235-239
26167286-1	2015	BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	46-67
25644746-5	2015	The JAK1/JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis and is currently under clinical development for polycythemia vera.	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
25644746-5	2015	The JAK1/JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis and is currently under clinical development for polycythemia vera.	ruxolitinib	24-35	Janus kinase 2	Homo sapiens	9-13
25315076-2	2015	In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy.	ruxolitinib	99-110	Janus kinase 1	Homo sapiens	137-141
25315076-2	2015	In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy.	ruxolitinib	99-110	Janus kinase 2	Homo sapiens	143-147
26131691-3	2015	Given this, drug development efforts have targeted the pathway with JAK inhibitors such as ruxolitinib.	ruxolitinib	91-102	hopscotch	Drosophila melanogaster	68-71
26131691-18	2015	While the JAK1/2 inhibitor ruxolitinib is effective, a $43,200 annual cost precludes widespread adoption.	ruxolitinib	27-38	Janus kinase 1	Homo sapiens	10-16
26085921-5	2015	When NK cells are co-cultured with helper-dependent adenoviral (HD-Ad) vector activated macrophages, IFN-gamma cytokine expression by NK cells increased significantly, which was inhibited effectively by ruxolitinib and CAPE, and there was an additive effect when both inhibitors were used.	ruxolitinib	203-214	interferon gamma	Homo sapiens	101-110
25824483-1	2015	Ruxolitinib (INCB018424) is the first JAK1/JAK2 inhibitor approved for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-42
25824483-1	2015	Ruxolitinib (INCB018424) is the first JAK1/JAK2 inhibitor approved for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	43-47
25824483-1	2015	Ruxolitinib (INCB018424) is the first JAK1/JAK2 inhibitor approved for treatment of myelofibrosis.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	38-42
25824483-1	2015	Ruxolitinib (INCB018424) is the first JAK1/JAK2 inhibitor approved for treatment of myelofibrosis.	ruxolitinib	13-23	Janus kinase 2	Homo sapiens	43-47
25824483-3	2015	To better understand how ruxolitinib modulates CD4(+) T cell responses, we undertook an in-depth analysis of CD4(+) T cell function upon ruxolitinib exposure.	ruxolitinib	25-36	CD4 molecule	Homo sapiens	47-50
25824483-3	2015	To better understand how ruxolitinib modulates CD4(+) T cell responses, we undertook an in-depth analysis of CD4(+) T cell function upon ruxolitinib exposure.	ruxolitinib	137-148	CD4 molecule	Homo sapiens	109-112
25824483-7	2015	Finally, we showed that ruxolitinib does not interfere with the T cell receptor signalling pathway, but impacts IL2-dependent STAT5 activation.	ruxolitinib	24-35	interleukin 2	Homo sapiens	112-115
25824483-7	2015	Finally, we showed that ruxolitinib does not interfere with the T cell receptor signalling pathway, but impacts IL2-dependent STAT5 activation.	ruxolitinib	24-35	signal transducer and activator of transcription 5A	Homo sapiens	126-131
26316485-1	2015	Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
26316485-1	2015	Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	24-28
25515354-7	2015	In randomized controlled phase 3 studies, the JAK1/JAK2 inhibitor ruxolitinib provided rapid and lasting improvement in MF-related splenomegaly and symptom burden as well as a survival advantage compared with placebo or best available therapy.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	46-50
26056473-2	2015	Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF, especially those with disease-related splenomegaly, intermediate- or high-risk disease, and constitutional symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
26056473-2	2015	Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF, especially those with disease-related splenomegaly, intermediate- or high-risk disease, and constitutional symptoms.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	20-24
25515354-7	2015	In randomized controlled phase 3 studies, the JAK1/JAK2 inhibitor ruxolitinib provided rapid and lasting improvement in MF-related splenomegaly and symptom burden as well as a survival advantage compared with placebo or best available therapy.	ruxolitinib	66-77	Janus kinase 2	Homo sapiens	51-55
25616577-1	2015	In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	38-52
25762644-5	2015	Conversely, STAT3 silencing or JAK1-2 inhibition with ruxolitinib blocks CM-enhanced EC proliferation.	ruxolitinib	54-65	Janus kinase 1	Homo sapiens	31-35
25762644-8	2015	Thus, targeting JAK1-2 with ruxolitinib blocks a final pathway that is common to multiple pro-angiogenic factors, suppresses EC-mediated PCC proliferation, and may be useful in PDACs with a strong pro-angiogenic signature.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	16-20
25762644-8	2015	Thus, targeting JAK1-2 with ruxolitinib blocks a final pathway that is common to multiple pro-angiogenic factors, suppresses EC-mediated PCC proliferation, and may be useful in PDACs with a strong pro-angiogenic signature.	ruxolitinib	28-39	crystallin gamma D	Homo sapiens	137-140
25616577-1	2015	In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	54-58
25616577-1	2015	In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis.	ruxolitinib	75-86	Janus kinase 2	Homo sapiens	60-64
25645356-4	2015	Moreover, ETP-ALL showed hyperactivation of STAT5 in response to interleukin-7, an effect that was abrogated by the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	133-144	signal transducer and activator of transcription 5A	Mus musculus	44-49
25870379-3	2015	Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	176-187	Janus kinase 1	Homo sapiens	156-160
25870379-3	2015	Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	176-187	Janus kinase 2	Homo sapiens	161-165
25645356-4	2015	Moreover, ETP-ALL showed hyperactivation of STAT5 in response to interleukin-7, an effect that was abrogated by the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	133-144	interleukin 7	Mus musculus	65-78
25931349-0	2015	Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.	ruxolitinib	26-37	Janus kinase 2	Homo sapiens	120-124
25805962-13	2015	Janus kinase (JAK) inhibitor ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of G-CSF, as evidenced by the levels of CD11b and CD34 expression.	ruxolitinib	29-40	colony stimulating factor 3	Homo sapiens	146-151
25805962-13	2015	Janus kinase (JAK) inhibitor ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of G-CSF, as evidenced by the levels of CD11b and CD34 expression.	ruxolitinib	29-40	integrin subunit alpha M	Homo sapiens	183-188
25805962-13	2015	Janus kinase (JAK) inhibitor ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of G-CSF, as evidenced by the levels of CD11b and CD34 expression.	ruxolitinib	29-40	CD34 molecule	Homo sapiens	193-197
25572172-1	2015	UNLABELLED: The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) has led to the clinical development of JAK kinase inhibitors, including ruxolitinib.	ruxolitinib	177-188	Janus kinase 2	Homo sapiens	34-38
25572172-1	2015	UNLABELLED: The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) has led to the clinical development of JAK kinase inhibitors, including ruxolitinib.	ruxolitinib	177-188	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	39-42
25749974-2	2015	Their analyses implicate constitutive activation of STAT3 in both malignant and nonmalignant bone marrow cell populations as a driver of aberrant cytokine secretion and as a cellular target mediating the therapeutic activity of ruxolitinib.	ruxolitinib	228-239	signal transducer and activator of transcription 3	Homo sapiens	52-57
25931349-2	2015	Inhibition of JAK2 activity by ruxolitinib (RX) results in growth inhibition and apoptosis of cells carrying the JAK2V617F mutation however the exact mechanisms regulating apoptosis have not been fully elucidated.	ruxolitinib	31-42	Janus kinase 2	Homo sapiens	14-18
25499760-3	2015	Using a mouse model of Ph+ ALL that accurately mimics the genetics, clinical behavior, and therapeutic response of the human disease, we show that a combination of 2 agents approved by the US Food and Drug Administration (dasatinib and ruxolitinib, which inhibit BCR-ABL and Janus kinases, respectively), significantly extends survival by targeting parallel signaling pathways.	ruxolitinib	236-247	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	263-270
25638222-1	2015	Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms and a survival benefit in 2 phase 3 trials in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-44
25638222-1	2015	Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms and a survival benefit in 2 phase 3 trials in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	45-49
25441108-0	2015	A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.	ruxolitinib	62-73	Janus kinase 1	Homo sapiens	26-51
25441108-1	2015	BACKGROUND: Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	49-53
25441108-1	2015	BACKGROUND: Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	54-58
25441108-10	2015	One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d.	ruxolitinib	75-86	C-reactive protein	Homo sapiens	66-69
25441108-11	2015	CONCLUSION: In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.	ruxolitinib	103-114	C-reactive protein	Homo sapiens	179-182
25721043-1	2015	In this issue of Blood, Appelmann et al provide evidence for prolonged survival and prevention of resistance in a mouse model of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, respectively.	ruxolitinib	292-303	Janus kinase 2	Mus musculus	251-265
25670523-2	2015	A ruxolitinib physiologically based pharmacokinetic model was constructed using all baseline PK data in healthy subjects, and verified by retrospective predictions of observed drug-drug interactions with rifampin (a potent CYP3A4 inducer), ketoconazole (a potent CYP3A4 reversible inhibitor) and erythromycin (a moderate time-dependent inhibitor of CYP3A4).	ruxolitinib	2-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	223-229
25260694-0	2015	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.	ruxolitinib	42-53	pericentriolar material 1	Homo sapiens	80-84
25260694-0	2015	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	85-89
25260694-0	2015	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	98-102
25260694-3	2015	With the discovery of inhibitors of the JAK2 tyrosine kinase and based on encouraging in vitro and in vivo data, we treated two male patients with myeloid neoplasms and a PCM1-JAK2 or a BCR-JAK2 fusion gene, respectively, with the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	251-262	Janus kinase 2	Homo sapiens	40-44
25260694-7	2015	This data highlight (1) the ongoing importance of cytogenetic analysis for the diagnostic work-up of myeloid neoplasms as it may guide targeted therapy and (2) remission under ruxolitinib may only be short-termed in JAK2 fusion genes but it may be an important bridging therapy prior to ASCT.	ruxolitinib	176-187	Janus kinase 2	Homo sapiens	216-220
25670523-2	2015	A ruxolitinib physiologically based pharmacokinetic model was constructed using all baseline PK data in healthy subjects, and verified by retrospective predictions of observed drug-drug interactions with rifampin (a potent CYP3A4 inducer), ketoconazole (a potent CYP3A4 reversible inhibitor) and erythromycin (a moderate time-dependent inhibitor of CYP3A4).	ruxolitinib	2-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	263-269
25670523-2	2015	A ruxolitinib physiologically based pharmacokinetic model was constructed using all baseline PK data in healthy subjects, and verified by retrospective predictions of observed drug-drug interactions with rifampin (a potent CYP3A4 inducer), ketoconazole (a potent CYP3A4 reversible inhibitor) and erythromycin (a moderate time-dependent inhibitor of CYP3A4).	ruxolitinib	2-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	263-269
25670523-3	2015	The model prospectively predicts that 100-200 mg daily dose of fluconazole, a dual inhibitor of CYP3A4 and 2C9, would increase ruxolitinib plasma concentration area under the curve by ~two-fold, and that as a perpetrator, ruxolitinib is highly unlikely to have any discernible effect on digoxin, a sensitive P-glycoprotein substrate.	ruxolitinib	127-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-110
25256963-2	2015	Ruxolitinib, a janus-activated kinase (JAK) 1/2 inhibitor, has proven to be beneficial in reduction of splenomegaly, improvement of constitutional symptoms, and possibly in overall survival.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-47
25601187-1	2015	Ruxolitinib (Jakavi( ), Jakafi( )) is an orally administered inhibitor of Janus kinases (JAK) 1 and 2 used in the management of patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	74-101
25662309-0	2015	Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.	ruxolitinib	7-18	signal transducer and activator of transcription 1	Homo sapiens	102-152
25662309-0	2015	Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation.	ruxolitinib	7-18	signal transducer and activator of transcription 1	Homo sapiens	154-159
25629741-1	2015	BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	27-53
26356267-1	2015	BACKGROUND/AIMS: The JAK1/JAK2 tyrosine kinase inhibitor ruxolitinib is widely used for the treatment of myeloproliferative neoplasm-associated myelofibrosis and other malignancies.	ruxolitinib	57-68	Janus kinase 1	Homo sapiens	21-25
25559089-4	2015	Protein kinases are highly attractive targets for drug discovery, as evidenced by the approval of almost 30 kinase inhibitors in oncology, and the successful development of the dual JAK1/2 (Janus kinase 1/2) inhibitor ruxolitinib for inflammatory indications.	ruxolitinib	218-229	Janus kinase 1	Homo sapiens	182-188
25405713-5	2015	In addition, a model for the binding mode of ruxolitinib to Janus kinase (JAK) 2 is proposed.	ruxolitinib	45-56	Janus kinase 2	Homo sapiens	60-80
26356267-1	2015	BACKGROUND/AIMS: The JAK1/JAK2 tyrosine kinase inhibitor ruxolitinib is widely used for the treatment of myeloproliferative neoplasm-associated myelofibrosis and other malignancies.	ruxolitinib	57-68	Janus kinase 2	Homo sapiens	26-30
26356267-10	2015	CONCLUSION: Ruxolitinib triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect in part requiring p38 MAP kinase activity.	ruxolitinib	12-23	mitogen-activated protein kinase 14	Homo sapiens	138-141
26356267-7	2015	RESULTS: A 48 hours exposure of human erythrocytes to ruxolitinib (25 microM) significantly increased the percentage of annexin-V-binding cells and significantly decreased forward scatter.	ruxolitinib	54-65	annexin A5	Homo sapiens	120-129
26356267-8	2015	Ruxolitinib did not significantly modify Fluo3-fluorescence and DCFDA fluorescence and the effect of ruxolitinib on annexin-V-binding was not significantly modified by removal of extracellular Ca2+.	ruxolitinib	101-112	annexin A5	Homo sapiens	116-125
26356267-9	2015	The effect of ruxolitinib on annexin-V-binding was, however, significantly blunted by the p38 MAP kinase inhibitor SB203580 and virtually abolished by the p38 MAP kinase inhibitor skepinone.	ruxolitinib	14-25	annexin A5	Homo sapiens	29-38
26356267-9	2015	The effect of ruxolitinib on annexin-V-binding was, however, significantly blunted by the p38 MAP kinase inhibitor SB203580 and virtually abolished by the p38 MAP kinase inhibitor skepinone.	ruxolitinib	14-25	mitogen-activated protein kinase 14	Homo sapiens	90-104
26356267-9	2015	The effect of ruxolitinib on annexin-V-binding was, however, significantly blunted by the p38 MAP kinase inhibitor SB203580 and virtually abolished by the p38 MAP kinase inhibitor skepinone.	ruxolitinib	14-25	mitogen-activated protein kinase 14	Homo sapiens	90-93
25738293-7	2015	Furthermore it was showed that some drugs like tofacitinib or ruxolitinib may influence CD by blocking IL-15 signaling and CD8+ T cell activity.	ruxolitinib	62-73	interleukin 15	Homo sapiens	103-108
26389774-3	2015	Ruxolitinib, a JAK1 and 2 inhibitor, is the only currently approved agent.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-25
26367195-1	2015	The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and constitutional symptoms in patients with myelofibrosis.	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	19-23
26367195-1	2015	The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and constitutional symptoms in patients with myelofibrosis.	ruxolitinib	39-50	Janus kinase 2	Homo sapiens	24-28
25757677-1	2015	The JAK1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-AB1-negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis and shortened survival.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	4-8
25757677-1	2015	The JAK1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-AB1-negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis and shortened survival.	ruxolitinib	28-39	Janus kinase 2	Homo sapiens	13-17
25586607-2	2015	Targeting of the JAK-STAT pathway has been the intense focus of therapeutic development and led to the approval of the JAK1/2 inhibitor, ruxolitinib.	ruxolitinib	137-148	Janus kinase 1	Homo sapiens	119-125
25433930-6	2014	Treatment with ruxolitinib (a JAK2 inhibitor) induced transient and partial control of the haematological symptoms but did not prevent UV flare.	ruxolitinib	15-26	Janus kinase 2	Homo sapiens	30-34
25501025-1	2014	Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high- and intermediate-risk myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-35
25501025-1	2014	Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high- and intermediate-risk myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	40-45
25549138-6	2014	Using Ruxolitinib and JAK2 as a drug target pair, here we describe in vitro screening methods that utilizes the mouse BAF3 cells expressing the random mutation library of JAK2 kinase.	ruxolitinib	6-17	Janus kinase 2	Mus musculus	171-175
25696866-2	2014	Furthermore, the oral JAK1/JAK2 inhibitor ruxolitinib, rationally designed to target activated JAK2 signaling in MPN, has been approved by the Food and Drug Administration (FDA) of the United States for the past 3 years for the treatment of intermediate- and advanced-phase myelofibrosis.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	22-26
25696866-2	2014	Furthermore, the oral JAK1/JAK2 inhibitor ruxolitinib, rationally designed to target activated JAK2 signaling in MPN, has been approved by the Food and Drug Administration (FDA) of the United States for the past 3 years for the treatment of intermediate- and advanced-phase myelofibrosis.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	27-31
25696866-2	2014	Furthermore, the oral JAK1/JAK2 inhibitor ruxolitinib, rationally designed to target activated JAK2 signaling in MPN, has been approved by the Food and Drug Administration (FDA) of the United States for the past 3 years for the treatment of intermediate- and advanced-phase myelofibrosis.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	95-99
25526003-1	2014	Ruxolitinib, a small molecule JAK-1/2 inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in November 2011, as the first therapeutic for the treatment of intermediate and high-risk myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	30-37
25520049-3	2014	Ruxolitinib, a JAK-1/2 inhibitor, is effective at controlling splenomegaly and constitutional symptoms, but has limited benefit in reversing bone marrow fibrosis or inducing complete or partial remissions.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-22
25213670-2	2014	We treated five non-small-cell lung cancer cell lines with cisplatin alone or with cisplatin and Jak2 inhibitor (ruxolitinib) and assessed cell viability, expression of Jak2 and STAT3 and cell apoptosis.	ruxolitinib	113-124	Janus kinase 2	Homo sapiens	97-101
25213670-6	2014	In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression.	ruxolitinib	82-93	Janus kinase 2	Homo sapiens	41-45
25213670-6	2014	In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression.	ruxolitinib	82-93	signal transducer and activator of transcription 3	Homo sapiens	50-55
25213670-6	2014	In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression.	ruxolitinib	82-93	signal transducer and activator of transcription 3	Homo sapiens	195-200
25213670-6	2014	In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression.	ruxolitinib	82-93	caspase 3	Homo sapiens	221-230
25232060-5	2014	The JAK inhibitors are effective in both JAK2-positive and JAK2-negative MF; one of them, ruxolitinib, is the current best available therapy for MF splenomegaly and constitutional symptoms.	ruxolitinib	90-101	Janus kinase 2	Homo sapiens	41-45
25232060-5	2014	The JAK inhibitors are effective in both JAK2-positive and JAK2-negative MF; one of them, ruxolitinib, is the current best available therapy for MF splenomegaly and constitutional symptoms.	ruxolitinib	90-101	Janus kinase 2	Homo sapiens	59-63
25390891-7	2014	More specifically, the JAK1/2 inhibitor Ruxolitinib enhances the growth of viruses that are sensitive to IFN due to (i) loss of function of the viral IFN antagonist (due to mutation or species-specific constraints) or (ii) mutations/host cell constraints that slow virus spread such that it can be controlled by the IFN response.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	23-29
25390891-7	2014	More specifically, the JAK1/2 inhibitor Ruxolitinib enhances the growth of viruses that are sensitive to IFN due to (i) loss of function of the viral IFN antagonist (due to mutation or species-specific constraints) or (ii) mutations/host cell constraints that slow virus spread such that it can be controlled by the IFN response.	ruxolitinib	40-51	interferon alpha 1	Homo sapiens	105-108
25390891-7	2014	More specifically, the JAK1/2 inhibitor Ruxolitinib enhances the growth of viruses that are sensitive to IFN due to (i) loss of function of the viral IFN antagonist (due to mutation or species-specific constraints) or (ii) mutations/host cell constraints that slow virus spread such that it can be controlled by the IFN response.	ruxolitinib	40-51	interferon alpha 1	Homo sapiens	150-153
25390891-7	2014	More specifically, the JAK1/2 inhibitor Ruxolitinib enhances the growth of viruses that are sensitive to IFN due to (i) loss of function of the viral IFN antagonist (due to mutation or species-specific constraints) or (ii) mutations/host cell constraints that slow virus spread such that it can be controlled by the IFN response.	ruxolitinib	40-51	interferon alpha 1	Homo sapiens	150-153
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	108-118	Janus kinase 1	Mus musculus	53-57
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	108-118	Janus kinase 2	Mus musculus	58-62
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	108-118	Janus kinase 1	Mus musculus	87-91
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	108-118	Janus kinase 2	Mus musculus	92-96
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	108-118	chemokine (C-X-C motif) receptor 3	Mus musculus	215-220
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	120-131	Janus kinase 1	Mus musculus	53-57
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	120-131	Janus kinase 2	Mus musculus	58-62
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	120-131	Janus kinase 1	Mus musculus	87-91
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	120-131	Janus kinase 2	Mus musculus	92-96
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	120-131	chemokine (C-X-C motif) receptor 3	Mus musculus	215-220
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	351-361	Janus kinase 1	Mus musculus	53-57
25289677-4	2014	While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD.	ruxolitinib	351-361	Janus kinase 1	Mus musculus	87-91
25289677-6	2014	In addition, prolonged administration of INCB018424 further improves survival after allo-HSCT and is superior to other JAK1/JAK2 inhibitors, such as TG101348 or AZD1480.	ruxolitinib	41-51	Janus kinase 1	Mus musculus	119-123
25289677-6	2014	In addition, prolonged administration of INCB018424 further improves survival after allo-HSCT and is superior to other JAK1/JAK2 inhibitors, such as TG101348 or AZD1480.	ruxolitinib	41-51	Janus kinase 2	Mus musculus	124-128
24497534-4	2014	Macrophage polarization was signal transducer and activator of transcription 3 dependent and was impaired by the Janus kinase inhibitor ruxolitinib.	ruxolitinib	136-147	signal transducer and activator of transcription 3	Homo sapiens	28-78
25207766-8	2014	Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib.	ruxolitinib	170-181	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	47-51
25207766-8	2014	Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib.	ruxolitinib	170-181	platelet derived growth factor receptor beta	Homo sapiens	70-76
25207766-8	2014	Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib.	ruxolitinib	170-181	erythropoietin receptor	Homo sapiens	123-127
25207766-8	2014	Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib.	ruxolitinib	170-181	Janus kinase 2	Homo sapiens	132-136
25197973-0	2014	c-Src binds to the cancer drug Ruxolitinib with an active conformation.	ruxolitinib	31-42	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-5
25197973-4	2014	In this paper, we determined the crystal structure of c-Src kinase domain in complex of Ruxolitinib at a resolution of 2.26 A.	ruxolitinib	88-99	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	54-59
25197973-5	2014	C-Src kinase domain adopts the DFG-in active conformation upon Ruxolitinib binding, indicating Ruxolitinib is a type I inhibitor for c-Src.	ruxolitinib	63-74	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-5
25197973-5	2014	C-Src kinase domain adopts the DFG-in active conformation upon Ruxolitinib binding, indicating Ruxolitinib is a type I inhibitor for c-Src.	ruxolitinib	95-106	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-5
25197973-5	2014	C-Src kinase domain adopts the DFG-in active conformation upon Ruxolitinib binding, indicating Ruxolitinib is a type I inhibitor for c-Src.	ruxolitinib	95-106	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	133-138
25197973-6	2014	Ruxolitinib forms two hydrogen bonds with Met341, a water-mediated hydrogen bond with Thr338, and a number of van der Waals contacts with c-Src.	ruxolitinib	0-11	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	138-143
25197973-7	2014	Ruxolitinib was then docked into the ligand-binding pocket of a previously solved JAK1 structure.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	82-86
25197973-8	2014	From the docking result, Ruxolitinib also binds JAK1 as a type I inhibitor, with more interactions and a higher shape complementarity with the ligand-binding pocket of JAK1 compared to that of c-Src.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	48-52
25197973-8	2014	From the docking result, Ruxolitinib also binds JAK1 as a type I inhibitor, with more interactions and a higher shape complementarity with the ligand-binding pocket of JAK1 compared to that of c-Src.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	168-172
25197973-8	2014	From the docking result, Ruxolitinib also binds JAK1 as a type I inhibitor, with more interactions and a higher shape complementarity with the ligand-binding pocket of JAK1 compared to that of c-Src.	ruxolitinib	25-36	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	193-198
25197973-9	2014	Since Ruxolitinib is a relatively small inhibitor and there is sizeable cavity between Ruxolitinib and c-Src ligand-binding pocket, we propose to modify Ruxolitinib to develop more potent inhibitors to c-Src.	ruxolitinib	6-17	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	103-108
25197973-9	2014	Since Ruxolitinib is a relatively small inhibitor and there is sizeable cavity between Ruxolitinib and c-Src ligand-binding pocket, we propose to modify Ruxolitinib to develop more potent inhibitors to c-Src.	ruxolitinib	6-17	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	202-207
25197973-9	2014	Since Ruxolitinib is a relatively small inhibitor and there is sizeable cavity between Ruxolitinib and c-Src ligand-binding pocket, we propose to modify Ruxolitinib to develop more potent inhibitors to c-Src.	ruxolitinib	87-98	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	202-207
25197973-9	2014	Since Ruxolitinib is a relatively small inhibitor and there is sizeable cavity between Ruxolitinib and c-Src ligand-binding pocket, we propose to modify Ruxolitinib to develop more potent inhibitors to c-Src.	ruxolitinib	87-98	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	202-207
24973641-2	2014	Therefore, we investigated whether targeting this pathway by the novel JAK inhibitor ruxolitinib could mitigate hepatic damage provoked by carbon tetrachloride (CCl4).	ruxolitinib	85-96	chemokine (C-C motif) ligand 4	Mus musculus	161-165
25043171-2	2014	Ruxolitinib, the first-in-class oral small molecule JAK1/2 inhibitor, has demonstrated clinical efficacy and shown a potential overall survival benefit in two randomized phase III clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	52-58
25180155-5	2014	Eventually, he was treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts.	ruxolitinib	32-43	Janus kinase 1	Homo sapiens	61-67
24778152-6	2014	Incubation of CLL cells with the JAK1/2 inhibitor ruxolitinib inhibited IgM-induced STAT3 phosphorylation and induced apoptosis of IgM-stimulated but not unstimulated CLL cells in a dose- and time-dependent manner.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	33-39
24778152-6	2014	Incubation of CLL cells with the JAK1/2 inhibitor ruxolitinib inhibited IgM-induced STAT3 phosphorylation and induced apoptosis of IgM-stimulated but not unstimulated CLL cells in a dose- and time-dependent manner.	ruxolitinib	50-61	signal transducer and activator of transcription 3	Homo sapiens	84-89
25189729-2	2014	JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF).	ruxolitinib	144-155	Janus kinase 2	Homo sapiens	0-4
25189730-5	2014	The rationale of combination of danazol or lenalidomide with ruxolitinib is mainly based on mitigation of anti-JAK2-mediated myelosuppression.	ruxolitinib	61-72	Janus kinase 2	Homo sapiens	111-115
25189730-6	2014	Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.	ruxolitinib	22-33	Janus kinase 2	Homo sapiens	141-145
24766055-8	2014	Resultant research in targeting the JAK/STAT pathway led to the approval of ruxolitinib, a JAK1/JAK2 inhibitor with activity in MPNs.	ruxolitinib	76-87	Janus kinase 1	Homo sapiens	91-95
24766055-8	2014	Resultant research in targeting the JAK/STAT pathway led to the approval of ruxolitinib, a JAK1/JAK2 inhibitor with activity in MPNs.	ruxolitinib	76-87	Janus kinase 2	Homo sapiens	96-100
25016807-3	2014	The JAK2 inhibitor ruxolitinib improves survival as well as splenomegaly and the clinical symptomatic burden in intermediate-2 or high risk myelofibrosis patients.	ruxolitinib	19-30	Janus kinase 2	Homo sapiens	4-8
25129481-8	2014	Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	71-75
25129481-8	2014	Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	80-84
24957147-0	2014	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.	ruxolitinib	40-51	Janus kinase 2	Mus musculus	0-4
24957147-0	2014	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.	ruxolitinib	40-51	signal transducer and activator of transcription 5A	Mus musculus	5-10
24957147-0	2014	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.	ruxolitinib	40-51	CD34 antigen	Mus musculus	90-94
24957147-3	2014	We investigated the role of this pathway using the JAK2 inhibitor, ruxolitinib (RUX).	ruxolitinib	67-78	Janus kinase 2	Mus musculus	51-55
24957147-3	2014	We investigated the role of this pathway using the JAK2 inhibitor, ruxolitinib (RUX).	ruxolitinib	80-83	Janus kinase 2	Mus musculus	51-55
24957147-4	2014	We demonstrated that the combination of RUX, at clinically achievable concentrations, with the specific and potent tyrosine kinase inhibitor nilotinib, reduced the activity of the JAK2/STAT5 pathway in vitro relative to either single agent alone.	ruxolitinib	40-43	Janus kinase 2	Mus musculus	180-184
24957147-4	2014	We demonstrated that the combination of RUX, at clinically achievable concentrations, with the specific and potent tyrosine kinase inhibitor nilotinib, reduced the activity of the JAK2/STAT5 pathway in vitro relative to either single agent alone.	ruxolitinib	40-43	signal transducer and activator of transcription 5A	Mus musculus	185-190
25379406-1	2014	We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib.	ruxolitinib	277-288	interferon alpha 2	Homo sapiens	254-272
24406841-7	2014	Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma.	ruxolitinib	15-26	tumor necrosis factor	Homo sapiens	76-103
24406841-7	2014	Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma.	ruxolitinib	15-26	interleukin 4	Homo sapiens	105-118
24406841-7	2014	Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma.	ruxolitinib	15-26	interleukin 4	Homo sapiens	120-124
24406841-7	2014	Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma.	ruxolitinib	15-26	interleukin 6	Homo sapiens	127-131
24406841-7	2014	Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma.	ruxolitinib	15-26	C-X-C motif chemokine ligand 8	Homo sapiens	136-140
24406841-7	2014	Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma.	ruxolitinib	15-26	interferon gamma	Homo sapiens	159-175
24711661-5	2014	Mechanistically, we could show that ruxolitinib impaired differentiation of CD4(+) T cells into IFN-gamma- and IL17A-producing cells, and that both T-cell phenotypes are linked to GVHD.	ruxolitinib	36-47	CD4 molecule	Homo sapiens	76-79
24711661-5	2014	Mechanistically, we could show that ruxolitinib impaired differentiation of CD4(+) T cells into IFN-gamma- and IL17A-producing cells, and that both T-cell phenotypes are linked to GVHD.	ruxolitinib	36-47	interferon gamma	Homo sapiens	96-105
24711661-5	2014	Mechanistically, we could show that ruxolitinib impaired differentiation of CD4(+) T cells into IFN-gamma- and IL17A-producing cells, and that both T-cell phenotypes are linked to GVHD.	ruxolitinib	36-47	interleukin 17A	Homo sapiens	111-116
24711661-6	2014	Conversely, ruxolitinib treatment in allo-HCT recipients increased FoxP3(+) regulatory T cells, which are linked to immunologic tolerance.	ruxolitinib	12-23	forkhead box P3	Homo sapiens	67-72
24867113-5	2014	Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, is the first therapy to be approved by the U.S. Food and Drug Administration for intermediate- or high-risk MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-41
24930769-3	2014	Furthermore, siRNA silencing or pharmacological inhibition of Aurora A and JAK2 with Alisertib and Ruxolitinib, respectively, is more effective than blocking each kinase alone at suppressing anchorage-dependent and -independent growth and invasion as well as at inducing apoptosis.	ruxolitinib	99-110	aurora kinase A	Homo sapiens	62-70
24930769-3	2014	Furthermore, siRNA silencing or pharmacological inhibition of Aurora A and JAK2 with Alisertib and Ruxolitinib, respectively, is more effective than blocking each kinase alone at suppressing anchorage-dependent and -independent growth and invasion as well as at inducing apoptosis.	ruxolitinib	99-110	Janus kinase 2	Homo sapiens	75-79
24583800-6	2014	The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, respectively, and additional ATP-competitive JAK inhibitors are in clinical development.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
24458439-1	2014	The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-II).	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
24764577-8	2014	Moreover, the JAK1/2 inhibitor ruxolitinib potently inhibited the anti-CD3-dependent production of IFN-gamma, a marker of the differentiation of Th cells along the tumor-inhibitory Th1 pathway.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	14-20
24764577-8	2014	Moreover, the JAK1/2 inhibitor ruxolitinib potently inhibited the anti-CD3-dependent production of IFN-gamma, a marker of the differentiation of Th cells along the tumor-inhibitory Th1 pathway.	ruxolitinib	31-42	interferon gamma	Homo sapiens	99-108
24458439-1	2014	The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-II).	ruxolitinib	24-35	Janus kinase 2	Homo sapiens	9-13
24458439-4	2014	Ruxolitinib improved survival independent of mutation profile and reduced the risk of death in patients harboring a set of prognostically detrimental mutations (ASXL1, EZH2, SRSF2, IDH1/2) with an hazard ratio of 0.57 (95% confidence interval: 0.30-1.08) vs best available therapy.	ruxolitinib	0-11	ASXL transcriptional regulator 1	Homo sapiens	161-166
24458439-4	2014	Ruxolitinib improved survival independent of mutation profile and reduced the risk of death in patients harboring a set of prognostically detrimental mutations (ASXL1, EZH2, SRSF2, IDH1/2) with an hazard ratio of 0.57 (95% confidence interval: 0.30-1.08) vs best available therapy.	ruxolitinib	0-11	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	168-172
24458439-4	2014	Ruxolitinib improved survival independent of mutation profile and reduced the risk of death in patients harboring a set of prognostically detrimental mutations (ASXL1, EZH2, SRSF2, IDH1/2) with an hazard ratio of 0.57 (95% confidence interval: 0.30-1.08) vs best available therapy.	ruxolitinib	0-11	serine and arginine rich splicing factor 2	Homo sapiens	174-179
24458439-4	2014	Ruxolitinib improved survival independent of mutation profile and reduced the risk of death in patients harboring a set of prognostically detrimental mutations (ASXL1, EZH2, SRSF2, IDH1/2) with an hazard ratio of 0.57 (95% confidence interval: 0.30-1.08) vs best available therapy.	ruxolitinib	0-11	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	181-187
24470592-5	2014	Jak2 deletion in vivo led to profound reduction in disease burden not seen with JAK inhibitors, and deletion of Jak2 following chronic ruxolitinib therapy markedly reduced mutant allele burden.	ruxolitinib	135-146	Janus kinase 2	Homo sapiens	112-116
24470592-7	2014	Combination therapy with the heat shock protein 90 (HSP90) inhibitor PU-H71 and ruxolitinib reduced total and phospho-JAK2 and achieved more potent inhibition of downstream signaling than ruxolitinib monotherapy.	ruxolitinib	80-91	heat shock protein 90 alpha family class A member 1	Homo sapiens	29-50
24470592-7	2014	Combination therapy with the heat shock protein 90 (HSP90) inhibitor PU-H71 and ruxolitinib reduced total and phospho-JAK2 and achieved more potent inhibition of downstream signaling than ruxolitinib monotherapy.	ruxolitinib	80-91	heat shock protein 90 alpha family class A member 1	Homo sapiens	52-57
24470592-7	2014	Combination therapy with the heat shock protein 90 (HSP90) inhibitor PU-H71 and ruxolitinib reduced total and phospho-JAK2 and achieved more potent inhibition of downstream signaling than ruxolitinib monotherapy.	ruxolitinib	80-91	Janus kinase 2	Homo sapiens	118-122
24470592-7	2014	Combination therapy with the heat shock protein 90 (HSP90) inhibitor PU-H71 and ruxolitinib reduced total and phospho-JAK2 and achieved more potent inhibition of downstream signaling than ruxolitinib monotherapy.	ruxolitinib	188-199	heat shock protein 90 alpha family class A member 1	Homo sapiens	29-50
24470592-7	2014	Combination therapy with the heat shock protein 90 (HSP90) inhibitor PU-H71 and ruxolitinib reduced total and phospho-JAK2 and achieved more potent inhibition of downstream signaling than ruxolitinib monotherapy.	ruxolitinib	188-199	heat shock protein 90 alpha family class A member 1	Homo sapiens	52-57
24258498-0	2014	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.	ruxolitinib	19-30	Janus kinase 1	Homo sapiens	40-44
24589536-2	2014	SUMMARY: Ruxolitinib, an oral tyrosine kinase inhibitor that targets the Janus-associated kinases (JAKs) 1 and 2, has been recently approved for the treatment of patients with intermediate- or high-risk myelofibrosis.	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	73-112
24589536-5	2014	Ruxolitinib is primarily metabolized by the cytochrome P-450 (CYP) 3A4 isoenzyme system; therefore, if concomitant use with a strong CYP3A4 inhibitor is unavoidable, an initial dosage reduction is warranted.	ruxolitinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-70
24589536-5	2014	Ruxolitinib is primarily metabolized by the cytochrome P-450 (CYP) 3A4 isoenzyme system; therefore, if concomitant use with a strong CYP3A4 inhibitor is unavoidable, an initial dosage reduction is warranted.	ruxolitinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-139
24589536-10	2014	CONCLUSION: By directly targeting both JAK1 and JAK2 through small-molecule inhibition, ruxolitinib elicits a reduction in splenomegaly and disease-related symptoms in patients with intermediate- or high-risk myelofibrosis while maintaining an acceptable toxicity profile and a low treatment-discontinuation rate.	ruxolitinib	88-99	Janus kinase 1	Homo sapiens	39-43
24589536-10	2014	CONCLUSION: By directly targeting both JAK1 and JAK2 through small-molecule inhibition, ruxolitinib elicits a reduction in splenomegaly and disease-related symptoms in patients with intermediate- or high-risk myelofibrosis while maintaining an acceptable toxicity profile and a low treatment-discontinuation rate.	ruxolitinib	88-99	Janus kinase 2	Homo sapiens	48-52
24598114-10	2014	Future studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification.	ruxolitinib	98-109	Janus kinase 2	Homo sapiens	83-87
24258498-0	2014	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.	ruxolitinib	19-30	Janus kinase 2	Homo sapiens	49-53
24258498-3	2014	Ruxolitinib, an oral JAK1/JAK2 inhibitor, is active in preclinical models of PV.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
24258498-3	2014	Ruxolitinib, an oral JAK1/JAK2 inhibitor, is active in preclinical models of PV.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	26-30
24292520-0	2014	Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.	ruxolitinib	120-131	Janus kinase 2	Homo sapiens	105-109
24381227-6	2014	Moreover, JAK2R564Q-expressing cells are much more sensitive to the JAK inhibitor, ruxolitinib, than JAK2V617F-expressers, suggesting that lower doses of this drug may be effective in treating patients with MPNs associated with alternative JAK2 mutations, allowing many undesirable adverse effects to be avoided.	ruxolitinib	83-94	Janus kinase 2	Homo sapiens	10-14
24292520-1	2014	The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	4-28
24292520-1	2014	The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms.	ruxolitinib	55-66	Janus kinase 2	Homo sapiens	40-44
24280282-4	2014	Taken together, our data provide a rationale for the therapeutic combination of TKIs and Ruxolitinib with the aim to eradicate primary BCR-ABL+ cells homed in BM niches.	ruxolitinib	89-100	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	135-142
24332884-2	2014	Anaphylactic symptoms including diarrhea and decreases in body temperature pursuant to oral ovalbumin (OVA) challenges in food allergy mice were attenuated by the daily oral administration of ruxolitinib.	ruxolitinib	192-203	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	92-101
23823659-0	2014	Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).	ruxolitinib	75-86	Janus kinase 2	Homo sapiens	43-47
24419350-2	2014	Ruxolitinib and tofacitinib are JAK1/2 inhibitors that are FDA approved for rheumatoid arthritis and myelofibrosis, respectively, but their therapeutic application for treatment of HIV infection was unexplored.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	32-36
24754420-8	2014	Ruxolitinib, an oral selective inhibitor of JAK1 and JAK2 kinases, has shown high efficacy in patients with high-risk PMF (or with myelofibrosis following polycythemia vera or essential thrombocythemia) to ameliorate disease symptoms and to reduce splenomegaly in randomized trials COMFORT-I and COMFORT-II.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	44-48
24754420-8	2014	Ruxolitinib, an oral selective inhibitor of JAK1 and JAK2 kinases, has shown high efficacy in patients with high-risk PMF (or with myelofibrosis following polycythemia vera or essential thrombocythemia) to ameliorate disease symptoms and to reduce splenomegaly in randomized trials COMFORT-I and COMFORT-II.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	53-57
24501543-7	2014	The JAK1/JAK2 inhibitor ruxolitinib is effective in improving splenomegaly, MF-related symptoms, and quality-of-life measures.	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
24501543-7	2014	The JAK1/JAK2 inhibitor ruxolitinib is effective in improving splenomegaly, MF-related symptoms, and quality-of-life measures.	ruxolitinib	24-35	Janus kinase 2	Homo sapiens	9-13
24763226-8	2014	Moreover, uPAR-mediated growth and motility is partially abolished upon treatment with the Jak1/Jak2 inhibitor INCB018424.	ruxolitinib	111-121	plasminogen activator, urokinase receptor	Homo sapiens	10-14
24763226-8	2014	Moreover, uPAR-mediated growth and motility is partially abolished upon treatment with the Jak1/Jak2 inhibitor INCB018424.	ruxolitinib	111-121	Janus kinase 1	Homo sapiens	91-95
24763226-8	2014	Moreover, uPAR-mediated growth and motility is partially abolished upon treatment with the Jak1/Jak2 inhibitor INCB018424.	ruxolitinib	111-121	Janus kinase 2	Homo sapiens	96-100
24195509-11	2014	The inhibition of JAK1 phosphorylation seemed sufficient to allow INCB018424-mediated apoptosis.	ruxolitinib	66-76	Janus kinase 1	Homo sapiens	18-22
27128228-1	2014	Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&amp;2 inhibitor that is cleared predominantly by metabolism.	ruxolitinib	57-68	Janus kinase 1	Homo sapiens	72-82
27128228-9	2014	The starting dose of ruxolitinib in subjects with any hepatic impairment or moderate or severe renal impairment should be decreased to 10 mg twice daily (BID) if their platelet counts are between 100 x 10(9) /L and 150 x 10(9) /L.	ruxolitinib	21-32	BH3 interacting domain death agonist	Homo sapiens	154-157
24883332-4	2014	Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.	ruxolitinib	76-87	Janus kinase 1	Homo sapiens	99-103
24883332-4	2014	Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.	ruxolitinib	76-87	Janus kinase 2	Homo sapiens	108-112
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	97-101
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	106-110
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	31-41	Janus kinase 1	Homo sapiens	97-101
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	31-41	Janus kinase 2	Homo sapiens	106-110
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	45-51	Janus kinase 1	Homo sapiens	97-101
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	45-51	Janus kinase 2	Homo sapiens	106-110
24756798-6	2014	The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors.	ruxolitinib	22-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
24756798-6	2014	The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors.	ruxolitinib	22-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
24368888-1	2013	PURPOSE: Ruxolitinib is an oral Janus kinase (JAK) 1/JAK2 inhibitor approved in the US for the treatment of intermediate-or high-risk myelofibrosis (MF).	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	32-52
24174625-1	2013	Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid reductions in splenomegaly and marked improvement in disease-related symptoms and quality of life in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-43
24174625-1	2013	Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid reductions in splenomegaly and marked improvement in disease-related symptoms and quality of life in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	44-48
24368888-1	2013	PURPOSE: Ruxolitinib is an oral Janus kinase (JAK) 1/JAK2 inhibitor approved in the US for the treatment of intermediate-or high-risk myelofibrosis (MF).	ruxolitinib	9-20	Janus kinase 2	Homo sapiens	53-57
24326545-10	2013	In parallel, clinical trials have been initiated involving the Jak2/3 (Janus kinase-2/3) inhibitor tofacitinib and Jak1/2 inhibitor ruxolitinib to block IL-15 signaling.	ruxolitinib	132-143	Janus kinase 1	Homo sapiens	115-121
24238036-3	2013	In 2 randomized phase III studies, the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib significantly improved splenomegaly and disease-related symptoms compared with placebo (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment [COMFORT-I]) or best available therapy (COMFORT-II) in patients with intermediate-2 or high-risk MF.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	39-59
24238036-3	2013	In 2 randomized phase III studies, the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib significantly improved splenomegaly and disease-related symptoms compared with placebo (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment [COMFORT-I]) or best available therapy (COMFORT-II) in patients with intermediate-2 or high-risk MF.	ruxolitinib	75-86	Janus kinase 2	Homo sapiens	60-64
24238036-7	2013	Patients benefit from ruxolitinib therapy across subgroups defined by age, MF type, risk category, performance status, JAK2 V617F mutation status, extent of splenomegaly, or presence of cytopenias.	ruxolitinib	22-33	Janus kinase 2	Homo sapiens	119-123
24038026-1	2013	COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis.	ruxolitinib	113-124	Janus kinase 2	Homo sapiens	88-102
24056820-0	2013	Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.	ruxolitinib	93-104	Janus kinase 1	Homo sapiens	58-62
24056820-0	2013	Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.	ruxolitinib	93-104	Janus kinase 2	Homo sapiens	63-67
24056820-1	2013	UNLABELLED: Ruxolitinib, a JAK1/JAK2 inhibitor, is currently the only pharmacological agent approved for the treatment of myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	27-31
24056820-1	2013	UNLABELLED: Ruxolitinib, a JAK1/JAK2 inhibitor, is currently the only pharmacological agent approved for the treatment of myelofibrosis.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	32-36
24101258-4	2013	Multiple additional JAK2 inhibitors are currently in or nearing phase III testing, including SAR302503 (fedratinib), SB1518 (pacritinib) and CYT387 (momelotinib), seeking to offer incremental benefits to ruxolitinib in regards to cytopenias or other disease features.	ruxolitinib	204-215	Janus kinase 2	Homo sapiens	20-24
24066969-2	2013	Approval of the first Janus kinase 2 (JAK2) inhibitor therapy, ruxolitinib, has improved splenomegaly, symptomatic burden, survival and perhaps fibrosis in some treated patients; however, other patients remain symptomatic and are in need of alternate therapeutic strategies.	ruxolitinib	63-74	Janus kinase 2	Homo sapiens	22-36
24066969-2	2013	Approval of the first Janus kinase 2 (JAK2) inhibitor therapy, ruxolitinib, has improved splenomegaly, symptomatic burden, survival and perhaps fibrosis in some treated patients; however, other patients remain symptomatic and are in need of alternate therapeutic strategies.	ruxolitinib	63-74	Janus kinase 2	Homo sapiens	38-42
24326545-10	2013	In parallel, clinical trials have been initiated involving the Jak2/3 (Janus kinase-2/3) inhibitor tofacitinib and Jak1/2 inhibitor ruxolitinib to block IL-15 signaling.	ruxolitinib	132-143	interleukin 15	Homo sapiens	153-158
24083419-3	2013	Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate- or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	51-55
24081659-4	2013	Treatment with the JAK1/2 inhibitor ruxolitinib lowered the white blood count and reduced spleen weight.	ruxolitinib	36-47	Janus kinase 1	Mus musculus	19-25
24030211-2	2013	Here, we evaluated VSV oncolysis of a panel of human head and neck cancer cells and showed that VSV resistance in SCC25 and SCC15 cells could be reversed with Janus kinase (JAK) 1/2 inhibitors (JAK inhibitor I and ruxolitinib).	ruxolitinib	214-225	Janus kinase 1	Homo sapiens	159-179
24501689-9	2013	In stark contrast, we showed that ruxolitinib, a JAK1/JAK2-selective tyrosine kinase inhibitor used to treat patients with myelofibrosis, dramatically impaired JAK1-STAT signaling downstream of all IHCA-associated gp130 mutants.	ruxolitinib	34-45	Janus kinase 1	Homo sapiens	49-53
24501689-9	2013	In stark contrast, we showed that ruxolitinib, a JAK1/JAK2-selective tyrosine kinase inhibitor used to treat patients with myelofibrosis, dramatically impaired JAK1-STAT signaling downstream of all IHCA-associated gp130 mutants.	ruxolitinib	34-45	Janus kinase 2	Homo sapiens	54-58
24501689-9	2013	In stark contrast, we showed that ruxolitinib, a JAK1/JAK2-selective tyrosine kinase inhibitor used to treat patients with myelofibrosis, dramatically impaired JAK1-STAT signaling downstream of all IHCA-associated gp130 mutants.	ruxolitinib	34-45	Janus kinase 1	Homo sapiens	160-164
24501689-9	2013	In stark contrast, we showed that ruxolitinib, a JAK1/JAK2-selective tyrosine kinase inhibitor used to treat patients with myelofibrosis, dramatically impaired JAK1-STAT signaling downstream of all IHCA-associated gp130 mutants.	ruxolitinib	34-45	interleukin 6 cytokine family signal transducer	Homo sapiens	214-219
24081976-4	2013	EXPERIMENTAL DESIGN: The combination of the JAK1/2 inhibitor ruxolitinib and panobinostat was investigated using two different mouse models of JAK2(V617F)-driven disease.	ruxolitinib	61-72	Janus kinase 1	Mus musculus	44-50
24251790-6	2013	The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.	ruxolitinib	56-67	Janus kinase 2	Mus musculus	9-13
24251790-6	2013	The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.	ruxolitinib	56-67	Janus kinase 1	Mus musculus	14-18
24251790-6	2013	The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.	ruxolitinib	56-67	myeloproliferative leukemia virus oncogene	Mus musculus	155-159
24251790-6	2013	The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F.	ruxolitinib	56-67	Janus kinase 2	Mus musculus	164-168
24083419-3	2013	Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate- or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	60-64
24084971-12	2013	Ruxolitinib is the first approved JAK2 inhibitor and has proved effective on symptoms and quality of life.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	34-38
23630205-0	2013	Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.	ruxolitinib	12-23	pericentriolar material 1	Homo sapiens	75-79
24283870-1	2013	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
24283870-1	2013	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	30-34
23770777-7	2013	Ruxolitinib-treated mice immunized with ovalbumin (OVA)/CpG induced markedly reduced in vivo activation and proliferation of OVA-specific CD8+ T cells compared with vehicle-treated controls.	ruxolitinib	0-11	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	40-49
23684482-1	2013	Patient-reported outcomes (PROs) and spleen size in patients not receiving therapy (N=154) in COMFORT-I, a randomized, double-blind study of the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis were evaluated.	ruxolitinib	165-176	Janus kinase 2	Homo sapiens	150-154
23672349-2	2013	Here, we report post-hoc analyses of the impact of ruxolitinib, a potent and selective JAK1 and JAK2 inhibitor, on disease-related symptoms and HRQoL in MF patients from the large phase 3 COMFORT-II study (N = 219).	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	87-91
23672349-2	2013	Here, we report post-hoc analyses of the impact of ruxolitinib, a potent and selective JAK1 and JAK2 inhibitor, on disease-related symptoms and HRQoL in MF patients from the large phase 3 COMFORT-II study (N = 219).	ruxolitinib	51-62	Janus kinase 2	Homo sapiens	96-100
24290217-7	2013	Of much interest, a combination of everolimus and the JAK1/2 inhibitor, ruxolitinib, showed strong synergism in inducing cell cycle arrest and blockade of cell proliferation.	ruxolitinib	72-83	Janus kinase 1	Homo sapiens	54-60
23630205-0	2013	Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	80-84
23670175-2	2013	Of these, the JAK1/2 inhibitor, ruxolitinib (INCB018424, Incyte Corporation) was recently approved for the treatment of patients with myelofibrosis (MF).	ruxolitinib	32-43	Janus kinase 1	Homo sapiens	14-20
23385614-1	2013	PURPOSE OF REVIEW: Although the approval of the janus kinase (JAK) inhibitor ruxolitinib for therapy of patients with myelofibrosis represents an important step in the development of targeted therapy for these patients, JAK inhibitors do not eradicate the disease, and a review of novel agents with mechanisms of action complementary to JAK2 enzymatic inhibition is timely.	ruxolitinib	77-88	Janus kinase 2	Homo sapiens	337-341
23542035-4	2013	Blocking IFNbeta signaling with Ruxolitinib, a JAK inhibitor, inhibited MCP-1 transcription.	ruxolitinib	32-43	interferon beta 1	Homo sapiens	9-16
23542035-4	2013	Blocking IFNbeta signaling with Ruxolitinib, a JAK inhibitor, inhibited MCP-1 transcription.	ruxolitinib	32-43	C-C motif chemokine ligand 2	Homo sapiens	72-77
23656643-7	2013	A patient with CNL carrying a JAK-activating CSF3R mutation had marked clinical improvement after the administration of the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	141-152	colony stimulating factor 3 receptor	Homo sapiens	45-50
23656643-7	2013	A patient with CNL carrying a JAK-activating CSF3R mutation had marked clinical improvement after the administration of the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	124-130
23560534-5	2013	Western blot confirmed that ruxolitinib blocked ERK, and consequently STAT5 activation, sorafenib inhibited ERK, P38 and STAT5, dasatinib blocked SRC and STAT5, and KNK437 decreased the stability of the JAK2 protein, reducing its expression.	ruxolitinib	28-39	signal transducer and activator of transcription 5A	Homo sapiens	70-75
23560534-5	2013	Western blot confirmed that ruxolitinib blocked ERK, and consequently STAT5 activation, sorafenib inhibited ERK, P38 and STAT5, dasatinib blocked SRC and STAT5, and KNK437 decreased the stability of the JAK2 protein, reducing its expression.	ruxolitinib	28-39	Janus kinase 2	Homo sapiens	203-207
23560534-7	2013	Furthermore, the combination of ruxolitinib with inhibitors that target these pathways has a strong synergistic effect, which may be due to decreased activation of the common effector, STAT5.	ruxolitinib	32-43	signal transducer and activator of transcription 5A	Homo sapiens	185-190
23406773-4	2013	Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematologic malignancies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-27
23406773-4	2013	Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematologic malignancies.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	32-36
23367873-2	2013	Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor.	ruxolitinib	78-89	Janus kinase 1	Homo sapiens	125-131
23367873-12	2013	EXPERT OPINION: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development.	ruxolitinib	126-137	Janus kinase 1	Homo sapiens	109-115
22875628-0	2013	Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	60-64
23445613-3	2013	Treatment with JAK tyrosine kinase inhibitor (TKI), for example, TG101209, TG101348 (SAR302503), or INCB018424 (ruxolitinib), inhibits mutant JAK2-mediated signaling.	ruxolitinib	100-110	Janus kinase 2	Homo sapiens	142-146
23445613-3	2013	Treatment with JAK tyrosine kinase inhibitor (TKI), for example, TG101209, TG101348 (SAR302503), or INCB018424 (ruxolitinib), inhibits mutant JAK2-mediated signaling.	ruxolitinib	112-123	Janus kinase 2	Homo sapiens	142-146
22875628-2	2013	Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN).	ruxolitinib	36-47	Janus kinase 1	Homo sapiens	19-25
22793267-7	2013	Recent Food and Drug Administration (FDA) approval of the first JAK2 inhibitor, ruxolitinib, signaled a new era for treatment of MF.	ruxolitinib	80-91	Janus kinase 2	Homo sapiens	64-68
24252238-7	2013	Ruxolitinib (Jakafi), a non-selective inhibitor of JAK1 &amp; 2, has been approved by FDA for patients with intermediate to high risk primary or secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	51-55
22875628-2	2013	Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN).	ruxolitinib	36-47	Janus kinase 2	Homo sapiens	77-81
22875628-3	2013	Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) &gt; 10 muM for all).	ruxolitinib	0-11	interleukin 3	Mus musculus	47-50
22875628-3	2013	Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) &gt; 10 muM for all).	ruxolitinib	0-11	ets variant 6	Mus musculus	67-71
22875628-3	2013	Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) &gt; 10 muM for all).	ruxolitinib	0-11	Janus kinase 2	Mus musculus	72-76
22875628-3	2013	Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) &gt; 10 muM for all).	ruxolitinib	0-11	BCR activator of RhoGEF and GTPase	Mus musculus	186-194
22875628-3	2013	Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) &gt; 10 muM for all).	ruxolitinib	0-11	FMS-like tyrosine kinase 3	Mus musculus	202-206
22875628-3	2013	Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) &gt; 10 muM for all).	ruxolitinib	0-11	zinc finger, MYM-type 2	Mus musculus	211-216
22875628-3	2013	Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) &gt; 10 muM for all).	ruxolitinib	0-11	fibroblast growth factor receptor 1	Mus musculus	217-222
22875628-8	2013	Our data, therefore, provide evidence that ruxolitinib is a promising therapy for treatment of patients with JAK2 fusion genes.	ruxolitinib	43-54	Janus kinase 2	Homo sapiens	109-113
24319228-5	2013	The JAK1/JAK2 inhibitor ruxolitinib is approved for treatment of MF in North America and Europe and other lead JAK inhibitors discussed herein (fedratinib [SAR302503], momelotinib [CYT387], and pacritinib [SB1518]), have entered advanced phases of trial investigation.	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
24319228-5	2013	The JAK1/JAK2 inhibitor ruxolitinib is approved for treatment of MF in North America and Europe and other lead JAK inhibitors discussed herein (fedratinib [SAR302503], momelotinib [CYT387], and pacritinib [SB1518]), have entered advanced phases of trial investigation.	ruxolitinib	24-35	Janus kinase 2	Homo sapiens	9-13
23307549-10	2013	Ruxolitinib is a small-molecule inhibitor of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	45-49
23307549-10	2013	Ruxolitinib is a small-molecule inhibitor of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	54-58
23039051-7	2012	CONCLUSION: Treatment with Ruxolitinib may have triggered the reactivation of latent tuberculosis because of an inhibition of Th1 response.	ruxolitinib	27-38	negative elongation factor complex member C/D	Homo sapiens	126-129
23186315-3	2012	AREAS COVERED: This review describes the pathogenesis, clinical features and current treatment of MF, clinical data for ruxolitinib, a potent oral JAK1/JAK2 inhibitor and the only therapy approved for the treatment of MF, and agents in development for the treatment of MF.	ruxolitinib	120-131	Janus kinase 1	Homo sapiens	147-151
23186315-3	2012	AREAS COVERED: This review describes the pathogenesis, clinical features and current treatment of MF, clinical data for ruxolitinib, a potent oral JAK1/JAK2 inhibitor and the only therapy approved for the treatment of MF, and agents in development for the treatment of MF.	ruxolitinib	120-131	Janus kinase 2	Homo sapiens	152-156
23042420-13	2012	Ruxolitinib is the first JAK1/2 inhibitor approved by the Food and Drug Administration (FDA) for the treatment of patients with intermediate- or high-risk MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-31
23391678-0	2013	Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-35
23391678-0	2013	Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	40-54
23391678-5	2013	In November 2011, ruxolitinib, an inhibitor of JAK1 and JAK2, was approved by the US Food and Drug Administration for the treatment of intermediate- or high-risk MF, including primary MF, post-PV MF, and post-ET MF.	ruxolitinib	18-29	Janus kinase 1	Homo sapiens	47-51
23391678-5	2013	In November 2011, ruxolitinib, an inhibitor of JAK1 and JAK2, was approved by the US Food and Drug Administration for the treatment of intermediate- or high-risk MF, including primary MF, post-PV MF, and post-ET MF.	ruxolitinib	18-29	Janus kinase 2	Homo sapiens	56-60
23061804-1	2012	Ruxolitinib is a selective inhibitor of Janus kinases (JAK) 1 and 2, which are involved in the signalling pathway of various cytokines and growth factors essential to haematopoiesis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	40-67
23051187-0	2012	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
23051187-0	2012	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	30-34
23051187-3	2012	Ruxolitinib is the first JAK1 and JAK2 inhibitor to be approved by the US Food and Drug Administration.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-29
23051187-3	2012	Ruxolitinib is the first JAK1 and JAK2 inhibitor to be approved by the US Food and Drug Administration.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	34-38
23051187-7	2012	The JAK1 and JAK2 inhibitor ruxolitinib has shown promising results in pre-clinical and clinical trials.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	4-8
23051187-7	2012	The JAK1 and JAK2 inhibitor ruxolitinib has shown promising results in pre-clinical and clinical trials.	ruxolitinib	28-39	Janus kinase 2	Homo sapiens	13-17
22955920-5	2012	Enhanced responses to ruxolitinib were observed in samples harboring JAK-activating lesions and higher levels of STAT5 phosphorylation.	ruxolitinib	22-33	signal transducer and activator of transcription 5A	Homo sapiens	113-118
23055361-4	2012	Recent data from two large phase-III studies showed that the JAK1 /2 inhibitor Ruxolitinib is very effective in the reduction of spleen size and the improvement of quality of life in MF patients.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	61-65
22281165-2	2012	INCB018424, a small molecule inhibitor of JAK1 and JAK2, inhibits cytokine-induced JAK/signal transducers and activators of transcription signaling and the resultant production of inflammatory proteins (eg, IL-17).	ruxolitinib	0-10	Janus kinase 1	Homo sapiens	42-46
22281165-2	2012	INCB018424, a small molecule inhibitor of JAK1 and JAK2, inhibits cytokine-induced JAK/signal transducers and activators of transcription signaling and the resultant production of inflammatory proteins (eg, IL-17).	ruxolitinib	0-10	Janus kinase 2	Homo sapiens	51-55
22281165-2	2012	INCB018424, a small molecule inhibitor of JAK1 and JAK2, inhibits cytokine-induced JAK/signal transducers and activators of transcription signaling and the resultant production of inflammatory proteins (eg, IL-17).	ruxolitinib	0-10	interleukin 17A	Homo sapiens	207-212
22904308-4	2012	We show in this paper that, Ruxolitinib, a recently described selective inhibitor of JAKs, increases TNF, IL-6, and IL-12 secretion in mouse bone marrow-derived macrophages stimulated with LPS.	ruxolitinib	28-39	tumor necrosis factor	Mus musculus	101-104
22904308-4	2012	We show in this paper that, Ruxolitinib, a recently described selective inhibitor of JAKs, increases TNF, IL-6, and IL-12 secretion in mouse bone marrow-derived macrophages stimulated with LPS.	ruxolitinib	28-39	interleukin 6	Mus musculus	106-110
22700718-1	2012	The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF).	ruxolitinib	154-165	Janus kinase 1	Homo sapiens	101-107
22700718-1	2012	The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF).	ruxolitinib	154-165	Janus kinase 1	Homo sapiens	136-142
23238141-2	2012	Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	50-54
22718840-0	2012	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.	ruxolitinib	84-95	Janus kinase 1	Homo sapiens	64-68
22718840-0	2012	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.	ruxolitinib	84-95	Janus kinase 2	Homo sapiens	69-73
22718840-1	2012	Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
22718840-1	2012	Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	20-24
22899477-0	2012	Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	34-38
22899477-0	2012	Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.	ruxolitinib	0-11	pericentriolar material 1	Homo sapiens	126-130
22899477-0	2012	Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	131-135
22852872-6	2012	In November 2011, the US Food and Drug Administration approved the use of the JAK1- and JAK2-selective inhibitor ruxolitinib for the treatment of patients with intermediate or high-risk myelofibrosis, including PMF, post-PV MF, and post-ET MF.	ruxolitinib	113-124	Janus kinase 1	Homo sapiens	78-82
22852872-6	2012	In November 2011, the US Food and Drug Administration approved the use of the JAK1- and JAK2-selective inhibitor ruxolitinib for the treatment of patients with intermediate or high-risk myelofibrosis, including PMF, post-PV MF, and post-ET MF.	ruxolitinib	113-124	Janus kinase 2	Homo sapiens	88-92
23238141-2	2012	Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	59-63
23238141-2	2012	Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	50-54
23238141-2	2012	Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor.	ruxolitinib	13-23	Janus kinase 2	Homo sapiens	59-63
22474318-6	2012	Ruxolitinib (Jakafi; Incyte) is a small-molecule inhibitor of JAK1/2 that has proved to be effective at reducing splenomegaly and ameliorating symptoms in myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	62-68
22544377-1	2012	On November 16, 2011, the U.S. Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.	ruxolitinib	91-102	Janus kinase 1	Homo sapiens	148-169
27175229-7	2012	At present, we have a new generation of inhibitors of JAK2 (Ruxolitinib, CYT387, SB1518, TG101348, with others in development), which have been shown to improve splenomegaly, improve symptomatic burden of illness and improve quality of life.	ruxolitinib	60-71	Janus kinase 2	Homo sapiens	54-58
22780211-4	2012	JAK2 ATP competitive inhibitors (ruxolitinib, lestaurtinib, SAR302503, SB1518 and CYT387) or drugs that indirectly inhibit the JAK-STAT pathway (everolimus) have documented major effects on splenomegaly and its constitutional symptoms.	ruxolitinib	33-44	Janus kinase 2	Homo sapiens	0-4
21602517-1	2012	Ruxolitinib, a selective Janus kinase (JAK) 1&amp;2 inhibitor in development for the treatment of myeloproliferative neoplasms, is primarily metabolized by CYP3A4.	ruxolitinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-162
21602517-2	2012	The effects of inhibition or induction of CYP3A4 on single oral dose ruxolitinib pharmacokinetics (PK) and pharmacodynamics (PD) were evaluated in healthy volunteers.	ruxolitinib	69-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
21602517-3	2012	Coadministration of ketoconazole (a potent CYP3A4 inhibitor) and erythromycin (a moderate CYP3A4 inhibitor) increased total ruxolitinib plasma exposure (AUC(0- )) by 91% and 27%, respectively, and ruxolitinib PD, as measured by the inhibition of interleukin (IL)-6-stimulated STAT3 phosphorylation in whole blood, was generally consistent with the PK observed.	ruxolitinib	124-135	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
21602517-4	2012	Pretreatment with rifampin, a potent CYP3A4 inducer, decreased ruxolitinib AUC(0- ) by 71% while resulting in only a 10% decrease in the overall PD activity.	ruxolitinib	63-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
21602517-6	2012	The collective PK/PD data suggest that starting doses of ruxolitinib should be reduced by 50% if coadministered with a potent CYP3A4 inhibitor, whereas adjustments in ruxolitinib starting doses may not be needed when coadministered with inducers or mild/moderate inhibitors of CYP3A4.	ruxolitinib	57-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
21926964-3	2012	We performed a high-throughput in vitro screen to identify point mutations in JAK2V617F that would be predicted to have potential clinical relevance and associated with drug resistance to the JAK2 inhibitor ruxolitinib (INCB018424).	ruxolitinib	207-218	Janus kinase 2	Mus musculus	78-82
21926964-3	2012	We performed a high-throughput in vitro screen to identify point mutations in JAK2V617F that would be predicted to have potential clinical relevance and associated with drug resistance to the JAK2 inhibitor ruxolitinib (INCB018424).	ruxolitinib	220-230	Janus kinase 2	Mus musculus	78-82
22279053-1	2012	On November 16, 2011, the Food and Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis.	ruxolitinib	64-75	Janus kinase 1	Homo sapiens	79-83
22279053-1	2012	On November 16, 2011, the Food and Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis.	ruxolitinib	64-75	Janus kinase 2	Homo sapiens	88-92
22375970-2	2012	We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	76-102
22375971-1	2012	BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	50-76
22319590-7	2012	Interestingly, treatment of NSCLC cells with the JAK1/2 inhibitor ruxolitinib has no effect on cell proliferation and viability in two-dimensional culture, but inhibits growth in soft agar and xenograft assays.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	49-55
23119228-7	2012	Discovery of the JAK2V617F mutation paved the way for drug discovery in MF, and the first JAK1/2 inhibitor, ruxolitinib, has been approved by FDA and Health Canada.	ruxolitinib	108-119	Janus kinase 1	Homo sapiens	90-96
22830345-4	2012	Ruxolitinib (previously known as INCB018424; Incyte Corporation, Wilmington, Delaware, USA) is a rationally designed potent oral JAK1 and JAK2 inhibitor that has undergone clinical trials in patients with PV, ET, and PMF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	129-133
22830345-4	2012	Ruxolitinib (previously known as INCB018424; Incyte Corporation, Wilmington, Delaware, USA) is a rationally designed potent oral JAK1 and JAK2 inhibitor that has undergone clinical trials in patients with PV, ET, and PMF.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	138-142
22399854-1	2012	Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	49-75
22034658-1	2011	Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	30-34
22034658-1	2011	Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	39-43
22034658-1	2011	Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	30-34
22034658-1	2011	Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials.	ruxolitinib	13-23	Janus kinase 2	Homo sapiens	39-43
22146225-1	2011	Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	102-106
22146225-1	2011	Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	111-115
22146225-1	2011	Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	141-145
22146225-1	2011	Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	146-150
22146225-2	2011	The suggested mechanism of action of ruxolitinib is attenuation of cytokine signaling via the inhibition of JAK1 and JAK2 (wild-type or mutated forms), resulting in antiproliferative and proapoptotic effects.	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	108-112
22146225-2	2011	The suggested mechanism of action of ruxolitinib is attenuation of cytokine signaling via the inhibition of JAK1 and JAK2 (wild-type or mutated forms), resulting in antiproliferative and proapoptotic effects.	ruxolitinib	37-48	Janus kinase 2	Homo sapiens	117-121
22399854-2	2012	By inhibiting JAK1 and JAK2, ruxolitinib modulates cytokine-stimulated intracellular signaling.	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	14-18
22399854-2	2012	By inhibiting JAK1 and JAK2, ruxolitinib modulates cytokine-stimulated intracellular signaling.	ruxolitinib	29-40	Janus kinase 2	Homo sapiens	23-27
22399854-3	2012	In a phase II clinical trial in patients with MF, ruxolitinib recipients exhibited durable reductions in spleen size, reductions in circulating pro-inflammatory cytokines, improvements in physical activity, weight gain, and alleviation of symptoms (including constitutional symptoms) in patients with and without JAK2 mutation.	ruxolitinib	50-61	Janus kinase 2	Homo sapiens	313-317
22362131-11	2011	Recently, the positive results of the first in class of the JAK1/JAK2 inhibitors, ruxolitinib (formerly INCB18242), from 2 large phase III studies were presented and are discussed herein.	ruxolitinib	82-93	Janus kinase 1	Homo sapiens	60-64
22362131-11	2011	Recently, the positive results of the first in class of the JAK1/JAK2 inhibitors, ruxolitinib (formerly INCB18242), from 2 large phase III studies were presented and are discussed herein.	ruxolitinib	82-93	Janus kinase 2	Homo sapiens	65-69
21705340-5	2011	These IL6-independent clones were dependent on NF-kappaB activity for their survival and proliferation but were resistant to dexamethasone and INCB018424, a selective Janus kinase 1/2 inhibitor.	ruxolitinib	143-153	interleukin 6	Mus musculus	6-9
21677670-3	2011	We hypothesized that local inhibition of cytokine signaling using topical administration of INCB018424, a small molecule inhibitor of JAK1 and JAK2, would provide benefit similar to systemic cytokine neutralization.	ruxolitinib	92-102	Janus kinase 1	Homo sapiens	134-138
21677670-3	2011	We hypothesized that local inhibition of cytokine signaling using topical administration of INCB018424, a small molecule inhibitor of JAK1 and JAK2, would provide benefit similar to systemic cytokine neutralization.	ruxolitinib	92-102	Janus kinase 2	Homo sapiens	143-147
21919691-0	2011	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	19-25
21919691-1	2011	Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	75-85
21919691-1	2011	Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	75-85
21635221-2	2011	In a recently completed Phase I?II study, ruxolitinib, a selective orally available JAK1 and JAK2 inhibitor, has shown efficacy in patients with advanced myelofibrosis.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	84-88
21635221-2	2011	In a recently completed Phase I?II study, ruxolitinib, a selective orally available JAK1 and JAK2 inhibitor, has shown efficacy in patients with advanced myelofibrosis.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	93-97
21635221-8	2011	Ruxolitinib, a potent JAK1 and JAK2 inhibitor, known to decrease spleen size and alleviate constitutional symptoms in myelofibrosis, represents a potentially promising agent for the treatment of leukemias by inhibiting the JAK?STAT signaling.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
21635221-8	2011	Ruxolitinib, a potent JAK1 and JAK2 inhibitor, known to decrease spleen size and alleviate constitutional symptoms in myelofibrosis, represents a potentially promising agent for the treatment of leukemias by inhibiting the JAK?STAT signaling.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	31-35
33970999-6	2021	Notably, we also find that established tumors may no longer require high levels of IL-7R expression upon secondary transplantation and can progress in the absence of IL-7, but remain sensitive to inhibitors of IL-7R-mediated signaling Ruxolitinib (Jak1), AZD1208 (Pim), Dactolisib (PI3K/mTOR), Palbociclib (Cdk4/6), and Venetoclax (Bcl-2).	ruxolitinib	235-246	Janus kinase 1	Homo sapiens	248-252
20130243-0	2010	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.	ruxolitinib	63-73	Janus kinase 1	Homo sapiens	46-52
20130243-5	2010	INCB018424 inhibited interleukin-6 signaling (50% inhibitory concentration [IC(50)] = 281nM), and proliferation of JAK2V617F(+) Ba/F3 cells (IC(50) = 127nM).	ruxolitinib	0-10	interleukin 6	Mus musculus	21-34
19468275-6	2009	In primary myelofibrosis, the JAK2 inhibitor, INCB018424, resulted in a rapid and marked reduction in splenomegaly and a clinical improvement, with a modest effect on JAK2 V617F burden.	ruxolitinib	46-56	Janus kinase 2	Homo sapiens	30-34
19468275-6	2009	In primary myelofibrosis, the JAK2 inhibitor, INCB018424, resulted in a rapid and marked reduction in splenomegaly and a clinical improvement, with a modest effect on JAK2 V617F burden.	ruxolitinib	46-56	Janus kinase 2	Homo sapiens	167-171
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	65-75	Janus kinase 1	Homo sapiens	57-63
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	65-75	Janus kinase 1	Homo sapiens	57-61
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	208-218	Janus kinase 2	Homo sapiens	38-42
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	208-218	Janus kinase 1	Homo sapiens	57-63
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	208-218	Janus kinase 1	Homo sapiens	57-61
20843246-3	2010	INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.	ruxolitinib	0-10	Janus kinase 1	Homo sapiens	37-51
20843246-3	2010	INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.	ruxolitinib	0-10	Janus kinase 1	Homo sapiens	53-57
20843246-3	2010	INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.	ruxolitinib	0-10	Janus kinase 2	Homo sapiens	63-67
20506062-0	2010	Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-29
20506062-0	2010	Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	34-38
20506062-1	2010	Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	85-89
20506062-1	2010	Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	94-98
20506062-1	2010	Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	85-89
20506062-1	2010	Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.	ruxolitinib	13-24	Janus kinase 2	Homo sapiens	94-98
20506062-7	2010	Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clinical indications.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	48-52
20363976-3	2010	Direct and indirect inhibition of the JAKs, with small molecule inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clinical measures of disease, consistent with their respective preclinical experiments.	ruxolitinib	95-105	Janus kinase 1	Rattus norvegicus	38-42
19552608-6	2009	Over a dozen JAK2 inhibitors are in development, with the leading compounds such as INCB018424, TG101348 and others showing promising early results particularly for control of disease associated splenomegaly and symptoms.	ruxolitinib	84-94	Janus kinase 2	Homo sapiens	13-17
33970999-6	2021	Notably, we also find that established tumors may no longer require high levels of IL-7R expression upon secondary transplantation and can progress in the absence of IL-7, but remain sensitive to inhibitors of IL-7R-mediated signaling Ruxolitinib (Jak1), AZD1208 (Pim), Dactolisib (PI3K/mTOR), Palbociclib (Cdk4/6), and Venetoclax (Bcl-2).	ruxolitinib	235-246	interleukin 7 receptor	Homo sapiens	210-215
33811972-2	2021	Compared to scl-GVHD controls, ruxolitinib-treated recipients showed significantly attenuated clinical and pathological severities of scl-GVHD in the skin and decreased frequencies of effector cells, CD4+ T cells, and CD11b+ macrophage/monocytes.	ruxolitinib	31-42	CD4 antigen	Mus musculus	200-203
33811972-0	2021	Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.	ruxolitinib	47-58	Janus kinase 1	Mus musculus	26-32
33811972-1	2021	The objective of this study was to examine the therapeutic effect of ruxolitinib, an orally administered selective Janus Kinase (JAK) 1/2 inhibitor, on chronic graft-versus-host disease (cGVHD) using a murine model of sclerodermatous GVHD (scl-GVHD).	ruxolitinib	69-80	Janus kinase 1	Mus musculus	115-137
33811972-2	2021	Compared to scl-GVHD controls, ruxolitinib-treated recipients showed significantly attenuated clinical and pathological severities of scl-GVHD in the skin and decreased frequencies of effector cells, CD4+ T cells, and CD11b+ macrophage/monocytes.	ruxolitinib	31-42	integrin alpha M	Mus musculus	218-223
33811972-3	2021	Regulatory CD4+ Foxp3+ T cells were expanded while IFN-gamma producing CD4+ T cells were significantly decreased in ruxolitinib-treated recipients.	ruxolitinib	116-127	CD4 antigen	Mus musculus	11-14
33811972-3	2021	Regulatory CD4+ Foxp3+ T cells were expanded while IFN-gamma producing CD4+ T cells were significantly decreased in ruxolitinib-treated recipients.	ruxolitinib	116-127	forkhead box P3	Mus musculus	16-21
33811972-3	2021	Regulatory CD4+ Foxp3+ T cells were expanded while IFN-gamma producing CD4+ T cells were significantly decreased in ruxolitinib-treated recipients.	ruxolitinib	116-127	interferon gamma	Mus musculus	51-60
33811972-3	2021	Regulatory CD4+ Foxp3+ T cells were expanded while IFN-gamma producing CD4+ T cells were significantly decreased in ruxolitinib-treated recipients.	ruxolitinib	116-127	CD4 antigen	Mus musculus	71-74
33811972-4	2021	Ruxolitinib suppressed not only the production of IFN-gamma from CD4+ T cells and MCP-1 from CD11b+ macrophage/monocytes, but also the proliferation of these cells in vitro.	ruxolitinib	0-11	interferon gamma	Mus musculus	50-59
33811972-4	2021	Ruxolitinib suppressed not only the production of IFN-gamma from CD4+ T cells and MCP-1 from CD11b+ macrophage/monocytes, but also the proliferation of these cells in vitro.	ruxolitinib	0-11	CD4 antigen	Mus musculus	65-68
33811972-4	2021	Ruxolitinib suppressed not only the production of IFN-gamma from CD4+ T cells and MCP-1 from CD11b+ macrophage/monocytes, but also the proliferation of these cells in vitro.	ruxolitinib	0-11	mast cell protease 1	Mus musculus	82-87
33811972-4	2021	Ruxolitinib suppressed not only the production of IFN-gamma from CD4+ T cells and MCP-1 from CD11b+ macrophage/monocytes, but also the proliferation of these cells in vitro.	ruxolitinib	0-11	integrin alpha M	Mus musculus	93-98
33811972-5	2021	Levels of both cytokines (IFN-gamma and MCP-1) were also reduced in the spleen and skin of ruxolitinib-treated recipients in vivo.	ruxolitinib	91-102	interferon gamma	Mus musculus	26-35
33811972-5	2021	Levels of both cytokines (IFN-gamma and MCP-1) were also reduced in the spleen and skin of ruxolitinib-treated recipients in vivo.	ruxolitinib	91-102	mast cell protease 1	Mus musculus	40-45
33811972-6	2021	IFN-gamma-induced MCP-1 production and migration of RAW 264.7 cells, a macrophage cell line, were inhibited by ruxolitinib.	ruxolitinib	111-122	interferon gamma	Mus musculus	0-9
33805426-0	2021	ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.	ruxolitinib	102-113	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	0-5
33805426-7	2021	In this work, we explored the role of ABCG2 in the transport of ruxolitinib and HU using human cell lines, RBCs, and in vitro differentiated erythroid progenitors.	ruxolitinib	64-75	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	38-43
33805426-9	2021	Using transfected K562 cells expressing three different levels of recombinant ABCG2, MPN RBCs, and cultured erythroblasts, we showed that ABCG2 potentiates ruxolitinib-induced cytotoxicity that was blocked by the ABCG2-specific inhibitor KO143 suggesting ruxolitinib intracellular import by ABCG2.	ruxolitinib	156-167	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-83
33805426-9	2021	Using transfected K562 cells expressing three different levels of recombinant ABCG2, MPN RBCs, and cultured erythroblasts, we showed that ABCG2 potentiates ruxolitinib-induced cytotoxicity that was blocked by the ABCG2-specific inhibitor KO143 suggesting ruxolitinib intracellular import by ABCG2.	ruxolitinib	156-167	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	138-143
33805426-9	2021	Using transfected K562 cells expressing three different levels of recombinant ABCG2, MPN RBCs, and cultured erythroblasts, we showed that ABCG2 potentiates ruxolitinib-induced cytotoxicity that was blocked by the ABCG2-specific inhibitor KO143 suggesting ruxolitinib intracellular import by ABCG2.	ruxolitinib	156-167	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	138-143
33805426-9	2021	Using transfected K562 cells expressing three different levels of recombinant ABCG2, MPN RBCs, and cultured erythroblasts, we showed that ABCG2 potentiates ruxolitinib-induced cytotoxicity that was blocked by the ABCG2-specific inhibitor KO143 suggesting ruxolitinib intracellular import by ABCG2.	ruxolitinib	156-167	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	138-143
33805426-9	2021	Using transfected K562 cells expressing three different levels of recombinant ABCG2, MPN RBCs, and cultured erythroblasts, we showed that ABCG2 potentiates ruxolitinib-induced cytotoxicity that was blocked by the ABCG2-specific inhibitor KO143 suggesting ruxolitinib intracellular import by ABCG2.	ruxolitinib	255-266	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	138-143
33805426-9	2021	Using transfected K562 cells expressing three different levels of recombinant ABCG2, MPN RBCs, and cultured erythroblasts, we showed that ABCG2 potentiates ruxolitinib-induced cytotoxicity that was blocked by the ABCG2-specific inhibitor KO143 suggesting ruxolitinib intracellular import by ABCG2.	ruxolitinib	255-266	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	138-143
33805426-9	2021	Using transfected K562 cells expressing three different levels of recombinant ABCG2, MPN RBCs, and cultured erythroblasts, we showed that ABCG2 potentiates ruxolitinib-induced cytotoxicity that was blocked by the ABCG2-specific inhibitor KO143 suggesting ruxolitinib intracellular import by ABCG2.	ruxolitinib	255-266	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	138-143
33805426-10	2021	In silico modeling analysis identified possible ruxolitinib-binding site locations within the cavities of ABCG2.	ruxolitinib	48-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	106-111
33805426-11	2021	Our study opens new perspectives in ruxolitinib efficacy research targeting cell types depending on ABCG2 expression and polymorphisms among patients.	ruxolitinib	36-47	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	100-105
33811972-6	2021	IFN-gamma-induced MCP-1 production and migration of RAW 264.7 cells, a macrophage cell line, were inhibited by ruxolitinib.	ruxolitinib	111-122	mast cell protease 1	Mus musculus	18-23
33811972-7	2021	However, supplement of MCP-1 recovered such effect of ruxolitinib.	ruxolitinib	54-65	mast cell protease 1	Mus musculus	23-28
33782031-1	2021	PURPOSE: The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with Myeloproliferative Neoplasms (MPNs).	ruxolitinib	30-41	Janus kinase 1	Homo sapiens	13-19
33811972-8	2021	In addition, blocking JAK-STAT signaling using ruxolitinib reduced the activation of STAT1 in stimulated immune effector cells.	ruxolitinib	47-58	Janus kinase 1	Mus musculus	22-25
33782031-7	2021	RESULTS: Exposure of JAK2 mutant cell lines to the triple combination of ruxolitinib, LEE011 and PIM447 resulted in expected on-target pharmacodynamic effects, as well as increased apoptosis and a decrease in the proportion of cells in S-phase, compared with ruxolitinib.	ruxolitinib	73-84	Janus kinase 2	Homo sapiens	21-25
33782031-7	2021	RESULTS: Exposure of JAK2 mutant cell lines to the triple combination of ruxolitinib, LEE011 and PIM447 resulted in expected on-target pharmacodynamic effects, as well as increased apoptosis and a decrease in the proportion of cells in S-phase, compared with ruxolitinib.	ruxolitinib	259-270	Janus kinase 2	Homo sapiens	21-25
33811972-8	2021	In addition, blocking JAK-STAT signaling using ruxolitinib reduced the activation of STAT1 in stimulated immune effector cells.	ruxolitinib	47-58	signal transducer and activator of transcription 1	Mus musculus	26-30
33811972-8	2021	In addition, blocking JAK-STAT signaling using ruxolitinib reduced the activation of STAT1 in stimulated immune effector cells.	ruxolitinib	47-58	signal transducer and activator of transcription 1	Mus musculus	85-90
33811972-9	2021	Taken together, these results suggest that ruxolitinib can prevent scl-GVHD by suppressing IFN-gamma produced by T cells and MCP-1 expression in macrophage/monocytes via inhibition of JAK-STAT signaling.	ruxolitinib	43-54	interferon gamma	Mus musculus	91-100
33811972-9	2021	Taken together, these results suggest that ruxolitinib can prevent scl-GVHD by suppressing IFN-gamma produced by T cells and MCP-1 expression in macrophage/monocytes via inhibition of JAK-STAT signaling.	ruxolitinib	43-54	mast cell protease 1	Mus musculus	125-130
33811972-9	2021	Taken together, these results suggest that ruxolitinib can prevent scl-GVHD by suppressing IFN-gamma produced by T cells and MCP-1 expression in macrophage/monocytes via inhibition of JAK-STAT signaling.	ruxolitinib	43-54	Janus kinase 1	Mus musculus	184-187
33811972-9	2021	Taken together, these results suggest that ruxolitinib can prevent scl-GVHD by suppressing IFN-gamma produced by T cells and MCP-1 expression in macrophage/monocytes via inhibition of JAK-STAT signaling.	ruxolitinib	43-54	signal transducer and activator of transcription 1	Mus musculus	188-192
33770100-7	2021	It is preceded by an increase in IFNB1 mRNA levels and can be blocked by siRNA targeting the type I IFN receptor IFNAR1 and by inhibition of Janus kinases by Ruxolitinib.	ruxolitinib	158-169	interferon beta 1	Homo sapiens	33-38
33810547-9	2021	This induction was abolished by the pretreatment of ruxolitinib, a leptin signaling inhibitor.	ruxolitinib	52-63	leptin	Homo sapiens	67-73
33803310-3	2021	Here we hypothesized that Ruxolitinib, an FDA-approved JAK inhibitor known to prevent IFN-gamma signaling, could be repurposed for host-directed therapy in AVHF.	ruxolitinib	26-37	interferon gamma	Mus musculus	86-95
34767056-4	2022	The JAK2 inhibitor ruxolitinib has recently been shown in clinical trials to be effective in SR/D aGVHD and cGVHD.	ruxolitinib	19-30	Janus kinase 2	Homo sapiens	4-8
25682576-1	2015	BACKGROUND: In the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF.	ruxolitinib	140-151	Janus kinase 1	Homo sapiens	105-124
25682576-1	2015	BACKGROUND: In the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF.	ruxolitinib	140-151	Janus kinase 2	Homo sapiens	125-129
34724284-11	2022	These results suggest that activation of the JAK2 and MEK-ERK pathways was more prevalent in MCPyV-negative than in MCPyV-positive MCC and the JAK inhibitor ruxolitinib inhibited MEK-ERK pathway activation.	ruxolitinib	157-168	Janus kinase 2	Homo sapiens	45-49
34724284-11	2022	These results suggest that activation of the JAK2 and MEK-ERK pathways was more prevalent in MCPyV-negative than in MCPyV-positive MCC and the JAK inhibitor ruxolitinib inhibited MEK-ERK pathway activation.	ruxolitinib	157-168	mitogen-activated protein kinase kinase 7	Homo sapiens	54-57
34724284-11	2022	These results suggest that activation of the JAK2 and MEK-ERK pathways was more prevalent in MCPyV-negative than in MCPyV-positive MCC and the JAK inhibitor ruxolitinib inhibited MEK-ERK pathway activation.	ruxolitinib	157-168	mitogen-activated protein kinase 1	Homo sapiens	58-61
34724284-11	2022	These results suggest that activation of the JAK2 and MEK-ERK pathways was more prevalent in MCPyV-negative than in MCPyV-positive MCC and the JAK inhibitor ruxolitinib inhibited MEK-ERK pathway activation.	ruxolitinib	157-168	mitogen-activated protein kinase kinase 7	Homo sapiens	179-182
34724284-11	2022	These results suggest that activation of the JAK2 and MEK-ERK pathways was more prevalent in MCPyV-negative than in MCPyV-positive MCC and the JAK inhibitor ruxolitinib inhibited MEK-ERK pathway activation.	ruxolitinib	157-168	mitogen-activated protein kinase 1	Homo sapiens	183-186
34074166-2	2022	Ruxolitinib, an oral selective JAK1/2 inhibitor, has recently shown efficacy and safety in the treatment of secondary HLH, which may be an alternative to intensive chemotherapy.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	31-37
34326465-2	2022	JAK2 kinase inhibitors, such as ruxolitinib, provide clinical benefit, but inhibition of wild-type (wt) JAK2 limits their clinical utility due to toxicity to normal cells, and small molecule inhibition of mutated JAK2 kinase activity can lead to drug resistance.	ruxolitinib	32-43	Janus kinase 2	Homo sapiens	0-4
34326465-2	2022	JAK2 kinase inhibitors, such as ruxolitinib, provide clinical benefit, but inhibition of wild-type (wt) JAK2 limits their clinical utility due to toxicity to normal cells, and small molecule inhibition of mutated JAK2 kinase activity can lead to drug resistance.	ruxolitinib	32-43	Janus kinase 2	Homo sapiens	213-217
33589712-1	2021	Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	25-39
33589712-1	2021	Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	41-45
33589712-1	2021	Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	51-55
33589712-5	2021	Gfap expression and Gfap+ cells were also suppressed in the differentiating neurospheres culture treated with ruxolitinib.	ruxolitinib	110-121	glial fibrillary acidic protein	Mus musculus	0-4
33589712-5	2021	Gfap expression and Gfap+ cells were also suppressed in the differentiating neurospheres culture treated with ruxolitinib.	ruxolitinib	110-121	glial fibrillary acidic protein	Mus musculus	20-24
29224367-2	2018	Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-36
29224367-2	2018	Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-42
29224367-2	2018	Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	44-48
26463833-3	2015	Ruxolitinib increased median survival from 1.8 to 2.7 months in patients with pancreatic cancer who had high levels of the inflammation marker C-reactive protein in their blood.	ruxolitinib	0-11	C-reactive protein	Homo sapiens	143-161
26380150-3	2015	Ruxolitinib, a potent inhibitor of Janus kinase (JAK) 1 and JAK2, was associated with an overall survival benefit and improvements in splenomegaly and patient-reported outcomes in patients with myelofibrosis in the two phase 3 COMFORT studies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	35-55
26380150-3	2015	Ruxolitinib, a potent inhibitor of Janus kinase (JAK) 1 and JAK2, was associated with an overall survival benefit and improvements in splenomegaly and patient-reported outcomes in patients with myelofibrosis in the two phase 3 COMFORT studies.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	60-64
34694880-2	2022	The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with anti-malarial therapy.	ruxolitinib	36-47	Janus kinase 1	Homo sapiens	18-24
34694880-4	2022	Ruxolitinib pharmacodynamics were assessed by inhibition of phosphorylation of signal transducer and activator of transcription 3 (pSTAT3).	ruxolitinib	0-11	signal transducer and activator of transcription 3	Homo sapiens	79-129
34521299-0	2022	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	34-40
34521299-1	2022	ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8).	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	92-98
34895069-4	2021	We found that ruxolitinib, dexamethasone, colchicine; dexamethasone, sitagliptin, baricitinib and galidesivir, ruxolitinib, hydroxychloroquine were the most effective compounds in binding PON1-w, PON1L55M and PON1Q192R respectively.	ruxolitinib	14-25	paraoxonase 1	Homo sapiens	188-192
34895069-4	2021	We found that ruxolitinib, dexamethasone, colchicine; dexamethasone, sitagliptin, baricitinib and galidesivir, ruxolitinib, hydroxychloroquine were the most effective compounds in binding PON1-w, PON1L55M and PON1Q192R respectively.	ruxolitinib	14-25	paraoxonase 1	Homo sapiens	209-213
34895069-4	2021	We found that ruxolitinib, dexamethasone, colchicine; dexamethasone, sitagliptin, baricitinib and galidesivir, ruxolitinib, hydroxychloroquine were the most effective compounds in binding PON1-w, PON1L55M and PON1Q192R respectively.	ruxolitinib	111-122	paraoxonase 1	Homo sapiens	188-192
34895069-4	2021	We found that ruxolitinib, dexamethasone, colchicine; dexamethasone, sitagliptin, baricitinib and galidesivir, ruxolitinib, hydroxychloroquine were the most effective compounds in binding PON1-w, PON1L55M and PON1Q192R respectively.	ruxolitinib	111-122	paraoxonase 1	Homo sapiens	209-213
34882211-0	2021	Degrading JAK2 in ALL by ruxolitinib-based PROTACs.	ruxolitinib	25-36	Janus kinase 2	Homo sapiens	10-14
34943910-5	2021	STAT1 and STAT2 were identified as being significantly overexpressed in the LFS patient, indicating ruxolitinib, a Janus kinase 1 and 2 inhibitors, as a potential therapy.	ruxolitinib	100-111	signal transducer and activator of transcription 2	Homo sapiens	10-15
34943910-5	2021	STAT1 and STAT2 were identified as being significantly overexpressed in the LFS patient, indicating ruxolitinib, a Janus kinase 1 and 2 inhibitors, as a potential therapy.	ruxolitinib	100-111	signal transducer and activator of transcription 1	Homo sapiens	0-5
34791813-7	2021	Gene expression studies suggested ruxolitinib had turned off interferon signaling in CLL cells and turned on genes associated with the activation of NFkappaB by TNF-alpha.	ruxolitinib	34-45	nuclear factor kappa B subunit 1	Homo sapiens	149-157
34791813-7	2021	Gene expression studies suggested ruxolitinib had turned off interferon signaling in CLL cells and turned on genes associated with the activation of NFkappaB by TNF-alpha.	ruxolitinib	34-45	tumor necrosis factor	Homo sapiens	161-170
34791813-8	2021	Ruxolitinib increased blood levels of TNF-alpha by cycle 3 and decreased the inhibitory cytokine IL-10.	ruxolitinib	0-11	tumor necrosis factor	Homo sapiens	38-47
34791813-8	2021	Ruxolitinib increased blood levels of TNF-alpha by cycle 3 and decreased the inhibitory cytokine IL-10.	ruxolitinib	0-11	interleukin 10	Homo sapiens	97-102
34253584-3	2021	To leverage these unique biologic features, we conducted an integrated human and murine study evaluating ruxolitinib, a JAK1/2 inhibitor that potently downregulates intracellular GM-CSF signaling.	ruxolitinib	105-116	Janus kinase 1	Mus musculus	120-126
34880598-3	2021	Ruxolitinib is a selective Janus kinases 1/2 inhibitor which has been shown to control acute (a) and chronic (c) GVHD while maintaining graft-versus-tumor effects.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	27-44
34808021-6	2022	Both ruxolitinib and obatoclax significantly reduced spleen weights in a murine Jak2V617F MPN model but did not show additive effect.	ruxolitinib	5-16	Janus kinase 2	Mus musculus	80-84
34867980-4	2021	Several JAK inhibitors have entered clinical trials, including ruxolitinib, the first JAK1/2 inhibitor to become commercially available for the treatment of myelofibrosis and polycythemia vera.	ruxolitinib	63-74	Janus kinase 1	Homo sapiens	86-92
34505930-12	2021	CONCLUSION: Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors.	ruxolitinib	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
34505930-12	2021	CONCLUSION: Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors.	ruxolitinib	12-23	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	160-166
34875179-3	2021	Ruxolitinib and fedratinib are approved JAK2 inhibitors that have produced meaningful benefits in terms of spleen reduction and symptom improvement, but there remain several unmet needs.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	40-44
34169526-1	2021	Ruxolitinib is an FDA-approved orally administered Janus kinase (JAK 1/2) inhibitor that reduces cytokine-induced inflammation.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	65-72
34169526-2	2021	As part of a randomized, Phase 2, open label trial, ruxolitinib (10 mg, bid) was administered to HIV+ , virologically suppressed individuals (33 men, 7 women) on antiretroviral therapy (ART), for 5 weeks.	ruxolitinib	52-63	BH3 interacting domain death agonist	Homo sapiens	72-75
34169526-6	2021	Ruxolitinib PK was adequately described with a 2-compartment model with first-order absorption and elimination with distribution volumes normalized to mean body weight (91.5 kg) and a separate typical CL for participants administered efavirenz (a known CYP3A4 inducer).	ruxolitinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	253-259
34816294-0	2022	Elevated REG3alpha predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy.	ruxolitinib	79-90	regenerating family member 3 alpha	Homo sapiens	9-18
34816294-9	2022	Elevated REG3alpha levels may predict refractory aGVHD after novel first-line therapy with steroids-ruxolitinib.	ruxolitinib	100-111	regenerating family member 3 alpha	Homo sapiens	9-18
34868078-4	2021	In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-gamma-chemokine signaling axis in the pathogenesis of vitiligo.	ruxolitinib	56-67	interferon gamma	Homo sapiens	148-157
34253584-3	2021	To leverage these unique biologic features, we conducted an integrated human and murine study evaluating ruxolitinib, a JAK1/2 inhibitor that potently downregulates intracellular GM-CSF signaling.	ruxolitinib	105-116	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	179-185
34655610-5	2022	The JAK1/2 inhibitor ruxolitinib strongly inhibited such effects on epidermal cells.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
34757578-9	2022	Meanwhile, the most effective corticosteroid, interleukin-6 antagonist, and Janus kinase (JAK) inhibitor were hydrocortisone, sarilumab, and ruxolitinib, respectively.	ruxolitinib	141-152	interleukin 6	Homo sapiens	46-59
34871267-0	2021	Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	15-19
34871267-6	2021	Recently, Ruxolitinib (a JAK2 inhibitor) has been shown to be very effective, especially in patients with refractory pruritis in the setting of other treatment modalities failure.	ruxolitinib	10-21	Janus kinase 2	Homo sapiens	25-29
34520107-4	2021	Ruxolitinib is a JAK-1/JAK-2 inhibitor and has showed its efficacy in suppressing IE and the immune system.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-22
34520107-4	2021	Ruxolitinib is a JAK-1/JAK-2 inhibitor and has showed its efficacy in suppressing IE and the immune system.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	23-28
34778129-0	2021	Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation.	ruxolitinib	31-42	adenosine deaminase RNA specific	Homo sapiens	84-89
34778129-3	2021	We describe herein the clinical picture and treatment response to the JAK-inhibitor ruxolitinib in a 5-year-old girl affected by Aicardi-Goutieres Syndrome type 6 (AGS6) due to ADAR1 mutation.	ruxolitinib	84-95	adenosine deaminase RNA specific	Homo sapiens	177-182
34771447-5	2021	IFN-beta exposure induced apoptosis in GSCs with intrinsically high IFN/STAT1 signaling, and this effect was abolished by the pharmacological inhibitor ruxolitinib and STAT1 knockdown.	ruxolitinib	152-163	IFN1@	Homo sapiens	0-8
34771447-5	2021	IFN-beta exposure induced apoptosis in GSCs with intrinsically high IFN/STAT1 signaling, and this effect was abolished by the pharmacological inhibitor ruxolitinib and STAT1 knockdown.	ruxolitinib	152-163	signal transducer and activator of transcription 1	Homo sapiens	72-77
34903489-4	2022	Janus kinase 2 (JAK2) inhibitor Ruxolitinib is the first-line treatment for intermediate-II or high-risk MF patients with splenomegaly and constitutional symptoms, but most MF patients develop resistance or intolerance to Ruxolitinib.	ruxolitinib	32-43	Janus kinase 2	Homo sapiens	0-14
34903489-4	2022	Janus kinase 2 (JAK2) inhibitor Ruxolitinib is the first-line treatment for intermediate-II or high-risk MF patients with splenomegaly and constitutional symptoms, but most MF patients develop resistance or intolerance to Ruxolitinib.	ruxolitinib	32-43	Janus kinase 2	Homo sapiens	16-20
34903489-4	2022	Janus kinase 2 (JAK2) inhibitor Ruxolitinib is the first-line treatment for intermediate-II or high-risk MF patients with splenomegaly and constitutional symptoms, but most MF patients develop resistance or intolerance to Ruxolitinib.	ruxolitinib	222-233	Janus kinase 2	Homo sapiens	0-14
34903489-4	2022	Janus kinase 2 (JAK2) inhibitor Ruxolitinib is the first-line treatment for intermediate-II or high-risk MF patients with splenomegaly and constitutional symptoms, but most MF patients develop resistance or intolerance to Ruxolitinib.	ruxolitinib	222-233	Janus kinase 2	Homo sapiens	16-20
34741118-2	2022	The JAK inhibitor Ruxolitinib can reduce constitutional symptoms but it does not substantially improve bone marrow fibrosis.	ruxolitinib	18-29	Janus kinase 2	Mus musculus	4-7
34680595-4	2021	A reduced ACE2/RBD binding inhibition activity of spike-specific antibodies was also observed, especially in ruxolitinib-treated patients.	ruxolitinib	109-120	angiotensin converting enzyme 2	Homo sapiens	10-14
34272171-1	2021	Over the last decade, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib has become widely established as the cornerstone of pharmacologic therapy for most patients with myelofibrosis (MF), providing dramatic and durable benefits in terms of splenomegaly and symptoms, and prolonging survival.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	26-48
34707996-2	2021	Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but the efficacy is variable.	ruxolitinib	42-53	pericentriolar material 1	Homo sapiens	89-93
34707996-2	2021	Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but the efficacy is variable.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	94-98
34707996-3	2021	Here, we report two patients diagnosed with MPN with PCM1-JAK2 fusion who were treated with ruxolitinib-based regimen, including the first case of ruxolitinib combined with pegylated interferon (Peg-IFN), and we conduct a literature review.	ruxolitinib	92-103	pericentriolar material 1	Homo sapiens	53-57
34707996-3	2021	Here, we report two patients diagnosed with MPN with PCM1-JAK2 fusion who were treated with ruxolitinib-based regimen, including the first case of ruxolitinib combined with pegylated interferon (Peg-IFN), and we conduct a literature review.	ruxolitinib	92-103	Janus kinase 2	Homo sapiens	58-62
34707996-3	2021	Here, we report two patients diagnosed with MPN with PCM1-JAK2 fusion who were treated with ruxolitinib-based regimen, including the first case of ruxolitinib combined with pegylated interferon (Peg-IFN), and we conduct a literature review.	ruxolitinib	147-158	pericentriolar material 1	Homo sapiens	53-57
34165774-0	2021	MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.	ruxolitinib	89-100	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	0-3
34165774-0	2021	MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.	ruxolitinib	89-100	calreticulin	Homo sapiens	50-54
34165774-0	2021	MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.	ruxolitinib	89-100	calreticulin	Homo sapiens	149-153
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
34165774-0	2021	MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.	ruxolitinib	89-100	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	55-58
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	0-11	calreticulin	Homo sapiens	115-127
34385593-4	2021	In a non-randomized prospective phase II multi-center study, we asked whether targeted inhibition of Janus kinase-mediated cytokine signaling using ruxolitinib is feasible and efficacious in SARS-CoV-2- induced ARDS with hyperinflammation.	ruxolitinib	148-159	janus kinase	None	101-113
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	0-11	calreticulin	Homo sapiens	129-133
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	21-25
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	13-16	calreticulin	Homo sapiens	115-127
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	13-16	calreticulin	Homo sapiens	129-133
34157510-3	2021	Ruxolitinib, a JAK1/2 inhibitor, has recently been approved for the treatment of acute GvHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
34480104-7	2021	Combined pharmacologic JAK2/ERK1/2 inhibition with ruxolitinib and ERK inhibitors reduced proliferation of Jak2V617F cells and corrected erythrocytosis and splenomegaly of Jak2V617F MPN mice.	ruxolitinib	51-62	mitogen-activated protein kinase 3	Mus musculus	28-34
34171557-3	2021	Herein, we identified that interferon-gamma (IFN-gamma), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as well as siRNA-mediated silencing of JAK1, STAT1, and IRF1.	ruxolitinib	238-249	interferon gamma	Homo sapiens	27-43
34480104-7	2021	Combined pharmacologic JAK2/ERK1/2 inhibition with ruxolitinib and ERK inhibitors reduced proliferation of Jak2V617F cells and corrected erythrocytosis and splenomegaly of Jak2V617F MPN mice.	ruxolitinib	51-62	Janus kinase 2	Mus musculus	107-111
34480104-7	2021	Combined pharmacologic JAK2/ERK1/2 inhibition with ruxolitinib and ERK inhibitors reduced proliferation of Jak2V617F cells and corrected erythrocytosis and splenomegaly of Jak2V617F MPN mice.	ruxolitinib	51-62	Janus kinase 2	Mus musculus	172-176
34518646-0	2021	Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).	ruxolitinib	49-60	janus-kinase	None	26-38
34693224-3	2021	In these cells, the clinical JAK inhibitors cerdulatinib, ruxolitinib, and tofacitinib reduced SLFN11 expression, but IFN did not further induce SLFN11 despite phosphorylated STAT1.	ruxolitinib	58-69	schlafen family member 11	Homo sapiens	95-101
34232994-2	2021	Experimental and early clinical reports have shown that ruxolitinib, a small molecule inhibitor of Janus kinases (JAKs) which are essential for cytokine signaling, may be therapeutic in HLH.	ruxolitinib	56-67	Janus kinase 1	Mus musculus	114-118
34232994-4	2021	High doses of ruxolitinib blocked IFN-g signaling only transiently after administration, consistent with human pharmacokinetics, and only continuously administered drug could prevent HLH development or treat established HLH.	ruxolitinib	14-25	interferon gamma	Homo sapiens	34-39
34232994-5	2021	Continuously administered ruxolitinib was therapeutic in only a narrow dose range and intermittently dosed ruxolitinib worsened survival and decreased bone marrow cellularity of animals concurrently treated with anti-IFN-g antibody, indicating a narrow therapeutic window and potential toxicity.	ruxolitinib	107-118	interferon gamma	Homo sapiens	217-222
34584433-2	2021	Herein, we present a 56-year-old woman with primary myelofibrosis who developed combined tuberculosis (TB) and cryptococcosis with extensive pulmonary, pleural, and nodal involvement during ruxolitinib therapy.	ruxolitinib	190-201	nodal growth differentiation factor	Homo sapiens	165-170
34210682-4	2021	Genetic co-targeting of the synergistic key regulator pair STAT5B and BCL2-associated athanogene 1 (BAG1) significantly reduced leukemia cell viability in vitro Pharmacologic inhibition with dual small molecule inhibitor therapy targeting this pair of key nodes further demonstrated enhanced anti-leukemia efficacy of combining the BCL-2 inhibitor venetoclax with the tyrosine kinase inhibitors ruxolitinib or dasatinib in vitro in human Ph-like ALL cell lines and in vivo in multiple childhood Ph-like ALL patient-derived xenograft models.	ruxolitinib	395-406	signal transducer and activator of transcription 5B	Homo sapiens	59-65
34210682-4	2021	Genetic co-targeting of the synergistic key regulator pair STAT5B and BCL2-associated athanogene 1 (BAG1) significantly reduced leukemia cell viability in vitro Pharmacologic inhibition with dual small molecule inhibitor therapy targeting this pair of key nodes further demonstrated enhanced anti-leukemia efficacy of combining the BCL-2 inhibitor venetoclax with the tyrosine kinase inhibitors ruxolitinib or dasatinib in vitro in human Ph-like ALL cell lines and in vivo in multiple childhood Ph-like ALL patient-derived xenograft models.	ruxolitinib	395-406	BAG cochaperone 1	Homo sapiens	70-98
34210682-4	2021	Genetic co-targeting of the synergistic key regulator pair STAT5B and BCL2-associated athanogene 1 (BAG1) significantly reduced leukemia cell viability in vitro Pharmacologic inhibition with dual small molecule inhibitor therapy targeting this pair of key nodes further demonstrated enhanced anti-leukemia efficacy of combining the BCL-2 inhibitor venetoclax with the tyrosine kinase inhibitors ruxolitinib or dasatinib in vitro in human Ph-like ALL cell lines and in vivo in multiple childhood Ph-like ALL patient-derived xenograft models.	ruxolitinib	395-406	BAG cochaperone 1	Homo sapiens	100-104
34505882-0	2021	Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.	ruxolitinib	67-78	Janus kinase 2	Homo sapiens	49-53
34505882-8	2021	In summary, IKZF1 deletion and a switch from cytokine dependence to activated BCR-like signaling phenotype represent putative mechanisms of ruxolitinib resistance in this case, recapitulating preclinical data on resistance to JAK inhibition in CRLF2-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.	ruxolitinib	140-151	IKAROS family zinc finger 1	Homo sapiens	12-17
34505882-8	2021	In summary, IKZF1 deletion and a switch from cytokine dependence to activated BCR-like signaling phenotype represent putative mechanisms of ruxolitinib resistance in this case, recapitulating preclinical data on resistance to JAK inhibition in CRLF2-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.	ruxolitinib	140-151	cytokine receptor like factor 2	Homo sapiens	244-249
34733993-13	2021	CALD1-mediated PD-L1 overexpression (OE) was via the activation of the JAK/STAT signaling pathway; this effect was blocked by the specific JAK inhibitor Ruxolitinib.	ruxolitinib	153-164	caldesmon 1	Homo sapiens	0-5
34733993-13	2021	CALD1-mediated PD-L1 overexpression (OE) was via the activation of the JAK/STAT signaling pathway; this effect was blocked by the specific JAK inhibitor Ruxolitinib.	ruxolitinib	153-164	CD274 molecule	Homo sapiens	15-20
34623777-3	2021	Ruxolitinib, a JAK-1 and JAK-2 inhibitor, is documented to have potent anti-inflammatory activity by targeting several cytokines and growth factors with proposed efficacy in the cytokine storm observed in severe COVID-19 patients; therefore, this study examines the efficacy and tolerability of ruxolitinib for adult COVID-19 patients.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-20
34623777-3	2021	Ruxolitinib, a JAK-1 and JAK-2 inhibitor, is documented to have potent anti-inflammatory activity by targeting several cytokines and growth factors with proposed efficacy in the cytokine storm observed in severe COVID-19 patients; therefore, this study examines the efficacy and tolerability of ruxolitinib for adult COVID-19 patients.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	25-30
34109505-0	2021	SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?	ruxolitinib	61-72	signal transducer and activator of transcription 1	Homo sapiens	37-42
34591931-8	2021	Moreover, differences in sensitivity of two CRLF2-drivenBCP-ALL cell lines to ruxolitinib were also seen.	ruxolitinib	78-89	cytokine receptor like factor 2	Homo sapiens	44-49
34587248-6	2022	We show that regulators of RAS signaling are critical for cell fitness and Ruxolitinib sensitivity and that CRKL depletion enhances Ruxolitinib sensitivity in RAS wild-type (WT) cells.	ruxolitinib	132-143	CRK like proto-oncogene, adaptor protein	Homo sapiens	108-112
34496019-5	2021	These effects were abrogated by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	56-67	Janus kinase 1	Mus musculus	36-40
34496019-5	2021	These effects were abrogated by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	56-67	Janus kinase 2	Homo sapiens	41-45
34638347-2	2021	The resistance of MF clones against the suppressive action of ruxolitinib may be due to intrinsic or extrinsic mechanisms leading to activity of additional pro-survival genes or signalling pathways that function independently of JAK2/STAT5.	ruxolitinib	62-73	Janus kinase 2	Homo sapiens	229-233
34638347-2	2021	The resistance of MF clones against the suppressive action of ruxolitinib may be due to intrinsic or extrinsic mechanisms leading to activity of additional pro-survival genes or signalling pathways that function independently of JAK2/STAT5.	ruxolitinib	62-73	signal transducer and activator of transcription 5A	Homo sapiens	234-239
34638347-6	2021	We also showed that proteasome gene expression is reduced by ruxolitinib in MF CD34+ cells and that additional targeting of proteasomal activity by carfilzomib enhances the inhibitory action of ruxolitinib in vitro.	ruxolitinib	61-72	CD34 molecule	Homo sapiens	79-83
34630428-6	2021	We investigated the impact of short-term treatment of BCL2 (venetoclax) or JAK1/2 (ruxolitinib) inhibition on recipient natural killer and T cell immunity and the subsequent effect on donor engraftment.	ruxolitinib	83-94	Janus kinase 1	Homo sapiens	75-81
34536415-10	2022	Moreover, an overview of the clinical course of the disease, including therapies, provides evidence for the therapeutic efficacy of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in inflammatory lung disease.	ruxolitinib	169-180	Janus kinase 1	Homo sapiens	136-158
34660133-3	2021	We present a 78-year-old female with a known diagnosis of primary myelofibrosis (PMF), on ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, presenting with altered mental status.	ruxolitinib	90-101	Janus kinase 1	Homo sapiens	105-131
34552486-3	2021	The JAK1/2 inhibitor, ruxolitinib, is now considered a novel therapy in inflammatory disease, and hypercytokinemia is an important feature of CAEBV.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-10
34552486-6	2021	Six out of seven patients became afebrile within 48 h. The AST/ALT level of three out of four patients decreased after ruxolitinib treatment.	ruxolitinib	119-130	solute carrier family 17 member 5	Homo sapiens	59-62
34322995-8	2021	Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	27-33
34322995-8	2021	Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells.	ruxolitinib	53-64	androgen receptor	Homo sapiens	106-123
34322995-8	2021	Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells.	ruxolitinib	53-64	androgen receptor	Homo sapiens	125-127
34171557-3	2021	Herein, we identified that interferon-gamma (IFN-gamma), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as well as siRNA-mediated silencing of JAK1, STAT1, and IRF1.	ruxolitinib	238-249	interferon gamma	Homo sapiens	45-54
34171557-3	2021	Herein, we identified that interferon-gamma (IFN-gamma), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as well as siRNA-mediated silencing of JAK1, STAT1, and IRF1.	ruxolitinib	238-249	CD47 molecule	Homo sapiens	147-151
34171557-3	2021	Herein, we identified that interferon-gamma (IFN-gamma), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as well as siRNA-mediated silencing of JAK1, STAT1, and IRF1.	ruxolitinib	238-249	Janus kinase 1	Homo sapiens	221-227
34531866-8	2021	In vitro treatment of HIV-infected CD4+ T cells with physiological concentrations of JAK1/2 inhibitors, ruxolitinib and baricitinib, used in clinical settings to target inflammation, reduced latent and productive infection events when added 24 hr after infection and blocked HIV reactivation from latent cells.	ruxolitinib	104-115	CD4 molecule	Homo sapiens	35-38
34531866-8	2021	In vitro treatment of HIV-infected CD4+ T cells with physiological concentrations of JAK1/2 inhibitors, ruxolitinib and baricitinib, used in clinical settings to target inflammation, reduced latent and productive infection events when added 24 hr after infection and blocked HIV reactivation from latent cells.	ruxolitinib	104-115	Janus kinase 1	Homo sapiens	85-91
34145036-2	2021	The JAK2 inhibitors Ruxolitinib and Fedratinib have been approved for treatment of MF, but they do not offer significant improvement of bone marrow fibrosis.	ruxolitinib	20-31	Janus kinase 2	Mus musculus	4-8
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	13-16
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	98-102
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 2	Homo sapiens	107-111
34423448-2	2022	Ruxolitinib, a selective inhibitor of JAK 1 and 2, significantly reduces constitutional symptoms and spleen size compared with placebo, and has significant clinical benefits in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-49
34396051-9	2021	Interestingly, ruxolitinib treatment induced increased phosphorylation of AXL indicating that activation of AXL might mediate resistance to ruxolitinib.	ruxolitinib	15-26	AXL receptor tyrosine kinase	Homo sapiens	74-77
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	121-125
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 2	Homo sapiens	126-130
34396051-9	2021	Interestingly, ruxolitinib treatment induced increased phosphorylation of AXL indicating that activation of AXL might mediate resistance to ruxolitinib.	ruxolitinib	15-26	AXL receptor tyrosine kinase	Homo sapiens	108-111
34396051-9	2021	Interestingly, ruxolitinib treatment induced increased phosphorylation of AXL indicating that activation of AXL might mediate resistance to ruxolitinib.	ruxolitinib	140-151	AXL receptor tyrosine kinase	Homo sapiens	74-77
34396051-9	2021	Interestingly, ruxolitinib treatment induced increased phosphorylation of AXL indicating that activation of AXL might mediate resistance to ruxolitinib.	ruxolitinib	140-151	AXL receptor tyrosine kinase	Homo sapiens	108-111
34422627-7	2021	Recombinant human CXCL10 induced JAK-STAT and PD-L1, while the CXCL10-CXCR3 and JAK-STAT inhibitors AMG487 or ruxolitinib reduced the expression of PD-L1 in HFF-1 cells.	ruxolitinib	110-121	CD274 molecule	Homo sapiens	148-153
34396051-10	2021	Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling.	ruxolitinib	74-85	AXL receptor tyrosine kinase	Homo sapiens	18-21
34396051-10	2021	Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling.	ruxolitinib	74-85	signal transducer and activator of transcription 3	Homo sapiens	99-104
34396051-10	2021	Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling.	ruxolitinib	74-85	signal transducer and activator of transcription 5A	Homo sapiens	106-111
34396051-10	2021	Consistently, the AXL inhibitor bemcentinib exerted additive effects with ruxolitinib via impaired STAT3, STAT5, and AKT signaling.	ruxolitinib	74-85	AKT serine/threonine kinase 1	Homo sapiens	117-120
34376782-1	2021	Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-ALL).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	87-91
34376782-1	2021	Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-ALL).	ruxolitinib	13-16	Janus kinase 2	Homo sapiens	87-91
34422627-7	2021	Recombinant human CXCL10 induced JAK-STAT and PD-L1, while the CXCL10-CXCR3 and JAK-STAT inhibitors AMG487 or ruxolitinib reduced the expression of PD-L1 in HFF-1 cells.	ruxolitinib	110-121	C-X-C motif chemokine ligand 10	Homo sapiens	63-69
34169393-0	2021	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.	ruxolitinib	20-31	erb-b2 receptor tyrosine kinase 2	Homo sapiens	78-82
34169393-2	2021	Ruxolitinib is an FDA approved inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	44-48
34169393-2	2021	Ruxolitinib is an FDA approved inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	53-57
34169393-3	2021	We performed a phase I/II trial investigating the safety and efficacy of the combination of trastuzumab and ruxolitinib in patients with trastuzumab-resistant metastatic HER2+ breast cancer.	ruxolitinib	108-119	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-174
34184542-0	2021	Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	15-19
34184542-0	2021	Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	20-24
34184542-2	2021	Material & methods: We tested ruxolitinib (a selective JAK1/2 inhibitor) efficacy in three different preclinical models of GvHD.	ruxolitinib	30-41	Janus kinase 1	Homo sapiens	55-61
34547879-0	2021	(Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report).	ruxolitinib	85-96	pericentriolar material 1	Homo sapiens	14-18
34547879-0	2021	(Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report).	ruxolitinib	85-96	Janus kinase 2	Homo sapiens	19-23
34445192-0	2021	Structural Basis of Inhibition of DCLK1 by Ruxolitinib.	ruxolitinib	43-54	doublecortin like kinase 1	Homo sapiens	34-39
34445192-3	2021	Here, we present our work to repurpose a Janus kinase 1 inhibitor, ruxolitinib as a DCLK1 inhibitor, showing micromolar binding affinity and inhibitory activity.	ruxolitinib	67-78	Janus kinase 1	Homo sapiens	41-55
34445192-3	2021	Here, we present our work to repurpose a Janus kinase 1 inhibitor, ruxolitinib as a DCLK1 inhibitor, showing micromolar binding affinity and inhibitory activity.	ruxolitinib	67-78	doublecortin like kinase 1	Homo sapiens	84-89
34445192-4	2021	Furthermore, to gain an insight into its interaction mode with DCLK1, a crystal structure of the ruxolitinib-complexed DCLK1 has been determined and analyzed.	ruxolitinib	97-108	doublecortin like kinase 1	Homo sapiens	63-68
34445192-4	2021	Furthermore, to gain an insight into its interaction mode with DCLK1, a crystal structure of the ruxolitinib-complexed DCLK1 has been determined and analyzed.	ruxolitinib	97-108	doublecortin like kinase 1	Homo sapiens	119-124
34445192-5	2021	Ruxolitinib as a nonspecific DCLK1 inhibitor characterized in this work is anticipated to provide a starting point for the structure-guided discovery of selective DCLK1 inhibitors.	ruxolitinib	0-11	doublecortin like kinase 1	Homo sapiens	29-34
34445192-5	2021	Ruxolitinib as a nonspecific DCLK1 inhibitor characterized in this work is anticipated to provide a starting point for the structure-guided discovery of selective DCLK1 inhibitors.	ruxolitinib	0-11	doublecortin like kinase 1	Homo sapiens	163-168
34539320-14	2021	Conclusion: Ruxolitinib may be life-saving in patients with ABO-incompatible transfusion reaction which follows a severe and catastrophic course.	ruxolitinib	12-23	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Homo sapiens	60-63
34367701-4	2021	While treatment with a JAK2 inhibitor (ruxolitinib) was not able to stop disease progression, combination treatment with inhibitors of both JAK2 and BCL2 (venetoclax) resulted in disease control for over 1.5 years.	ruxolitinib	39-50	Janus kinase 2	Homo sapiens	23-27
34367186-2	2021	Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway.	ruxolitinib	0-11	Janus kinase 1	Mus musculus	36-43
34359628-8	2021	Finally, JAK1/2-STAT6 pathway inhibition by ruxolitinib, an FDA approved drug, in cell line models and in one T-LBL primary sample led to cell proliferation reduction and increased apoptosis.	ruxolitinib	44-55	Janus kinase 1	Homo sapiens	9-15
34359628-8	2021	Finally, JAK1/2-STAT6 pathway inhibition by ruxolitinib, an FDA approved drug, in cell line models and in one T-LBL primary sample led to cell proliferation reduction and increased apoptosis.	ruxolitinib	44-55	signal transducer and activator of transcription 6	Homo sapiens	16-21
34367186-2	2021	Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	94-98
34367186-2	2021	Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway.	ruxolitinib	0-11	signal transducer and activator of transcription 3	Mus musculus	99-104
34367186-2	2021	Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway.	ruxolitinib	13-16	Janus kinase 1	Mus musculus	36-43
34367186-2	2021	Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway.	ruxolitinib	13-16	Janus kinase 2	Mus musculus	94-98
34367186-2	2021	Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway.	ruxolitinib	13-16	signal transducer and activator of transcription 3	Mus musculus	99-104
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	tumor necrosis factor	Mus musculus	97-106
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	interferon gamma	Mus musculus	108-117
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	high mobility group box 1	Mus musculus	119-124
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	interleukin 1 alpha	Mus musculus	126-134
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	interleukin 2	Mus musculus	136-140
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	interleukin 6	Mus musculus	146-150
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	Janus kinase 2	Mus musculus	240-244
34367186-14	2021	Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation.	ruxolitinib	13-16	signal transducer and activator of transcription 3	Mus musculus	245-250
34367186-17	2021	Rux application suppressed lipopolysaccharide (LPS)-induced NLRP3 inflammasome secretion and JAK2/STAT3 pathway activation in the OGD/R model in vitro.	ruxolitinib	0-3	NLR family, pyrin domain containing 3	Mus musculus	60-65
34367186-17	2021	Rux application suppressed lipopolysaccharide (LPS)-induced NLRP3 inflammasome secretion and JAK2/STAT3 pathway activation in the OGD/R model in vitro.	ruxolitinib	0-3	Janus kinase 2	Mus musculus	93-97
34367186-17	2021	Rux application suppressed lipopolysaccharide (LPS)-induced NLRP3 inflammasome secretion and JAK2/STAT3 pathway activation in the OGD/R model in vitro.	ruxolitinib	0-3	signal transducer and activator of transcription 3	Mus musculus	98-103
34372612-9	2021	Treatment with the JAK inhibitor ruxolitinib suppressed STAT5 phosphorylation and expression of the key anti-viral response protein MX1 and enhanced the anti-TCL activity of Reolysin in both HTLV-1-positive and negative cells.	ruxolitinib	33-44	signal transducer and activator of transcription 5A	Homo sapiens	56-61
34372612-9	2021	Treatment with the JAK inhibitor ruxolitinib suppressed STAT5 phosphorylation and expression of the key anti-viral response protein MX1 and enhanced the anti-TCL activity of Reolysin in both HTLV-1-positive and negative cells.	ruxolitinib	33-44	MX dynamin like GTPase 1	Homo sapiens	132-135
34260836-3	2021	In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.	ruxolitinib	26-37	Janus kinase 1	Homo sapiens	55-59
34260836-3	2021	In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.	ruxolitinib	26-37	Janus kinase 2	Homo sapiens	60-64
34361917-11	2021	Collectively, we propose ruxolitinib could attenuate endotoxin-induced uveitis and rescue visual functions in rats by inhibiting the JAK2-STAT3 pathway.	ruxolitinib	25-36	Janus kinase 2	Rattus norvegicus	133-137
34361917-11	2021	Collectively, we propose ruxolitinib could attenuate endotoxin-induced uveitis and rescue visual functions in rats by inhibiting the JAK2-STAT3 pathway.	ruxolitinib	25-36	signal transducer and activator of transcription 3	Rattus norvegicus	138-143
34371735-6	2021	Ruxolitinib was designed as a molecule with low nanomolar potency selective for JAK1 and 2 enzymes, but without significant inhibition of non-JAK kinases, as well as physicochemical properties for both topical and oral administration.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	80-90
34371735-8	2021	Ruxolitinib cream represents a novel, JAK1/2 selective therapy that can be delivered directly to the skin to treat a number of cytokine-driven, inflammatory dermatoses.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-44
34196308-5	2021	Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1.	ruxolitinib	69-80	Janus kinase 1	Mus musculus	49-53
34196308-5	2021	Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1.	ruxolitinib	69-80	Janus kinase 2	Mus musculus	54-58
34196308-5	2021	Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1.	ruxolitinib	69-80	CD274 antigen	Mus musculus	91-96
34196308-5	2021	Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1.	ruxolitinib	69-80	programmed cell death 1	Mus musculus	229-232
34276662-2	2021	The effect of the JAK1/2 kinase inhibitor ruxolitinib on treating steroid-refractory acute GVHD has been verified by the REACH1/2 study; however, its safety and efficacy in patients with steroid-refractory chronic GVHD (SR-cGVHD) remain unclear.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	18-24
34167562-7	2021	RESULTS: All NOTCH1-signaling-dependent T-ALL cell lines were sensitive to MRK-560 and its combination with ruxolitinib or imatinib in JAK1- or ABL1-dependent cell lines synergistically inhibited leukemia proliferation.	ruxolitinib	108-119	notch receptor 1	Homo sapiens	13-19
34167562-7	2021	RESULTS: All NOTCH1-signaling-dependent T-ALL cell lines were sensitive to MRK-560 and its combination with ruxolitinib or imatinib in JAK1- or ABL1-dependent cell lines synergistically inhibited leukemia proliferation.	ruxolitinib	108-119	mitogen-activated protein kinase kinase kinase 20	Homo sapiens	75-78
34167562-7	2021	RESULTS: All NOTCH1-signaling-dependent T-ALL cell lines were sensitive to MRK-560 and its combination with ruxolitinib or imatinib in JAK1- or ABL1-dependent cell lines synergistically inhibited leukemia proliferation.	ruxolitinib	108-119	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	144-148
34440089-0	2021	Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway.	ruxolitinib	0-11	Janus kinase 2	Mus musculus	80-84
34440089-0	2021	Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway.	ruxolitinib	0-11	signal transducer and activator of transcription 1	Mus musculus	85-92
34440089-0	2021	Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway.	ruxolitinib	0-11	aldehyde dehydrogenase family 1, subfamily A3	Mus musculus	93-100
34440089-8	2021	Furthermore, the nuclear translocation STAT1 and STAT3 heterodimers were markedly diminished by ruxolitinib treatment, possibly resulting in decreased ALDH1A3 activation.	ruxolitinib	96-107	signal transducer and activator of transcription 1	Mus musculus	39-44
34440089-8	2021	Furthermore, the nuclear translocation STAT1 and STAT3 heterodimers were markedly diminished by ruxolitinib treatment, possibly resulting in decreased ALDH1A3 activation.	ruxolitinib	96-107	signal transducer and activator of transcription 3	Mus musculus	49-54
34440089-8	2021	Furthermore, the nuclear translocation STAT1 and STAT3 heterodimers were markedly diminished by ruxolitinib treatment, possibly resulting in decreased ALDH1A3 activation.	ruxolitinib	96-107	aldehyde dehydrogenase family 1, subfamily A3	Mus musculus	151-158
34440089-10	2021	Collectively, our studies suggest that ruxolitinib might suppress the ALDH1A3 activation through the JAK2/STAT1/3 pathway in cholangiocarcinoma, and trials should be undertaken to evaluate its efficacy in clinical therapy.	ruxolitinib	39-50	aldehyde dehydrogenase family 1, subfamily A3	Mus musculus	70-77
34440089-10	2021	Collectively, our studies suggest that ruxolitinib might suppress the ALDH1A3 activation through the JAK2/STAT1/3 pathway in cholangiocarcinoma, and trials should be undertaken to evaluate its efficacy in clinical therapy.	ruxolitinib	39-50	Janus kinase 2	Mus musculus	101-105
34440089-10	2021	Collectively, our studies suggest that ruxolitinib might suppress the ALDH1A3 activation through the JAK2/STAT1/3 pathway in cholangiocarcinoma, and trials should be undertaken to evaluate its efficacy in clinical therapy.	ruxolitinib	39-50	signal transducer and activator of transcription 1	Mus musculus	106-113
34276662-6	2021	After ruxolitinib treatment, the percentage of CD4 cells increased from 18.20% to 23.22% (P<0.001), while the percentages of NK (CD16+CD56+) cells and regulatory T cells (CD4+CD127 +- CD25+) decreased (P<0.001, P<0.001).	ruxolitinib	6-17	CD4 molecule	Homo sapiens	47-50
34276662-6	2021	After ruxolitinib treatment, the percentage of CD4 cells increased from 18.20% to 23.22% (P<0.001), while the percentages of NK (CD16+CD56+) cells and regulatory T cells (CD4+CD127 +- CD25+) decreased (P<0.001, P<0.001).	ruxolitinib	6-17	Fc gamma receptor IIIa	Homo sapiens	129-133
34276662-6	2021	After ruxolitinib treatment, the percentage of CD4 cells increased from 18.20% to 23.22% (P<0.001), while the percentages of NK (CD16+CD56+) cells and regulatory T cells (CD4+CD127 +- CD25+) decreased (P<0.001, P<0.001).	ruxolitinib	6-17	neural cell adhesion molecule 1	Homo sapiens	134-138
34276662-6	2021	After ruxolitinib treatment, the percentage of CD4 cells increased from 18.20% to 23.22% (P<0.001), while the percentages of NK (CD16+CD56+) cells and regulatory T cells (CD4+CD127 +- CD25+) decreased (P<0.001, P<0.001).	ruxolitinib	6-17	CD4 molecule	Homo sapiens	171-174
34276662-6	2021	After ruxolitinib treatment, the percentage of CD4 cells increased from 18.20% to 23.22% (P<0.001), while the percentages of NK (CD16+CD56+) cells and regulatory T cells (CD4+CD127 +- CD25+) decreased (P<0.001, P<0.001).	ruxolitinib	6-17	interleukin 7 receptor	Homo sapiens	175-180
34276662-6	2021	After ruxolitinib treatment, the percentage of CD4 cells increased from 18.20% to 23.22% (P<0.001), while the percentages of NK (CD16+CD56+) cells and regulatory T cells (CD4+CD127 +- CD25+) decreased (P<0.001, P<0.001).	ruxolitinib	6-17	interleukin 2 receptor subunit alpha	Homo sapiens	184-188
34276662-8	2021	Moreover, we observed a significant increase in IL-10 levels after ruxolitinib treatment (P=0.025) and a remarkable decrease in levels of suppression of tumorigenicity 2 (ST2) from 229.90 ng/ml to 72.65 ng/ml.	ruxolitinib	67-78	interleukin 10	Homo sapiens	48-53
35363892-2	2022	Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-31
34097138-10	2021	Most recently, ruxolitinib, a JAK1/2 inhibitor targeting JAK-STAT signaling downstream from CSF3R, has emerged as a potentially promising new candidate for the treatment of CNL.	ruxolitinib	15-26	Janus kinase 1	Homo sapiens	30-36
34097138-10	2021	Most recently, ruxolitinib, a JAK1/2 inhibitor targeting JAK-STAT signaling downstream from CSF3R, has emerged as a potentially promising new candidate for the treatment of CNL.	ruxolitinib	15-26	colony stimulating factor 3 receptor	Homo sapiens	92-97
34073410-4	2021	Numerous JAK inhibitors (JAKinibs) have entered clinical trials, including the JAK1/2 inhibitor Ruxolitinib approved for the treatment of MPN.	ruxolitinib	96-107	Janus kinase 1	Homo sapiens	79-85
34124276-1	2021	The majority of diffuse large B-cell lymphoma (DLBCL) patients develop relapsed or refractory disease after standard ruxolitinib, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, which is partly related to a dysregulated tumor immune microenvironment.	ruxolitinib	117-128	DNA damage inducible transcript 3	Homo sapiens	192-196
34349069-6	2021	Based on these findings, an investigator-initiated clinical research of a JAK1/2 inhibitor ruxolitinib for CAEBV infection was initiated in January 2019.	ruxolitinib	91-102	Janus kinase 1	Homo sapiens	74-80
34206393-4	2021	However, IL-6 and the JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors-endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor-1 alpha (HIF-1alpha)-in patients with polycythemia vera (PV).	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	22-28
34206393-4	2021	However, IL-6 and the JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors-endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor-1 alpha (HIF-1alpha)-in patients with polycythemia vera (PV).	ruxolitinib	39-50	nitric oxide synthase 3	Homo sapiens	86-127
34206393-4	2021	However, IL-6 and the JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors-endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor-1 alpha (HIF-1alpha)-in patients with polycythemia vera (PV).	ruxolitinib	39-50	nitric oxide synthase 3	Homo sapiens	129-133
34206393-4	2021	However, IL-6 and the JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors-endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor-1 alpha (HIF-1alpha)-in patients with polycythemia vera (PV).	ruxolitinib	39-50	vascular endothelial growth factor A	Homo sapiens	136-140
34206393-4	2021	However, IL-6 and the JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors-endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor-1 alpha (HIF-1alpha)-in patients with polycythemia vera (PV).	ruxolitinib	39-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	146-178
34206393-4	2021	However, IL-6 and the JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors-endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor-1 alpha (HIF-1alpha)-in patients with polycythemia vera (PV).	ruxolitinib	39-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	180-190
34097573-4	2022	Flow cytometry, microscopy and other assays found that potent JAK1/2 inhibitors baricitinib and ruxolitinib reduced platelet adhesion to collagen, as well as platelet aggregation, secretion and integrin alphaIIbbeta3 activation in response to the glycoprotein VI (GPVI) agonist collagen-related peptide (CRP-XL).	ruxolitinib	96-107	Janus kinase 1	Homo sapiens	62-68
34097573-4	2022	Flow cytometry, microscopy and other assays found that potent JAK1/2 inhibitors baricitinib and ruxolitinib reduced platelet adhesion to collagen, as well as platelet aggregation, secretion and integrin alphaIIbbeta3 activation in response to the glycoprotein VI (GPVI) agonist collagen-related peptide (CRP-XL).	ruxolitinib	96-107	glycoprotein VI platelet	Homo sapiens	247-262
34097573-4	2022	Flow cytometry, microscopy and other assays found that potent JAK1/2 inhibitors baricitinib and ruxolitinib reduced platelet adhesion to collagen, as well as platelet aggregation, secretion and integrin alphaIIbbeta3 activation in response to the glycoprotein VI (GPVI) agonist collagen-related peptide (CRP-XL).	ruxolitinib	96-107	glycoprotein VI platelet	Homo sapiens	264-268
34097573-5	2022	Western blot analysis demonstrated that jakinibs reduced Akt phosphorylation and activation following GPVI activation, where ruxolitinib and baricitinib prevented DAPP1 phosphorylation.	ruxolitinib	125-136	dual adaptor of phosphotyrosine and 3-phosphoinositides 1	Homo sapiens	163-168
34140953-10	2021	Clinical evidence that JAK2 inhibition by ruxolitinib in MF neither reliably reduces malignant clonal burden nor eliminates cytokine elevations, suggests targeting cytokine mediated signaling as a therapeutic strategy, which is being pursued in new clinical trials.	ruxolitinib	42-53	Janus kinase 2	Homo sapiens	23-27
35363892-2	2022	Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	25-31
35604239-0	2022	Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
35595725-9	2022	Imaging analysis detected phosphotyrosine STAT3 in MF patients" BM fibrocytes, and transfection of fibrocytes with STAT3-siRNA or treatment with a JAK1/2 inhibitor ruxolitinib reduced GLI1 and MMP2/9 levels.	ruxolitinib	164-175	Janus kinase 1	Homo sapiens	147-153
34068690-7	2021	The constitutive activation of the tyrosine kinase JAK2 is targeted by ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor for PV patients who are resistant or intolerant to cytoreductive treatment with hydroxyurea.	ruxolitinib	71-82	Janus kinase 2	Homo sapiens	51-55
34068690-7	2021	The constitutive activation of the tyrosine kinase JAK2 is targeted by ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor for PV patients who are resistant or intolerant to cytoreductive treatment with hydroxyurea.	ruxolitinib	71-82	Janus kinase 1	Homo sapiens	86-90
34068690-7	2021	The constitutive activation of the tyrosine kinase JAK2 is targeted by ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor for PV patients who are resistant or intolerant to cytoreductive treatment with hydroxyurea.	ruxolitinib	71-82	Janus kinase 2	Homo sapiens	91-95
35597252-1	2022	BACKGROUND: The phase 3b, randomised, open-label RESPONSE-2 study in patients with inadequately controlled polycythaemia vera without splenomegaly showed superiority of the Janus kinase (JAK) 1 and JAK2 inhibitor ruxolitinib versus best available therapy for the primary endpoint of haematocrit control at week 28.	ruxolitinib	213-224	Janus kinase 1	Homo sapiens	173-193
35635540-1	2022	Ruxolitinib (RUX), a small molecule inhibitor of JAK1/JAK2, has been identified as the possible novel targeted agent for the treatment of hemophagocytic lymphohistiocytosis (HLH).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	49-53
35635540-1	2022	Ruxolitinib (RUX), a small molecule inhibitor of JAK1/JAK2, has been identified as the possible novel targeted agent for the treatment of hemophagocytic lymphohistiocytosis (HLH).	ruxolitinib	0-11	Janus kinase 2	Homo sapiens	54-58
35635540-1	2022	Ruxolitinib (RUX), a small molecule inhibitor of JAK1/JAK2, has been identified as the possible novel targeted agent for the treatment of hemophagocytic lymphohistiocytosis (HLH).	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	49-53
35635540-1	2022	Ruxolitinib (RUX), a small molecule inhibitor of JAK1/JAK2, has been identified as the possible novel targeted agent for the treatment of hemophagocytic lymphohistiocytosis (HLH).	ruxolitinib	13-16	Janus kinase 2	Homo sapiens	54-58
35589917-1	2022	Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD).	ruxolitinib	71-82	Janus kinase 1	Mus musculus	47-53
35507130-3	2022	We here assessed the impact of ruxolitinib on the JAK-STAT1/3 pathway in DN STAT3 patients" cells.	ruxolitinib	31-42	signal transducer and activator of transcription 1	Homo sapiens	54-61
35507130-5	2022	We also describe the impact of ruxolitinib on cytokine-induced STAT1 signaling in these patients.	ruxolitinib	31-42	signal transducer and activator of transcription 1	Homo sapiens	63-68
35507130-8	2022	Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells.	ruxolitinib	44-55	Janus kinase 1	Homo sapiens	27-31
35507130-8	2022	Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells.	ruxolitinib	44-55	signal transducer and activator of transcription 1	Homo sapiens	103-108
35507130-8	2022	Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells.	ruxolitinib	44-55	signal transducer and activator of transcription 3	Homo sapiens	131-136
35507130-8	2022	Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells.	ruxolitinib	44-55	signal transducer and activator of transcription 1	Homo sapiens	141-146
35595725-9	2022	Imaging analysis detected phosphotyrosine STAT3 in MF patients" BM fibrocytes, and transfection of fibrocytes with STAT3-siRNA or treatment with a JAK1/2 inhibitor ruxolitinib reduced GLI1 and MMP2/9 levels.	ruxolitinib	164-175	GLI family zinc finger 1	Homo sapiens	184-188
35595725-9	2022	Imaging analysis detected phosphotyrosine STAT3 in MF patients" BM fibrocytes, and transfection of fibrocytes with STAT3-siRNA or treatment with a JAK1/2 inhibitor ruxolitinib reduced GLI1 and MMP2/9 levels.	ruxolitinib	164-175	matrix metallopeptidase 2	Homo sapiens	193-199
35151642-4	2022	ATRA enhanced PD-L1 expression through increasing its protein stability and protein synthesis, which was suppressed by JAK pan-inhibitor ruxolitinib (RUX), but was enhanced by the combination with IFN-gamma.	ruxolitinib	137-148	CD274 molecule	Homo sapiens	14-19
35368221-1	2022	BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	87-101
35368221-1	2022	BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2.	ruxolitinib	12-23	Janus kinase 2	Homo sapiens	106-120
35368221-1	2022	BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2.	ruxolitinib	58-69	Janus kinase 1	Homo sapiens	87-101
35368221-1	2022	BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2.	ruxolitinib	58-69	Janus kinase 2	Homo sapiens	106-120
35437311-1	2022	Outside of clinical trials and before commercial availability for acute and chronic graft-versus-host disease (GVHD), the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was available to US patients with steroid-refractory GVHD through an open-label, multicenter expanded access program (EAP) sponsored by Incyte Corporation.	ruxolitinib	158-169	Janus kinase 1	Homo sapiens	122-142
35437311-1	2022	Outside of clinical trials and before commercial availability for acute and chronic graft-versus-host disease (GVHD), the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was available to US patients with steroid-refractory GVHD through an open-label, multicenter expanded access program (EAP) sponsored by Incyte Corporation.	ruxolitinib	158-169	Janus kinase 2	Homo sapiens	143-147
35128632-0	2022	Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.	ruxolitinib	106-117	hepcidin antimicrobial peptide	Homo sapiens	0-8
35352806-6	2022	Jak2 is activated in Nras mutant HSC and progenitors (HSPCs) and inhibiting Jak2 with Ruxolitinib significantly decreases Stat5 activation and HSPC hyper-proliferation in vivo in NrasG12D mice.	ruxolitinib	86-97	Janus kinase 2	Mus musculus	0-4
35352806-6	2022	Jak2 is activated in Nras mutant HSC and progenitors (HSPCs) and inhibiting Jak2 with Ruxolitinib significantly decreases Stat5 activation and HSPC hyper-proliferation in vivo in NrasG12D mice.	ruxolitinib	86-97	neuroblastoma ras oncogene	Mus musculus	21-25
35352806-6	2022	Jak2 is activated in Nras mutant HSC and progenitors (HSPCs) and inhibiting Jak2 with Ruxolitinib significantly decreases Stat5 activation and HSPC hyper-proliferation in vivo in NrasG12D mice.	ruxolitinib	86-97	Janus kinase 2	Mus musculus	76-80
35352806-6	2022	Jak2 is activated in Nras mutant HSC and progenitors (HSPCs) and inhibiting Jak2 with Ruxolitinib significantly decreases Stat5 activation and HSPC hyper-proliferation in vivo in NrasG12D mice.	ruxolitinib	86-97	signal transducer and activator of transcription 5A	Mus musculus	122-127
35278531-6	2022	The erythropoietin receptor activates Janus kinase 2 (Jak2) and we found treatment of Fancc-/- mice with ruxolitinib (Jak1/2-inhibitor) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes.	ruxolitinib	105-116	erythropoietin receptor	Mus musculus	4-27
35278531-6	2022	The erythropoietin receptor activates Janus kinase 2 (Jak2) and we found treatment of Fancc-/- mice with ruxolitinib (Jak1/2-inhibitor) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes.	ruxolitinib	105-116	Janus kinase 2	Mus musculus	38-52
35278531-6	2022	The erythropoietin receptor activates Janus kinase 2 (Jak2) and we found treatment of Fancc-/- mice with ruxolitinib (Jak1/2-inhibitor) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes.	ruxolitinib	105-116	Janus kinase 2	Mus musculus	54-58
35278531-6	2022	The erythropoietin receptor activates Janus kinase 2 (Jak2) and we found treatment of Fancc-/- mice with ruxolitinib (Jak1/2-inhibitor) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes.	ruxolitinib	105-116	Fanconi anemia, complementation group C	Mus musculus	86-91
35278531-8	2022	Transcriptome analysis of these cells identified enhanced activity of pathways for metabolism of reactive oxygen species, and decreased apoptosis and autophagy related pathways, as major ruxolitinib-effects in Fancc-/- mice.	ruxolitinib	187-198	Fanconi anemia, complementation group C	Mus musculus	210-215
35368384-2	2022	The Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib reduces inflammatory cytokine concentrations in disorders characterised by cytokine dysregulation, including graft-versus-host disease, myelofibrosis, and secondary hemophagocytic lymphohistiocytosis.	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	4-23
35368384-2	2022	The Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib reduces inflammatory cytokine concentrations in disorders characterised by cytokine dysregulation, including graft-versus-host disease, myelofibrosis, and secondary hemophagocytic lymphohistiocytosis.	ruxolitinib	39-50	Janus kinase 2	Homo sapiens	24-28
35368384-3	2022	We assessed whether treatment with the JAK1/JAK2 inhibitor ruxolitinib would be beneficial in patients with COVID-19 admitted to hospital.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	39-43
35368384-3	2022	We assessed whether treatment with the JAK1/JAK2 inhibitor ruxolitinib would be beneficial in patients with COVID-19 admitted to hospital.	ruxolitinib	59-70	Janus kinase 2	Homo sapiens	44-48
35266648-3	2022	Inhibition of IFNG pathway by the JAK1/2 inhibitor ruxolitinib or knocking out Stat1 gene abrogated the IFNG-induced melanogenesis.	ruxolitinib	51-62	interferon gamma	Homo sapiens	14-18
35266648-3	2022	Inhibition of IFNG pathway by the JAK1/2 inhibitor ruxolitinib or knocking out Stat1 gene abrogated the IFNG-induced melanogenesis.	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	34-40
35443042-6	2022	Ruxolitinib, an oral selective JAK1/2 inhibitor, received FDA approval for the treatment of steroid-refractory acute GVHD in 2019 and remains the only agent approved for acute GVHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	31-37
35382859-2	2022	Here, we aim to determine the effect and underlying mechanism of JAK1/2 inhibition on liver fibrosis and hepatic stellate cells (HSCs) and further explore the therapeutic efficacy of Ruxolitinib, a JAK1/2 selective inhibitor, on preventing and reversing liver fibrosis in mice.	ruxolitinib	183-194	Janus kinase 1	Mus musculus	198-204
35382859-5	2022	The effects of Ruxolitinib (JAK1/2 inhibitor) on liver fibrosis were studied in LX-2 cells and two progressive and reversible fibrosis animal models (carbon tetrachloride (CCl4), Thioacetamide (TAA)).	ruxolitinib	15-26	Janus kinase 1	Homo sapiens	28-34
35382859-8	2022	Importantly, Ruxolitinib significantly attenuated fibrosis progression, improved cell damage, and accelerated fibrosis reversal in the liver of mice treated with CCl4 or TAA.	ruxolitinib	13-24	chemokine (C-C motif) ligand 4	Mus musculus	162-166
35151642-4	2022	ATRA enhanced PD-L1 expression through increasing its protein stability and protein synthesis, which was suppressed by JAK pan-inhibitor ruxolitinib (RUX), but was enhanced by the combination with IFN-gamma.	ruxolitinib	150-153	CD274 molecule	Homo sapiens	14-19
35434097-7	2022	The patient was treated with the JAK2 inhibitor-ruxolitinib according to peripheral blood cells, although myelofibrosis was improved, the splenomegaly did not reduce.	ruxolitinib	48-59	Janus kinase 2	Homo sapiens	33-37
35337171-5	2022	Recently, the FDA approved the use of ruxolitinib, a JAK1/2 inhibitor, in the treatment of acute steroid-refractory GVHD (SR-aGVHD), highlighting the role of JAK inhibition in this immune deregulation.	ruxolitinib	38-49	Janus kinase 1	Homo sapiens	53-59
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	172-182	indoleamine 2,3-dioxygenase 1	Homo sapiens	31-35
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	172-182	Janus kinase 1	Homo sapiens	59-62
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	172-182	signal transducer and activator of transcription 1	Homo sapiens	63-68
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	184-195	indoleamine 2,3-dioxygenase 1	Homo sapiens	31-35
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	184-195	Janus kinase 1	Homo sapiens	59-62
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	184-195	signal transducer and activator of transcription 1	Homo sapiens	63-68
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	184-195	Janus kinase 1	Homo sapiens	200-206
35131871-4	2022	Here we show in Pax5+/- mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigates the risk of B-ALL following exposure to infection; 1 of 29 animals treated with ruxolitinib developed B-ALL versus 8 of 34 untreated mice.	ruxolitinib	103-114	paired box 5	Mus musculus	16-20
35131871-4	2022	Here we show in Pax5+/- mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigates the risk of B-ALL following exposure to infection; 1 of 29 animals treated with ruxolitinib developed B-ALL versus 8 of 34 untreated mice.	ruxolitinib	103-114	Janus kinase 1	Mus musculus	118-124
35131871-5	2022	Ruxolitinib treatment preferentially targeted Pax5+/- versus wild-type B-cell progenitors and exerted unique effects on the Pax5+/- B-cell progenitor transcriptional program.	ruxolitinib	0-11	paired box 5	Mus musculus	46-50
35131544-5	2022	Furthermore, propionate-induced IFIT expression is dependent on IFN type I and/or type III-mediated signalling since pre-treatment of A549 cells with Ruxolitinib, a specific JAK1/2 tyrosine kinase inhibitor, prior to stimulation with propionate, inhibited the upregulation of IFIT1 expression.	ruxolitinib	150-161	Janus kinase 1	Homo sapiens	174-180
35218354-0	2022	Ruxolitinib Inhibits IFNgamma-stimulated Sjogren"s Salivary Gland MSC HLA-DR Expression and Chemokine-Dependent T-cell Migration.	ruxolitinib	0-11	interferon gamma	Homo sapiens	21-29
35218354-4	2022	The objective of this study was to define the immunobiology of IFNgamma-exposed SG-MSCs with and without the JAK1 & 2 inhibitor, ruxolitinib.	ruxolitinib	129-140	interferon gamma	Homo sapiens	63-71
35218354-8	2022	RESULTS: We found that IFNgamma promoted expression of SG-MSC immunomodulatory markers, including HLA-DR, and this expression was inhibited by ruxolitinib.	ruxolitinib	143-154	interferon gamma	Homo sapiens	23-31
35218354-11	2022	Ruxolitinib blocks chemotaxis through inhibition of SG-MSC production of CXCL9, CXCL10, and CXCL11.	ruxolitinib	0-11	C-X-C motif chemokine ligand 9	Homo sapiens	73-78
35218354-11	2022	Ruxolitinib blocks chemotaxis through inhibition of SG-MSC production of CXCL9, CXCL10, and CXCL11.	ruxolitinib	0-11	C-X-C motif chemokine ligand 10	Homo sapiens	80-86
35218354-11	2022	Ruxolitinib blocks chemotaxis through inhibition of SG-MSC production of CXCL9, CXCL10, and CXCL11.	ruxolitinib	0-11	C-X-C motif chemokine ligand 11	Homo sapiens	92-98
35218354-12	2022	CONCLUSIONS: These findings establish that ruxolitinib inhibits IFNgamma-induced expression of SG-MSC immunomodulatory markers and chemokines.	ruxolitinib	43-54	interferon gamma	Homo sapiens	64-72
35218354-13	2022	Ruxolitinib also reverses IFNgamma-induced CD4+ T cell chemotaxis, through inhibition of CXCL9, -10, and -11.	ruxolitinib	0-11	interferon gamma	Homo sapiens	26-34
35218354-13	2022	Ruxolitinib also reverses IFNgamma-induced CD4+ T cell chemotaxis, through inhibition of CXCL9, -10, and -11.	ruxolitinib	0-11	CD4 molecule	Homo sapiens	43-46
35218354-13	2022	Ruxolitinib also reverses IFNgamma-induced CD4+ T cell chemotaxis, through inhibition of CXCL9, -10, and -11.	ruxolitinib	0-11	C-X-C motif chemokine ligand 9	Homo sapiens	89-108
35131254-1	2022	Ruxolitinib is a Janus kinase 1/2 inhibitor (JAK1/2) that blocks signal transduction of interferon-gamma, a critical cytokine involved in the pathogenesis of cutaneous lichen planus (LP).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	45-51
35131254-1	2022	Ruxolitinib is a Janus kinase 1/2 inhibitor (JAK1/2) that blocks signal transduction of interferon-gamma, a critical cytokine involved in the pathogenesis of cutaneous lichen planus (LP).	ruxolitinib	0-11	interferon gamma	Homo sapiens	88-104
35186752-5	2022	RNA sequencing identified 126 genes that were regulated by both FUS-DDIT3 expression and JAK1/2 inhibition using ruxolitinib.	ruxolitinib	113-124	FUS RNA binding protein	Homo sapiens	64-67
35186752-5	2022	RNA sequencing identified 126 genes that were regulated by both FUS-DDIT3 expression and JAK1/2 inhibition using ruxolitinib.	ruxolitinib	113-124	DNA damage inducible transcript 3	Homo sapiens	68-73
35186752-5	2022	RNA sequencing identified 126 genes that were regulated by both FUS-DDIT3 expression and JAK1/2 inhibition using ruxolitinib.	ruxolitinib	113-124	Janus kinase 1	Homo sapiens	89-95
35370398-8	2022	Results: After pre-treatment with voriconazole, no significant change existed in Tmax, while Cmax, T1/2, AUClast, and AUCinf of ruxolitinib were significantly increased by 50.4%, 81.3%, 110.1%, and 118.3%, respectively, and CL/F was significantly decreased to 43.6% compared with patients receiving ruxolitinib alone.	ruxolitinib	128-139	CD6 molecule	Homo sapiens	93-103
35370398-8	2022	Results: After pre-treatment with voriconazole, no significant change existed in Tmax, while Cmax, T1/2, AUClast, and AUCinf of ruxolitinib were significantly increased by 50.4%, 81.3%, 110.1%, and 118.3%, respectively, and CL/F was significantly decreased to 43.6% compared with patients receiving ruxolitinib alone.	ruxolitinib	128-139	cytokine receptor like factor 1	Homo sapiens	224-228
35269680-5	2022	Furthermore, in the MDA-MB-468 xenograft mouse model, we demonstrated the synergistic antitumor effect of ruxolitinib and calcitriol combination treatment, including the alteration of c-PARP, cyclin D1, and c-Myc expression, without significant drug toxicity.	ruxolitinib	106-117	cyclin D1	Mus musculus	192-201
35269680-5	2022	Furthermore, in the MDA-MB-468 xenograft mouse model, we demonstrated the synergistic antitumor effect of ruxolitinib and calcitriol combination treatment, including the alteration of c-PARP, cyclin D1, and c-Myc expression, without significant drug toxicity.	ruxolitinib	106-117	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	207-212
35169231-6	2022	Pharmacologic JAK2 inhibition with ruxolitinib also leads to defects in cholesterol efflux and accelerates atherosclerosis.	ruxolitinib	35-46	Janus kinase 2	Mus musculus	14-18
35232350-7	2022	JAK inhibitors, notably ruxolitinib, a, JAK1 or 2 blockers, make cell lines and mouse models more susceptible to radiotherapy, biological response modifier therapy, and oncolytic viral treatment.	ruxolitinib	24-35	Janus kinase 1	Mus musculus	40-44
34847081-11	2022	Additionally, there were loose architecture and reduced collagen and desmoglein expression, which could be reversed by treatment with ruxolitinib/doxycycline/TGF-beta1.	ruxolitinib	134-145	transforming growth factor beta 1	Homo sapiens	158-167
35020848-4	2022	JAK2 inhibition by ruxolitinib mimicked loss of TSLPR function in vivo and further decreased TSLP expression in the EAE mouse brain.	ruxolitinib	19-30	Janus kinase 2	Mus musculus	0-4
35020848-4	2022	JAK2 inhibition by ruxolitinib mimicked loss of TSLPR function in vivo and further decreased TSLP expression in the EAE mouse brain.	ruxolitinib	19-30	cytokine receptor-like factor 2	Mus musculus	48-53
35020848-4	2022	JAK2 inhibition by ruxolitinib mimicked loss of TSLPR function in vivo and further decreased TSLP expression in the EAE mouse brain.	ruxolitinib	19-30	thymic stromal lymphopoietin	Mus musculus	93-97
35020848-6	2022	In vitro experiments using BV-2murine microglia revealed that TSLP directly induced NLRP3 expression, phosphorylation of JAK2 but not JAK1orJAK3, and IL-1beta release, which were markedly inhibited by ruxolitinib.	ruxolitinib	201-212	thymic stromal lymphopoietin	Mus musculus	62-66
35020848-6	2022	In vitro experiments using BV-2murine microglia revealed that TSLP directly induced NLRP3 expression, phosphorylation of JAK2 but not JAK1orJAK3, and IL-1beta release, which were markedly inhibited by ruxolitinib.	ruxolitinib	201-212	Janus kinase 2	Mus musculus	121-125
35020848-8	2022	In addition, ruxolitinib suppressed the increase in IL-17A expression in the EAE mouse brain.	ruxolitinib	13-24	interleukin 17A	Mus musculus	52-58
34644371-1	2022	Targeted inhibitors of JAK2 (e.g. ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation.	ruxolitinib	34-45	Janus kinase 2	Homo sapiens	23-27
35159191-10	2022	We showed that microglia co-culture failed to induce chemoresistance of gp130-/- MB cells, and that combination treatment using gp130 inhibitors, or with the JAK inhibitor ruxolitinib, effectively overcame the observed resistance to vincristine in gp130 expressing MB cells.	ruxolitinib	172-183	interleukin 6 cytokine family signal transducer	Homo sapiens	72-77
35159191-10	2022	We showed that microglia co-culture failed to induce chemoresistance of gp130-/- MB cells, and that combination treatment using gp130 inhibitors, or with the JAK inhibitor ruxolitinib, effectively overcame the observed resistance to vincristine in gp130 expressing MB cells.	ruxolitinib	172-183	interleukin 6 cytokine family signal transducer	Homo sapiens	248-253
35264503-8	2022	Along with the activated STAT5 pathway, a common feature across all AEL cases, these AEL cases exhibited enhanced cell proliferation and heme metabolism, and they showed high sensitivity to ruxolitinib in in vitro and in xenograft models, highlighting the potential role of JAK2 inhibition in AEL therapeutics.	ruxolitinib	190-201	signal transducer and activator of transcription 5A	Homo sapiens	25-30
35264503-8	2022	Along with the activated STAT5 pathway, a common feature across all AEL cases, these AEL cases exhibited enhanced cell proliferation and heme metabolism, and they showed high sensitivity to ruxolitinib in in vitro and in xenograft models, highlighting the potential role of JAK2 inhibition in AEL therapeutics.	ruxolitinib	190-201	Janus kinase 2	Homo sapiens	274-278